<SEC-DOCUMENT>0001610618-18-000042.txt : 20180510
<SEC-HEADER>0001610618-18-000042.hdr.sgml : 20180510
<ACCEPTANCE-DATETIME>20180510160750
ACCESSION NUMBER:		0001610618-18-000042
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		55
CONFORMED PERIOD OF REPORT:	20180331
FILED AS OF DATE:		20180510
DATE AS OF CHANGE:		20180510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cidara Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001610618
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				461537286
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36912
		FILM NUMBER:		18822542

	BUSINESS ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-752-6170

	MAIL ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	K2 THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20140611
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cdtx10-q2018x03.htm
<DESCRIPTION>CIDARA THERAPEUTICS, INC. FORM 10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s390723C8C84A5508A1F296073E8993A6"></a></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:18pt;"><font style="font-family:Arial;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:18pt;"><font style="font-family:Arial;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">WASHINGTON, DC 20549</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:34.69785575048733%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:18pt;"><font style="font-family:Arial;font-size:18pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:34.69785575048733%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">(Mark One)</font></div><div style="line-height:120%;padding-top:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;font-weight:bold;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">FOR THE QUARTERLY PERIOD ENDED </font><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">MARCH&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;font-weight:bold;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Commission file number: 001-36912</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:34.69785575048733%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:24pt;"><font style="font-family:Arial;font-size:24pt;font-weight:bold;">CIDARA THERAPEUTICS, INC.</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:34.69785575048733%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">46-1537286</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(State or Other Jurisdiction of </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Incorporation or Organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(I.R.S. Employer </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">6310 Nancy Ridge Drive, Suite 101</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">San Diego, CA&#160;&#160;92121</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">(858) 752-6170</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Address of Principal Executive Offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(Registrant&#8217;s Telephone Number, Including Area Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:34.69785575048733%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:8.5pt;"><font style="font-family:Arial;font-size:8.5pt;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;Yes&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:8.5pt;">x</font><font style="font-family:Arial;font-size:8.5pt;">&#160;&#160;&#160;No&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:8.5pt;">o</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:8.5pt;"><font style="font-family:Arial;font-size:8.5pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;Yes&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:8.5pt;">x</font><font style="font-family:Arial;font-size:8.5pt;">&#160;&#160;&#160;No&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:8.5pt;">o</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:8.5pt;"><font style="font-family:Arial;font-size:8.5pt;">Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:23%;"></td><td style="width:3%;"></td><td style="width:46%;"></td><td style="width:25%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Arial;font-size:8.5pt;">Large accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Wingdings;font-size:8.5pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Arial;font-size:8.5pt;">Accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Wingdings;font-size:8.5pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Arial;font-size:8.5pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Wingdings;font-size:8.5pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Arial;font-size:8.5pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Arial;font-size:8.5pt;">Smaller reporting company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Wingdings;font-size:8.5pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Arial;font-size:8.5pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Wingdings;font-size:8.5pt;">x</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:8.5pt;"><font style="font-family:Arial;font-size:8.5pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </font><font style="font-family:Wingdings;font-size:8.5pt;">o</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:8.5pt;"><font style="font-family:Arial;font-size:8.5pt;">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:8.5pt;">o</font><font style="font-family:Arial;font-size:8.5pt;">&#160;&#160;&#160;No&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:8.5pt;">x</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:8.5pt;"><font style="font-family:Arial;font-size:8.5pt;">As of </font><font style="font-family:Arial;font-size:8.5pt;">April&#160;30, 2018</font><font style="font-family:Arial;font-size:8.5pt;">, the registrant had </font><font style="font-family:Arial;font-size:8.5pt;">21,391,057</font><font style="font-family:Arial;font-size:8.5pt;">&#32;shares of Common Stock ($</font><font style="font-family:Arial;font-size:8.5pt;">0.0001</font><font style="font-family:Arial;font-size:8.5pt;">&#32;par value) outstanding.</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="s03821761FB9A52CD8868D522597D2FF6"></a></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">CIDARA THERAPEUTICS, INC.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:90%;"></td><td style="width:5%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;font-weight:bold;" href="#s37C6B17CEB045AB4A8D7F417D86899F3"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">PART I. FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s37C6B17CEB045AB4A8D7F417D86899F3">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s03E6B4EFD1065D5F892A89711C4FE1B4"><font style="font-family:Arial;font-size:9.5pt;">Item&#160;1. Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s03E6B4EFD1065D5F892A89711C4FE1B4">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s71969673E76C561F925452EE39833A61"><font style="font-family:Arial;font-size:9.5pt;">Condensed Consolidated Balance Sheets as of March 31, 2018 (unaudited) and December 31, 2017</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s71969673E76C561F925452EE39833A61">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s476FDAB6EB7F59099FEFE4F82FEEC0E0"><font style="font-family:Arial;font-size:9.5pt;">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2018 and 2017 (unaudited)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s476FDAB6EB7F59099FEFE4F82FEEC0E0">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s18340B263849516D9AEE857B0BF832F6"><font style="font-family:Arial;font-size:9.5pt;">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2018 and 2017 (unaudited)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s18340B263849516D9AEE857B0BF832F6">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s50813B70C3D850B5B20CE29ECB5D9E92"><font style="font-family:Arial;font-size:9.5pt;">Notes to Condensed Consolidated Financial Statements (unaudited)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s50813B70C3D850B5B20CE29ECB5D9E92">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s1200F48317DB5FB98985738F6EBA66B5"><font style="font-family:Arial;font-size:9.5pt;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s1200F48317DB5FB98985738F6EBA66B5">16</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s4CA4CFC963F55B838E905D72C552C4F7"><font style="font-family:Arial;font-size:9.5pt;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s4CA4CFC963F55B838E905D72C552C4F7">23</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s2B67818E953F541A951975310D425406"><font style="font-family:Arial;font-size:9.5pt;">Item&#160;4. Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s2B67818E953F541A951975310D425406">23</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;font-weight:bold;" href="#s8A596B1661525371A84673E461CBD7D8"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">PART II. OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s2B67818E953F541A951975310D425406">23</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s0E958F7498185D7095EDB58D50426389"><font style="font-family:Arial;font-size:9.5pt;">Item&#160;1. Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s0E958F7498185D7095EDB58D50426389">25</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s1D6EF33C9F125DF5B0A271FD2849F977"><font style="font-family:Arial;font-size:9.5pt;">Item&#160;1A. Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s1D6EF33C9F125DF5B0A271FD2849F977">25</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s748821928EFE544DA78397441D4E745A"><font style="font-family:Arial;font-size:9.5pt;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s748821928EFE544DA78397441D4E745A">53</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s09C305FFBF8251AB9C3D351AA1A323DB"><font style="font-family:Arial;font-size:9.5pt;">Item&#160;3. Defaults Upon Senior Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s09C305FFBF8251AB9C3D351AA1A323DB">53</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s79D2DD8EE60A59F7B51A5467867F513E"><font style="font-family:Arial;font-size:9.5pt;">Item&#160;4. Mine Safety Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s79D2DD8EE60A59F7B51A5467867F513E">53</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#sE46D0F97F83351C4BCE4F4E39470E0C8"><font style="font-family:Arial;font-size:9.5pt;">Item&#160;5. Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#sE46D0F97F83351C4BCE4F4E39470E0C8">53</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#sD805B9F948B85D55BA59A7E49CAE3D2F"><font style="font-family:Arial;font-size:9.5pt;">Item&#160;6. Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#sD805B9F948B85D55BA59A7E49CAE3D2F">53</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;font-weight:bold;" href="#s2FE6EA8DA1C6599A877E7AEF3C1D370D"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">SIGNATURES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><a style="font-family:Arial;font-size:9.5pt;" href="#s2FE6EA8DA1C6599A877E7AEF3C1D370D">54</a></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s37C6B17CEB045AB4A8D7F417D86899F3"></a></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART I. FINANCIAL INFORMATION</font></div><div><a name="s03E6B4EFD1065D5F892A89711C4FE1B4"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM&#160;1. FINANCIAL STATEMENTS</font></div><div><a name="s71969673E76C561F925452EE39833A61"></a></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">CIDARA THERAPEUTICS, INC.</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Condensed</font><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">&#32;Consolidated Balance Sheets</font><font style="font-family:Arial;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:9.5pt;">&#160;&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">(In thousands, except share and per share data)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">52,218</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">60,813</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,973</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">14,501</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,719</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2,035</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">68,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">77,670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">936</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,044</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">321</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">321</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">70,247</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">79,035</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS' EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2,999</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2,590</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,516</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,921</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2,571</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Current portion of term loan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2,083</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2,667</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11,519</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">12,085</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Term loan, less debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">7,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">7,206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">19,328</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">19,291</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Commitments and contingencies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Stockholders' equity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding at March 31, 2018 and December 31, 2017, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2018 and December 31, 2017; 21,395,077 and 21,389,736 shares issued and outstanding, respectively, at March 31, 2018; 20,534,993 and 20,525,688 shares issued and outstanding, respectively, at December 31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">217,073</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">209,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(166,138</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(149,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">50,919</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">59,744</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total liabilities and stockholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">70,247</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">79,035</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">See accompanying notes.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="s476FDAB6EB7F59099FEFE4F82FEEC0E0"></a></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">CIDARA THERAPEUTICS, INC.</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Condensed</font><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">&#32;Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">(unaudited)</font><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Three Months Ended<br>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">(In thousands, except share and per share data)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,199</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">10,243</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,155</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">16,810</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,398</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(16,810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(13,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Other income:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Interest income, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total other income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(16,749</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(13,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Other comprehensive loss:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Unrealized loss on short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(16,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(13,401</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(0.80</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(0.80</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Shares used to compute basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">20,894,353</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">16,795,366</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">See accompanying notes.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s18340B263849516D9AEE857B0BF832F6"></a></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">CIDARA THERAPEUTICS, INC.</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Condensed</font><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">&#32;Consolidated Statements of Cash Flows</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">(unaudited)</font><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Three Months Ended<br>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(16,749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(13,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,461</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,051</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Amortization of debt issuance costs and debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Amortization of discount or premium on short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">36</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Changes in assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:36px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(416</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:36px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Accounts payable and accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">549</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(799</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:36px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Accrued compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(1,129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:28px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(14,722</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(14,518</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Purchases of short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(5,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Maturities of short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6,285</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11,400</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(116</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:28px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Net cash provided by investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">451</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11,284</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Proceeds from issuance of common stock, net of issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Proceeds from exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">144</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Repurchase of unvested restricted stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:28px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6,468</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Net decrease in cash, cash equivalents, and restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(7,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(3,169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Cash, cash equivalents, and restricted cash at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">60,813</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">85,367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Cash, cash equivalents, and restricted cash at end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">53,010</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">82,198</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Supplemental disclosure of cash flows:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Interest paid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">137</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">118</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Non-cash financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Vesting of early exercised stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Deferred financing costs incurred but not yet paid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">See accompanying notes.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="s50813B70C3D850B5B20CE29ECB5D9E92"></a></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">CIDARA THERAPEUTICS, INC.</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:6pt;"><font style="font-family:Arial;font-size:6pt;"><br></font></div><div><a name="s9CCFD5EC1C11553A8244FD7CC880EC48"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">1. THE COMPANY AND BASIS OF PRESENTATION</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Description of Business</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives. The Company&#8217;s product portfolio is comprised of proprietary product candidates for the treatment of serious fungal and bacterial infections.&#160;In March 2016, the Company formed a wholly-owned subsidiary, Cidara Therapeutics UK Limited, in England for the purpose of developing its product candidates in Europe.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced net losses and negative cash flows from operating activities since its inception. At </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, the Company had an accumulated deficit of </font><font style="font-family:Arial;font-size:9.5pt;">$166.1 million</font><font style="font-family:Arial;font-size:9.5pt;">. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure. </font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In accordance with ASU 2014-15, management is required to perform a two-step analysis over its ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company's ability to continue as a going concern (step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (step 2). The evaluation period is through one year beyond the date the financial statements were released (assumed to be through May 9, 2019).</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company has prepared cash flow forecasts which indicate, based on its current cash resources available and access to capital under its Loan Agreement with Pacific Western Bank that it will not have sufficient resources to fund its business, including its ongoing clinical trials, for at least the next 12 months from the date of this filing.  </font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company will need to raise additional capital to fund its losses from operations. It anticipates raising capital through debt and equity financing, through government funding or through collaborations or partnerships with other entities. Debt or equity financing, government funding or collaborations and partnerships with other entities may not be available on a timely basis on terms acceptable to the Company, or at all. If the Company is not able to secure adequate additional funding, the Company may be forced to delay, reduce or eliminate its research and development programs or future commercialization efforts, or to make reductions in spending, extend payment terms with suppliers, liquidate or grant rights to assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Management has developed a plan to implement cost cutting measures to reduce its working capital requirements over the next 12 months if an adequate level of financing is not secured. The plan includes the delay of certain of the Company&#8217;s development activities, a delay in hiring and a reduction of other discretionary expenditures that are within the Company&#8217;s control. Any of the actions contemplated by the implementation of this plan, if required, could have an adverse impact on the Company&#8217;s ability to achieve certain of its planned objectives during 2018, and thus, materially harm the Company&#8217;s business.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Unaudited Interim Financial Data</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">2017</font><font style="font-family:Arial;font-size:9.5pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Consolidation</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s consolidated financial statements relate to estimating the fair value of the Company&#8217;s stock options and certain accruals, including those related to nonclinical and clinical activities. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Segment Information</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as </font><font style="font-family:Arial;font-size:9.5pt;">one</font><font style="font-family:Arial;font-size:9.5pt;">&#32;operating segment.</font></div><div><a name="sE29447FDEC33564C8EE5073BD73783BE"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cash, and Cash Equivalents, and Restricted Cash</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Restricted cash represents cash held in a segregated bank account related to a commercial letter of credit to facilitate payment to a foreign supplier.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Investments Available-for-Sale</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in accumulated other comprehensive loss. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. The amortization of premiums and accretion of discounts is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income. Securities with maturity dates of 12 months or less from the date of purchase are classified as short-term investments and securities with maturity dates of more than 12 months are classified as long-term investments.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company&#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. Periodically, the Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Patent Costs</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications), and such costs are included in general and administrative expenses in the accompanying statements of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">7</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Income Taxes</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company follows the FASB's ASC 740, Income Taxes, in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the "Tax Act"), which among other provisions, reduced the U.S. corporate tax rate from 35% to 21%, effective January 1, 2018.&#160; Due to the timing of the enactment and the complexity involved in applying the provisions of the Tax Act, the Company made reasonable estimates of the effects and recorded provisional amounts in our financial statements as of December 31, 2017.  As the Company collects and prepares necessary data, and continues to interpret the Tax Act and any additional guidance issued by the U.S. Treasury Department, the Internal Revenue Service (IRS) and other standard-setting bodies, the Company may make adjustments to the provisional amounts. Those adjustments may affect deferred tax balances.  However, due to the valuation allowance position, the Company expects there will be no net impact to the financial statements. The Company did not make any such adjustments during the quarter ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">. Any adjustments to account for the tax effects of the Tax Act would be made in a subsequent quarter.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company recognizes revenues when customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under Accounting Standards Update ("ASU") No. 2014-09 ("ASU 2014-09"): (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Grant Funding</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company has received research and development funding through a grant from CARB-X, a public-private partnership focused on antibacterials. The Company has evaluated the terms of the grant to assess its obligations and the classification of funding received. Amounts billable for funded research and development are recognized in the statement of operations as a reduction to research and development expense over the grant period as the related costs are incurred to meet the Company's obligations.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Research and Development Costs</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Comprehensive Loss</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. The Company&#8217;s only component of other comprehensive loss is unrealized losses on marketable securities. Comprehensive losses have been reflected in the condensed consolidated statements of operations and comprehensive loss for all periods presented.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">8</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Stock-based Compensation</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company accounts for stock-based compensation expense related to employee stock options and employee stock purchase plan rights by estimating the fair value on the date of grant using the Black-Scholes option pricing model.&#160;The fair value of Restricted Stock Units (RSUs) and Performance-based RSUs (PRSUs) granted to employees is estimated based on the closing price of the Company's common stock on the date of grant. &#160;For awards subject to time-based vesting conditions, stock-based compensation expense is recognized ratably over the requisite service period of the awards. For awards subject to performance-based vesting conditions, the Company assesses the probability of achievement of the individual milestones under the stock-based awards and recognizes stock-based compensation expense over the implicit service period commencing once the Company believes the performance criteria is probable of achievement.  The Company accounts for stock options, RSUs, and PRSUs granted to non-employees using the fair value approach. These stock-based awards are subject to periodic revaluation over their vesting terms. </font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested restricted common stock subject to repurchase, warrants, and RSUs and options outstanding under the Company&#8217;s stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock options and RSUs issued and outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,352,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,130,426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">17,331</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">17,331</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock subject to repurchase</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">5,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">21,197</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,375,312</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,168,954</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company follows ASC 820-10 issued by the FASB with respect to fair value reporting for financial assets and liabilities.  The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, and long-term debt. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, prepaid expenses, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. The fair value of short-term investments is based upon market prices quoted on the last day of the fiscal period or other observable market inputs. The Company believes that the fair value of long-term debt approximates its carrying value.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recently Issued Accounting Standards</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Recently Issued Accounting Standards Not Yet Adopted</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">During 2016, the FASB issued ASU 2016-02, &#8220;Leases,&#8221; which requires that operating lease arrangements longer than 12 months result in an entity recognizing an asset and liability. The updated guidance is effective for interim and annual periods beginning after December 15, 2018, and early adoption is permitted. The Company currently expects that its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and operating </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">9</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">lease liabilities upon the adoption of ASU&#160;2016-02, which will increase the total assets and total liabilities that it reports relative to such amounts prior to adoption.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Recently Adopted Accounting Standards</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">During 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)," which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 outlines a five-step process for revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards, and also requires enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenues and cash flows from contracts with customers.  Numerous ASUs were issued in 2016 and 2017 to require additional disclosures, to provide clarification on a number of specific issues pertaining to ASU 2014-09, and to defer the effective date for ASU 2014-09 to interim and annual periods beginning after December 31, 2017.  The Company adopted ASC 606 effective January 1, 2018.  The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.</font></div><div><a name="s001D8A6780DD5D0DB2B2D0ACDC7D0442"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">3. SHORT-TERM INVESTMENTS</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:9.5pt;">The following table summarizes the available-for-sale securities held at </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:9.5pt;">&#32;(in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">As of March 31, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Corporate debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,991</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">As of December 31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Corporate debt</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">14,509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">14,501</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">14,509</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">14,501</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">All available-for-sale securities held at </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:9.5pt;">&#32;had maturities of less than </font><font style="font-family:Arial;font-size:9.5pt;">one year</font><font style="font-family:Arial;font-size:9.5pt;">.  Unrealized gains and losses on available-for-sale securities are included as a component of other comprehensive loss. The securities in unrealized loss positions have not been in a continuous unrealized loss position for 12 months or longer.  The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.  The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. During the three months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">2017</font><font style="font-family:Arial;font-size:9.5pt;">, respectively, the Company did not recognize any impairment or gains or losses on sales of available-for-sale securities.</font></div><div><a name="sE3CAAF92A2BF53DD8E2BB0ADDA04141A"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">4. FAIR VALUE MEASUREMENTS</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company follows ASC 820-10, Fair Value Measurements and Disclosures, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on the borrowing rates available to the Company for loans with similar terms, which is considered a Level 2 input as described below, the Company believes that the fair value of long-term debt approximates its carrying value.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company classifies investments in money market funds within Level 1 as the prices are available from quoted prices in active markets.  Investments in commercial paper, corporate debt and reverse repurchase agreements are classified </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">10</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">within Level 2 as these instruments are valued using observable market inputs including reported trades, broker/dealer quotes, bids and/or offers.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">None</font><font style="font-family:Arial;font-size:9.5pt;">&#32;of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The following tables summarize the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">TOTAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">LEVEL 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">LEVEL 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">LEVEL 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">U.S. Treasury reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">46,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">46,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Corporate debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total assets at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">66,011</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">59,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">U.S. Treasury reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">48,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">48,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Corporate debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">15,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">15,101</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total assets at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">74,657</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11,556</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">63,101</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sEE2B577A5BF65CD390DFACEE678BFCDB"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">5. DEBT</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-style:italic;font-weight:bold;">Term Loans</font><font style="font-family:Arial;font-size:9.5pt;">&#8212; On October 3, 2016, the Company entered into a loan and security agreement, (the "Loan Agreement"), with Pacific Western Bank, as the collateral agent and a lender (the "Lender"), pursuant to which the Lender agreed to lend to the Company up to&#160;</font><font style="font-family:Arial;font-size:9.5pt;">$20.0 million</font><font style="font-family:Arial;font-size:9.5pt;">&#160;in a series of term loans. Contemporaneously, the Company borrowed&#160;</font><font style="font-family:Arial;font-size:9.5pt;">$10.0 million</font><font style="font-family:Arial;font-size:9.5pt;">&#160;from the Lender (the "Term A Loan").</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Under the terms of the Loan Agreement, because the Company achieved of positive Phase 2 clinical results from the STRIVE Phase 2 clinical trial of rezafungin by March 31, 2018 (the "Milestone"), the Company may, at its sole discretion through&#160;October&#160;3, 2018, borrow from the Lender up to an additional&#160;</font><font style="font-family:Arial;font-size:9.5pt;">$10.0 million</font><font style="font-family:Arial;font-size:9.5pt;">&#160;(the "Term B Loan," and together with the Term A Loan, the "Term Loans").  Upon the occurrence of certain events, including but not limited to the Company&#8217;s failure to satisfy its payment obligations under the Loan Agreement, the breach of certain of its other covenants under the Loan Agreement, including any future milestone put into place to replace the Milestone, or the occurrence of a material adverse change, the collateral agent will have the right, among other remedies, to declare all principal and interest and other amounts due to the Lender under the Loan Agreement immediately due and payable.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company&#8217;s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of the Company&#8217;s current and future assets, other than its intellectual property, which is subject to a double negative pledge.&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Term Loans mature on October&#160;3, 2020 (the "Maturity Date").&#160; Payments under the Term Loans will be interest-only through October 2, 2018, which includes an extension of&#160;</font><font style="font-family:Arial;font-size:9.5pt;">six months</font><font style="font-family:Arial;font-size:9.5pt;">&#160;which was triggered when the Milestone was achieved. The interest-only period will be followed by&#160;</font><font style="font-family:Arial;font-size:9.5pt;">24</font><font style="font-family:Arial;font-size:9.5pt;">&#160;monthly payments of principal and interest. The Term Loans will bear interest at a variable annual rate equal to the greater of (i)&#160;</font><font style="font-family:Arial;font-size:9.5pt;">4.5%</font><font style="font-family:Arial;font-size:9.5pt;">&#160;or (ii)&#160;the Lender&#8217;s prime interest rate plus&#160;</font><font style="font-family:Arial;font-size:9.5pt;">1.0%</font><font style="font-family:Arial;font-size:9.5pt;">. At </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, the Term Loans bear interest at </font><font style="font-family:Arial;font-size:9.5pt;">5.75</font><font style="font-family:Arial;font-size:9.5pt;">%.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">As of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, future principal payments due under the Term A Loan are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Year ended:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">December 31, 2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">December 31, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total future principal payments due under the Term A Loan</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">10,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s72C169BFEDFE5010A1FF71C0BC198B9B"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">6. STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Preferred Stock</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Under the amended and restated certificate of incorporation, the Company&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to&#160;</font><font style="font-family:Arial;font-size:9.5pt;">10,000,000</font><font style="font-family:Arial;font-size:9.5pt;">&#160;shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had&#160;</font><font style="font-family:Arial;font-size:9.5pt;">10,000,000</font><font style="font-family:Arial;font-size:9.5pt;">&#160;shares of preferred stock authorized and&#160;</font><font style="font-family:Arial;font-size:9.5pt;">no</font><font style="font-family:Arial;font-size:9.5pt;">&#32;shares of preferred stock issued or outstanding at&#160;</font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">. </font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Common Stock</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company had&#160;</font><font style="font-family:Arial;font-size:9.5pt;">200,000,000</font><font style="font-family:Arial;font-size:9.5pt;">&#160;shares of common stock authorized as of&#160;</font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">. Holders of outstanding shares of common stock are entitled to&#160;</font><font style="font-family:Arial;font-size:9.5pt;">one</font><font style="font-family:Arial;font-size:9.5pt;">&#160;vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company&#8217;s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company&#8217;s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in the net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. The common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are&#160;</font><font style="font-family:Arial;font-size:9.5pt;">no</font><font style="font-family:Arial;font-size:9.5pt;">&#32;dividends in arrears or default. All shares of common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In November 2017, the Company began to sell shares of common stock under a controlled equity sales agreement with Cantor Fitzgerald &amp; Co.  During the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, the Company sold </font><font style="font-family:Arial;font-size:9.5pt;">847,937</font><font style="font-family:Arial;font-size:9.5pt;">&#32;shares of common stock for net proceeds of approximately </font><font style="font-family:Arial;font-size:9.5pt;">$6.4 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;after deducting placement agent fees. </font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Common Stock Reserved for Future Issuance</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock reserved for future issuance is as follows (in common stock equivalent shares):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:71%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">17,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">17,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Stock options and RSUs issued and outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,352,640</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,099,173</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Authorized for future stock awards under the Company's option plans</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">789,288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,006,307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Authorized for future issuance under the ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">586,148</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">380,875</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">5,745,407</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,503,686</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sC5C0E703DB7558CBA3214C18590A6D4D"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">7. STOCK INCENTIVE PLANS</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2015 Equity Incentive Plan</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Equity Incentive Plan (&#8220;2015 EIP&#8221;).&#160;&#160;Under the 2015 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors, or consultants of the Company.&#160;&#160;The number of shares of stock available for issuance under the 2015 EIP will be automatically increased each January 1 </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">12</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">by&#160;</font><font style="font-family:Arial;font-size:9.5pt;">4%</font><font style="font-family:Arial;font-size:9.5pt;">&#160;of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31 or such lesser number as determined by the Company&#8217;s board of directors.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2015 EIP. Stock options granted by the Company generally vest over a&#160;</font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">- or </font><font style="font-family:Arial;font-size:9.5pt;">four</font><font style="font-family:Arial;font-size:9.5pt;">-year period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to </font><font style="font-family:Arial;font-size:9.5pt;">10</font><font style="font-family:Arial;font-size:9.5pt;">&#32;years&#160;from the date of grant. The exercise price for stock options granted under the 2015 EIP must be at a price no less than&#160;</font><font style="font-family:Arial;font-size:9.5pt;">100%</font><font style="font-family:Arial;font-size:9.5pt;">&#160;of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than&#160;</font><font style="font-family:Arial;font-size:9.5pt;">10%</font><font style="font-family:Arial;font-size:9.5pt;">&#160;of the voting power of all classes of stock of the Company, the exercise price shall be no less than&#160;</font><font style="font-family:Arial;font-size:9.5pt;">110%</font><font style="font-family:Arial;font-size:9.5pt;">&#160;of the estimated value on the date of grant.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2015 Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Employee Stock Purchase Plan ("ESPP").&#160;The number of shares of stock available for issuance under the ESPP will be automatically increased each January 1 by the lesser of (i)&#160;</font><font style="font-family:Arial;font-size:9.5pt;">1%</font><font style="font-family:Arial;font-size:9.5pt;">&#160;of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31, (ii)&#160;</font><font style="font-family:Arial;font-size:9.5pt;">490,336</font><font style="font-family:Arial;font-size:9.5pt;">&#160;shares, or (iii) such lesser number as determined by the Company&#8217;s board of directors.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The ESPP allows substantially all employees to purchase the Company&#8217;s common stock through a payroll deduction at a price equal to </font><font style="font-family:Arial;font-size:9.5pt;">85%</font><font style="font-family:Arial;font-size:9.5pt;">&#32;of the lower of the fair market value of the stock as of the beginning or the end of each purchase period.&#160;An employee&#8217;s payroll deductions under the ESPP are limited to </font><font style="font-family:Arial;font-size:9.5pt;">15%</font><font style="font-family:Arial;font-size:9.5pt;">&#32;of the employee&#8217;s eligible compensation.  During the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended&#160;</font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">,&#160;</font><font style="font-family:Arial;font-size:9.5pt;">no</font><font style="font-family:Arial;font-size:9.5pt;">&#160;shares were issued pursuant to the ESPP.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Restricted Stock</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company permits exercise of certain stock options prior to vesting.&#160;&#160;Any such exercised shares are restricted and subject to repurchase by the Company until the conditions for vesting are met.&#160;&#160;At </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:9.5pt;">, the liabilities for the cash received from the early exercise of stock options were </font><font style="font-family:Arial;font-size:9.5pt;">$12,000</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">$21,000</font><font style="font-family:Arial;font-size:9.5pt;">, respectively, and were classified in accrued liabilities on the balance sheet. The Company reduces the liability as the underlying shares vest in accordance with the vesting terms outlined in the stock option agreements, which are generally </font><font style="font-family:Arial;font-size:9.5pt;">4 years</font><font style="font-family:Arial;font-size:9.5pt;">.  At </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, </font><font style="font-family:Arial;font-size:9.5pt;">5,341</font><font style="font-family:Arial;font-size:9.5pt;">&#32;unvested shares were subject to repurchase by the Company.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Restricted Stock Units</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The following table summarizes RSU and PRSU activity during the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:81%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Number of<br>RSUs and PRSUs</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">227,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">RSUs and PRSUs granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">30,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">RSUs and PRSUs vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">RSUs and PRSUs canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Outstanding at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">257,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">For the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, stock-based compensation expense related to RSUs and PRSUs was approximately </font><font style="font-family:Arial;font-size:9.5pt;">$67,000</font><font style="font-family:Arial;font-size:9.5pt;">.  At </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, estimated unrecognized compensation expense related to RSUs and PRSUs granted to employees was approximately </font><font style="font-family:Arial;font-size:9.5pt;">$1.4 million</font><font style="font-family:Arial;font-size:9.5pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Stock Options</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The following table summarizes stock option activity during the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Contractual Life</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">in Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Total Aggregate</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Intrinsic Value (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,099,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">7.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">8.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,009,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4.29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(12,147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Options canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(1,136</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Outstanding at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,095,140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">8.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">837</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Vested and expected to vest at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,095,140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6.90</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">8.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">837</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Exercisable at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,937,526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">7.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">7.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">746</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Stock-based compensation expense recognized for restricted shares, RSUs, PRSUs, stock options, and the ESPP has been reported in the statements of operations as follows (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Three Months Ended<br>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">821</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">619</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,461</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,051</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The weighted-average grant date fair value of employee stock options granted by the Company during the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;was </font><font style="font-family:Arial;font-size:9.5pt;">$3.02</font><font style="font-family:Arial;font-size:9.5pt;">&#32;per share. The total grant date fair value of employee stock options that vested during the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;was </font><font style="font-family:Arial;font-size:9.5pt;">$1.2 million</font><font style="font-family:Arial;font-size:9.5pt;">. As of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, total unrecognized share-based compensation expense related to unvested employee stock options of the Company was approximately </font><font style="font-family:Arial;font-size:9.5pt;">$8.4 million</font><font style="font-family:Arial;font-size:9.5pt;">. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately </font><font style="font-family:Arial;font-size:9.5pt;">2.3</font><font style="font-family:Arial;font-size:9.5pt;">&#32;years.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">As of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, total unrecognized compensation expense related to the ESPP was approximately </font><font style="font-family:Arial;font-size:9.5pt;">$0.4 million</font><font style="font-family:Arial;font-size:9.5pt;">. This unrecognized compensation cost is expected to be recognized over approximately </font><font style="font-family:Arial;font-size:9.5pt;">0.9 years</font><font style="font-family:Arial;font-size:9.5pt;">.</font></div><div><a name="s77B9C6FD2B035F77810F658A6F991F5F"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">8. SIGNIFICANT AGREEMENTS AND CONTRACTS</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Combating Antibiotic Resistant Bacteria Accelerator (CARB-X) Subaward Agreement</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">On March 30, 2017, the Company entered into a Cost Reimbursement Research Subaward Agreement (the "Subaward Agreement") with the Trustees of Boston University. Under the Subaward Agreement, the Company is a subawardee under the CARB-X program. CARB-X is a public-private partnership focused on antibacterials, created by the U.S. Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), and National Institute of Allergy and Infectious Diseases (NIAID). CARB-X is funded by BARDA and the London-based Wellcome Trust, a global charitable foundation (Wellcome), and administered by the Boston University School of Law.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The subaward was intended to support development of the Company's CD201 product candidate.  Under the Subaward Agreement, during an initial phase that began on April 1, 2017 and ends upon acceptance by the U.S. Food and Drug Administration of an initial new drug application, CARB-X would reimburse up to </font><font style="font-family:Arial;font-size:9.5pt;">$3.9 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;of qualifying development expenses. If all of the milestones in such initial phase are met, the CARB-X Joint Oversight Committee will evaluate the progress made in such initial phase and determine whether to exercise its option to fund a second stage. During the second stage, CARB-X would reimburse up to </font><font style="font-family:Arial;font-size:9.5pt;">$3.0 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;of qualifying development expenses through a Phase 1 clinical trial. Such second stage would be subject to a new subaward agreement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">14</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Under the Subaward Agreement, the Company is reimbursed for direct costs incurred plus allowable indirect costs which consist of fringe benefits and allowable general and administrative expenses.  For the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;month period ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, the Company recognized reductions to research and development expenses of approximately </font><font style="font-family:Arial;font-size:9.5pt;">$3,000</font><font style="font-family:Arial;font-size:9.5pt;">&#32;for costs eligible for reimbursement under the Subaward Agreement.  As of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, billed accounts receivable were </font><font style="font-family:Arial;font-size:9.5pt;">$0.1 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and unbilled accounts receivable were </font><font style="font-family:Arial;font-size:9.5pt;">$0.2 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;related to reimbursable expenses under the Subaward Agreement.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Subaward Agreement can be terminated upon the delivery of </font><font style="font-family:Arial;font-size:9.5pt;">30</font><font style="font-family:Arial;font-size:9.5pt;">&#32;days written notice to the Company for default or convenience. Upon receipt of a notice of termination, the Company must discontinue contract activities and CARB-X must pay the Company a final settlement based on eligible expenses incurred under the Subaward Agreement.&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Based on preclinical studies of CD201 as well as preclinical studies of antibody-drug conjugates (ADCs) from the Cloudbreak program, the Company decided in February 2018 to cease development of CD201 to focus on the more promising ADCs for the same indication. Based on the decision to focus efforts on the ADCs, the Company will no longer be seeking funding under the Subaward Agreement relating to CD201.</font></div><div><a name="s7D301050478B5C19B932ED41858FAFFA"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">9. COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Litigation</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are </font><font style="font-family:Arial;font-size:9.5pt;">no</font><font style="font-family:Arial;font-size:9.5pt;">&#32;claims or actions pending against the Company as of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;which will have, individually or in the aggregate, a material adverse effect on its business, liquidity, financial position, or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in such matters may arise from time to time that may harm the Company&#8217;s business.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Lease Obligations</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In June 2014, the Company entered into an operating lease agreement for laboratory and office space in San Diego, California. Amendments for additional space were entered into in February 2015, March 2015, and August 2015.&#160;&#160;The lease expires in December 2018 with options for </font><font style="font-family:Arial;font-size:9.5pt;">two</font><font style="font-family:Arial;font-size:9.5pt;">&#32;individual </font><font style="font-family:Arial;font-size:9.5pt;">two</font><font style="font-family:Arial;font-size:9.5pt;">-year extensions. The lease is subject to charges for common area maintenance and other costs, and base rent is subject to </font><font style="font-family:Arial;font-size:9.5pt;">3%</font><font style="font-family:Arial;font-size:9.5pt;">&#32;annual increases every July. Rent expense is being recorded on a straight-line basis over the life of the lease.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Future minimum payments required under the lease as of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;are summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">562</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">562</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Rent expense was </font><font style="font-family:Arial;font-size:9.5pt;">$174,000</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">$179,000</font><font style="font-family:Arial;font-size:9.5pt;">&#32;for the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">2017</font><font style="font-family:Arial;font-size:9.5pt;">, respectively.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Contractual Obligations</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company enters into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or within </font><font style="font-family:Arial;font-size:9.5pt;">30</font><font style="font-family:Arial;font-size:9.5pt;">&#32;days of notice.</font></div><div><a name="s217DB168D5F95568B5A00EBC50569AD8"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">10. SUBSEQUENT EVENTS</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In May 2018, the Company announced that it and Rutgers University had been awarded a </font><font style="font-family:Arial;font-size:9.5pt;">$5.5 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;partnership grant from the U.S. National Institute of Allergy and Infectious Diseases ("NIAID") of the National Institutes of Health ("NIH"), an agency of the United States Department of Health and Human Services.  The grant will fund the continued research and development of the Company's Cloudbreak antibody-drug conjugate ("ADC") platform.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">15</font></div></div><hr style="page-break-after:always"><div><a name="s1200F48317DB5FB98985738F6EBA66B5"></a></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">You should read the following discussion and analysis together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report, and our Annual Report on Form 10-K, or our Annual Report, for the year ended </font><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">, filed with the Securities and Exchange Commission, or the SEC, on February 27, 2018.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-style:italic;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the &#8220;safe harbor&#8221; created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, clinical and nonclinical data, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A, &#8220;Risk Factors&#8221; in this Quarterly Report and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made and we do not assume any obligation to update any forward-looking statements.</font></div><div><a name="sB64D70705E0F5BE2AE226F518D5B7EC9"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Overview</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We are a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. We are developing a balanced pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Our lead product candidate is rezafungin acetate, an intravenous formulation of a novel echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious, invasive fungal infections. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In addition, we are developing our antibody-drug conjugates, or ADCs, for multidrug-resistant bacterial infections as part of our proprietary Cloudbreak&#8482; platform, which is designed to discover compounds that directly kill pathogens and also direct a patient&#8217;s immune system to attack and eliminate bacterial, fungal or viral pathogens.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Rezafungin</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Rezafungin is a novel molecule in the echinocandin class of antifungals. We are developing rezafungin for the treatment and prevention of serious, invasive fungal infections, including candidemia and invasive candidiasis, associated with high mortality rates.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">STRIVE clinical trial</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In March 2018, we reported topline results from Part A of our global, randomized Phase 2 clinical trial of rezafungin, called the STRIVE trial.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">STRIVE is an international, multicenter, double-blind clinical trial evaluating the safety, tolerability and efficacy of once-weekly dosing of rezafungin compared to once-daily dosing of caspofungin in patients with candidemia and/or invasive candidiasis. In Part A, patients were randomized to one of two rezafungin arms or to the caspofungin arm. In the two rezafungin arms of the trial, patients received either 400 mg of rezafungin administered intravenously once weekly for two to four weeks (Group 1) or 400 mg for the first week followed by 200 mg once weekly for up to four weeks in total (Group 2). In the comparator arm (Group 3), patients received daily caspofungin administered intravenously according to the approved prescribing information, with an optional step down to oral fluconazole. The STRIVE trial results we reported include efficacy data from 92 treated patients (the mycological intent-to-treat, or mITT, population) and safety and tolerability results from 104 patients, from 31 trial sites in North America and Europe. The trial was not statistically powered to demonstrate superiority or non-inferiority and therefore comparisons of efficacy are directional.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">STRIVE Part A met its primary objectives related to tolerability and safety of rezafungin in the treatment of candidemia/invasive candidiasis. Topline efficacy data are summarized in Table 1. Overall success is defined as eradication of&#160;Candida&#160;from the blood or infected organ, plus clinical cure, which is defined as resolution of clinical signs of infection </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">16</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">which were present at baseline. Additionally, clinical response is assessed by the principal investigator based on the clinical and microbiological resolution of disease.</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:30%;"></td><td style="width:23%;"></td><td style="width:23%;"></td><td style="width:24%;"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">Table 1: Overall Response and Principal Investigator (PI) Assessment of Clinical Response at Day 14 and All-Cause Mortality in the mITT Population</font></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">Group 1: <br>Rezafungin once weekly 400 mg<br>N= 33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">Group 2: <br>Rezafungin once weekly 400mg Week 1/200mg <br>N= 31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">Group 3: <br>Caspofungin once daily <br>70 mg Day 1/50 mg <br>N= 28</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">n (%)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">Overall Success (Day 14)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">19 (57.6)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">22 (71.0)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">18 (64.3)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">&#160;&#160;&#160;&#160;&#160;Failure</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">7 (21.2)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6 (19.4)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">8 (28.6)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">&#160;&#160;&#160;&#160;&#160;Indeterminate</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">7 (21.2)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3 (9.7)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2 (7.1)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">Overall Success (Day 14) (excluding Indeterminates</font><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;"><sup style="vertical-align:top;line-height:120%;font-size:pt">a</sup></font><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">19/26 (73.1)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">22/28 (78.6)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">18/26 (69.2)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">&#160;&#160;&#160;&#160;&#160;Failure</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">7/26 (26.9)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">6/28 (21.4)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">8/26 (30.8)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">Clinical Cure (Day 14) by PI Assessment</font><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;"><sup style="vertical-align:top;line-height:120%;font-size:pt">b</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">25 (75.8)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">24 (77.4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">20 (71.4)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">&#160;&#160;&#160;&#160;&#160;Failure</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">7 (21.2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">4 (12.9)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">8 (28.6)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">&#160;&#160;&#160;&#160;&#160;Indeterminate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">1 (3.0)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">3 (9.7)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">0</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">Mortality (Day 30)</font><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;"><sup style="vertical-align:top;line-height:120%;font-size:pt">c</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">5 (15.2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1 (3.2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3 (10.7)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">Mortality (Overall)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">5 (15.2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3 (9.7)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">5 (17.9)</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font><font style="font-family:Arial;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">a</sup></font><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">Indeterminate response indicates inability to assess outcome due to missing data point(s), most of which related to missed visits or difficulties in obtaining the multiple repeat blood draws for the culture required for full assessment.<br></font><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;"><sup style="vertical-align:top;line-height:120%;font-size:pt">b</sup></font><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">Outcome that most closely approximates the primary outcome in prior candidemia/invasive candidiasis clinical trials.<br></font><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;"><sup style="vertical-align:top;line-height:120%;font-size:pt">c</sup></font><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">Primary outcome measure for planned Phase 3 ReSTORE trial to assess rezafungin in treatment of candidemia and/or invasive candidiasis.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We further evaluated the 12 indeterminate outcomes in the Overall Success primary endpoint (Table 2), as well as the reasons for these indeterminate outcomes (Table 3).  We assessed whether the principal investigator designated these outcomes as cure or failure, irrespective of any missing data points.</font></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">When the investigator-assessed outcomes are considered as surrogates for the programmatic indeterminate responses for the Overall Response outcome at Day 14, Overall Success rates are as follows:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.22807017543859%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:26%;"></td><td style="width:24%;"></td><td style="width:24%;"></td><td style="width:26%;"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">Table 2: Overall Response Adjusted for Investigators' Assessment of Programmatic Indeterminate Outcomes</font></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">Group 1: </font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">Rezafungin once weekly 400 mg</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">N= 33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">Group 2: </font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">Rezafungin once weekly 400mg Wk1/200mg </font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">N= 31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">Group 3: </font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">Caspofungin once daily </font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">70 mg D1/50 mg </font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">N= 28</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;font-weight:bold;">n (%)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">Overall Success (Day 14)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">24 (72.7)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">23 (74.2)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">20 (71.4)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#1a1918;">Failures</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">9 (27.3)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">8 (25.8)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">8 (28.6)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">17</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">A summary of the 12 patients with indeterminate outcomes on the primary endpoint of Overall Success is as follows:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:23%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td colspan="12" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Table 3: Assessment of Programmatic Indeterminate Overall Response</font></div></td></tr><tr><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Reason for Indeterminate Response:</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;color:#1a1918;">Group 1: </font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;color:#1a1918;">Rezafungin once weekly</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;color:#1a1918;">400 mg</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">N= 7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;color:#1a1918;">Group 2: </font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;color:#1a1918;">Rezafungin once weekly </font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;color:#1a1918;">400mg Wk1/200mg </font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">N= 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;color:#1a1918;">Group 3: </font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;color:#1a1918;">Caspofungin once daily </font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;color:#1a1918;">70 mg D1/50 mg </font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">N= 2</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Investigator Assessment of Clinical Response</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Cure</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Indeterminate (I) / Failure (F)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Cure</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Indeterminate (I) / Failure (F)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Cure</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Indeterminate (I) / Failure (F)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Systemic Signs assessment not completed</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1 (F)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Inadequate number of cultures</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Lost to Follow-up prior to Day 14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1 (I)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Withdrew consent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1 (I)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Missed systemic signs at baseline</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Non-compliance with study</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1 (I)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Rezafungin was generally well-tolerated at both dosing regimens. Treatment emergent adverse events were observed in most patients, with an incidence of 88.6 percent in Group 1, 94.4 percent in Group 2, and 81.8 percent in Group 3. </font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The rates of severe adverse events were 37.1 percent, 27.8 percent, and 39.4 percent, respectively. There were six adverse events leading to study drug discontinuation across all study groups: four in Group 1, one in Group 2 and one in Group 3. Two of the six adverse events were considered possibly related to study drug, one in Group 1 and one in Group 3.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">There were two serious adverse events possibly related to study drug: one in Group 2 and one in Group 3, and both patients fully recovered.  There were no deaths related to study drug, and there were no concerning trends in System Organ Class groups or specific adverse events.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Clinical development plans</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Based on the STRIVE Part A trial results, we plan to initiate two Phase 3 clinical trials of rezafungin, subject to having sufficient financial resources:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Phase 3 ReSTORE Treatment Trial: A single, global, randomized, double-blind, controlled Phase 3 pivotal clinical trial in patients with candidemia and/or invasive candidiasis. The design will be similar to the STRIVE study.  The primary outcome measure for the U.S. is expected to be all-cause mortality at day 30.  We expect this study to enroll approximately 150-180 mITT patients, depending on the primary outcome measure required by the E.U. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Phase 3 ReSPECT Prophylaxis (Prevention) Trial: Subject to approval of U.S. and E.U. regulatory authorities, a single, global, randomized, double-blind, controlled Phase 3 pivotal clinical trial in patients undergoing allogeneic bone marrow transplant to assess rezafungin in a 90-day prophylaxis regimen to prevent infections due to </font><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">Candida</font><font style="font-family:Arial;font-size:9.5pt;">, </font><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">Aspergillus</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">Pneumocystis</font><font style="font-family:Arial;font-size:9.5pt;">. Rezafungin will be dosed once weekly and compared to a regimen containing two drugs (an azole and Bactrim) dosed once daily, for 90 days, at which time fungal-free survival (the primary outcome measure) will be measured. The trial will include adults with underlying conditions including acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndrome(s), lymphoma and aplastic anemia. </font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">With the expected size of the Phase 3 treatment study, we estimate that the total number of patients exposed to our selected dose and duration of rezafungin treatment will be less than the target safety database of 300 patients. For this reason, as well as to maintain enrollment momentum before the start of the Phase 3 study, we are continuing enrollment at STRIVE study sites. This continuation of the STRIVE study, which we call STRIVE Part B, will evaluate the dose selected from the initial portion of the STRIVE study in comparison to caspofungin in a 2:1 randomization regime. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">18</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">QT clinical trial</font></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In March 2018 we also announced the results of our definitive Phase 1 QT clinical trial of rezafungin conducted in accordance with FDA guidance.  The QT clinical trial was a Phase 1, single-center, randomized, comparative study of the effect of single-ascending doses of rezafungin, IV placebo, and a single oral dose of moxifloxacin (positive control) in healthy adult subjects. The primary objective was to assess the effects of rezafungin on QT interval. Secondary objectives included assessments of other cardiac conduction parameters, including PR intervals, QRS intervals and heart rate.</font></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The trial enrolled 60 healthy adult subjects into two cohorts of 30 subjects, each with three dose groups, rezafungin (600 mg IV in Cohort 1 and 1400 mg IV in Cohort 2), IV placebo and oral moxifloxacin.  The rezafungin doses of 600 mg and 1400 mg were selected to achieve peak concentrations up to 2.5-fold higher than the expected peak concentration of the 400 mg dose given once-weekly for three weeks. The trial was conducted in accordance with FDA feedback and relevant guidance.</font></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The results of the trial indicated that rezafungin in single doses up to 1400 mg IV had no significant effect on QT prolongation or on any of the other cardiac conduction parameters tested.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cloudbreak Immunotherapy Platform</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We continue to advance our Cloudbreak immunotherapy platform, which we believe has broad potential applications across a wide spectrum of infectious diseases, including bacterial, fungal and viral infections.&#160;&#160;</font><font style="font-family:Arial;font-size:9pt;">We believe that our Cloudbreak immunotherapy platform is a fundamentally new approach for th</font><font style="font-family:Arial;font-size:9.5pt;">e treatment of infectious disease. To date, we have generated preclinical, </font><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">in vivo</font><font style="font-family:Arial;font-size:9.5pt;">&#32;proof of concept data in both our Cloudbreak antibacterial program and our Cloudbreak antifungal program. </font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We had selected a lead Cloudbreak development candidate, CD201, a bispecific antimicrobial immunotherapy for the treatment of multidrug-resistant Gram-negative bacterial infections.  Based on preclinical studies of CD201 as well as preclinical studies of ADCs from our Cloudbreak program, we decided in February 2018 to cease development of CD201 to focus on the more promising ADCs for the same indication.  We had received a grant from the Combating Antibiotic Resistance Accelerator, or CARB-X, to help advance the development of CD201.&#160; Based on our decision to focus efforts on our ADCs, we will no longer be seeking funding under our CARB-X grant agreement relating to CD201.</font></div><div><a name="sEB8CA74C0849501D9B1D5489BAAB09C0"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">FINANCIAL OPERATIONS OVERVIEW</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenues</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">To date, we have not generated any revenues.  In the future, we may generate revenue from a combination of license fees and other upfront payments, other funded research and development agreements, milestone payments, product sales, government and other third-party funding and royalties in connection with strategic alliances. We expect that any revenue we generate will fluctuate from quarter-to-quarter as a result of the timing of qualifying reimbursable expenses.  In addition, future revenues could fluctuate based on the timing of our achievement of nonclinical, clinical, regulatory and commercialization milestones, the timing and amount of payments relating to such milestones and the extent to which any of our products are approved and successfully commercialized. If we are unable to fund our development costs or we are unable to develop product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenues and our results of operations and financial position would be adversely affected.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Research and development expenses</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">To date, our research and development expenses have related primarily to nonclinical development of our rezafungin and CD201 product candidates and our Cloudbreak immunotherapy technology platform, as well as clinical development of rezafungin and CD101 topical. Research and development expenses consist of wages, benefits and stock-based compensation for research and development employees, as well as the cost of scientific consultants, facilities and overhead expenses, laboratory supplies, manufacturing expenses and nonclinical and clinical trial costs.&#160;&#160;We accrue clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies or activities within studies and other events.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Research and development costs are expensed as incurred and costs incurred by third parties are expensed as the contracted work is performed. We accrue for costs incurred as the services are being provided by monitoring the status of the study or project and the invoices received from our external service providers. We adjust our accruals as actual costs become known.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">19</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We have received research and development funding through a grant from CARB-X.  We have evaluated the terms of the grant to assess our obligations and the classification of funding received. Amounts received for funded research and development are recognized in the statement of operations as a reduction to research and development expense over the grant period as the related costs are incurred to meet our obligations.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase over the next several years as we continue to conduct nonclinical and clinical studies, expand our research and development pipeline and progress our product candidates through clinical trials. However, it is difficult to determine with certainty the duration, costs and timing to complete our current or future nonclinical programs and clinical trials of our product candidates.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">per patient trial costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the number of patients that participate in the trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the number of sites included in the trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the countries in which the trials are conducted;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the length of time required to enroll eligible patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the number of doses that patients receive;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the drop-out or discontinuation rates of patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">potential additional safety monitoring or other studies requested by regulatory agencies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the duration of patient follow-up;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the phase of development of the product candidates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the efficacy and safety profile of the product candidates.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;background-color:#ffffff;">Research and development expenses by major program or category were as follows (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:73.09941520467837%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Three Months Ended<br>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Rezafungin</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">8,486</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">CD101 topical</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">840</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Cloudbreak immunotherapy platform</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Personnel costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,368</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2,805</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Other research and development expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">822</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,199</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">10,243</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We typically deploy our employees, consultants and infrastructure resources across our programs. Thus, some of our research and development expenses are not attributable to an individual program but are included in other research and development expenses as shown above.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate&#8217;s commercial potential.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In February 2017, we reported results from our Phase 2 clinical trial of CD101 topical, which was designed to evaluate gel and ointment topical formulations of CD101 in women with moderate-to-severe vulvovaginal candidiasis, or VVC. The study found that while the gel and ointment topical formulations of CD101 tested in the study were well tolerated, both formulations were similar in efficacy to each other but lower in clinical and mycological cure rates compared to oral fluconazole. As a result, we discontinued the CD101 topical development program for VVC.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">20</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">General and administrative expenses</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning, and support functions. Other general and administrative expenses include facility and overhead costs not otherwise included in research and development expenses, consultant expenses, travel expenses and professional fees for auditing, tax, legal, and other services. </font></div><div><a name="sDD088388C51958B49705ACC04FFE7CB7"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In March 2017, we entered into a Subaward Agreement with CARB-X, under which CARB-X will reimburse us for qualifying development expenses for CD201.  We reflect these costs reimbursed under this agreement as a reduction of our research and development expenses.  See Note 2 to our financial statements for additional information.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In 2017 and 2018, we granted Restricted Stock Units (RSUs) and Performance-based RSUs (PRSUs) to employees.  We estimate the fair value of RSUs and PRSUs based on the closing price of the Company's common stock on the date of grant.  For awards subject to time-based vesting conditions, stock-based compensation expense is recognized ratably over the requisite service period of the awards.  For awards subject to performance-based vesting conditions, we assess the probability of achievement of the individual milestones under the stock-based awards and recognize stock-based compensation expense over the implicit service period commencing once we believe the performance criteria is probable of achievement.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The preparation of our unaudited financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and the revenues and expenses incurred during the reported periods. We believe that the estimates, assumptions and judgments involved in the accounting policies described in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and under Note 2 to our financial statements contained in our Annual Report have the greatest potential impact on our financial statements, so we consider them to be our critical accounting policies and estimates. Other than our accounting for those items discussed above, there were no material changes to our critical accounting policies and estimates during the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">.</font></div><div><a name="s55013D881ACE527D844DB48CBD4CD9EE"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">RESULTS OF OPERATIONS</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Comparison of the three months ended </font><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2017</font><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:9.5pt;">The following table summarizes our results of operations for the three months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">2017</font><font style="font-family:Arial;font-size:9.5pt;">&#32;(in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Three Months Ended<br>March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">10,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2,956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,611</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,155</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">456</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Other income, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">Research and development expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Research and development expenses were </font><font style="font-family:Arial;font-size:9.5pt;">$13.2 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;for the three months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, compared to </font><font style="font-family:Arial;font-size:9.5pt;">$10.2 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;for the three months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2017</font><font style="font-family:Arial;font-size:9.5pt;">.&#160; The majority of the increase in research and development expense is due to higher clinical expenses associated with the rezafungin STRIVE study. Increases in rezafungin expenses were partially offset by decreases in CD101 topical expenses due to the discontinuation of that program in February 2017.</font></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">General and administrative expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">General and administrative expenses were </font><font style="font-family:Arial;font-size:9.5pt;">$3.6 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;for the three months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">$3.2 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;for the three months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2017</font><font style="font-family:Arial;font-size:9.5pt;">. The increase in general and administrative expenses was primarily related to personnel and consulting costs.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">21</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">Other Income</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Other income during the three month period ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;related to income generated from cash held in interest-bearing investments, which was partially offset by interest expense incurred in connection with our loan from Pacific Western Bank.</font></div><div><a name="s292D61E95F755BF0ABB2845071F7EF81"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">LIQUIDITY AND CAPITAL RESOURCES</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Since our inception through May 8, 2018, we have received </font><font style="font-family:Arial;font-size:9.5pt;">$217.3 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;in gross proceeds to fund our operations, primarily through private placements of convertible preferred stock, convertible notes, our initial public offering, our entry into a debt facility in October 2016 with Pacific Western Bank, our October 2016 public offering of common stock, our October 2017 private placement of common stock, and sales of common stock under our controlled equity sales agreement.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">As of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, we had </font><font style="font-family:Arial;font-size:9.5pt;">$52.2 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;in cash and cash equivalents, </font><font style="font-family:Arial;font-size:9.5pt;">$0.8 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;in restricted cash, and </font><font style="font-family:Arial;font-size:9.5pt;">$14.0 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;in short term investments. The following table shows a summary of our cash flows for the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">2017</font><font style="font-family:Arial;font-size:9.5pt;">&#32;(in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Three Months Ended<br>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Net cash provided by (used in):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(14,722</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(14,518</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6,468</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Net decrease in cash, cash equivalents, and restricted cash</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(7,803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(3,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">Operating activities</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Net cash used in operating activities was </font><font style="font-family:Arial;font-size:9.5pt;">$14.7 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;for the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, compared to </font><font style="font-family:Arial;font-size:9.5pt;">$14.5 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;for the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2017</font><font style="font-family:Arial;font-size:9.5pt;">. The increase in net cash used in operating activities was attributable primarily to our net loss of </font><font style="font-family:Arial;font-size:9.5pt;">$16.7 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;for the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;compared to a net loss of </font><font style="font-family:Arial;font-size:9.5pt;">$13.4 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;for the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2017</font><font style="font-family:Arial;font-size:9.5pt;">. For all periods presented, the primary use of cash was to fund research and development activities for our product candidates, which activities and uses of cash we expect to continue to increase for the foreseeable future.</font></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">Investing activities</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our primary investing activities during the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">2017</font><font style="font-family:Arial;font-size:9.5pt;">&#32;consisted of purchases and maturities of short-term investments. For the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">2017</font><font style="font-family:Arial;font-size:9.5pt;">, we received proceeds of </font><font style="font-family:Arial;font-size:9.5pt;">$6.3 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">$11.4 million</font><font style="font-family:Arial;font-size:9.5pt;">, respectively, from the maturity of short-term investments.  We purchased approximately </font><font style="font-family:Arial;font-size:9.5pt;">$5.8 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;of short-term investments during the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">Financing activities</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Net cash provided by financing activities during the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;primarily consisted of net proceeds from the sale of common stock.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Operating Capital Requirements</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">To continue to fund operations, we will need to raise additional capital. We may obtain additional financing in the future through the issuance of our common stock, through other equity or debt financings, through government funding or through collaborations or partnerships with other companies. We may not be able to raise additional capital on terms acceptable to us, or at all, and any failure to raise capital as and when needed could compromise our ability to execute on our business plan. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts, make reductions in spending, extend payment terms with suppliers, liquidate or grant rights to assets where possible or suspend or curtail planned programs. Any of these actions could materially harm our business, results of operations and future prospects.&#160;&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Management performed an analysis of the Company's ability to continue as a going concern.  We believe, based on our current operating plans, that our existing cash, cash equivalents and marketable securities, access to capital under our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">22</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Loan Agreement with Pacific Western Bank, and anticipated interest income will not be sufficient to fund our operating expenses and capital expenditure requirements through at least the next twelve months. </font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We have developed a plan to implement cost cutting measures to reduce our working capital requirements over the next 12 months if an adequate level of financing is not secured. The plan includes the delay of certain of our development activities, a delay in hiring and a reduction of other discretionary expenditures that are within our control. Any of the actions contemplated by the implementation of this plan, if required, could have an adverse impact on our ability to achieve certain of our planned objectives during 2018, and thus, materially harm the Company&#8217;s business.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our ability to successfully transition to profitability will be dependent upon achieving a level of product sales adequate to support our cost structure. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.</font></div><div><a name="s9BDD4BFCF4C55EBB924DCAD9EF3F91DB"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">CONTRACTUAL OBLIGATIONS AND COMMITMENTS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">There have been no material changes, outside of the ordinary course of business, in our outstanding contractual obligations from those disclosed within &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as contained in our Annual Report.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">As of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, we did not have any off-balance sheet arrangements.</font></div><div><a name="s4CA4CFC963F55B838E905D72C552C4F7"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The primary objectives of our investment activities are to ensure liquidity and to preserve principal while at the same time maximizing the income we receive from our cash and cash equivalents without significantly increasing risk. Additionally, we established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The market risk inherent in our financial instruments and in our financial position is the potential loss arising from adverse changes in interest rates.&#160;&#160;We generally hold our cash in checking and savings accounts and invest excess capital in money market funds, certificates of deposit, corporate debt and commercial paper. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. To minimize our exposure to adverse shifts in interest rates, we invest in short-term securities and ensure that the maximum average maturity of our investments does not exceeded 12 months.&#160;&#160;If a 10% change in interest rates had occurred on&#160;</font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, this change would not have had a significant impact on the fair value of our investment portfolio as of that date.</font></div><div><a name="s2B67818E953F541A951975310D425406"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM&#160;4. CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">As of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">23</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">An evaluation was also performed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">24</font></div></div><hr style="page-break-after:always"><div><a name="s8A596B1661525371A84673E461CBD7D8"></a></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART II. OTHER INFORMATION</font></div><div><a name="s0E958F7498185D7095EDB58D50426389"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM&#160;1. LEGAL PROCEEDINGS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">None.</font></div><div><a name="s1D6EF33C9F125DF5B0A271FD2849F977"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM&#160;1A. RISK FACTORS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">You should carefully consider the following risk factors, as well as the other information in this report, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. When evaluating our business, you should consider all of the factors described as well as the other information in our Annual Report, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The risk factors set forth below that are marked with an asterisk (*)&#160;contain changes to the similarly titled risk factors included in Item&#160;1A of our Annual Report. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline and you may lose all or part of your investment.&#160;&#160;Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</font></div><div><a name="sfb366bd07cdb477b967c722001c2b5b2"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Financial Position and Need for Additional Capital</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">*We are an early stage biotechnology company that has incurred significant operating losses since our inception and we anticipate that we will continue to incur substantial operating losses for the foreseeable future. We may never achieve or maintain profitability.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Since our inception, we have incurred significant operating losses. Our net loss was </font><font style="font-family:Arial;font-size:9.5pt;">$16.7 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">$13.4 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;for the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">&#32;month periods ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;and </font><font style="font-family:Arial;font-size:9.5pt;">2017</font><font style="font-family:Arial;font-size:9.5pt;">, respectively.  As of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, we had an accumulated deficit of </font><font style="font-family:Arial;font-size:9.5pt;">$166.1 million</font><font style="font-family:Arial;font-size:9.5pt;">. To date, we have financed our operations primarily through private placements of convertible preferred stock and convertible notes, our initial public offering of our common stock, or our IPO, our October 2016 term loan facility with Pacific Western Bank, or Pacific Western, our October 2016 follow-on public offering of common stock, our October 2017 private placement of common stock, and sales of common stock during the fourth quarter of 2017 and the first quarter of 2018 under our controlled equity sales agreement with Cantor Fitzgerald &amp; Co.  We have devoted substantially all of our financial resources and efforts to research and development. We have completed Part A of our STRIVE Phase 2 clinical trial of rezafungin and we are conducting Part B of the STRIVE study and Phase 1 and non-clinical studies of rezafungin and preclinical studies of our ADCs.&#160;&#160;We expect that it will be many years, if ever, before we receive regulatory approval and have a product candidate available for commercialization. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future.  Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">submit INDs to the FDA and equivalent filings to other regulatory authorities and seek approval of our clinical protocols by institutional review boards, or IRBs, at clinical trial sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">advance rezafungin through clinical development;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">continue the preclinical development of our ADCs or any other product candidates from our Cloudbreak immunotherapy platform or otherwise, and advance one or more of such product candidates into clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">seek marketing approvals for our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">establish or contract for a sales, marketing and distribution infrastructure to commercialize any product candidates for which we obtain marketing approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">maintain, expand and enforce our intellectual property portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">hire additional manufacturing, clinical, regulatory, quality assurance and scientific personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">add operational, financial and management systems and personnel, including personnel to support product development; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">acquire or in-license other product candidates and technologies.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">To become and remain profitable, we must develop and eventually commercialize one or more products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">25</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those product candidates for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we do, may never generate revenue that is significant or large enough to achieve profitability.&#160;&#160;Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">*We will need substantial additional funding to advance the development of our product candidates. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our drug development and discovery programs or commercialization efforts.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, initiate clinical trials of and seek marketing approval for our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution of the approved product. Furthermore, we expect to incur additional costs associated with operating as a public company. Our future capital requirements will depend on many factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our product candidates and Cloudbreak platform;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the costs, timing and outcome of any regulatory review of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the costs and timing of commercialization activities, including manufacturing, marketing, sales and distribution, for any product candidates that receive marketing approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">our ability to establish and maintain collaborations, when and if necessary, on favorable terms, if at all; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the extent to which we acquire or in-license other product candidates and technologies.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Identifying potential development candidates and conducting preclinical studies and clinical trials are time consuming, expensive and uncertain processes that take years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales for any of our current or future product candidates. In addition, our product candidates, if approved, may not achieve commercial success.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Accordingly, we will need substantial additional funding in connection with our continuing operations and to achieve our goals. Since December&#160;6, 2012 (inception) through </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, our operations have been financed primarily by gross proceeds of approximately </font><font style="font-family:Arial;font-size:9.5pt;">$217.3 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;from the issuance of convertible debt securities, the sale of shares of convertible preferred stock, the sale of shares of our common stock in our IPO, our October 2016 term loan facility with Pacific Western, our October 2016 follow-on public offering of common stock, our October 2017 private placement of common stock, and sales of common stock during the fourth quarter of 2017 and the first quarter of 2018 under our controlled equity sales agreement with Cantor Fitzgerald &amp; Co.  As of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, we had </font><font style="font-family:Arial;font-size:9.5pt;">$52.2 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;in cash and cash equivalents, </font><font style="font-family:Arial;font-size:9.5pt;">$0.8 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;in restricted cash, and </font><font style="font-family:Arial;font-size:9.5pt;">$14.0 million</font><font style="font-family:Arial;font-size:9.5pt;">&#32;in short term investments. </font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We have prepared cash flow forecasts which indicate, based on current cash resources available, that we will not have sufficient resources to fund our business for at least the next 12 months from the issuance of these financial statements.  We plan to continue to fund our operating expenses and capital expenditure requirements through debt and equity financing, through government funding or through collaborations or partnerships with other entities.  Debt or equity financing, government funding or collaborations and partnerships with other entities may not be available on a timely basis, on acceptable terms, or at all.  </font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We have developed a plan to implement cost cutting measures to reduce our working capital requirements over the next 12 months if an adequate level of financing is not secured. The plan includes the delay of certain of our development activities, a delay in hiring and a reduction of other discretionary expenditures that are within our control.  Any of the actions contemplated by the implementation of this plan, if required, could have an adverse impact on our ability to achieve certain of our planned objectives during 2018, and thus, materially harm our business.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:9.5pt;">If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts, make reductions in spending, extend payment terms with suppliers, liquidate or grant rights to assets where possible or suspend or curtail planned programs</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">26</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Any of these actions could materially harm our business, results of operations and future prospects. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional financing due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our operating plans.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">*Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity and debt financings, as well as potentially entering into collaborations, strategic alliances and licensing arrangements or receiving government and/or charitable grants or contracts. Other than our term loan facility with Pacific Western, which is subject to the fulfillment of specified conditions, we do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may be secured by all or a portion of our assets. There can be no assurances that we will be able to enter into contracts with or receive grants from the United States government or charitable organizations to support our programs. The process of obtaining grants and contracts is lengthy and uncertain and we will have to compete with other companies and institutions for each grant or contract. United States government grants and contracts typically contain unfavorable termination provisions and are subject to audit and modification by the government at its sole discretion, which will subject us to additional risks. If we receive a United States government grant or contract, we would be required to comply with numerous laws and regulations relating to the formation, administration and performance of the grant or contract, which can make it more difficult for us to retain our rights under such grant or contract and result in increased costs.  If we raise funds by entering into collaborations, strategic alliances or licensing arrangements with third parties or by receiving charitable grants, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or through collaborations, strategic alliances, licensing arrangements or government or charitable programs when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Our short operating history may make it difficult for you to evaluate the success of our business to date and assess our future viability.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We were founded in December 2012 and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, identifying potential development and product candidates, undertaking preclinical studies and conducting clinical trials. We have not yet demonstrated our ability to successfully complete large-scale, pivotal clinical trials required for regulatory approval of our product candidates, obtain marketing approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Typically, it takes many years to develop one new product from the time it is discovered to when it is commercially available. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history or if we had product candidates in advanced clinical trials.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors that may alter or delay our plans. We will need to continue to transition from a company with a research focus to a company capable of supporting late-stage development activities and, if a product candidate is approved, a company with commercial activities. We may not be successful in any step of such a transition.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">*The terms of our term loan facility place restrictions on our operating and financial flexibility and failure to comply with covenants or to satisfy certain conditions of the agreement governing the debt facility may result in acceleration of our repayment obligations and foreclosure on our pledged assets, which could significantly harm our liquidity, financial condition, operating results, business and prospects and cause the price of our common stock to decline. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In October 2016, we entered into a loan and security agreement with Pacific Western, or the Loan Agreement, under which we borrowed $10.0 million and may borrow up to an additional $10.0 million on or prior to October 3, 2018, subject to certain terms and conditions set forth therein, including our achievement of certain milestones. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The outstanding principal balance under the Loan Agreement is secured by a security interest in substantially all of our assets, other than intellectual property, which is subject to a double negative pledge. The Loan Agreement requires us to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">27</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">comply with a number of customary affirmative and restrictive covenants, including covenants that limit our ability to, among other things: transfer any part of our business or property; merge or consolidate with another entity or otherwise experience a change in control, incur additional indebtedness; encumber the collateral securing the loan, declare or pay any cash dividend or make distributions on our capital stock, repurchase or redeem any class of stock or other equity interest, acquire, own or make investments, and make certain capitalized expenditures over a specified threshold, in each case subject to exceptions. In addition, the Loan Agreement contains an operating covenant, which required us to achieve positive data from a Phase 2 clinical trial of rezafungin on or before March&#160;31, 2018. This operating covenant was achieved in Part A of the STRIVE study, but the operating covenant will be reset in 2018. The Loan Agreement also includes standard events of default, including a provision that Pacific Western could declare an event of default upon the occurrence of any event that it interprets as having a material adverse effect on (i)&#160;our operations, business or financial condition and subsidiaries taken as a whole; (ii)&#160;our ability to perform or pay the secured obligations under the Loan Agreement and related agreements; or (iii)&#160;the collateral pledged to Pacific Western under the Loan Agreement.&#160;Upon such determination, Pacific Western could declare all obligations under the Loan Agreement immediately due and payable.&#160;Although, in and of itself, the occurrence of adverse results or delays in any clinical study or the denial, delay or limitation of approval of or taking of any other regulatory action by the FDA or another governmental entity will not constitute a material adverse effect under the Loan Agreement, Pacific Western may determine that such an event together with contemporaneous events or circumstances constitutes a material adverse effect upon our business, operations, properties, assets, or financial condition or upon our ability to perform or pay the secured obligations under the Loan Agreement. If we default under the facility, Pacific Western may accelerate all of our repayment obligations. At such time, we may not have enough available cash or be able to raise additional funds on satisfactory terms, if at all, through equity or debt financings to repay our indebtedness at the time any such repayment is required.  If we are unable to access funds to meet those obligations or to renegotiate the Loan Agreement, Pacific Western could take control of and may sell our pledged assets. In such an event, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant to others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. If our assets were liquidated, Pacific Western&#8217;s right to repayment would be senior to the rights of our stockholders to receive any proceeds from the liquidation.&#160;Any declaration by Pacific Western of an event of default could significantly harm our liquidity, financial condition, operating results, business, and prospects and cause the price of our common stock to decline.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We may incur additional indebtedness in the future. The debt instruments governing such indebtedness may contain provisions that are as, or more, restrictive than the provisions governing our existing indebtedness under the Loan Agreement. If we are unable to repay, refinance or restructure our indebtedness when payment is due, the lenders could proceed against the collateral or force us into bankruptcy or liquidation.</font></div><div><a name="sB68E47BDA89D580E9768E8489D08E299"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Drug Discovery, Development and Commercialization</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">*We are very early in our development efforts, which may not be successful.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We have completed three Phase 1 clinical trials of rezafungin, as well as Part A of the STRIVE Phase 2 clinical trial of rezafungin in candidemia and invasive candidiasis.&#160;&#160;We are also conducting preclinical studies of antibody-drug conjugates, or ADCs, from our Cloudbreak program for infections caused by multidrug-resistant Gram-negative pathogens.  Because of the early stage of our development efforts, the timing and costs of the clinical development and regulatory paths we will follow and marketing approvals remain uncertain. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our early-stage product candidates. The success of rezafungin and any other product candidates we may develop will depend on many factors, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">successful completion of preclinical studies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">successful enrollment in, and completion of, clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">demonstrating safety and efficacy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">receipt of marketing approvals from applicable regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">launching commercial sales of the product candidates, if and when approved, whether alone or selectively in collaboration with others;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">28</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">acceptance of the product candidates, if and when approved, by patients, the medical community and third-party payers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">effectively competing with other therapies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">a continued acceptable safety profile of the products following approval; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">enforcing and defending intellectual property rights and claims.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">If we do not accomplish one or more of these goals in a timely manner, or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would harm our business.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">*If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials could occur at any stage of testing.</font><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:9.5pt;">&#32;The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a particular clinical trial do not necessarily predict final results of that trial. For example, the fact that Part A of the STRIVE study met its primary objectives related to tolerability and safety of rezafungin in the treatment of candidemia and invasive candidiasis does not guarantee success in the ongoing Part B of the STRIVE study or in our planned Phase 3 trials in treatment and prophylaxis of invasive fungal infections. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Moreover, preclinical and clinical data are often susceptible to multiple interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. For example, the historically observed high rate of correlation for clinical efficacy for antifungals, antibacterials and other anti-infectives based on preclinical data may not apply for our current or future product candidates, and any of the potential benefits that we anticipate for human clinical use may not be realized.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or in a given country;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">regulators may require that trials or studies be conducted, or sized or otherwise designed in ways, that were unforeseen in order to begin planned studies or to obtain marketing authorization;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">clinical trials of our product candidates may produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional clinical trials, modify planned clinical trial designs or abandon product development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">enrollment in these clinical trials may be slower than we anticipate, clinical sites may drop out of our clinical trials or participants may drop out of these clinical trials at a higher rate than we anticipate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks due to serious and unexpected side effects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the cost of clinical trials of our product candidates may be greater than we anticipate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the FDA or comparable foreign regulatory authorities could require that we perform more studies than, or evaluate clinical endpoints other than, those that we currently expect;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the supply of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be delayed or insufficient or the quality of such materials may be inadequate; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">29</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">we may be required to delay studies due to financial constraints.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">If we are required to conduct additional clinical trials or other tests of our product candidates beyond those that we currently contemplate, if we are unable to complete clinical trials of our product candidates or other tests successfully or in a timely manner, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">be delayed in obtaining marketing approval for our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">not obtain marketing approval at all;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">obtain approval for indications or patient populations that are not as broad as intended or desired;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">be subject to additional post-marketing testing requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">be subject to significant restrictions on reimbursement from public and/or private payers; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">have the product removed from the market after obtaining marketing approval.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Product development costs will also increase if we experience delays in testing or in receiving marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates, could allow our competitors to bring products to market before we do, could increase competition from generics of the same class and could impair our ability to successfully commercialize our product candidates, any of which may harm our business and results of operations.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If we experience delays or difficulties in enrolling patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or analogous regulatory authorities outside the United States or if we do not believe that the number of patients required by such regulatory agencies in any clinical trial can be enrolled in a reasonable timeframe. In addition, some of our competitors may have ongoing or new clinical trials for product candidates that would treat the same indications as our product candidates or be used in the same patients and, therefore, patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment is also affected by other factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">severity of the disease under investigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">availability, safety and efficacy of approved medications or other investigational medications being studied clinically for the disease under investigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">eligibility criteria for the trial in question;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">perceived risks and benefits of the product candidate under study;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">efforts to facilitate timely enrollment in clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">reluctance of physicians to encourage patient participation in clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the ability to monitor patients adequately during and after treatment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the proximity and availability of clinical trial sites for prospective patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">delays or failures in maintaining an adequate supply of quality drug product for use in clinical trials; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">changing treatment patterns that may reduce the burden of disease which our product candidates address.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our inability to enroll a sufficient number of patients for our clinical trials, or to enroll such patients in a timely manner, would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If serious adverse effects or unexpected characteristics of our product candidates are identified during development, we may need to abandon or limit our development of some or all of our product candidates.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">All of our programs are in preclinical development or are in early stages of clinical development and their risk of failure is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">30</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">receive marketing approval. If our product candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. For example, the pharmacokinetic properties, such as a longer half-life or less frequent dosing regimen, that differentiate rezafungin from other echinocandins could have side effects that we have not anticipated and the consequences of such side effects could be more severe than have been seen with other echinocandins that have shorter half-lives or more frequent dosing regimens or are dosed at lower concentrations than we expect for rezafungin. Further, the treatment advantages that we are predicting for rezafungin, such as lower healthcare costs resulting from an ability to administer rezafungin once-weekly or the predicted ability of rezafungin to be effective against resistant strains of fungal pathogens, may not be realized.  For our ADCs, the bispecific mechanism of action, including the use of the immune system, may lead to side effects that are not anticipated based on the preclinical work we have conducted to date.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In the biotechnology industry, many agents that initially show promise in early stage testing may later be found to cause side effects that prevent further development of the agents. In addition, fungal and bacterial infections can occur in patients with co-morbidities and weakened immune systems, and there may be adverse events and deaths in our clinical trials that are attributable to factors other than investigational use of our product candidates.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We have limited financial resources. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential than opportunities we pursue. For example, because we believe that an NDA filing for rezafungin for prophylaxis can be supported by one Phase 3 trial in prophylaxis, together with the data from our planned Phase 3 clinical trial in the treatment of candidemia and invasive candidiasis and the remainder of our rezafungin treatment program, if financial constraints require us to choose between our planned rezafungin treatment and prophylaxis programs, we may be required to choose our treatment program and forego or delay our prophylaxis program.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target markets for a particular product candidate or opportunity, we may relinquish valuable rights to that product candidate or opportunity through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate or opportunity.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payers and others in the medical community necessary for commercial success.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payers and others in the medical community for us to achieve commercial success. If our product candidates do not achieve an adequate level of acceptance, we may not generate sufficient product revenue to become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the efficacy and potential advantages compared to alternative therapies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the size of the markets in the countries in which approvals are obtained;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">terms, limitations or warnings contained in any labeling approved by the FDA or other regulatory agency;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">our ability to offer any approved products for sale at competitive prices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">convenience and ease of administration compared to alternative treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the willingness of the target patient population to try new therapies or dosing regimens;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the willingness of physicians to prescribe these therapies and, in the case of rezafungin, transition to a once-weekly dosing regimen from traditional once-daily dosing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the strength of marketing and distribution support;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the success of competing products and the marketing efforts of our competitors;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">31</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">sufficient third-party coverage and adequate reimbursement; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the prevalence and severity of any side effects.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates, if and when they are approved.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any approved product, we must either develop a sales and marketing organization or outsource these functions to third parties.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">There are risks involved both with establishing our own sales and marketing capabilities and with entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly and our investment would be lost if we cannot reposition our sales and marketing personnel.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the inability of sales personnel to obtain access to physicians or to achieve adequate numbers of prescriptions for any future products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of these product revenues to us may be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties and any of them may fail to market and sell our products effectively, including by failing to devote the necessary resources and attention. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Regulatory incentives to develop drugs for treatment of infectious diseases have increased interest and activity in this area and will lead to increased competition for clinical investigators and clinical trial subjects, as well as for future prescriptions, if any of our product candidates are successfully developed and approved. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the indications on which we are focusing our product development efforts. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Rezafungin will primarily compete with antifungal classes for the treatment and prevention of systemic fungal infections such as candidemia and invasive candidiasis, which include polyenes, azoles and echinocandins. Approved branded echinocandin antifungal therapies include Cancidas (caspofungin, marketed by Merck&#160;&amp; Co.), Eraxis (anidulafungin, marketed by Pfizer Inc.) and Mycamine (micafungin, marketed by Astellas Pharma US, Inc.). There will be generics of one or more of the current echinocandins available at the time of rezafungin market approval, which will create added competition.&#160;&#160;In addition, there are other generic products approved for candidemia, marketed by companies such as Baxter Healthcare Corporation, Mylan Inc. and Glenmark Generics Inc., among others. In addition to approved therapies, we expect that rezafungin will compete with product candidates that we are aware of in clinical development by third parties, such as SCY-078 (being developed by Scynexis, Inc.).</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">32</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our ADCs will compete against approved and investigational agents for the treatment of bacterial infections.  We may develop other product candidates from our Cloudbreak immunotherapy platform for the treatment of invasive bacterial, fungal or viral infections.&#160;&#160;We are aware of a number of approved and investigational therapies in these areas.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are developing or that would render our product candidates obsolete or non-competitive. Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their products sooner than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Many of our competitors have significantly greater name recognition, financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These same competitors may invent technology that competes with our rezafungin program or our Cloudbreak immunotherapy platform.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">These third parties may compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Even if we are able to commercialize any product candidates, these products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. In the United States, new and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product-licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial marketing approval is granted. As a result, we might obtain marketing approval for a drug in a particular country but then be subject to price regulations that delay its commercial launch, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to commercialize and generate revenue from one or more product candidates, even if our product candidates obtain marketing approval.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health programs, private health insurers, integrated delivery networks and other third-party payers. Third-party payers decide which medications they will pay for and establish reimbursement levels. A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payers have attempted to control costs by limiting coverage and the amount of payment for particular medications. Increasingly, third-party payers are requiring that drug companies provide predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, if reimbursement is available, the level of reimbursement may not be sufficient for commercial success. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">There may be significant delays in obtaining coverage and adequate reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for coverage and reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Coverage and reimbursement rates may vary according to the use of the drug and the medical circumstances under which it is used may be based on reimbursement levels already set for lower cost products or procedures or may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payers and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Commercial third-party payers often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded programs and private payers for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize our approved products and our overall financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">33</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit the commercialization of any product candidates we may develop.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and we will face an even greater risk if we commercially sell any products that receive marketing approval. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">decreased demand for any product candidates that we may develop;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">injury to our reputation and significant negative media attention;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">withdrawal of clinical trial participants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">significant costs and distraction of management to defend any related litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the initiation of investigations by regulatory bodies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">substantial monetary awards to trial participants or patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">loss of revenue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">product recalls, withdrawals or labeling, marketing or promotional restrictions; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the inability to commercialize any products we may develop.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Although we have product liability insurance for our clinical trials, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we continue or expand our clinical trials and if we successfully commercialize any products. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees in our workplace, including those resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, chemical, hazardous or radioactive materials.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We may not be successful in our efforts to identify, discover, in-license or acquire potential product candidates.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We are developing our ADCs for the treatment of multidrug-resistant bacterial infections, including those caused by pathogens harboring the </font><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">mcr-1</font><font style="font-family:Arial;font-size:9.5pt;">&#32;gene. We currently do not have any development candidates from the Cloudbreak platform.  Our Cloudbreak immunotherapy platform and other drug discovery efforts may not be successful in identifying additional molecules that could be developed as drug therapies. Our research programs may initially show promise in identifying such potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons. In particular, our research methodology used may not be successful in identifying compounds with sufficient potency, bioavailability or efficacy to be potential product candidates. In addition, our potential product candidates may, on further study, be shown to have harmful side effects or other negative characteristics.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Research programs to identify new product candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on potential product candidates that ultimately prove to be unsuccessful. If </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">34</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">we are unable to identify, in-license or acquire suitable compounds for preclinical and clinical development, we will not be able to generate product revenue, which would harm our financial position and adversely impact our stock price. </font></div><div><a name="s55DF5CFA35FB589C9D735D2BA45D5AEE"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Dependence on Third Parties</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We intend to continue to rely on third parties to conduct our clinical trials and to conduct some aspects of our research and preclinical testing and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We currently rely and expect to continue to rely on third parties, such as contract research organizations, contract manufacturers of clinical supplies, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials and to conduct some aspects of our research and preclinical testing. Any of these third parties may terminate their engagements with us at any time. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If we need to enter into alternative arrangements, it would delay our product development activities.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and other international regulatory agencies require us to comply with standards, commonly referred to as Good Clinical Practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, available at www.clinicaltrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We have no experience manufacturing product candidates on a clinical or commercial scale and will be dependent on third parties for the manufacture of our product candidates. If we experience problems with any of these third parties, they could delay clinical development or marketing approval of our product candidates or our ability to sell any approved products.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We do not have any manufacturing facilities. We currently rely, and expect to continue to rely, on third-party manufacturers for the manufacture of our product candidates for preclinical studies and clinical trials and for commercial supply of any of these product candidates for which we obtain marketing approval. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We may be unable to establish agreements with third-party manufacturers for preclinical, clinical or commercial supply on terms favorable to us, or at all. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">reliance on the third party for regulatory compliance and quality assurance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the possible breach of the manufacturing agreement by the third party, including the inability to supply sufficient quantities or to meet quality standards or timelines; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Third-party manufacturers may not be able to comply with current U.S. Good Manufacturing Practice requirements, or cGMPs, or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with cGMPs or other applicable regulations, even if such failures do not relate specifically to our product candidates or approved products, could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Any product that we develop may compete with other product candidates and products for access to these manufacturing facilities. There are a limited number of manufacturers that operate under cGMPs and that might be capable of manufacturing for us.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Any performance failure on the part of our existing or future manufacturers, including a failure that may not relate specifically to our product candidate or approved product, could delay clinical development or marketing approval or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">35</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">adversely impact our ability to generate commercial sales. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We currently rely, and expect to continue to rely, on third parties to release, label, store and distribute drug supplies for our clinical trials. Any performance failure on the part of these third parties, including a failure that may not relate specifically to our product candidate or approved product, could delay or otherwise adversely impact clinical development or marketing approval of our product candidates or commercialization of our drugs, producing additional losses and depriving us of potential revenue. </font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Moreover, our manufacturers and suppliers may experience difficulties related to their overall businesses and financial stability, which could result in delays or interruptions of supply of our product candidates or approved products. </font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We do not have alternate manufacturing plans in place at this time. If we need to change to other manufacturers, the FDA and comparable foreign regulators may have to approve these manufacturers&#8217; facilities and processes prior to our use, which would require new testing and compliance inspections.  In addition, the new manufacturers would have to be educated in or independently develop the processes necessary for production.  This would result in delays and costs, and in the case of approved products, the potential loss of revenue.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">*We may seek to selectively establish collaborations and, if we are unable to establish them on commercially reasonable terms or at all, we may have to alter our development and commercialization plans.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with other pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates. We do not currently have any such collaborations.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Those factors may include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the design or results of preclinical studies or clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the likelihood of approval by the FDA or similar regulatory authorities outside the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the potential market for the subject product candidate in the territories that are the subject of the collaboration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the costs and complexities of manufacturing and delivering such product candidate to patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the potential of competing products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">industry and market conditions generally.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The collaborator may also consider alternative product candidates for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">To the extent we enter into any collaborations, we may depend on collaborators for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We may selectively seek third-party collaborators for the development and commercialization of our product candidates. Our likely potential collaborators include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We do not currently have any such arrangements and if we enter into any such arrangements with any third parties in the future, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Collaborations involving our product candidates pose many risks to us, including that:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">36</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates or products if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">a collaborator with marketing and distribution rights to one or more product candidates or products may not commit sufficient resources to the marketing and distribution of such drugs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or proprietary information or expose us to potential litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or products or that result in costly litigation or arbitration that diverts management attention and resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">we may lose certain valuable rights under circumstances identified in our collaboration agreements if we undergo a change of control;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all; and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">if a future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">If our ability to generate revenue under any of our collaboration agreements is adversely impacted by any of these risks, our share of the revenues generated by the product, if approved, under the terms of the collaboration could be insufficient to allow us to achieve or maintain profitability or the product may be less valuable to us than if we had not entered into the collaboration. </font></div><div><a name="s87F8F9FAE5A85F6DA251269028D10086"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If we are unable to take full advantage of regulatory programs designed to expedite drug development or provide other incentives, our development programs may be adversely impacted.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:9.5pt;">There are a number of incentive programs administered by the FDA and other regulatory bodies to facilitate development of drugs in areas of unmet medical need.  Rezafungin received the designations as a Qualified Infectious Disease Product, or QIDP, a fast track product and an orphan drug in the U.S. for the treatment of </font><font style="font-family:Arial;font-size:10pt;">candidemia and invasive candidiasis.</font><font style="font-family:Arial;font-size:9.5pt;">&#160;&#160;We have also either applied for or are planning to seek QIDP, fast track and orphan drug designations for rezafungin for prophylaxis, as well as an orphan drug designation for rezafungin for treatment and prophylaxis in Europe.  Our product candidates may not qualify for or maintain designations under these or other incentive programs under any of the FDA&#8217;s existing or future programs to expedite drug development in areas of unmet medical need. Our inability to fully take advantage of these incentive programs may require us to run larger trials, incur delays, lose opportunities that may not otherwise be available to us, lose marketing exclusivity for which we would otherwise be eligible and incur greater expense in the development of our product candidates.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">37</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be impaired.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, release, safety, efficacy, regulatory filings, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries. For example, in order to commence clinical trials of our product candidates in the United States, we must file an IND and obtain FDA agreement to proceed. The FDA may place our development program on clinical hold and require further preclinical testing prior to allowing our clinical trials to proceed.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We must obtain marketing approval in each jurisdiction in which we market our products. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not submitted a marketing application or received approval to market any of our product candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party contract research organizations to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process, testing and release and inspection of manufacturing facilities and personnel by the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The process of obtaining marketing approvals, both in the United States and elsewhere, is expensive, may take many years and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. We cannot assure you that we will ever obtain any marketing approvals in any jurisdiction. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical or other studies, changes in the manufacturing process or facilities or clinical trials. Moreover, approval by the FDA or an equivalent foreign authority does not ensure approval by regulatory authorities in any other countries or jurisdictions but a failure to obtain marketing approval in one jurisdiction may adversely impact the likelihood of approval in other jurisdictions. In addition, varying interpretations of the data obtained from preclinical testing, manufacturing and product testing and clinical trials could delay, limit or prevent marketing approval of a product candidate. Additionally, any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Any product candidate for which we obtain marketing approval could be subject to marketing restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes and facilities, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of promotional materials and safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements for product facilities, quality assurance and corresponding maintenance of records and documents and requirements regarding the distribution of samples to physicians and related recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we do not comply with these restrictions, we may be subject to enforcement actions.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In addition, later discovery of previously unknown problems with our products, manufacturers or manufacturing processes and facilities or failure to comply with regulatory requirements, may result in, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">restrictions on such products, manufacturers or manufacturing processes or facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">restrictions on the labeling, marketing, distribution or use of a product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">requirements to conduct post-approval clinical trials, other studies or other post-approval commitments;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">38</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">warning or untitled letters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">withdrawal of the products from the market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">refusal to approve pending applications or supplements to approved applications that we submit;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">recall of products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">fines, restitution or disgorgement of profits or revenue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">suspension or withdrawal of marketing approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">refusal to permit the import or export of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">product seizure; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">injunctions or the imposition of civil or criminal penalties.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Our relationships with customers, health care professionals and third-party payers will be subject to applicable healthcare laws, which could expose us to penalties, including administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare programs such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profits and earnings.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Healthcare professionals and third-party payers will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with customers, healthcare professionals and third-party payers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research, market, sell and distribute our medicines for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following, among others:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the federal healthcare anti-kickback statute, which prohibits persons and entities from, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the federal false claims laws, which impose criminal and civil penalties, including civil whistleblower or qui tam actions under the federal Civil False Claims Act, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">HIPAA, as amended by HITECH, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the federal false statements statute enacted under HIPAA, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the federal transparency requirements under the Affordable Care Act, which require, among other things, certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Department of Health and Human Services information related to physician payments and other transfers of value and physician ownership and investment interests; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">analogous state laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business activities, including sales or marketing arrangements and claims involving healthcare items or services including, in some states, those reimbursed by non-governmental third-party payers, including private insurers, and some state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments or other transfers of value provided to physicians and other health care providers and entities or marketing expenditures.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs.&#160; Interpretations of standards of compliance under these laws and regulations are rapidly changing and subject to varying interpretations and it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">39</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other laws that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations, any of which could diminish our future profits or earnings. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations.&#160; Compliance with these legal standards could impair our ability to compete in domestic and international markets.&#160; We can face criminal liability and other serious consequences for violations, which can harm our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities.&#160; Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector.&#160; We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals.&#160; We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations.&#160; We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. &#160;Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">For example, in March 2010, President Obama signed into law the Affordable Care Act, a sweeping law intended to, among other things, broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The Affordable Care Act and subsequent regulations revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes, which could increase the amount of Medicaid drug rebates to states. Further, the law imposes a significant annual fee on companies that manufacture or import branded prescription drug products. Substantial new provisions affecting compliance have also been enacted, which may affect our business practices with healthcare practitioners. Since its enactment there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, as well as recent efforts by the Trump administration to repeal and replace certain aspects of the Affordable Care Act and we expect such challenges to continue. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandated by the Affordable Care Act. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the Affordable Care Act have been enacted. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Additionally, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain fees mandated by the Affordable Care Act, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share and the medical device excise tax on non-exempt medical devices. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amends the Affordable Care Act, effective January 1, 2019, to close the coverage gap in most Medicare drug plans and also increases in 2019 the percentage that a drug manufacturer must discount the cost of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">40</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">prescription drugs from 50 percent under current law to 70 percent. Congress also could consider additional legislation to repeal or repeal and replace other elements of the Affordable Care Act. Although the full effect of the Affordable Care Act remains uncertain, the law appears likely to continue the pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. In addition, there have been several recent Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. Further, the Trump administration&#8217;s budget proposal for fiscal year 2019 contains additional drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid and to eliminate cost sharing for generic drugs for low-income patients. While any proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.  At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We expect that additional healthcare reform measures will be adopted within and outside the United States in the future, any of which could add difficulty to the regulatory approval processes for our product candidates or limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. The continuing efforts of third-party payors to contain or reduce costs of healthcare may adversely affect the demand for any drug products for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability and the level of taxes that we are required to pay.</font></div><div><a name="s8C75F9D50EAB5E97A96A359848CAF527"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If our efforts to protect the proprietary nature of the intellectual property related to rezafungin, our Cloudbreak compounds or our other product candidates or compounds are not adequate, we may not be able to compete effectively in our markets.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements to protect the intellectual property related to rezafungin and our other product candidates and compounds. Any involuntary disclosure to or misappropriation by third parties of our proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our markets.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain and our commercial success will depend on our ability to obtain patents and maintain adequate protection for rezafungin, our ADCs and other compounds and product candidates in the United States and other countries. We currently hold issued U.S. utility and foreign patents and multiple pending U.S. utility patent applications, pending U.S. provisional patent applications and pending international, foreign national and regional counterpart patent applications covering various aspects of rezafungin, our ADCs and our Cloudbreak immunotherapy platform and other technology. The patent applications may fail to result in issued patents in the United States or in foreign countries or jurisdictions. Even if the applications do successfully issue, third parties may challenge the patents.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Further, the existing and/or future patents, if any, may be too narrow to prevent third parties from developing or designing around these patents. If the sufficiency of the breadth or strength of protection provided by the patent and patent applications we own with respect to rezafungin or our ADCs or the patents we pursue related to any of our other product candidates or compounds is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize the product candidates or compounds. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced, although a patent term extension or supplementary protection certificate having varied scope may be available in certain jurisdictions to compensate for some of the lost patent term. In addition, we do not know whether:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">we were the first to make the inventions covered by each of our pending patent applications or our issued patents;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">41</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">we were the first to file patent applications for these inventions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">others will independently develop similar or alternative technologies or duplicate any of our technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">any of our pending patent applications will result in issued patents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">any of our patents, once issued, will be valid or enforceable or will issue with claims sufficient to protect our products or will be challenged by third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">any patents issued to us will provide us with any competitive advantages;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">we will develop additional proprietary technologies that are patentable; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the patents of others will have an adverse effect on our business.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In addition, patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. In September 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The United States Patent and Trademark Office, or USPTO, developed new regulations and procedures to govern administration of the Leahy-Smith Act and many of the substantive changes to patent law associated with the Leahy-Smith Act and, in particular, the first to file provisions, only became effective in March 2013. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition and prospects.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable in one or more jurisdictions, inventions for which patents are difficult to enforce and any other elements of our drug discovery program that involve proprietary know-how, information and technology that is not covered by patents. Although we require all of our employees, consultants, advisers and third parties who have access to our proprietary know-how, information and technology to enter into confidentiality agreements, we cannot be certain that this know-how, information and technology will not be disclosed or used in an unauthorized manner or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">There also may be challenges or other disputes concerning the inventorship, ownership or right to use our intellectual property. For example, our consultants and advisors may have obligations to assign certain inventions and/or know-how that they develop to third-party entities in certain instances, and these third parties may challenge our ownership or other rights to our intellectual property, which would adversely affect our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">An inability to obtain, enforce and defend patents covering our proprietary technologies would materially and adversely affect our business prospects and financial condition. Further, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the United States. We may encounter significant problems in protecting, enforcing and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of the intellectual property related to our technologies to third parties or are otherwise unable to protect, enforce or defend our intellectual property, we will not be able to establish or, if established, maintain a competitive advantage in our markets, which could materially adversely affect our business, operating results and financial condition.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies and our patent protection could be reduced or eliminated for non-compliance with these requirements.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various foreign or jurisdictional governmental patent agencies in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm to pay these fees due to foreign patent agencies. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. Such </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">42</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">noncompliance events are outside of our direct control for (1)&#160;non-U.S. patents and patent applications owned by us and, (2)&#160;if applicable in the future, patents and patent applications licensed to us by another entity. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents with claims to materials, methods of manufacture or methods of treatment related to the use or manufacture of rezafungin, our ADCs and/or our other product candidates or compounds.  If any third-party patents were held by a court of competent jurisdiction to cover the rezafungin or ADC manufacturing process, any molecules formed during these processes or the final products or any use thereof, the holders of any such patents may be able to block our ability to commercialize the product unless we obtained a license under the applicable patent or patents or until such patents expire. These same issues and risks arise in connection with any other product candidates we develop as well. We cannot predict whether we would be able to obtain a license on commercially reasonable terms, or at all.  Any inability to obtain such a license under the applicable patents on commercially reasonable terms, or at all, would have a material adverse effect on our ability to commercialize the affected product until such patents expire.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In addition, third parties may obtain patents in the future and claim that our product candidates and/or the use of our technologies infringes upon these patents. Furthermore, parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees in the case of willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing products, which may be impossible and/or require substantial time and monetary expenditure. In addition, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of one or more of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, or at all. In that event, we would not be able to further develop and commercialize such product candidates, which could harm our business significantly.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We may be required to file lawsuits or take other actions to protect or enforce our patents, which could be expensive, time consuming and unsuccessful.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Competitors may infringe our current or future patents. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our asserted patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Pursuit of these claims would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Interference proceedings or derivative proceedings provoked by third parties or brought by the USPTO may be necessary to determine the entitlement to patent protection with respect to our patents or patent applications. An unfavorable outcome could result in a loss of our patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, or at all. Litigation or patent office proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent misappropriation of our trade secrets or confidential information, particularly in countries where the laws or legal process may not protect those rights as fully as in the United States.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">43</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Issued patents covering our product candidates and technologies could be found invalid or unenforceable if challenged in court or the USPTO.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">If we initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or our technologies, the defendant could counterclaim that the patent covering our product candidate or our technology, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates or our technologies. The outcome following legal assertions of invalidity and/or unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art or that prior art that was cited during prosecution, but not relied on by the patent examiner, will not be revisited. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection directed to our product candidates or technologies. Such a loss of patent rights could have a material adverse impact on our business.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve both technological and legal complexity, and are therefore costly, time-consuming and inherently uncertain. In addition, the United States has implemented wide-ranging patent reform legislation, including patent office administrative proceedings that offer broad opportunities to third parties to challenge issued patents. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, the USPTO and foreign governmental bodies and tribunals, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in</font><font style="font-family:Arial;font-size:9.5pt;font-style:italic;">&#32;Assoc. for Molecular Pathology v. Myriad Genetics, Inc.,</font><font style="font-family:Arial;font-size:9.5pt;">&#32;the U.S. Supreme Court held in 2013 that certain claims to DNA molecules are not patentable and lower courts have since been applying this case in the context of other types of biological subject matter. We cannot predict how future decisions by the courts, the U.S. Congress, the USPTO or foreign governmental bodies or tribunals may impact the value of our patent rights.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws and legal processes of some foreign countries do not protect intellectual property to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patents to develop their own products and further, may export otherwise infringing products to territories where we have patents but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Many companies have encountered significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put any of our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly developing countries. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of any of our current or future patents, requiring us to engage in complex, lengthy and costly litigation or other proceedings. Certain countries in Europe and developing countries, including China and India, have </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">44</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if any of our patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors, and academic or research institutions. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Provisions in our contract with the Trustees of Boston University, or BU, relating to the Combating Antibiotic Resistant Bacteria Accelerator, or CARB-X, program, required by the U.S. government or the Wellcome Trust may affect our intellectual property rights.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Certain of our activities relating to our CD201 program were subject to reimbursement under our Cost Reimbursement Research Subaward Agreement, or the CARB-X Subaward Agreement, with the Trustees of Boston University.  CARB-X is funded by the U.S. Biomedical Advanced Research and Development Authority, or BARDA, and the Wellcome Trust, or Wellcome, a global charitable foundation. When new technologies are developed with U.S. government funding, the government obtains certain rights in any resulting patents, including the right to a nonexclusive license authorizing the government to use the invention. These rights may permit the government to disclose our confidential information to third parties and to exercise &#8220;march-in&#8221; rights to use or allow third parties to use our patented technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the U.S. government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, U.S. government-funded inventions must be reported to the government, U.S. government funding must be disclosed in any resulting patent applications and our rights in such inventions may be subject to certain requirements to manufacture products in the U.S.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In addition, subject to such march-in rights, if we have not exploited or further developed intellectual property rights relating to the product candidates subject to reimbursement under the CARB-X program by the date that is five years after the end of the activities funded by CARB-X under the CARB-X Subaward Agreement in any country, Wellcome will have the option to take responsibility for the exclusive commercialization and exploitation of such intellectual property rights in such country. In such event, such intellectual property rights relating to such country will be assigned to Wellcome and Wellcome will share revenues and equity holdings relating to such exploitation with us on a 50%/50% basis, net of Wellcome&#8217;s related costs. In the event we license such intellectual property rights to a third party prior to the exercise of such option rights by Wellcome, such option rights shall terminate, provided that the third party license agreement contains a requirement for the licensee to use diligent efforts to exploit such intellectual property rights, with a reversion right to us in the event of a violation of such diligence requirement and provided that Wellcome has approved such third party license agreement in writing.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We have decided to discontinue development of CD201.  If the U.S. government or Wellcome takes any of these actions with respect to our intellectual property rights, such actions may adversely impact our product candidates or our ability to develop future candidates, we may be unable to obtain a significant commercial advantage from our intellectual property and our potential revenue opportunities could be limited substantially. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">45</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to U.S. Government Contracts and Grants</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Our use of government funding adds uncertainty to our research and commercialization efforts and may impose requirements that increase our costs.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Contracts funded by the U.S. government and its agencies, including our CARB-X Subaward Agreement, include provisions that reflect the government&#8217;s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">terminate agreements, in whole or in part, for any reason or no reason;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">reduce or modify the government&#8217;s obligations under such agreements without the consent of the other party;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">claim rights, including intellectual property rights, in products and data developed under such agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">audit contract-related costs and fees, including allocated indirect costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">suspend the contractor from receiving new contracts pending resolution of alleged violations of procurement laws or regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">suspend or debar the contractor from doing future business with the government;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">control and potentially prohibit the export of products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">pursue criminal or civil remedies under the Federal Civil Monetary Penalties Act and the Federal Civil False Claims Act and similar remedy provisions specific to government agreements.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In addition, government contracts contain additional requirements that may increase our costs of doing business, reduce our profits and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">specialized accounting systems unique to government contracts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">public disclosures of certain contract information, which may enable competitors to gain insights into our research program; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">mandatory socioeconomic compliance requirements, including labor standards, anti-human-trafficking, non-discrimination and affirmative action programs and environmental compliance requirements.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">If we fail to maintain compliance with these requirements, we may be subject to potential liability and to termination of our contracts.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If we do not receive all of the funds under our CARB-X Subaward Agreement or are unable to generate additional revenues from additional contracts, we may be forced to suspend or terminate one or more of our preclinical programs.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">A substantial amount of our development activities relating to our CD201 program were funded under our CARB-X Subaward Agreement.  Based on our decision to cease development of CD201, we will no longer be seeking funding for CD201 under this agreement.  There can be no assurances that we will be able to enter into new contracts with the United States government or other sources of funding to support any program resulting from our Cloudbreak platform.  The process of obtaining government contracts is lengthy and uncertain and we will have to compete with other companies and institutions for each contract. Further, changes in government budgets and agendas may result in a decreased and de-prioritized emphasis on supporting the discovery and development of anti-infective products. If we cannot obtain or maintain government or other funding for our programs, we may be forced to discontinue those programs.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Our business is subject to audit by the U.S. government under our CARB-X Subaward Agreement and a negative audit could adversely affect our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">United States government agencies routinely audit and investigate government contractors and recipients of Federal grants. These agencies review a contractor&#8217;s performance under its contracts, cost structure and compliance with applicable laws, regulations and standards.  BU also has the right to audit our activities under our CARB-X Subaward Agreement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">46</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Government agencies also review the adequacy of, and a contractor&#8217;s compliance with, its internal control systems and policies, including the contractor&#8217;s purchasing, property, estimating, compensation and management information systems. Any costs found to be improperly allocated to a specific contract will not be reimbursed, while such costs already reimbursed must be refunded. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">If an audit uncovers improper or illegal activities, we may be subject to civil and criminal penalties and administrative sanctions, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">termination of contracts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">forfeiture of profits;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">suspension of payments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">fines; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">suspension or prohibition from conducting business with the United States government.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In addition, we could suffer serious reputational harm if allegations of impropriety were made against us, which could cause our stock price to decrease.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Laws and regulations affecting government contracts make it more expensive and difficult for us to successfully conduct our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We must comply with numerous laws and regulations relating to the formation, administration and performance of government contracts, which can make it more difficult for us to retain our rights under our CARB-X Subaward Agreement. These laws and regulations affect how we conduct business with government agencies. Among the most significant government contracting regulations that affect our business are:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the Federal Acquisition Regulations, or FAR, and agency-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and include other requirements such as the Anti-Kickback Statute and Foreign Corrupt Practices Act;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">export and import control laws and regulations; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Any changes in applicable laws and regulations could restrict our ability to maintain our existing CARB-X Subaward Agreement and obtain new contracts, which could limit our ability to conduct our business and materially adversely affect our results of operations.</font></div><div><a name="s4B60F354A79F55DB968881CEA45103EA"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Employee Matters and Managing Growth</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Our future success depends on our ability to retain our senior management team and to attract, retain and motivate qualified personnel.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We are highly dependent upon our senior management team, as well as the other principal members of our research and development teams. All of our executive officers are employed &#8220;at will,&#8221; meaning we or they may terminate the employment relationship at any time. We maintain &#8220;key person&#8221; insurance for our Chief Executive Officer but not for any of our other executives or employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Recruiting and retaining qualified scientific, clinical, manufacturing, regulatory, quality assurance and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisers, including scientific, regulatory, quality assurance and clinical advisers, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisers may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">47</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We expect to expand our operations and may encounter difficulties in managing our growth, which could disrupt our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We expect to expand the scope of our operations, particularly in the areas of drug development, manufacturing, clinical, regulatory affairs, quality assurance and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. We may not be able to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel. Moreover, the expected expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In the future, we may enter into transactions to acquire other businesses, products or technologies and our ability to do so successfully is unproven. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may fail to strengthen our competitive position and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results.</font></div><div><a name="sC032649C16B15474AAA5434D0D5640BB"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Ownership of our Common Stock</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">*The price of our stock may be volatile and you could lose all or part of your investment.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this report, these factors include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the commencement, timing, enrollment or results of the current and planned clinical trials of our product candidates or any future clinical trials we may conduct or changes in the development status of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter, "complete response" letter, or a request for additional information;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">adverse results, suspensions, terminations or delays in pre-clinical or clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial or development program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">changes in laws or regulations applicable to our products, including but not limited to requirements for approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">adverse developments concerning our contract manufacturers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices or acceptable quality;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">our inability to establish collaborations if needed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">our failure to commercialize our product candidates successfully, or at all;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">additions or departures of key scientific or management personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">unanticipated serious safety concerns related to the use of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the introduction of new products or services offered by us or our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">announcements of significant acquisitions, strategic partnerships, joint ventures, government grants or contracts or capital commitments by us or our competitors;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">48</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">our ability to effectively manage our growth;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the size and growth of our fungal infection, bacterial infection or other target markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">our ability to successfully enter new markets or develop additional product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">actual or anticipated variations in quarterly operating results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">our cash position and our ability to raise additional capital and the manner and terms on which we raise it or the expectation of future fundraising activities by us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">publication of research reports or other media coverage about us or our industry or our therapeutic approaches in particular or positive or negative recommendations or withdrawal of research coverage by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">changes in the market valuations of similar companies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">overall performance of the equity markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">sales of our common stock by us or our stockholders in the future or the expectation of such sales;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the trading volume of our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">changes in accounting practices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">ineffectiveness of our internal controls;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">disputes or other developments relating to proprietary rights, including patent rights, litigation matters and our ability to obtain patent protection for our technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">significant lawsuits, including patent or stockholder litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">general political and economic conditions; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">other events or factors, many of which are beyond our control.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In addition, the stock market in general, and The NASDAQ Global Market and pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. You may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our executive officers, directors and 5% stockholders&#160;and their affiliates currently beneficially own a significant percentage of our outstanding voting stock. These stockholders have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We are an emerging growth company and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act, or the JOBS Act, enacted in April 2012. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">49</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company through 2020, although circumstances could cause us to lose that status earlier. We will remain an emerging growth company until the earlier of (a)&#160;December 31, 2020, (b)&#160;the last day of the fiscal year in which we have total annual gross revenue of at least $1&#160;billion, (c)&#160;the last day of the fiscal year in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700&#160;million as of the prior June&#160;30th and (d)&#160;the date on which we have issued more than $1&#160;billion in non-convertible debt during the prior three-year period.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We incur significant costs as a result of operating as a public company and our management will be required to devote substantial time to compliance initiatives.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Securities Exchange Act of 1934, which require, among other things, that we file with the Securities and Exchange Commission, or the SEC, annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The NASDAQ Global Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of our IPO. We intend to take advantage of this legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the political environment and the level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We expect the rules and regulations applicable to public companies to continue to result in substantial legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. These costs could decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, these rules and regulations could make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">*Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. We had </font><font style="font-family:Arial;font-size:9.5pt;">21,389,736</font><font style="font-family:Arial;font-size:9.5pt;">&#32;shares of common stock outstanding as of March 31, 2018.&#160;We are unable to predict the effect that sales may have on the prevailing market price of our common stock.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Sales of our common stock by current stockholders may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate and may make it more difficult for you to sell shares of our common stock. In addition, shares of common stock that are either issuable upon the exercise of outstanding options or warrants or reserved for future issuance under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">50</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">701 under the Securities Act.&#160;If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Certain holders of our securities are entitled to rights with respect to the registration of their shares under the Securities Act.&#160; Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act.&#160; Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">*Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating as a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales and new investors could gain rights, preferences and privileges senior to our existing stockholders.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Pursuant to our 2015 Equity Incentive Plan, or the 2015 EIP, our management is authorized to grant stock options to our employees, directors and consultants.&#160;The number of shares of our common stock reserved for issuance under the 2015 EIP will automatically increase on January&#160;1 of each year through and including January&#160;1, 2025, by 4% of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year or a lesser number of shares determined by our board of directors. Additionally, the number of shares of our common stock reserved for issuance under our 2015 Employee Stock Purchase Plan, or the ESPP, will automatically increase on January&#160;1 of each year through and including January&#160;1, 2025, by the lesser of 1% of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year or 490,336 shares. Unless our board of directors elects not to increase the number of shares available for future grant each year under the 2015 EIP and the ESPP, our stockholders may experience additional dilution, which could cause our stock price to fall.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We have broad discretion in the use of working capital and may not use it effectively.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our management will have broad discretion in the application of our working capital. Because of the number and variability of factors that will determine our use of our working capital, its ultimate use may vary substantially from its currently intended use. Our management might not apply our working capital in ways that ultimately increase the value of your investment. We expect to use our working capital to fund research and development activities and general operating expenses. The failure by our management to apply this working capital effectively could harm our business. Pending its use, we may invest our working capital in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply our working capital in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer or by a majority of the total number of authorized directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">51</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">*Because we will have an even number of members of our board of directors after our 2018 annual meeting of stockholders, deadlocks may occur in our board of directors&#8217; decision-making process, which may delay or prevent critical decisions from being made.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">One of our current directors, Robert Perez, has notified us that he does not plan to stand for reelection at our 2018 annual meeting of stockholders. Our board of directors has determined that from and after the annual meeting, the size of the board of directors will be set at six. Since we will then have an even number of directors, deadlocks may occur when such directors disagree on a particular decision or course of action. Our amended and restated certificate of incorporation and amended and restated bylaws do not contain any mechanisms for resolving potential deadlocks. While our directors are under a duty to act in the best interest of our company, any deadlocks may impede the further development of our business in that such deadlocks may delay or prevent critical decisions regarding our development.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income may be limited. As a result of capital raising and other transactions that have occurred since our inception in 2012, we may or may not have experienced an &#8220;ownership change.&#8221; We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As of December 31, 2017, we </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">52</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">had U.S. net operating loss carryforwards of approximately </font><font style="font-family:Arial;font-size:9.5pt;">$122.5 million</font><font style="font-family:Arial;font-size:9.5pt;">, which begin to expire in 2033, which could be limited if we experience an &#8220;ownership change.&#8221;</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Our business and operations would suffer in the event of system failures.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and we may incur substantial costs to attempt to recover or reproduce the data. If any disruption or security breach resulted in a loss of or damage to our data or applications or inappropriate disclosure of confidential or proprietary information, we could incur liability and/or the further development of our product candidates could be delayed.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Our operations are vulnerable to interruption by natural disasters, power loss, terrorist activity and other events beyond our control, the occurrence of which could materially harm our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Businesses located in California have, in the past, been subject to electrical blackouts as a result of a shortage of available electrical power and any future blackouts could disrupt our operations. We are vulnerable to a major earthquake, wildfire, inclement weather and other natural and man-made disasters and we have not undertaken a systematic analysis of the potential consequences to our business as a result of any such natural disaster and do not have an applicable recovery plan in place. We carry only limited business interruption insurance that would compensate us for actual losses from interruption of our business that may occur and any losses or damages incurred by us in excess of insured amounts could cause our business to materially suffer.</font></div><div><a name="s748821928EFE544DA78397441D4E745A"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Use of Proceeds</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">On April 14, 2015, our Registration Statements on Form S-1 (file Nos. 333-202740 and 333-203414) were declared effective by the SEC for our initial public offering of common stock, which was completed on April 20, 2015.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;background-color:#ffffff;">There has been no material change in the expected use of the net proceeds from our initial public offering as described in our final prospectus filed with the SEC. Through</font><font style="font-family:Arial;font-size:9.5pt;background-color:#ffffff;">&#32;</font><font style="font-family:Arial;font-size:9.5pt;background-color:#ffffff;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;background-color:#ffffff;">, we used</font><font style="font-family:Arial;font-size:9.5pt;background-color:#ffffff;">&#32;</font><font style="font-family:Arial;font-size:9.5pt;background-color:#ffffff;">$66.1 million</font><font style="font-family:Arial;font-size:9.5pt;background-color:#ffffff;">&#32;</font><font style="font-family:Arial;font-size:9.5pt;background-color:#ffffff;">of the net proceeds from the offering to fund ongoing research and development activities and</font><font style="font-family:Arial;font-size:9.5pt;background-color:#ffffff;">&#32;</font><font style="font-family:Arial;font-size:9.5pt;">general operating expenses</font><font style="font-family:Arial;font-size:9.5pt;background-color:#ffffff;">.</font><font style="font-family:Arial;font-size:9.5pt;">&#32;We intend to use the remaining proceeds to fund our ongoing and future clinical development of rezafungin; the preclinical development, IND-enabling studies and early clinical trials of CD201, our antibody-drug conjugates and/or any other Cloudbreak development candidates; research and discovery efforts related to the expansion of our Cloudbreak immunotherapy platform; and working capital, including general operating expenses. Pending such uses, we&#160;plan to continue investing the unused proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.</font></div><div><a name="s09C305FFBF8251AB9C3D351AA1A323DB"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">None.</font></div><div><a name="s79D2DD8EE60A59F7B51A5467867F513E"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM&#160;4. MINE SAFETY DISCLOSURE</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Not applicable.</font></div><div><a name="sE46D0F97F83351C4BCE4F4E39470E0C8"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM&#160;5. OTHER INFORMATION</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">None.</font></div><div><a name="sD805B9F948B85D55BA59A7E49CAE3D2F"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;-sec-extract:summary;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">53</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 6. EXHIBITS</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3.1(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1610618/000119312515146688/d914065dex31.htm"><font style="font-family:Arial;font-size:9.5pt;">Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3.2(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1610618/000119312515146688/d914065dex32.htm"><font style="font-family:Arial;font-size:9.5pt;">Amended and Restated Bylaws of the Registrant, as currently in effect.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4.1(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1610618/000119312515119340/d843130dex41.htm"><font style="font-family:Arial;font-size:9.5pt;">Form of Common Stock Certificate of the Registrant.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4.2(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1610618/000119312515091277/d843130dex42.htm"><font style="font-family:Arial;font-size:9.5pt;">Second Amended and Restated Investor Rights Agreement, by and among the Registrant and certain of its stockholders, dated February 10, 2015.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4.3(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1610618/000119312516729294/d161044dex102.htm"><font style="font-family:Arial;font-size:9.5pt;">Form of Warrant to Purchase Common Stock issued to Pacific Western Bank.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit311.htm"><font style="font-family:Arial;font-size:9.5pt;">Certification of the Principal Executive Officer pursuant to Rule 13a-14(A) promulgated under the Securities Exchange Act of 1934.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit312.htm"><font style="font-family:Arial;font-size:9.5pt;">Certification of the Principal Financial Officer pursuant to Rule 13a-14(A) promulgated under the Securities Exchange Act of 1934.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">32.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit321.htm"><font style="font-family:Arial;font-size:9.5pt;">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(B) promulgated under the Securities Exchange Act of 1934.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">32.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit322.htm"><font style="font-family:Arial;font-size:9.5pt;">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(B) promulgated under the Securities Exchange Act of 1934.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">XBRL Instance Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">XBRL Taxonomy Extension Schema Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">XBRL Taxonomy Extension Definition Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">XBRL Taxonomy Extension Label Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed on April 24, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(2)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-202740), as amended, originally filed with the SEC on March 13, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(3)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Incorporated by reference to the Registrant's Current Report on Form 8-K, filed on October 3, 2016.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;-sec-extract:summary;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><a name="s2FE6EA8DA1C6599A877E7AEF3C1D370D"></a></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:4%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Cidara Therapeutics, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Date: May 10, 2018</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">/s/ Jeffrey Stein, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Jeffrey Stein, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Date: May 10, 2018</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">/s/ Matthew Onaitis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Matthew Onaitis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Chief Financial Officer and General Counsel</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">54</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD70719462DC656AF8D7F56F3B3F52606"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">PURSUANT TO RULE 13a-14(a) and 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">I, Jeffrey Stein, Ph.D., certify that:</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1. I have reviewed this quarterly report on Form 10-Q of Cidara Therapeutics, Inc.;</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:8px;text-indent:73px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:8px;text-indent:73px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">b. evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:8px;text-indent:73px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">c. disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:8px;text-indent:73px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:8px;text-indent:73px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;font-size:9.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Date: May 10, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">/s/ Jeffrey Stein, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Jeffrey Stein, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312.htm
<DESCRIPTION>CERTIFICATION OF CFO PUSRUANT TO SECURITIES EXCHANGE ACT OF 1934
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDEBD78A76E4252FAB011D4DA8FE468A3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">PURSUANT TO RULE 13a-14(a) and 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">I, Matthew Onaitis, certify that:</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1. I have reviewed this quarterly report on Form 10-Q of Cidara Therapeutics, Inc.;</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:8px;text-indent:73px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:8px;text-indent:73px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">b. evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:8px;text-indent:73px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">c. disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:8px;text-indent:73px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:8px;text-indent:73px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;font-size:9.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Date: May 10, 2018</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">/s/ Matthew Onaitis</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Matthew Onaitis</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Chief Financial Officer and General Counsel</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO SARBANES-OXLEY ACT OF 2002
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD3691FF467F5545E8EEBFFD877C0E89C"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;text-indent:37px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In connection with the quarterly report of Cidara Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended </font><font style="font-family:Arial;font-size:9.5pt;background-color:#ffffff;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jeffrey Stein, Ph.D., President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></div><div style="line-height:120%;padding-top:8px;text-indent:73px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="line-height:120%;padding-top:8px;text-indent:73px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;font-size:9.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Date: May 10, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">/s/ Jeffrey Stein, Ph.D.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Jeffrey Stein, Ph.D.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section&#160;1350 and is not being filed as part of the Report or as a separate disclosure document.</font></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit322.htm
<DESCRIPTION>CERTIFICATION OF CFO PURSUANT TO SARBANES-OXLEY ACT OF 2002
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD5A6B5A1F4D25F8092116E6A01C134AC"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Exhibit 32.2</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;text-indent:37px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In connection with the quarterly report of Cidara Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended </font><font style="font-family:Arial;font-size:9.5pt;background-color:#ffffff;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">&#32;as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Matthew Onaitis, Chief Financial Officer and General Counsel of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></div><div style="line-height:120%;padding-top:8px;text-indent:73px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="line-height:120%;padding-top:8px;text-indent:73px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;font-size:9.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Date: May 10, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">/s/ Matthew Onaitis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Matthew Onaitis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Chief Financial Officer and General Counsel</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section&#160;1350 and is not being filed as part of the Report or as a separate disclosure document.</font></div><div style="line-height:120%;padding-top:16px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>cdtx-20180331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:E2C40C664B275CC8B5EAE412C145B997,x:88e092b70f954e1ebeeb9a9d077b006f-->
<xbrli:xbrl xmlns:cdtx="http://cidara.com/20180331" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="cdtx-20180331.xsd" xlink:type="simple" />
	<xbrli:context id="FD2018Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Apr30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cdtx_CommonStockSubjectToRepurchaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdtx:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdtx:CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cdtx_CommonStockSubjectToRepurchaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdtx:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdtx:CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct3_us-gaap_DebtInstrumentAxis_cdtx_LoanandSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:LoanandSecurityAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-03</xbrli:startDate>
			<xbrli:endDate>2016-10-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct3_us-gaap_DebtInstrumentAxis_cdtx_LoanandSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:LoanandSecurityAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_DebtInstrumentAxis_cdtx_LoanandSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:LoanandSecurityAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct3_us-gaap_DebtInstrumentAxis_cdtx_LoanandSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:LoanandSecurityAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-03</xbrli:startDate>
			<xbrli:endDate>2016-10-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct3_us-gaap_DebtInstrumentAxis_cdtx_TermLoanBMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:TermLoanBMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct3_us-gaap_DebtInstrumentAxis_cdtx_TermLoanAMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:TermLoanAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_DebtInstrumentAxis_cdtx_TermLoanAMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:TermLoanAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_SubsidiarySaleOfStockAxis_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_cdtx_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_AwardTypeAxis_cdtx_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_AwardTypeAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_AwardTypeAxis_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_AwardTypeAxis_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q1_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1EquityIncentivePlan_us-gaap_PlanNameAxis_cdtx_TwoThousandFifteenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1EquityIncentivePlan_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1EquityIncentivePlan_us-gaap_PlanNameAxis_cdtx_TwoThousandFifteenEquityIncentivePlanMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1EquityIncentivePlan_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_us-gaap_PlanNameAxis_cdtx_TwoThousandFifteenEquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cdtx:MoreThanTenPercentVotingRightsClassesOfStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1EquityIncentivePlan_us-gaap_PlanNameAxis_cdtx_TwoThousandFifteenEquityIncentivePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cdtx_CommonStockSubjectToRepurchaseMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdtx:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1EquityIncentivePlan_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1CARBX_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-30</xbrli:startDate>
			<xbrli:endDate>2017-03-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2May10_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="option">
		<xbrli:measure>cdtx:option</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>cdtx:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="claim">
		<xbrli:measure>cdtx:claim1</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="payment">
		<xbrli:measure>cdtx:payment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="vote_per_share">
		<xbrli:measure>cdtx:vote_per_share</xbrli:measure>
	</xbrli:unit>
	<cdtx:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2016Q4" decimals="-3" id="Fact-3329E888872C52B8B4CF45C2EAF5413C" unitRef="usd">85367000</cdtx:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<cdtx:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q1" decimals="-3" id="Fact-D9592FFB65865BB5BEA3B371282B2D3C" unitRef="usd">82198000</cdtx:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<cdtx:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q4" decimals="-3" id="Fact-086C4A4A9CCE52CAB48515FA64BBD9A4" unitRef="usd">60813000</cdtx:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<cdtx:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q1" decimals="-3" id="Fact-EDF455D9689B5AB699120273C49AAD19" unitRef="usd">53010000</cdtx:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<cdtx:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2017Q1QTD" decimals="-3" id="Fact-93881F6537FF528794E71E36A664509A" unitRef="usd">-3169000</cdtx:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<cdtx:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2018Q1YTD" decimals="-3" id="Fact-08FDD81C2769527C80776931CEBEBA0E" unitRef="usd">-7803000</cdtx:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<cdtx:CommonStockDividendsInArrearsOrDefault contextRef="FD2018Q1YTD" decimals="INF" id="Fact-8CBE4C5F336C5902B10F4D51B90E6025" unitRef="usd">0</cdtx:CommonStockDividendsInArrearsOrDefault>
	<cdtx:ContractualObligationContractTerminationNoticePeriod contextRef="FD2018Q1YTD" id="Fact-7DD8B27F285256D99C71D133936E195B">P30D</cdtx:ContractualObligationContractTerminationNoticePeriod>
	<cdtx:DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone contextRef="D2016Q4Oct3_us-gaap_DebtInstrumentAxis_cdtx_LoanandSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember" id="Fact-4B6B6D70282D5026965EF4C0CC8E603C">P6M</cdtx:DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone>
	<cdtx:DebtInstrumentMaximumBorrowingCapacity contextRef="I2016Q4Oct3_us-gaap_DebtInstrumentAxis_cdtx_LoanandSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember" decimals="INF" id="Fact-09507632C3D5573C923112A4696C4F30" unitRef="usd">20000000.0</cdtx:DebtInstrumentMaximumBorrowingCapacity>
	<cdtx:DebtInstrumentMaximumBorrowingCapacity contextRef="I2016Q4Oct3_us-gaap_DebtInstrumentAxis_cdtx_TermLoanBMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember" decimals="INF" id="Fact-A5BBD6BA9B8657C6A2717A84082D3071" unitRef="usd">10000000.0</cdtx:DebtInstrumentMaximumBorrowingCapacity>
	<cdtx:DebtInstrumentNumberofPaymentsofPrincipalandInterest contextRef="I2016Q4Oct3_us-gaap_DebtInstrumentAxis_cdtx_LoanandSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember" decimals="INF" id="Fact-86501A5960EE5050876059E0A68765A2" unitRef="payment">24</cdtx:DebtInstrumentNumberofPaymentsofPrincipalandInterest>
	<cdtx:DebtSecuritiesAvailableForSaleGainLoss contextRef="FD2017Q1QTD" decimals="INF" id="Fact-164E12E0F9CCB81A858B3A67FC5F40D1" unitRef="usd">0</cdtx:DebtSecuritiesAvailableForSaleGainLoss>
	<cdtx:DebtSecuritiesAvailableForSaleGainLoss contextRef="FD2018Q1YTD" decimals="INF" id="Fact-62307D9936FE95A9AD6F3A67FC5636FC" unitRef="usd">0</cdtx:DebtSecuritiesAvailableForSaleGainLoss>
	<cdtx:DeferredFinancingCostIncurredButNotYetPaid contextRef="FD2017Q1QTD" decimals="-3" id="Fact-74F7B693EB607B6808D71795A9162713" unitRef="usd">0</cdtx:DeferredFinancingCostIncurredButNotYetPaid>
	<cdtx:DeferredFinancingCostIncurredButNotYetPaid contextRef="FD2018Q1YTD" decimals="-3" id="Fact-6C308A6753B63FB5ED161795A919662A" unitRef="usd">133000</cdtx:DeferredFinancingCostIncurredButNotYetPaid>
	<cdtx:IncreaseInBaseRentAnnual contextRef="FD2018Q1YTD" decimals="INF" id="Fact-BF6F8396CB1E5397A8B9BDDD03812FDE" unitRef="number">0.03</cdtx:IncreaseInBaseRentAnnual>
	<cdtx:MaturityPeriodOfShortTermInvestments contextRef="FD2017Q4YTD" id="Fact-F6C091EE9DD7562991C23725A0EACF62">P1Y</cdtx:MaturityPeriodOfShortTermInvestments>
	<cdtx:MaturityPeriodOfShortTermInvestments contextRef="FD2018Q1YTD" id="Fact-DDEA0BD4892E556DBD1A92E8A15DB067">P1Y</cdtx:MaturityPeriodOfShortTermInvestments>
	<cdtx:NumberOfOperatingLeaseOptionsForExtension contextRef="FD2018Q1YTD" decimals="INF" id="Fact-56FD515BF8FA5926B2BA610A1C72F026" unitRef="option">2</cdtx:NumberOfOperatingLeaseOptionsForExtension>
	<cdtx:NumberOfVotesEntitlementForEachShareHeld contextRef="FD2018Q1YTD" decimals="INF" id="Fact-E28FCE2DB0CA5EEEB793EE77F2FB6FF6" unitRef="vote_per_share">1</cdtx:NumberOfVotesEntitlementForEachShareHeld>
	<cdtx:ReductioninResearchandDevelopmentExpense contextRef="FD2018Q1QTD_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-38EFAD247375565A8303061EE48473C8" unitRef="usd">3000</cdtx:ReductioninResearchandDevelopmentExpense>
	<cdtx:RevenueRecognitionAgreementTerminationPeriodForWrittenNotice contextRef="D2017Q1CARBX_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" id="Fact-B736D848315C302335EB1836F2498ED9">P30D</cdtx:RevenueRecognitionAgreementTerminationPeriodForWrittenNotice>
	<cdtx:RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase contextRef="D2017Q1CARBX_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-C7FB18CAF4D65707A789940ABA4AF864" unitRef="usd">3900000</cdtx:RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase>
	<cdtx:RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage contextRef="D2017Q1CARBX_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-4D5E8786E01B553D824EF0058E88FF32" unitRef="usd">3000000</cdtx:RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage>
	<cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage contextRef="D2015Q1EquityIncentivePlan_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" decimals="INF" id="Fact-8B313CC04DB458008E838C298EDF0DC0" unitRef="number">0.01</cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage>
	<cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage contextRef="D2015Q1EquityIncentivePlan_us-gaap_PlanNameAxis_cdtx_TwoThousandFifteenEquityIncentivePlanMember" decimals="INF" id="Fact-BF411CE6C87D5D13BBA5C94B2F50FE34" unitRef="number">0.04</cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage>
	<cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold contextRef="D2015Q1EquityIncentivePlan_us-gaap_PlanNameAxis_cdtx_TwoThousandFifteenEquityIncentivePlanMember" decimals="INF" id="Fact-1E8025549C9C53E5AF9A93BEDDA7FC02" unitRef="number">0.1</cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold>
	<cdtx:SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="-3" id="Fact-F5884562C4FE53B6924D49EAB2B8283F" unitRef="usd">21000</cdtx:SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent>
	<cdtx:SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent contextRef="FI2018Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="-3" id="Fact-716EDBACF0EC565EA8DC76338208153C" unitRef="usd">12000</cdtx:SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent>
	<cdtx:VestingOfEarlyExercisedStockOptions contextRef="FD2017Q1QTD" decimals="-3" id="Fact-6A22BCB4430053879CADB1803C0AD1EC" unitRef="usd">16000</cdtx:VestingOfEarlyExercisedStockOptions>
	<cdtx:VestingOfEarlyExercisedStockOptions contextRef="FD2018Q1YTD" decimals="-3" id="Fact-1211E2E14CBA5326B8E12B1552DE9A2C" unitRef="usd">9000</cdtx:VestingOfEarlyExercisedStockOptions>
	<dei:AmendmentFlag contextRef="FD2018Q1YTD" id="Fact-6314C578F0615A13BCE4AAEF50EFF2A9">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2018Q1YTD" id="Fact-8A0CFA9C23E85AB586C4046EDBFD55B6">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2018Q1YTD" id="Fact-60EC00BD1CC35C8F86945FBBD3A76FE6">Q1</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2018Q1YTD" id="Fact-C0B30DD59B5E537AA22E1749F5473A7C">2018</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2018Q1YTD" id="Fact-66951D6DA61D5723BE1DBF4DFE9C49AC">2018-03-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2018Q1YTD" id="Fact-25363BF99FDE57C1A775C26E94ED216E">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2018Q1YTD" id="Fact-C6D2C4BDA2345DED80FBB026B88421F4">0001610618</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2018Q2Apr30" decimals="INF" id="Fact-86DB7CCD65085609AEF3DA35EEB9C1B1" unitRef="shares">21391057</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2018Q1YTD" id="Fact-511E7794E2DE5056BEAAFBF9F7EC063D">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2018Q1YTD" id="Fact-B502E70B5B51524195DFAE20E42AA235">Cidara Therapeutics, Inc.</dei:EntityRegistrantName>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-3635AECBC37F529BAA9006EE0246D300" unitRef="usd">2590000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-5D06DC1059095B99B253DACCA4E8BF92" unitRef="usd">2999000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-C8442A6CDA9A5A55971D927D43ED453F" unitRef="usd">321000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-2EE7BB50888E5EF0820B6080EF87D6FF" unitRef="usd">288000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2017Q1QTD" decimals="-3" id="Fact-BF9299C93C3071DA0790177EAA542024" unitRef="usd">39000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2018Q1YTD" decimals="-3" id="Fact-F2E00069C87B5EADB11F56BA4ACB5091" unitRef="usd">-36000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-FF982298A1F7515A836EAB9196016F81" unitRef="usd">4257000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-A068CE0FA0AB53488F3583D2B27CA56C" unitRef="usd">4516000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4" decimals="-3" id="Fact-947F62376B5E5CF79D16BDBBB93FFD70" unitRef="usd">-8000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q1" decimals="-3" id="Fact-E84EC01A9E815BF9A3CA5686586EF45E" unitRef="usd">-18000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2017Q4" decimals="-3" id="Fact-659032F06B785AF7A50007BF5D122C6A" unitRef="usd">209140000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2018Q1" decimals="-3" id="Fact-095C55396D5857EDA9DD143C44EF328D" unitRef="usd">217073000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1QTD" decimals="-3" id="Fact-327FD69D39C55D9D83644519456BFA26" unitRef="usd">1051000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-AC5F711A4ADA5C689DC5544402F1C7ED" unitRef="usd">619000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-230B91A41ECD56A6B2E7610E87F2E169" unitRef="usd">432000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-8CF45EEFF3E05F5CBD022FFADA2AA25C" unitRef="usd">821000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-68D48DD961E45321BD68FE2E462EE9FB" unitRef="usd">640000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD" decimals="-3" id="Fact-F535F8E3BAE2577B8A30ACBAD37A23B5" unitRef="usd">1461000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" decimals="0" id="Fact-90E5E214899E55B4A3B6EF5237389B9F" unitRef="usd">67000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2017Q1QTD" decimals="-3" id="Fact-2021D46AF7BB516C596B177EAA58AD64" unitRef="usd">19000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2018Q1YTD" decimals="-3" id="Fact-2A7073CE33FD562BABD90397AC30FFE5" unitRef="usd">20000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1QTD" decimals="0" id="Fact-F366E4756CB75693B422347E85CA5C58" unitRef="shares">3168954</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember" decimals="0" id="Fact-B44F17B1CFA6531983B3AC5C6A4745C1" unitRef="shares">3130426</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cdtx_CommonStockSubjectToRepurchaseMember" decimals="0" id="Fact-E676E9CD010B5C6DBC2530BD747FC310" unitRef="shares">21197</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-2F15A8C941A451B1AFC5C8864F2537E1" unitRef="shares">17331</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q1YTD" decimals="0" id="Fact-172B6CA7CA98570C8C87BE75CB741533" unitRef="shares">4375312</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember" decimals="0" id="Fact-FFEA81C3C4E65F058FAE1753AB511537" unitRef="shares">4352640</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cdtx_CommonStockSubjectToRepurchaseMember" decimals="0" id="Fact-C3456CC20F3250779CC613E97D92DF08" unitRef="shares">5341</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-A5375063917350E2BE28FF89172970FC" unitRef="shares">17331</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-3" id="Fact-9D8719110B1D5E0FAA5C836748755240" unitRef="usd">79035000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2018Q1" decimals="-3" id="Fact-0FB6283BB8B2518DAEC947F61DC7EFC1" unitRef="usd">70247000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-01D5DE5A95BE5E1587D6160CF02B6199" unitRef="usd">77670000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-04124C6C1BA25A869AE26B0E2733F8FA" unitRef="usd">68990000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-73607F0C5C1C58C6A27269FDAA6C53B9" unitRef="usd">11556000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5E470701D31856A78F83CA4750330A41" unitRef="usd">63101000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0FABF1CAB481547496846276841634F2" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-898C0B9A019C54A7A19D19CE479AAB37" unitRef="usd">74657000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C7D180E8ACF45BB9910CC4A6EF8C9780" unitRef="usd">6038000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A60871C372F75CDBA010BCCFBBABB665" unitRef="usd">59973000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A0D0089FA7F15C828083EB3049012435" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D55F4C8E2D4150E5B00B750513079B00" unitRef="usd">66011000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-CD2B5C3DC23A5C48BB94E81AA7EA2507" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A8635A34CEDA539FA08BA88B4D6C5073" unitRef="usd">15101000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1B10563C613D5BC9869FB37D5455E652" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6943A76F9C7355F18C52934CB39A8C68" unitRef="usd">15101000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-98C491469D4F597FAB61C23F7AF6B806" unitRef="usd">11556000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-53340B0C7FA052BE8E506F564592A160" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C62695BE043353569D4B1C2D708F2099" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6A38A03597AC5A29A0643782CA95A950" unitRef="usd">11556000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A415CFC9543B1B3AF7E9181882729C75" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DCF4DF6737A3A95ECE6F181886AD14CE" unitRef="usd">48000000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-15386A22D54DE5A68B1B18188AEB033D" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-AA1824370441C80679F318187F8507EA" unitRef="usd">48000000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-277A970434A25EB78C07E6FBA3DC90E2" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-3062F7C2CFC955528DE6C934F31367B7" unitRef="usd">13973000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" id="Fact-E30AEEA10F085E83A8855E015AD40316" unitRef="usd" xsi:nil="true" />
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-60FCEDDAED935041AF30CFD1D6A7122D" unitRef="usd">13973000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-2D2386FF4D6051FAB2B7ACEA8DCCB1A0" unitRef="usd">6038000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1494E14BAC5954CFB566743C03841111" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-BB2CDC0DD18255518E4B98D5979BD35A" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-4701B9ABC7B057C9945772ED9910A534" unitRef="usd">6038000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-046E0B8BFEBC53FDBB3A1FDC43C4281A" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C90BC80B4DCB5252897FF993296E8222" unitRef="usd">46000000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-7F81A7D8E3A05F4C82AED896156C5C25" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-67D8BC9646E6534280698583442D85C0" unitRef="usd">46000000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4" decimals="-3" id="Fact-9D53E4FC25AE5AB589A70FEA893B8307" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-34A4AAEFD91E590E9A2D2BD5450C1647" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q1" decimals="-3" id="Fact-BF805026D57250BB9A0A973DAA2315C5" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q1_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-6E1E0AAD12B0506E87B3FD24C48739F7" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4" decimals="-3" id="Fact-5565EE6B0D88531B82EA45167A05959D" unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-6AD586C0D8D651A8BBC618B61C209229" unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q1" decimals="-3" id="Fact-715B0E0A454559E29D909EAD4E2C0D38" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q1_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-180FD45790A655D0B0FC9B6099BFF3EE" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4" decimals="-3" id="Fact-EB701FAC04DA5925BF7D06FD62664617" unitRef="usd">14509000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-6663FC19C0685D60A5548A8BF13721CD" unitRef="usd">14509000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q1" decimals="-3" id="Fact-49E4DF8679325939ACA34605D9767A8B" unitRef="usd">13991000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q1_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-3C83DFD6184556568A896601CFCCCFA3" unitRef="usd">13991000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-5475881945635B9EA9DFED6437918197" unitRef="usd">14501000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-51FD6750F5F15BA9AC6417E8A7D369B2" unitRef="usd">13973000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4" decimals="-3" id="Fact-E64EA043BBE956FBA904C4E5AB5099BD" unitRef="usd">14501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-5543D01DCE555D548A71F94088880056" unitRef="usd">14501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q1" decimals="-3" id="Fact-35203B43055B518EB532BEB9B5D9B211" unitRef="usd">13973000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q1_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-E4F76C84C3C75D18AE686A33E7F71A90" unitRef="usd">13973000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:BilledContractReceivables contextRef="FI2018Q1_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-11C4B81EFC3D5FA991DAD68FEC3A283D" unitRef="usd">100000</us-gaap:BilledContractReceivables>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-D29C4A409E3E947290C218E1EC3C14B3" unitRef="usd">60813000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q1" decimals="-3" id="Fact-4398509207B758FBBEEBD60B83EE30DF" unitRef="usd">52218000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" id="Fact-9513C198C8BA54B18BD4E859C2F4E738" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q1" id="Fact-04D1E5DA882058DB90ACCE0BB6BD77C2" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2017Q4" decimals="INF" id="Fact-2AC690F26D795949B7D9A9A60273A7B3" unitRef="shares">4503686</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2017Q4_us-gaap_AwardTypeAxis_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember" decimals="INF" id="Fact-16A869D659DD51ADB7B8C6CAA938831C" unitRef="shares">3099173</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2017Q4_us-gaap_AwardTypeAxis_cdtx_EmployeeStockPurchasePlanMember" decimals="INF" id="Fact-528F5A87E8B85C4C9FDB97F6CDA3C1AB" unitRef="shares">380875</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2017Q4_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEquityIncentivePlanMember" decimals="INF" id="Fact-46E3A4B02BB754B3A8D605E11D89924B" unitRef="shares">1006307</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-8F752ED2DF41F3713C6718263B3819FC" unitRef="shares">17331</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q1" decimals="INF" id="Fact-80D25DD3A6995C7D938E31BB76D30463" unitRef="shares">5745407</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q1_us-gaap_AwardTypeAxis_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember" decimals="INF" id="Fact-865BF9C2E52C57F29B1F3FD608DECF89" unitRef="shares">4352640.00</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q1_us-gaap_AwardTypeAxis_cdtx_EmployeeStockPurchasePlanMember" decimals="INF" id="Fact-011580F65F0D50509334F5F5436D1AD2" unitRef="shares">586148</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q1_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEquityIncentivePlanMember" decimals="INF" id="Fact-AAF4D0DFB7325FC1A20E23530D7B40C6" unitRef="shares">789288</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q1_us-gaap_AwardTypeAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-A91678A26E7793FFB1221826371EE18A" unitRef="shares">17331</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-0A10784985FE5125B1A03948739D9A8F" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q1" decimals="INF" id="Fact-FC8EF40BDC0E513F816DB6F96910D65C" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-60B15E74BBA8505BB70B0476F9BBE000" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q1" decimals="INF" id="Fact-2C50771131B255DFBCE16AFBC6F2AD36" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-F2B84FC430E85D5C923EA139E61B95C5" unitRef="shares">21389736</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q1" decimals="INF" id="Fact-C7AB24278DDD5F3A86862D2D668D46DA" unitRef="shares">21395077</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-E976087F5FC05ACF9F266DE2F864F19F" unitRef="shares">20525688</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q1" decimals="INF" id="Fact-9E282EDC76C25EE791C2EAF5D111E54E" unitRef="shares">20534993</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-8BEE41BB482A5984B49F031ADA11BA91" unitRef="usd">2000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2018Q1" decimals="-3" id="Fact-8C1972DFACFD5C52A3510D2E65630542" unitRef="usd">2000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q1QTD" decimals="-3" id="Fact-243C6BA99CF9549BB0F0A87057E62DFF" unitRef="usd">-13401000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q1YTD" decimals="-3" id="Fact-5C495995F8955658909FA29516BFCAD0" unitRef="usd">-16759000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="D2016Q4Oct3_us-gaap_DebtInstrumentAxis_cdtx_LoanandSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" decimals="INF" id="Fact-3DBD3ADC65645C439FECFBFE6C69A22F" unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2016Q4Oct3_us-gaap_DebtInstrumentAxis_cdtx_TermLoanAMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember" decimals="INF" id="Fact-48C0EA94BFCD54A59AE821FE90D129DD" unitRef="usd">10000000.0</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_cdtx_LoanandSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember" decimals="INF" id="Fact-A7D64300373A57BE8FD147ADC728D631" unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2016Q4Oct3_us-gaap_DebtInstrumentAxis_cdtx_LoanandSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember" decimals="INF" id="Fact-D6B0102965885DDA8D220CE475DF23BB" unitRef="number">0.045</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DepreciationAndAmortization contextRef="FD2017Q1QTD" decimals="-3" id="Fact-DF49C2E0559E50868BF7B1B6AC3F4101" unitRef="usd">198000</us-gaap:DepreciationAndAmortization>
	<us-gaap:DepreciationAndAmortization contextRef="FD2018Q1YTD" decimals="-3" id="Fact-D8410B686C2D54FA87FD3DD52A426EEB" unitRef="usd">139000</us-gaap:DepreciationAndAmortization>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q1QTD" decimals="2" id="Fact-ED264BAE318957BEAD92FB3A7FA5FCF3" unitRef="usdPerShare">-0.80</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q1YTD" decimals="2" id="Fact-BBCA00D9BF7756458E3F42D934CC064F" unitRef="usdPerShare">-0.80</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-36224283B4CE596FBA3AD0093B408F43" unitRef="usd">2571000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-0A218F6A0C495DAF842AE01FFA59B7DE" unitRef="usd">1921000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2018Q1" decimals="-5" id="Fact-58FAE86BE1555E1A8316F173FB44F906" unitRef="usd">8400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2018Q1YTD" id="Fact-7E66526DBC685159924D10FC32D1B10B">P2Y3M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" id="Fact-0DF279BB3E235CCAB64DE136A66A9F92">P10M21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="FI2018Q1_us-gaap_AwardTypeAxis_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" decimals="-5" id="Fact-C04CFD8FB5375604BF335DE5E690DAEE" unitRef="usd">1400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="FI2018Q1_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-5517CDE2FF0950618FD4CF11C42E8411" unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q1QTD" decimals="-3" id="Fact-A6678CC77BCE5F8CAF8320DF4AB6FFDA" unitRef="usd">3155000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q1YTD" decimals="-3" id="Fact-9DEC8FEE680A56F795088FC55E23FED9" unitRef="usd">3611000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GrantsReceivable contextRef="I2018Q2May10_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-7A8663B5E53AA5E8317B458617CFC39A" unitRef="usd">5500000</us-gaap:GrantsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2017Q1QTD" decimals="-3" id="Fact-6327EDA954D35CF4B2D8600CF3CAF5E4" unitRef="usd">-799000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2018Q1YTD" decimals="-3" id="Fact-1E15307B8981554EBD3529C553F6541F" unitRef="usd">549000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="FD2017Q1QTD" decimals="-3" id="Fact-32F9AFDA1FBF564CA4205BD150118B21" unitRef="usd">-1129000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="FD2018Q1YTD" decimals="-3" id="Fact-BB90905D589954EEBBC663C19216BE6E" unitRef="usd">-650000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q1QTD" decimals="-3" id="Fact-4386A68BE4235940AE61EC56A15CB50A" unitRef="usd">416000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2018Q1YTD" decimals="-3" id="Fact-6788D8E9672F525CA17D15DC9A6049A5" unitRef="usd">-482000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2017Q1QTD" decimals="-3" id="Fact-7E2EE12CF77A5C868C4E2C58F7965773" unitRef="usd">0</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2018Q1YTD" decimals="-3" id="Fact-D5D2233EEA705CDFA0FA9D1BC1219733" unitRef="usd">61000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestPaid contextRef="FD2017Q1QTD" decimals="-3" id="Fact-13DAC599E357567D8A2C884C654ABBB2" unitRef="usd">118000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2018Q1YTD" decimals="-3" id="Fact-27561349002D5B67BA54124A8F64B052" unitRef="usd">137000</us-gaap:InterestPaid>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2017Q1QTD" decimals="-3" id="Fact-B1E7A2A49CAF5B61837393E607F9810A" unitRef="usd">179000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2018Q1YTD" decimals="-3" id="Fact-77F08A7708EE5919A61F0768698B4086" unitRef="usd">174000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm contextRef="FD2018Q1YTD" id="Fact-4952762D658D5976BF1DA62029F482FB">P2Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-3" id="Fact-C720059D627B5F658460390B7125DB13" unitRef="usd">19291000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2018Q1" decimals="-3" id="Fact-CC74BDFF298453E0A9E50330E6C5E28C" unitRef="usd">19328000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-1136285AF23A5820A35290F1C6058D53" unitRef="usd">79035000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q1" decimals="-3" id="Fact-C3F81CA12EC05188A076193C745EEDD4" unitRef="usd">70247000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-9B91D09DAA7255A3BA5DE824BB77A109" unitRef="usd">12085000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-DFF642837C7658DB87E55BD6B94AD170" unitRef="usd">11519000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LoansPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-02ACB37D789E56B78DC5BD27D38AEEA2" unitRef="usd">2667000</us-gaap:LoansPayableCurrent>
	<us-gaap:LoansPayableCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-D60233B58DCE57C487AABD8E4553BFCB" unitRef="usd">2083000</us-gaap:LoansPayableCurrent>
	<us-gaap:LongTermDebt contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_cdtx_TermLoanAMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember" decimals="-3" id="Fact-B741A4026F825882AF1064E169D07873" unitRef="usd">10000000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_cdtx_TermLoanAMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember" decimals="-3" id="Fact-4D680EE40F3156CAB4B8B47BE9BA548F" unitRef="usd">4167000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_cdtx_TermLoanAMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember" decimals="-3" id="Fact-D685012F07A954AFBDF1BF4104E34093" unitRef="usd">5000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_cdtx_TermLoanAMember_us-gaap_LongtermDebtTypeAxis_cdtx_TermLoanMember" decimals="-3" id="Fact-F89D4702E340597AB53E2BF23D468FE4" unitRef="usd">833000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
	<us-gaap:LongTermLoansPayable contextRef="FI2017Q4" decimals="-3" id="Fact-4E0948AB2D8D5748A426D7B6E416D125" unitRef="usd">7206000</us-gaap:LongTermLoansPayable>
	<us-gaap:LongTermLoansPayable contextRef="FI2018Q1" decimals="-3" id="Fact-A19657E14DD55F929A35C291CCCF32E6" unitRef="usd">7809000</us-gaap:LongTermLoansPayable>
	<us-gaap:LossContingencyPendingClaimsNumber contextRef="FI2018Q1" decimals="INF" id="Fact-CE34A81DE83D5D9B97E4A22E240F85BC" unitRef="claim">0</us-gaap:LossContingencyPendingClaimsNumber>
	<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="FD2017Q1QTD" decimals="-3" id="Fact-BB1E6202AB2F577DAF2E35826B423C0D" unitRef="usd">65000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="FD2018Q1YTD" decimals="-3" id="Fact-E2B04D4621045E3CA75678D207824D03" unitRef="usd">6468000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2017Q1QTD" decimals="-3" id="Fact-643C78E76F2B5F9FACBE2F5EC00C2C20" unitRef="usd">11284000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2018Q1YTD" decimals="-3" id="Fact-BE1BD36C2A3D58B8B744DE25BD8A93B1" unitRef="usd">451000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2017Q1QTD" decimals="-3" id="Fact-46A8FCE2062459EEB4581192F2E38532" unitRef="usd">-14518000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2018Q1YTD" decimals="-3" id="Fact-3E50B3897DFC543B8B871243A7706192" unitRef="usd">-14722000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1QTD" decimals="-3" id="Fact-CCAFE34D12065DB48F8E9DABB8D3A03E" unitRef="usd">-13398000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1YTD" decimals="-3" id="Fact-0724831C159E5E2CA447EC68A04B80D3" unitRef="usd">-16749000</us-gaap:NetIncomeLoss>
	<us-gaap:NumberOfOperatingSegments contextRef="FD2018Q1YTD" decimals="INF" id="Fact-432A1150589458659175B959352F5081" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:OperatingExpenses contextRef="FD2017Q1QTD" decimals="-3" id="Fact-0E5146CBED0E5E4193E32CD7FA9C1FDE" unitRef="usd">13398000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q1YTD" decimals="-3" id="Fact-845E8A14570A5AB9A15D5B8A95300E28" unitRef="usd">16810000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q1QTD" decimals="-3" id="Fact-324CC9BED38F5ED1BDE833723931CFCF" unitRef="usd">-13398000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q1YTD" decimals="-3" id="Fact-95EA78C04E8057989A37BE35FA1C15AA" unitRef="usd">-16810000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2018Q1" decimals="-3" id="Fact-08858EAC960459B7B950CDAE5EE94376" unitRef="usd">562000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="FI2018Q1" decimals="-3" id="Fact-117A83B00BE65006892398D19469375F" unitRef="usd">562000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-DFD51F0E8A935ED99D2211C023B3EC18" unitRef="usd">321000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q1" decimals="-3" id="Fact-70D25D7859D7544BA9F93AFD9951EE53" unitRef="usd">321000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q1QTD" decimals="-3" id="Fact-9EBEDBC1714D562492BDEC5941AB4429" unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2018Q1YTD" decimals="-3" id="Fact-0A12AD0C9B135CD5A08F117CF892357A" unitRef="usd">-10000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q1QTD" decimals="-3" id="Fact-B897C149DD585ECBAC29975E33EED7F2" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q1YTD" decimals="-3" id="Fact-570F7AD2D62F52A5B4959C0A5F227D56" unitRef="usd">61000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="FD2017Q1QTD" decimals="INF" id="Fact-A607A60567FF007E426C317D00A9B330" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="FD2018Q1YTD" decimals="INF" id="Fact-213122FC69317B0D3B48317D00B14122" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:PaymentsForRepurchaseOfEquity contextRef="FD2017Q1QTD" decimals="-3" id="Fact-013982CBF05B5E8A89FAC078CA99B30F" unitRef="usd">79000</us-gaap:PaymentsForRepurchaseOfEquity>
	<us-gaap:PaymentsForRepurchaseOfEquity contextRef="FD2018Q1YTD" decimals="-3" id="Fact-EF10EFF22B645D7F84CA51134D88769B" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfEquity>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q1QTD" decimals="-3" id="Fact-5B115B95A96A5BB087E541C2433B0F7B" unitRef="usd">116000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q1YTD" decimals="-3" id="Fact-E763BF53BA2853279F4EB649B13B3CA0" unitRef="usd">31000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquireShortTermInvestments contextRef="FD2017Q1QTD" decimals="-3" id="Fact-5F499DEE8EA45C7EA5CE838CC4BD0ECD" unitRef="usd">0</us-gaap:PaymentsToAcquireShortTermInvestments>
	<us-gaap:PaymentsToAcquireShortTermInvestments contextRef="FD2018Q1YTD" decimals="-3" id="Fact-5038F4A1EBD45E2CAD8E26BDBB1A5717" unitRef="usd">5803000</us-gaap:PaymentsToAcquireShortTermInvestments>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-ECC9DAAA1EA75D22A117069D0DE2044E" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q1" decimals="INF" id="Fact-20A98ADE39185B6D8E9E91D234FF818E" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-D353C3D0952C587AA3E6A808B42DCAE7" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q1" decimals="INF" id="Fact-F378A34894D35CA98D1A9C50A32F62B6" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-9AC9ED732160547EA295FFA258FA3429" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q1" decimals="INF" id="Fact-E49F6FE3C6E8505BA88AD1E025AF6021" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-5C08AA32156757A2877AC0AF03D6E099" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q1" decimals="INF" id="Fact-BA3F6ED6599A5AC8B3DF5B1879C67DE6" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-C0A80614EB8E53EDB28016C96518DD78" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2018Q1" decimals="-3" id="Fact-C3196FA42FA9536CB6AB57618CF6CA97" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-3A40B3D591CB506DAF8D236E3209F7E0" unitRef="usd">2035000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-CD603BBB46CD5EAFAD9009B193026EDE" unitRef="usd">1719000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2017Q1QTD" decimals="-3" id="Fact-26C9995E8D2A209C154C177AA1504437" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2018Q1YTD" decimals="-3" id="Fact-9C701F0153B9DAF7E0FF177AA003A019" unitRef="usd">6440000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="FD2017Q1QTD" decimals="-3" id="Fact-C641B6FE57765CBC98A654F544A4C594" unitRef="usd">11400000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="FD2018Q1YTD" decimals="-3" id="Fact-4BDBB21D6DA45EEAACF59C3A871556A6" unitRef="usd">6285000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2017Q1QTD" decimals="-3" id="Fact-88D563BBAE5E56BF98B12A790D8EE4DB" unitRef="usd">144000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2018Q1YTD" decimals="-3" id="Fact-ACCF1E87645C5909975FA921246B1660" unitRef="usd">28000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q4" decimals="-3" id="Fact-A44733B7BC695422933A8965B94AEBA6" unitRef="usd">1044000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q1" decimals="-3" id="Fact-84D77BFC6FC45041973B10D0E4254E89" unitRef="usd">936000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q1QTD" decimals="-3" id="Fact-4644D341080A515EB74CFA454021D0EA" unitRef="usd">10243000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q1YTD" decimals="-3" id="Fact-BCE6022DF41A5CD89B94E57D6BB588F7" unitRef="usd">13199000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-C7C4085C94743809B80D176B5A4DF24E" unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q1" decimals="-3" id="Fact-457DC3328051FB22FFD2176B5A53FB56" unitRef="usd">792000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-3" id="Fact-CEE3ADB8EA315CE8BD160EF8F1A43BB6" unitRef="usd">-149390000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q1" decimals="-5" id="Fact-778D525A0E9A5FBEB2A526D83B17B5AF" unitRef="usd">-166100000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q1" decimals="-3" id="Fact-FE7D09BC89B05DAD817BA0DC73AA4C37" unitRef="usd">-166138000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="FD2018Q1YTD_us-gaap_SubsidiarySaleOfStockAxis_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" decimals="-5" id="Fact-D3900DBC5B0463724D6F1822F781C6BF" unitRef="usd">6400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="FD2018Q1YTD_us-gaap_SubsidiarySaleOfStockAxis_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" decimals="INF" id="Fact-2D69DAB6F02D6F9E93BF1822A2D90BA5" unitRef="shares">847937</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q1QTD" decimals="-3" id="Fact-EC1A58A26A1C5715B9FA16E09D67AF0F" unitRef="usd">1051000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q1YTD" decimals="-3" id="Fact-6E68A36909175939B1DCA032209CB101" unitRef="usd">1461000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2015Q1EquityIncentivePlan_us-gaap_PlanNameAxis_cdtx_TwoThousandFifteenEquityIncentivePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-033AD5CA68FD59FBA9070D9BAFF2D7E4">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2015Q1EquityIncentivePlan_us-gaap_PlanNameAxis_cdtx_TwoThousandFifteenEquityIncentivePlanMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-A6BD5C2218EB51779D69A693F9B1EFCD">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" id="Fact-E773FB9803E658089BE4B1C5304D0434">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" decimals="INF" id="Fact-0CDE99024F07530C8D1D5732747D00AD" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" decimals="INF" id="Fact-50750FD2075350FB91E6D76BF0601D9F" unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" decimals="INF" id="Fact-0312AD4A07465F068948B1AB57AD09B6" unitRef="shares">227500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q1_us-gaap_AwardTypeAxis_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" decimals="INF" id="Fact-D0F4B47D80835D07B484DB8D8B9E7E19" unitRef="shares">257500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" decimals="INF" id="Fact-8BEBA0827A9054678D444021B7ED50FD" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef="FI2015Q1_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" decimals="INF" id="Fact-AF89CFCBBFFF5FD994F697EEB385A815" unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2015Q1EquityIncentivePlan_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-190E65C05805595B9A8B9FA5B742438C" unitRef="shares">490336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2018Q1" decimals="INF" id="Fact-F6275A51DB85505EA17866DED94935D2" unitRef="shares">1937526</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2018Q1" decimals="2" id="Fact-ABC29913944B514A8960179E0FD5F9C0" unitRef="usdPerShare">7.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2018Q1YTD" decimals="INF" id="Fact-9D74D74A6D625AE497BC6C84557F89B3" unitRef="shares">1136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2018Q1YTD" decimals="INF" id="Fact-55CB33FFEBC0564BBAC39D4F01DA724E" unitRef="shares">1009250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q1YTD" decimals="2" id="Fact-963280766F9850179B1835F839FD8187" unitRef="usdPerShare">3.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2017Q4" decimals="-3" id="Fact-1BBBEF48C06D8BFB23FB182BBEED8246" unitRef="usd">2264000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2018Q1" decimals="-3" id="Fact-0109D2EEAF6F5C58A9E92DE0604B2550" unitRef="usd">837000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4" decimals="INF" id="Fact-7A8BEF5E72DC55ADB970D10F038BF4FD" unitRef="shares">3099173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q1" decimals="INF" id="Fact-E68C39F700FC56F6BBFD335F759A0EFF" unitRef="shares">4095140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4" decimals="2" id="Fact-68B736DDCF175D5EA5CC59678E403B83" unitRef="usdPerShare">7.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q1" decimals="2" id="Fact-74BC6C7A89825443AB69641D1C19C90B" unitRef="usdPerShare">6.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2018Q1" decimals="-3" id="Fact-56FF20E81EE557629FB8DEC2B851C04E" unitRef="usd">837000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2018Q1" decimals="INF" id="Fact-77D25796B2E75B5E94F7D203A61FC517" unitRef="shares">4095140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2018Q1" decimals="2" id="Fact-64F4F35C8DE05E8CAC58DED7D4C56CEF" unitRef="usdPerShare">6.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2018Q1YTD" decimals="2" id="Fact-E789BD9D950357B3985D89E13BF729B1" unitRef="usdPerShare">2.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2018Q1YTD" decimals="2" id="Fact-4ECC1047141457D080FDD69138942028" unitRef="usdPerShare">11.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q1YTD" decimals="2" id="Fact-904CAB825F0B516786326E812349AA80" unitRef="usdPerShare">4.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="D2015Q1EquityIncentivePlan_us-gaap_PlanNameAxis_cdtx_TwoThousandFifteenEquityIncentivePlanMember" id="Fact-504AD354EFF35D04A304AF5B53AE081D">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2018Q1" decimals="-3" id="Fact-E9C88E347C0959279734008BD3407AC4" unitRef="usd">746000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q1YTD" id="Fact-81E13385EDAB5D949C4D59E0D5AD4424">P7Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="FI2018Q1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cdtx_CommonStockSubjectToRepurchaseMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" decimals="INF" id="Fact-CE1B4C9FA9765C1B89D0D66468D339B1" unitRef="shares">5341</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q4YTD" id="Fact-47491604EFBE67740338182BBEE39BFD">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q1YTD" id="Fact-12FA670541195D96848E5FF714F71962">P8Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q1YTD" id="Fact-FD8861690CE7504F904074C392122C26">P8Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2018Q1YTD" decimals="-5" id="Fact-F4E8B4D7B06E54179ECC1E38ED95A821" unitRef="usd">1200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="D2015Q1EquityIncentivePlan_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" decimals="INF" id="Fact-03FA1FBED6C455F7A360994A98157A45" unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="D2015Q1EquityIncentivePlan_us-gaap_ConversionOfStockByUniqueDescriptionAxis_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_us-gaap_PlanNameAxis_cdtx_TwoThousandFifteenEquityIncentivePlanMember" decimals="INF" id="Fact-8E1221099CD35181893F2C6FA7386A6C" unitRef="number">1.1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="D2015Q1EquityIncentivePlan_us-gaap_PlanNameAxis_cdtx_TwoThousandFifteenEquityIncentivePlanMember" decimals="INF" id="Fact-9F1391CFAB2D54AA832BD467F13ABBE0" unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" decimals="INF" id="Fact-463FFA1E966F5EB9A4BAE700FB4215A3" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q1YTD" decimals="INF" id="Fact-E74339AE26BC59BCB344E079649CAD81" unitRef="shares">12147</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-50C1862FE03F5402A646163B1B3EBC02" unitRef="usd">59744000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1" decimals="-3" id="Fact-1C17D00D93E45E69BAB452A0806B67C6" unitRef="usd">50919000</us-gaap:StockholdersEquity>
	<us-gaap:StraightLineRent contextRef="FD2017Q1QTD" decimals="-3" id="Fact-C39B31DD74955D6EBAD721ED815FF427" unitRef="usd">5000</us-gaap:StraightLineRent>
	<us-gaap:StraightLineRent contextRef="FD2018Q1YTD" decimals="-3" id="Fact-6E424F44C25E50E5B90A41951FCE20E9" unitRef="usd">10000</us-gaap:StraightLineRent>
	<us-gaap:UnbilledContractsReceivable contextRef="FI2018Q1_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-44A007EA5890500DB2F42281489F066D" unitRef="usd">200000</us-gaap:UnbilledContractsReceivable>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q1QTD" decimals="0" id="Fact-89FEF20C09465C53928425971D5CC746" unitRef="shares">16795366</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q1YTD" decimals="0" id="Fact-F82401B91F3150B8807D70F54A9A4290" unitRef="shares">20894353</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<cdtx:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="FD2018Q1YTD" id="Fact-3AD08BF165B1511F81CBE295A1CEF236">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The following table summarizes the available-for-sale securities held at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;As of March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Corporate debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;13,991&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;(18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;13,991&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;(18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Corporate debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;14,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;(8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;14,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;14,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;(8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;14,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</cdtx:DebtSecuritiesAvailableForSaleTableTextBlock>
	<cdtx:UnauditedInterimFinancialDataPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-C4C0582ACE795064A8D6816F9BBFBD56">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Unaudited Interim Financial Data&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&amp;#160;Certain information and footnote disclosures normally included in the Company&amp;#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&amp;#8217;s financial position and results of operations for the interim periods ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</cdtx:UnauditedInterimFinancialDataPolicyTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-4A9709F8E8845453912A9CE662AFC089">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company has a limited operating history and the sales and income potential of the Company&amp;#8217;s business and market are unproven. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced net losses and negative cash flows from operating activities since its inception. At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, the Company had an accumulated deficit of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$166.1 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&amp;#8217;s cost structure. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;In accordance with ASU 2014-15, management is required to perform a two-step analysis over its ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company's ability to continue as a going concern (step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (step 2). The evaluation period is through one year beyond the date the financial statements were released (assumed to be through May 9, 2019).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company has prepared cash flow forecasts which indicate, based on its current cash resources available and access to capital under its Loan Agreement with Pacific Western Bank that it will not have sufficient resources to fund its business, including its ongoing clinical trials, for at least the next 12 months from the date of this filing.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company will need to raise additional capital to fund its losses from operations. It anticipates raising capital through debt and equity financing, through government funding or through collaborations or partnerships with other entities. Debt or equity financing, government funding or collaborations and partnerships with other entities may not be available on a timely basis on terms acceptable to the Company, or at all. If the Company is not able to secure adequate additional funding, the Company may be forced to delay, reduce or eliminate its research and development programs or future commercialization efforts, or to make reductions in spending, extend payment terms with suppliers, liquidate or grant rights to assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&amp;#8217;s business, results of operations and future prospects.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Management has developed a plan to implement cost cutting measures to reduce its working capital requirements over the next 12 months if an adequate level of financing is not secured. The plan includes the delay of certain of the Company&amp;#8217;s development activities, a delay in hiring and a reduction of other discretionary expenditures that are within the Company&amp;#8217;s control. Any of the actions contemplated by the implementation of this plan, if required, could have an adverse impact on the Company&amp;#8217;s ability to achieve certain of its planned objectives during 2018, and thus, materially harm the Company&amp;#8217;s business.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="FD2018Q1YTD" id="Fact-4B479B75BB4F5FD09CF45C1B3C1F2C27">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;THE COMPANY AND BASIS OF PRESENTATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Description of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives. The Company&amp;#8217;s product portfolio is comprised of proprietary product candidates for the treatment of serious fungal and bacterial infections.&amp;#160;In March 2016, the Company formed a wholly-owned subsidiary, Cidara Therapeutics UK Limited, in England for the purpose of developing its product candidates in Europe.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company has a limited operating history and the sales and income potential of the Company&amp;#8217;s business and market are unproven. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced net losses and negative cash flows from operating activities since its inception. At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, the Company had an accumulated deficit of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$166.1 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&amp;#8217;s cost structure. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;In accordance with ASU 2014-15, management is required to perform a two-step analysis over its ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company's ability to continue as a going concern (step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (step 2). The evaluation period is through one year beyond the date the financial statements were released (assumed to be through May 9, 2019).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company has prepared cash flow forecasts which indicate, based on its current cash resources available and access to capital under its Loan Agreement with Pacific Western Bank that it will not have sufficient resources to fund its business, including its ongoing clinical trials, for at least the next 12 months from the date of this filing.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company will need to raise additional capital to fund its losses from operations. It anticipates raising capital through debt and equity financing, through government funding or through collaborations or partnerships with other entities. Debt or equity financing, government funding or collaborations and partnerships with other entities may not be available on a timely basis on terms acceptable to the Company, or at all. If the Company is not able to secure adequate additional funding, the Company may be forced to delay, reduce or eliminate its research and development programs or future commercialization efforts, or to make reductions in spending, extend payment terms with suppliers, liquidate or grant rights to assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&amp;#8217;s business, results of operations and future prospects.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Management has developed a plan to implement cost cutting measures to reduce its working capital requirements over the next 12 months if an adequate level of financing is not secured. The plan includes the delay of certain of the Company&amp;#8217;s development activities, a delay in hiring and a reduction of other discretionary expenditures that are within the Company&amp;#8217;s control. Any of the actions contemplated by the implementation of this plan, if required, could have an adverse impact on the Company&amp;#8217;s ability to achieve certain of its planned objectives during 2018, and thus, materially harm the Company&amp;#8217;s business.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Unaudited Interim Financial Data&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&amp;#160;Certain information and footnote disclosures normally included in the Company&amp;#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&amp;#8217;s financial position and results of operations for the interim periods ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Basis of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&amp;#8217;s consolidated financial statements relate to estimating the fair value of the Company&amp;#8217;s stock options and certain accruals, including those related to nonclinical and clinical activities. Although the estimates are based on the Company&amp;#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; operating segment.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
	<us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="FD2018Q1YTD" id="Fact-4A5B007A41BF579FAC42755D3146E35E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Cash, and Cash Equivalents, and Restricted Cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Restricted cash represents cash held in a segregated bank account related to a commercial letter of credit to facilitate payment to a foreign supplier.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-6ABEA5FEB87F5E1CA2811773B2E95BA5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;SIGNIFICANT AGREEMENTS AND CONTRACTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Combating Antibiotic Resistant Bacteria Accelerator (CARB-X) Subaward Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;On March 30, 2017, the Company entered into a Cost Reimbursement Research Subaward Agreement (the "Subaward Agreement") with the Trustees of Boston University. Under the Subaward Agreement, the Company is a subawardee under the CARB-X program. CARB-X is a public-private partnership focused on antibacterials, created by the U.S. Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), and National Institute of Allergy and Infectious Diseases (NIAID). CARB-X is funded by BARDA and the London-based Wellcome Trust, a global charitable foundation (Wellcome), and administered by the Boston University School of Law.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The subaward was intended to support development of the Company's CD201 product candidate.  Under the Subaward Agreement, during an initial phase that began on April 1, 2017 and ends upon acceptance by the U.S. Food and Drug Administration of an initial new drug application, CARB-X would reimburse up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$3.9 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; of qualifying development expenses. If all of the milestones in such initial phase are met, the CARB-X Joint Oversight Committee will evaluate the progress made in such initial phase and determine whether to exercise its option to fund a second stage. During the second stage, CARB-X would reimburse up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; of qualifying development expenses through a Phase 1 clinical trial. Such second stage would be subject to a new subaward agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Under the Subaward Agreement, the Company is reimbursed for direct costs incurred plus allowable indirect costs which consist of fringe benefits and allowable general and administrative expenses.  For the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; month period ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, the Company recognized reductions to research and development expenses of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$3,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; for costs eligible for reimbursement under the Subaward Agreement.  As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, billed accounts receivable were &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; and unbilled accounts receivable were &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; related to reimbursable expenses under the Subaward Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Subaward Agreement can be terminated upon the delivery of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; days written notice to the Company for default or convenience. Upon receipt of a notice of termination, the Company must discontinue contract activities and CARB-X must pay the Company a final settlement based on eligible expenses incurred under the Subaward Agreement.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Based on preclinical studies of CD201 as well as preclinical studies of antibody-drug conjugates (ADCs) from the Cloudbreak program, the Company decided in February 2018 to cease development of CD201 to focus on the more promising ADCs for the same indication. Based on the decision to focus efforts on the ADCs, the Company will no longer be seeking funding under the Subaward Agreement relating to CD201.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-495496F9456A5250A53E658762F78669">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; claims or actions pending against the Company as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; which will have, individually or in the aggregate, a material adverse effect on its business, liquidity, financial position, or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in such matters may arise from time to time that may harm the Company&amp;#8217;s business.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Lease Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;In June 2014, the Company entered into an operating lease agreement for laboratory and office space in San Diego, California. Amendments for additional space were entered into in February 2015, March 2015, and August 2015.&amp;#160;&amp;#160;The lease expires in December 2018 with options for &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; individual &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;-year extensions. The lease is subject to charges for common area maintenance and other costs, and base rent is subject to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; annual increases every July. Rent expense is being recorded on a straight-line basis over the life of the lease.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Future minimum payments required under the lease as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; are summarized as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Rent expense was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$174,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$179,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Contractual Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company enters into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or within &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; days of notice.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-8454C472E2B15399A7E42CE78051233F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Comprehensive Loss&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. The Company&amp;#8217;s only component of other comprehensive loss is unrealized losses on marketable securities. Comprehensive losses have been reflected in the condensed consolidated statements of operations and comprehensive loss for all periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2018Q1YTD" id="Fact-71B13E2A1E2F5F5DA4E265D63AF8E424">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company&amp;#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. Periodically, the Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-97D3B3002DB651E28383D911344E455D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Basis of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-EF05B3ACDD1E59628B398AABE68C1684">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;DEBT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-style:italic;font-weight:bold;"&gt;Term Loans&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212; On October 3, 2016, the Company entered into a loan and security agreement, (the "Loan Agreement"), with Pacific Western Bank, as the collateral agent and a lender (the "Lender"), pursuant to which the Lender agreed to lend to the Company up to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;in a series of term loans. Contemporaneously, the Company borrowed&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;from the Lender (the "Term A Loan").&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Under the terms of the Loan Agreement, because the Company achieved of positive Phase 2 clinical results from the STRIVE Phase 2 clinical trial of rezafungin by March 31, 2018 (the "Milestone"), the Company may, at its sole discretion through&amp;#160;October&amp;#160;3, 2018, borrow from the Lender up to an additional&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;(the "Term B Loan," and together with the Term A Loan, the "Term Loans").  Upon the occurrence of certain events, including but not limited to the Company&amp;#8217;s failure to satisfy its payment obligations under the Loan Agreement, the breach of certain of its other covenants under the Loan Agreement, including any future milestone put into place to replace the Milestone, or the occurrence of a material adverse change, the collateral agent will have the right, among other remedies, to declare all principal and interest and other amounts due to the Lender under the Loan Agreement immediately due and payable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company&amp;#8217;s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of the Company&amp;#8217;s current and future assets, other than its intellectual property, which is subject to a double negative pledge.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Term Loans mature on October&amp;#160;3, 2020 (the "Maturity Date").&amp;#160; Payments under the Term Loans will be interest-only through October 2, 2018, which includes an extension of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;six months&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;which was triggered when the Milestone was achieved. The interest-only period will be followed by&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;24&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;monthly payments of principal and interest. The Term Loans will bear interest at a variable annual rate equal to the greater of (i)&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4.5%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;or (ii)&amp;#160;the Lender&amp;#8217;s prime interest rate plus&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;. At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, the Term Loans bear interest at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;5.75&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;%.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, future principal payments due under the Term A Loan are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Year ended:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;December 31, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total future principal payments due under the Term A Loan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2018Q1YTD" id="Fact-F1FFABE4D76455FABBB2F3B6BE259D02">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;STOCK INCENTIVE PLANS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;2015 Equity Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;In March 2015, the Company&amp;#8217;s board of directors and stockholders approved and adopted the 2015 Equity Incentive Plan (&amp;#8220;2015 EIP&amp;#8221;).&amp;#160;&amp;#160;Under the 2015 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors, or consultants of the Company.&amp;#160;&amp;#160;The number of shares of stock available for issuance under the 2015 EIP will be automatically increased each January 1 by&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;of the outstanding number of shares of the Company&amp;#8217;s common stock on the immediately preceding December 31 or such lesser number as determined by the Company&amp;#8217;s board of directors.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2015 EIP. Stock options granted by the Company generally vest over a&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;- or &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;-year period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; years&amp;#160;from the date of grant. The exercise price for stock options granted under the 2015 EIP must be at a price no less than&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;of the voting power of all classes of stock of the Company, the exercise price shall be no less than&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;110%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;of the estimated value on the date of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;2015 Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;In March 2015, the Company&amp;#8217;s board of directors and stockholders approved and adopted the 2015 Employee Stock Purchase Plan ("ESPP").&amp;#160;The number of shares of stock available for issuance under the ESPP will be automatically increased each January 1 by the lesser of (i)&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;of the outstanding number of shares of the Company&amp;#8217;s common stock on the immediately preceding December 31, (ii)&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;490,336&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;shares, or (iii) such lesser number as determined by the Company&amp;#8217;s board of directors.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The ESPP allows substantially all employees to purchase the Company&amp;#8217;s common stock through a payroll deduction at a price equal to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; of the lower of the fair market value of the stock as of the beginning or the end of each purchase period.&amp;#160;An employee&amp;#8217;s payroll deductions under the ESPP are limited to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; of the employee&amp;#8217;s eligible compensation.  During the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; months ended&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;shares were issued pursuant to the ESPP.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Restricted Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company permits exercise of certain stock options prior to vesting.&amp;#160;&amp;#160;Any such exercised shares are restricted and subject to repurchase by the Company until the conditions for vesting are met.&amp;#160;&amp;#160;At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, the liabilities for the cash received from the early exercise of stock options were &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$12,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$21,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, respectively, and were classified in accrued liabilities on the balance sheet. The Company reduces the liability as the underlying shares vest in accordance with the vesting terms outlined in the stock option agreements, which are generally &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4 years&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;.  At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;5,341&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; unvested shares were subject to repurchase by the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Restricted Stock Units&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The following table summarizes RSU and PRSU activity during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Number of&lt;br clear="none"/&gt;RSUs and PRSUs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;227,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:9px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;RSUs and PRSUs granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;30,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:9px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;RSUs and PRSUs vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:9px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;RSUs and PRSUs canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Outstanding at March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;257,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, stock-based compensation expense related to RSUs and PRSUs was approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$67,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;.  At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, estimated unrecognized compensation expense related to RSUs and PRSUs granted to employees was approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The following table summarizes stock option activity during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Contractual Life&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;in Years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Total Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Intrinsic Value (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;3,099,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;7.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;8.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;2,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:9px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;1,009,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:9px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;(12,147&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;2.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:9px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Options canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;(1,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;11.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Outstanding at March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4,095,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;6.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;8.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Vested and expected to vest at March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4,095,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;6.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;8.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Exercisable at March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;1,937,526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;7.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;7.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Stock-based compensation expense recognized for restricted shares, RSUs, PRSUs, stock options, and the ESPP has been reported in the statements of operations as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;432&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;821&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;619&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;1,461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;1,051&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The weighted-average grant date fair value of employee stock options granted by the Company during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$3.02&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; per share. The total grant date fair value of employee stock options that vested during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, total unrecognized share-based compensation expense related to unvested employee stock options of the Company was approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$8.4 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;2.3&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, total unrecognized compensation expense related to the ESPP was approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;. This unrecognized compensation cost is expected to be recognized over approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;0.9 years&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-F9EDEE1EAA1257189596BF7EE5A4BEF2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested restricted common stock subject to repurchase, warrants, and RSUs and options outstanding under the Company&amp;#8217;s stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2018Q1YTD" id="Fact-9720D8B6621252E6BC8F639A77E7DA20">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;FAIR VALUE MEASUREMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company follows ASC 820-10, Fair Value Measurements and Disclosures, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on the borrowing rates available to the Company for loans with similar terms, which is considered a Level 2 input as described below, the Company believes that the fair value of long-term debt approximates its carrying value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company classifies investments in money market funds within Level 1 as the prices are available from quoted prices in active markets.  Investments in commercial paper, corporate debt and reverse repurchase agreements are classified within Level 2 as these instruments are valued using observable market inputs including reported trades, broker/dealer quotes, bids and/or offers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;None&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; of the Company&amp;#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The following tables summarize the Company&amp;#8217;s financial instruments measured at fair value on a recurring basis (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;TOTAL&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;LEVEL 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;LEVEL 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;LEVEL 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;6,038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;6,038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;U.S. Treasury reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;46,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;46,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Corporate debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total assets at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;66,011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;6,038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;59,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;11,556&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;11,556&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;U.S. Treasury reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;48,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;48,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Corporate debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;15,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;15,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total assets at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;74,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;11,556&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;63,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-A05E462F4F2A59F38172678284758D6B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company follows ASC 820-10 issued by the FASB with respect to fair value reporting for financial assets and liabilities.  The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company&amp;#8217;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, and long-term debt. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, prepaid expenses, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. The fair value of short-term investments is based upon market prices quoted on the last day of the fiscal period or other observable market inputs. The Company believes that the fair value of long-term debt approximates its carrying value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-0D42B2C69D415A49BFBFC15ED3FE66A0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company follows the FASB's ASC 740, Income Taxes, in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&amp;#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the "Tax Act"), which among other provisions, reduced the U.S. corporate tax rate from 35% to 21%, effective January 1, 2018.&amp;#160; Due to the timing of the enactment and the complexity involved in applying the provisions of the Tax Act, the Company made reasonable estimates of the effects and recorded provisional amounts in our financial statements as of December 31, 2017.  As the Company collects and prepares necessary data, and continues to interpret the Tax Act and any additional guidance issued by the U.S. Treasury Department, the Internal Revenue Service (IRS) and other standard-setting bodies, the Company may make adjustments to the provisional amounts. Those adjustments may affect deferred tax balances.  However, due to the valuation allowance position, the Company expects there will be no net impact to the financial statements. The Company did not make any such adjustments during the quarter ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;. Any adjustments to account for the tax effects of the Tax Act would be made in a subsequent quarter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InvestmentPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-4DD523EF891F5A5C95CFC73442893A8F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Investments Available-for-Sale&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in accumulated other comprehensive loss. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. The amortization of premiums and accretion of discounts is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income. Securities with maturity dates of 12 months or less from the date of purchase are classified as short-term investments and securities with maturity dates of more than 12 months are classified as long-term investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
	<us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-37CFAC73AB2C5FA8A513FD1FA4608FB1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;SHORT-TERM INVESTMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The following table summarizes the available-for-sale securities held at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;As of March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Corporate debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;13,991&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;(18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;13,991&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;(18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Corporate debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;14,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;(8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;14,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;14,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;(8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;14,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;All available-for-sale securities held at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; had maturities of less than &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;one year&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;.  Unrealized gains and losses on available-for-sale securities are included as a component of other comprehensive loss. The securities in unrealized loss positions have not been in a continuous unrealized loss position for 12 months or longer.  The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.  The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company&amp;#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. During the three months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, respectively, the Company did not recognize any impairment or gains or losses on sales of available-for-sale securities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-58B635ABC19E5DF0B4A9CCB1CD9E2604">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Recently Issued Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;During 2016, the FASB issued ASU 2016-02, &amp;#8220;Leases,&amp;#8221; which requires that operating lease arrangements longer than 12 months result in an entity recognizing an asset and liability. The updated guidance is effective for interim and annual periods beginning after December 15, 2018, and early adoption is permitted. The Company currently expects that its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and operating lease liabilities upon the adoption of ASU&amp;#160;2016-02, which will increase the total assets and total liabilities that it reports relative to such amounts prior to adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Recently Adopted Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;During 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)," which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 outlines a five-step process for revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards, and also requires enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenues and cash flows from contracts with customers.  Numerous ASUs were issued in 2016 and 2017 to require additional disclosures, to provide clarification on a number of specific issues pertaining to ASU 2014-09, and to defer the effective date for ASU 2014-09 to interim and annual periods beginning after December 31, 2017.  The Company adopted ASC 606 effective January 1, 2018.  The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2018Q1YTD" id="Fact-90269078F3645472838BBD5DA538AEA6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Grant Funding&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company has received research and development funding through a grant from CARB-X, a public-private partnership focused on antibacterials. The Company has evaluated the terms of the grant to assess its obligations and the classification of funding received. Amounts billable for funded research and development are recognized in the statement of operations as a reduction to research and development expense over the grant period as the related costs are incurred to meet the Company's obligations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Research and Development Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&amp;#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-63CF69EE53D95FCD9495DC41BBE67479">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company recognizes revenues when customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under Accounting Standards Update ("ASU") No. 2014-09 ("ASU 2014-09"): (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Under the Subaward Agreement, the Company is reimbursed for direct costs incurred plus allowable indirect costs which consist of fringe benefits and allowable general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2018Q1YTD" id="Fact-9030F2F34A405DE7B2DFC8688A896A20">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Common stock options and RSUs issued and outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4,352,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;3,130,426&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;17,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;17,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Common stock subject to repurchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;5,341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;21,197&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4,375,312&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;3,168,954&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2018Q1YTD" id="Fact-AE3EE157E6995F688802C0AD54B221F1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Stock-based compensation expense recognized for restricted shares, RSUs, PRSUs, stock options, and the ESPP has been reported in the statements of operations as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;432&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;821&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;619&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;1,461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;1,051&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2018Q1YTD" id="Fact-4C08DAFCFF335FE6B6FBCE004E285B70">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The following tables summarize the Company&amp;#8217;s financial instruments measured at fair value on a recurring basis (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;TOTAL&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;LEVEL 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;LEVEL 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;LEVEL 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;6,038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;6,038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;U.S. Treasury reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;46,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;46,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Corporate debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;13,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total assets at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;66,011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;6,038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;59,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;11,556&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;11,556&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;U.S. Treasury reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;48,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;48,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Corporate debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;15,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;15,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total assets at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;74,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;11,556&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;63,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2018Q1YTD" id="Fact-2F2FB13ED83D54C98F61031508655898">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Future minimum payments required under the lease as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; are summarized as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2018Q1YTD" id="Fact-2AAF29FEB97459A6B497F5CB8521BE1B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, future principal payments due under the Term A Loan are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Year ended:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;December 31, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total future principal payments due under the Term A Loan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2018Q1YTD" id="Fact-09DB0EB336025ADFA78D968E73187D84">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The following table summarizes stock option activity during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Contractual Life&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;in Years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Total Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Intrinsic Value (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;3,099,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;7.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;8.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;2,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:9px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;1,009,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:9px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;(12,147&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;2.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:9px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Options canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;(1,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;11.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Outstanding at March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4,095,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;6.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;8.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Vested and expected to vest at March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4,095,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;6.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;8.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Exercisable at March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;1,937,526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;7.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;7.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="FD2018Q1YTD" id="Fact-55FA53AB0D185A609C42C9507AA7EDEA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The following table summarizes RSU and PRSU activity during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;Number of&lt;br clear="none"/&gt;RSUs and PRSUs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;227,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:9px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;RSUs and PRSUs granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;30,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:9px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;RSUs and PRSUs vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:9px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;RSUs and PRSUs canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Outstanding at March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;257,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
	<us-gaap:ScheduleOfStockByClassTextBlock contextRef="FD2018Q1YTD" id="Fact-EB1B02C3134B5B81BE4E1924920F32B2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Common stock reserved for future issuance is as follows (in common stock equivalent shares):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;17,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;17,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Stock options and RSUs issued and outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4,352,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;3,099,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Authorized for future stock awards under the Company's option plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;789,288&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;1,006,307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Authorized for future issuance under the ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;586,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;380,875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;5,745,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4,503,686&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-0CAFAD0DABA5559091F93467089C10BC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; operating segment.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-B47F37E701715B2286F8BE1C64E6C3D1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Patent Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications), and such costs are included in general and administrative expenses in the accompanying statements of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2018Q1YTD" id="Fact-74F896226EEF5EA89B25003570F06DC0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Stock-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company accounts for stock-based compensation expense related to employee stock options and employee stock purchase plan rights by estimating the fair value on the date of grant using the Black-Scholes option pricing model.&amp;#160;The fair value of Restricted Stock Units (RSUs) and Performance-based RSUs (PRSUs) granted to employees is estimated based on the closing price of the Company's common stock on the date of grant. &amp;#160;For awards subject to time-based vesting conditions, stock-based compensation expense is recognized ratably over the requisite service period of the awards. For awards subject to performance-based vesting conditions, the Company assesses the probability of achievement of the individual milestones under the stock-based awards and recognizes stock-based compensation expense over the implicit service period commencing once the Company believes the performance criteria is probable of achievement.  The Company accounts for stock options, RSUs, and PRSUs granted to non-employees using the fair value approach. These stock-based awards are subject to periodic revaluation over their vesting terms. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2018Q1YTD" id="Fact-BD7647F009165FC1884FE04E9BAD1ABF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Cash, and Cash Equivalents, and Restricted Cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Restricted cash represents cash held in a segregated bank account related to a commercial letter of credit to facilitate payment to a foreign supplier.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Investments Available-for-Sale&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in accumulated other comprehensive loss. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. The amortization of premiums and accretion of discounts is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income. Securities with maturity dates of 12 months or less from the date of purchase are classified as short-term investments and securities with maturity dates of more than 12 months are classified as long-term investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company&amp;#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. Periodically, the Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Patent Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications), and such costs are included in general and administrative expenses in the accompanying statements of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company follows the FASB's ASC 740, Income Taxes, in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&amp;#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the "Tax Act"), which among other provisions, reduced the U.S. corporate tax rate from 35% to 21%, effective January 1, 2018.&amp;#160; Due to the timing of the enactment and the complexity involved in applying the provisions of the Tax Act, the Company made reasonable estimates of the effects and recorded provisional amounts in our financial statements as of December 31, 2017.  As the Company collects and prepares necessary data, and continues to interpret the Tax Act and any additional guidance issued by the U.S. Treasury Department, the Internal Revenue Service (IRS) and other standard-setting bodies, the Company may make adjustments to the provisional amounts. Those adjustments may affect deferred tax balances.  However, due to the valuation allowance position, the Company expects there will be no net impact to the financial statements. The Company did not make any such adjustments during the quarter ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;. Any adjustments to account for the tax effects of the Tax Act would be made in a subsequent quarter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company recognizes revenues when customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under Accounting Standards Update ("ASU") No. 2014-09 ("ASU 2014-09"): (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Grant Funding&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company has received research and development funding through a grant from CARB-X, a public-private partnership focused on antibacterials. The Company has evaluated the terms of the grant to assess its obligations and the classification of funding received. Amounts billable for funded research and development are recognized in the statement of operations as a reduction to research and development expense over the grant period as the related costs are incurred to meet the Company's obligations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Research and Development Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&amp;#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Comprehensive Loss&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. The Company&amp;#8217;s only component of other comprehensive loss is unrealized losses on marketable securities. Comprehensive losses have been reflected in the condensed consolidated statements of operations and comprehensive loss for all periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Stock-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company accounts for stock-based compensation expense related to employee stock options and employee stock purchase plan rights by estimating the fair value on the date of grant using the Black-Scholes option pricing model.&amp;#160;The fair value of Restricted Stock Units (RSUs) and Performance-based RSUs (PRSUs) granted to employees is estimated based on the closing price of the Company's common stock on the date of grant. &amp;#160;For awards subject to time-based vesting conditions, stock-based compensation expense is recognized ratably over the requisite service period of the awards. For awards subject to performance-based vesting conditions, the Company assesses the probability of achievement of the individual milestones under the stock-based awards and recognizes stock-based compensation expense over the implicit service period commencing once the Company believes the performance criteria is probable of achievement.  The Company accounts for stock options, RSUs, and PRSUs granted to non-employees using the fair value approach. These stock-based awards are subject to periodic revaluation over their vesting terms. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested restricted common stock subject to repurchase, warrants, and RSUs and options outstanding under the Company&amp;#8217;s stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Common stock options and RSUs issued and outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4,352,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;3,130,426&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;17,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;17,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Common stock subject to repurchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;5,341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;21,197&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4,375,312&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;3,168,954&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company follows ASC 820-10 issued by the FASB with respect to fair value reporting for financial assets and liabilities.  The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company&amp;#8217;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, and long-term debt. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, prepaid expenses, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. The fair value of short-term investments is based upon market prices quoted on the last day of the fiscal period or other observable market inputs. The Company believes that the fair value of long-term debt approximates its carrying value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Recently Issued Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;During 2016, the FASB issued ASU 2016-02, &amp;#8220;Leases,&amp;#8221; which requires that operating lease arrangements longer than 12 months result in an entity recognizing an asset and liability. The updated guidance is effective for interim and annual periods beginning after December 15, 2018, and early adoption is permitted. The Company currently expects that its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and operating lease liabilities upon the adoption of ASU&amp;#160;2016-02, which will increase the total assets and total liabilities that it reports relative to such amounts prior to adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Recently Adopted Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;During 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)," which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 outlines a five-step process for revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards, and also requires enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenues and cash flows from contracts with customers.  Numerous ASUs were issued in 2016 and 2017 to require additional disclosures, to provide clarification on a number of specific issues pertaining to ASU 2014-09, and to defer the effective date for ASU 2014-09 to interim and annual periods beginning after December 31, 2017.  The Company adopted ASC 606 effective January 1, 2018.  The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-34C7F48CD93D53F9BC1BB22F512C7ADD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;STOCKHOLDERS&amp;#8217; EQUITY&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Under the amended and restated certificate of incorporation, the Company&amp;#8217;s board of directors has the authority, without further action by the stockholders, to issue up to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;10,000,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;10,000,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;shares of preferred stock authorized and&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; shares of preferred stock issued or outstanding at&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The Company had&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;200,000,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;shares of common stock authorized as of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;. Holders of outstanding shares of common stock are entitled to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;&amp;#160;vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company&amp;#8217;s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company&amp;#8217;s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in the net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. The common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; dividends in arrears or default. All shares of common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;In November 2017, the Company began to sell shares of common stock under a controlled equity sales agreement with Cantor Fitzgerald &amp;amp; Co.  During the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;, the Company sold &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;847,937&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; shares of common stock for net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$6.4 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; after deducting placement agent fees. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Common Stock Reserved for Future Issuance&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Common stock reserved for future issuance is as follows (in common stock equivalent shares):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;17,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;17,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Stock options and RSUs issued and outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4,352,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;3,099,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Authorized for future stock awards under the Company's option plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;789,288&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;1,006,307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Authorized for future issuance under the ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;586,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;380,875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;5,745,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;4,503,686&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2018Q1YTD" id="Fact-638F93A1A219593CB72884923801BB56">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;SUBSEQUENT EVENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;In May 2018, the Company announced that it and Rutgers University had been awarded a &lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;$5.5 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt; partnership grant from the U.S. National Institute of Allergy and Infectious Diseases ("NIAID") of the National Institutes of Health ("NIH"), an agency of the United States Department of Health and Human Services.  The grant will fund the continued research and development of the Company's Cloudbreak antibody-drug conjugate ("ADC") platform.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2018Q1YTD" id="Fact-0CDAD2E8CF9755CFBC6A61FFC74A14C6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial;font-size:9.5pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&amp;#8217;s consolidated financial statements relate to estimating the fair value of the Company&amp;#8217;s stock options and certain accruals, including those related to nonclinical and clinical activities. Although the estimates are based on the Company&amp;#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>cdtx-20180331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cidara.com/20180331" xmlns:cdtx="http://cidara.com/20180331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20180331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20180331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20180331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20180331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://cidara.com/role/CommitmentsAndContingencies">
        <link:definition>2109100 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://cidara.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2409402 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsRequiredDetails" roleURI="http://cidara.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsRequiredDetails">
        <link:definition>2409403 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Payments Required (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://cidara.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2309301 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompanyAndBasisOfPresentation" roleURI="http://cidara.com/role/CompanyAndBasisOfPresentation">
        <link:definition>2101100 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompanyAndBasisOfPresentationDetails" roleURI="http://cidara.com/role/CompanyAndBasisOfPresentationDetails">
        <link:definition>2401401 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://cidara.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1003000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" roleURI="http://cidara.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://cidara.com/role/Debt">
        <link:definition>2105100 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://cidara.com/role/DebtNarrativeDetails">
        <link:definition>2405402 - Disclosure - DEBT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleOfFuturePrincipalPaymentsDetails" roleURI="http://cidara.com/role/DebtScheduleOfFuturePrincipalPaymentsDetails">
        <link:definition>2405403 - Disclosure - DEBT - Schedule of Future Principal Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://cidara.com/role/DebtTables">
        <link:definition>2305301 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://cidara.com/role/DocumentAndEntityInformation">
        <link:definition>0002000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://cidara.com/role/FairValueMeasurements">
        <link:definition>2104100 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://cidara.com/role/FairValueMeasurementsDetails">
        <link:definition>2404402 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://cidara.com/role/FairValueMeasurementsTables">
        <link:definition>2304301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShortTermInvestments" roleURI="http://cidara.com/role/ShortTermInvestments">
        <link:definition>2103100 - Disclosure - SHORT-TERM INVESTMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShortTermInvestmentsDetails" roleURI="http://cidara.com/role/ShortTermInvestmentsDetails">
        <link:definition>2403402 - Disclosure - SHORT-TERM INVESTMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShortTermInvestmentsTables" roleURI="http://cidara.com/role/ShortTermInvestmentsTables">
        <link:definition>2303301 - Disclosure - SHORT-TERM INVESTMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsAndContracts" roleURI="http://cidara.com/role/SignificantAgreementsAndContracts">
        <link:definition>2108100 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsAndContractsDetails" roleURI="http://cidara.com/role/SignificantAgreementsAndContractsDetails">
        <link:definition>2408401 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlans" roleURI="http://cidara.com/role/StockIncentivePlans">
        <link:definition>2107100 - Disclosure - STOCK INCENTIVE PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansNarrativeDetails" roleURI="http://cidara.com/role/StockIncentivePlansNarrativeDetails">
        <link:definition>2407402 - Disclosure - STOCK INCENTIVE PLANS  - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails" roleURI="http://cidara.com/role/StockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails">
        <link:definition>2407405 - Disclosure - STOCK INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansSummaryOfRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsActivityDetails" roleURI="http://cidara.com/role/StockIncentivePlansSummaryOfRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsActivityDetails">
        <link:definition>2407403 - Disclosure - STOCK INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansSummaryOfStockOptionActivityDetails" roleURI="http://cidara.com/role/StockIncentivePlansSummaryOfStockOptionActivityDetails">
        <link:definition>2407404 - Disclosure - STOCK INCENTIVE PLANS - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansTables" roleURI="http://cidara.com/role/StockIncentivePlansTables">
        <link:definition>2307301 - Disclosure - STOCK INCENTIVE PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://cidara.com/role/StockholdersEquity">
        <link:definition>2106100 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://cidara.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2406402 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" roleURI="http://cidara.com/role/StockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>2406403 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://cidara.com/role/StockholdersEquityTables">
        <link:definition>2306301 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://cidara.com/role/SubsequentEvents">
        <link:definition>2110100 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://cidara.com/role/SubsequentEventsDetails">
        <link:definition>2410401 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails">
        <link:definition>2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract" name="CashFlowNoncashFinancingActivitiesDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_CommonStockDividendsInArrearsOrDefault" name="CommonStockDividendsInArrearsOrDefault" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember" name="CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cdtx_CommonStockSubjectToRepurchaseMember" name="CommonStockSubjectToRepurchaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_ContractualObligationContractTerminationNoticePeriod" name="ContractualObligationContractTerminationNoticePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" name="ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone" name="DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_DebtInstrumentMaximumBorrowingCapacity" name="DebtInstrumentMaximumBorrowingCapacity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest" name="DebtInstrumentNumberofPaymentsofPrincipalandInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="cdtx_DebtSecuritiesAvailableForSaleGainLoss" name="DebtSecuritiesAvailableForSaleGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="cdtx_DebtSecuritiesAvailableForSaleTableTextBlock" name="DebtSecuritiesAvailableForSaleTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_DeferredFinancingCostIncurredButNotYetPaid" name="DeferredFinancingCostIncurredButNotYetPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cdtx_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cdtx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_IncreaseInBaseRentAnnual" name="IncreaseInBaseRentAnnual" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cdtx_LoanandSecurityAgreementMember" name="LoanandSecurityAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_MaturityPeriodOfShortTermInvestments" name="MaturityPeriodOfShortTermInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" name="MoreThanTenPercentVotingRightsClassesOfStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_NumberOfOperatingLeaseOptionsForExtension" name="NumberOfOperatingLeaseOptionsForExtension" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_NumberOfVotesEntitlementForEachShareHeld" name="NumberOfVotesEntitlementForEachShareHeld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_ReductioninResearchandDevelopmentExpense" name="ReductioninResearchandDevelopmentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" name="RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice" name="RevenueRecognitionAgreementTerminationPeriodForWrittenNotice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase" name="RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage" name="RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="cdtx_TermLoanAMember" name="TermLoanAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cdtx_TermLoanBMember" name="TermLoanBMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cdtx_TermLoanMember" name="TermLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" name="TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" name="TwoThousandFifteenEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cdtx_TwoThousandFifteenEquityIncentivePlanMember" name="TwoThousandFifteenEquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_UnauditedInterimFinancialDataPolicyTextBlock" name="UnauditedInterimFinancialDataPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="cdtx_VestingOfEarlyExercisedStockOptions" name="VestingOfEarlyExercisedStockOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>cdtx-20180331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://cidara.com/role/CommitmentsAndContingencies" xlink:href="cdtx-20180331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="cdtx-20180331.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsRequiredDetails" xlink:href="cdtx-20180331.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsRequiredDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CommitmentsAndContingenciesTables" xlink:href="cdtx-20180331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CompanyAndBasisOfPresentation" xlink:href="cdtx-20180331.xsd#CompanyAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CompanyAndBasisOfPresentationDetails" xlink:href="cdtx-20180331.xsd#CompanyAndBasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:href="cdtx-20180331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="cdtx-20180331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="cdtx-20180331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="cdtx-20180331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/Debt" xlink:href="cdtx-20180331.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/DebtNarrativeDetails" xlink:href="cdtx-20180331.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/DebtScheduleOfFuturePrincipalPaymentsDetails" xlink:href="cdtx-20180331.xsd#DebtScheduleOfFuturePrincipalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/DebtTables" xlink:href="cdtx-20180331.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/DocumentAndEntityInformation" xlink:href="cdtx-20180331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/FairValueMeasurements" xlink:href="cdtx-20180331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/FairValueMeasurementsDetails" xlink:href="cdtx-20180331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/FairValueMeasurementsTables" xlink:href="cdtx-20180331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/ShortTermInvestments" xlink:href="cdtx-20180331.xsd#ShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/ShortTermInvestmentsDetails" xlink:href="cdtx-20180331.xsd#ShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/ShortTermInvestmentsTables" xlink:href="cdtx-20180331.xsd#ShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SignificantAgreementsAndContracts" xlink:href="cdtx-20180331.xsd#SignificantAgreementsAndContracts" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SignificantAgreementsAndContractsDetails" xlink:href="cdtx-20180331.xsd#SignificantAgreementsAndContractsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlans" xlink:href="cdtx-20180331.xsd#StockIncentivePlans" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlansNarrativeDetails" xlink:href="cdtx-20180331.xsd#StockIncentivePlansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails" xlink:href="cdtx-20180331.xsd#StockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlansSummaryOfRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsActivityDetails" xlink:href="cdtx-20180331.xsd#StockIncentivePlansSummaryOfRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlansSummaryOfStockOptionActivityDetails" xlink:href="cdtx-20180331.xsd#StockIncentivePlansSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlansTables" xlink:href="cdtx-20180331.xsd#StockIncentivePlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockholdersEquity" xlink:href="cdtx-20180331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockholdersEquityNarrativeDetails" xlink:href="cdtx-20180331.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:href="cdtx-20180331.xsd#StockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockholdersEquityTables" xlink:href="cdtx-20180331.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SubsequentEvents" xlink:href="cdtx-20180331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SubsequentEventsDetails" xlink:href="cdtx-20180331.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cdtx-20180331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" xlink:href="cdtx-20180331.xsd#SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cdtx-20180331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="cdtx-20180331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://cidara.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsRequiredDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_1261866d-0058-b147-bcc2-b0839e573baf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_1261866d-0058-b147-bcc2-b0839e573baf" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://cidara.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/CompanyAndBasisOfPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/CompanyAndBasisOfPresentationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_30444800-bccf-94eb-16a7-6eb32a0bf8df" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_30444800-bccf-94eb-16a7-6eb32a0bf8df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d6e62e4f-fa41-c5ac-31c0-f175f0c219a7" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d6e62e4f-fa41-c5ac-31c0-f175f0c219a7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e20e4396-1ab7-d9ec-b779-e1a72ae620da" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e20e4396-1ab7-d9ec-b779-e1a72ae620da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaap_LoansPayableCurrent_6fc30cd7-3358-ef1a-8a2d-4d262ab979e4" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_LoansPayableCurrent_6fc30cd7-3358-ef1a-8a2d-4d262ab979e4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaap_LongTermLoansPayable_40dd4942-5348-0175-b137-79fc78256987" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LongTermLoansPayable_40dd4942-5348-0175-b137-79fc78256987" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_D2568B265DE12B505315178925CE4C47" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_D2568B265DE12B505315178925CE4C47" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_35d7e9b2-6ffb-6e68-f590-8605f30d5f8a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_DepreciationAndAmortization_35d7e9b2-6ffb-6e68-f590-8605f30d5f8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fe59972c-181e-b516-7ec1-09a40fc27526" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fe59972c-181e-b516-7ec1-09a40fc27526" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StraightLineRent" xlink:label="loc_us-gaap_StraightLineRent_4d4cdfe2-b957-6ee9-00f4-4cd4fb9b1417" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_StraightLineRent_4d4cdfe2-b957-6ee9-00f4-4cd4fb9b1417" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_880f9863-dd81-7240-4418-c9f1ba4fd53e" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_880f9863-dd81-7240-4418-c9f1ba4fd53e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_04170815-b2b6-fb8f-5ca6-e1c62554f777" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_04170815-b2b6-fb8f-5ca6-e1c62554f777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_3358d115-01c9-6550-edda-293e7863fabe" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_3358d115-01c9-6550-edda-293e7863fabe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_D2568B265DE12B505315178925CE4C47" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7eefdb79-b488-fe99-9b8e-a51ddf6de5ad" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7eefdb79-b488-fe99-9b8e-a51ddf6de5ad" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_39ec8106-b5d8-c4fd-2af7-167ed8b78e3a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_39ec8106-b5d8-c4fd-2af7-167ed8b78e3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_D2568B265DE12B505315178925CE4C47" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_53bb4e1b-52b6-1bb1-1672-d14ea634a154" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_53bb4e1b-52b6-1bb1-1672-d14ea634a154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_0c7e1bb4-0316-a815-e61f-9e3418f395f2" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity_0c7e1bb4-0316-a815-e61f-9e3418f395f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_df373d95-9aed-55aa-3255-855344ae0add" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_df373d95-9aed-55aa-3255-855344ae0add" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_045a7791-44b8-d416-a735-af6ac83e7eb3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_045a7791-44b8-d416-a735-af6ac83e7eb3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c3f75946-8339-c884-022f-1e599b08f0f5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c3f75946-8339-c884-022f-1e599b08f0f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2b63fac5-7a72-3880-3fd2-630099895af7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2b63fac5-7a72-3880-3fd2-630099895af7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://cidara.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/DebtNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/DebtScheduleOfFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6baa2d31-3357-b671-25ea-61502c236830" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6baa2d31-3357-b671-25ea-61502c236830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fff555d3-22e2-1be9-15a7-f79f0064a4bb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fff555d3-22e2-1be9-15a7-f79f0064a4bb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c5420c55-b70f-9186-5b0e-88de7d1b3712" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c5420c55-b70f-9186-5b0e-88de7d1b3712" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://cidara.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_a0a1fd33-7636-70e3-0b76-f0755fa3c462" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureRecurring_a0a1fd33-7636-70e3-0b76-f0755fa3c462" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://cidara.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/ShortTermInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/ShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_84c4a6c6-0ef3-3da8-6f9e-7c79d920503a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_84c4a6c6-0ef3-3da8-6f9e-7c79d920503a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e53108a7-1cbc-ad68-00fa-93ab35ee9629" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e53108a7-1cbc-ad68-00fa-93ab35ee9629" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d38a4602-a509-ea84-d4a7-84b6783fb543" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d38a4602-a509-ea84-d4a7-84b6783fb543" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://cidara.com/role/ShortTermInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/SignificantAgreementsAndContracts" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/SignificantAgreementsAndContractsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/StockIncentivePlans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/StockIncentivePlansNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/StockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/StockIncentivePlansSummaryOfRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/StockIncentivePlansSummaryOfStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/StockIncentivePlansTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/StockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/SubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>cdtx-20180331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://cidara.com/role/CommitmentsAndContingencies" xlink:href="cdtx-20180331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="cdtx-20180331.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsRequiredDetails" xlink:href="cdtx-20180331.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsRequiredDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CommitmentsAndContingenciesTables" xlink:href="cdtx-20180331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CompanyAndBasisOfPresentation" xlink:href="cdtx-20180331.xsd#CompanyAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CompanyAndBasisOfPresentationDetails" xlink:href="cdtx-20180331.xsd#CompanyAndBasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:href="cdtx-20180331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="cdtx-20180331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="cdtx-20180331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="cdtx-20180331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/Debt" xlink:href="cdtx-20180331.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/DebtNarrativeDetails" xlink:href="cdtx-20180331.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/DebtScheduleOfFuturePrincipalPaymentsDetails" xlink:href="cdtx-20180331.xsd#DebtScheduleOfFuturePrincipalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/DebtTables" xlink:href="cdtx-20180331.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/DocumentAndEntityInformation" xlink:href="cdtx-20180331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/FairValueMeasurements" xlink:href="cdtx-20180331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/FairValueMeasurementsDetails" xlink:href="cdtx-20180331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/FairValueMeasurementsTables" xlink:href="cdtx-20180331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/ShortTermInvestments" xlink:href="cdtx-20180331.xsd#ShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/ShortTermInvestmentsDetails" xlink:href="cdtx-20180331.xsd#ShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/ShortTermInvestmentsTables" xlink:href="cdtx-20180331.xsd#ShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SignificantAgreementsAndContracts" xlink:href="cdtx-20180331.xsd#SignificantAgreementsAndContracts" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SignificantAgreementsAndContractsDetails" xlink:href="cdtx-20180331.xsd#SignificantAgreementsAndContractsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlans" xlink:href="cdtx-20180331.xsd#StockIncentivePlans" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlansNarrativeDetails" xlink:href="cdtx-20180331.xsd#StockIncentivePlansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails" xlink:href="cdtx-20180331.xsd#StockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlansSummaryOfRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsActivityDetails" xlink:href="cdtx-20180331.xsd#StockIncentivePlansSummaryOfRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlansSummaryOfStockOptionActivityDetails" xlink:href="cdtx-20180331.xsd#StockIncentivePlansSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlansTables" xlink:href="cdtx-20180331.xsd#StockIncentivePlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockholdersEquity" xlink:href="cdtx-20180331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockholdersEquityNarrativeDetails" xlink:href="cdtx-20180331.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:href="cdtx-20180331.xsd#StockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockholdersEquityTables" xlink:href="cdtx-20180331.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SubsequentEvents" xlink:href="cdtx-20180331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SubsequentEventsDetails" xlink:href="cdtx-20180331.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cdtx-20180331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" xlink:href="cdtx-20180331.xsd#SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cdtx-20180331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="cdtx-20180331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://cidara.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsRequiredDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/CompanyAndBasisOfPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/CompanyAndBasisOfPresentationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_A9D8F964DDF75BBBD04718E5BEAEA173" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:to="loc_us-gaap_DebtInstrumentTable_A9D8F964DDF75BBBD04718E5BEAEA173" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_A026A27F0E16A78E1E4E18E5BEAE8510" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A9D8F964DDF75BBBD04718E5BEAEA173" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_A026A27F0E16A78E1E4E18E5BEAE8510" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_CC65DB211004E7F1632F18E5BEAE41AB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A026A27F0E16A78E1E4E18E5BEAE8510" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_CC65DB211004E7F1632F18E5BEAE41AB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_CC65DB211004E7F1632F18E5BEAE41AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A026A27F0E16A78E1E4E18E5BEAE8510" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_CC65DB211004E7F1632F18E5BEAE41AB" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TermLoanMember" xlink:label="loc_cdtx_TermLoanMember_360A64E065CE49BC979E18E5BEAE4158" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_CC65DB211004E7F1632F18E5BEAE41AB" xlink:to="loc_cdtx_TermLoanMember_360A64E065CE49BC979E18E5BEAE4158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7C64A45E11D44F77DB4E18E5BEAE8D80" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A9D8F964DDF75BBBD04718E5BEAEA173" xlink:to="loc_us-gaap_DebtInstrumentAxis_7C64A45E11D44F77DB4E18E5BEAE8D80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1B8C606990ECAE4E97B818E5BEAEA146_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7C64A45E11D44F77DB4E18E5BEAE8D80" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1B8C606990ECAE4E97B818E5BEAEA146_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1B8C606990ECAE4E97B818E5BEAEA146" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7C64A45E11D44F77DB4E18E5BEAE8D80" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1B8C606990ECAE4E97B818E5BEAEA146" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_LoanandSecurityAgreementMember" xlink:label="loc_cdtx_LoanandSecurityAgreementMember_D0B3493803A89D8A6D7318E5BEAEB556" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1B8C606990ECAE4E97B818E5BEAEA146" xlink:to="loc_cdtx_LoanandSecurityAgreementMember_D0B3493803A89D8A6D7318E5BEAEB556" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TermLoanAMember" xlink:label="loc_cdtx_TermLoanAMember_2B64B08F1725CF9A308F18E5BEAEB4DC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1B8C606990ECAE4E97B818E5BEAEA146" xlink:to="loc_cdtx_TermLoanAMember_2B64B08F1725CF9A308F18E5BEAEB4DC" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TermLoanBMember" xlink:label="loc_cdtx_TermLoanBMember_EA62D7933E552AFF370F18E5BEAEED96" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1B8C606990ECAE4E97B818E5BEAEA146" xlink:to="loc_cdtx_TermLoanBMember_EA62D7933E552AFF370F18E5BEAEED96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_84F33D4253CD3F55CC4418E5BEAEE94B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A9D8F964DDF75BBBD04718E5BEAEA173" xlink:to="loc_us-gaap_VariableRateAxis_84F33D4253CD3F55CC4418E5BEAEE94B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_F2D39F6646D3868A3C0918E5BEAE5B38_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_84F33D4253CD3F55CC4418E5BEAEE94B" xlink:to="loc_us-gaap_VariableRateDomain_F2D39F6646D3868A3C0918E5BEAE5B38_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_F2D39F6646D3868A3C0918E5BEAE5B38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_84F33D4253CD3F55CC4418E5BEAEE94B" xlink:to="loc_us-gaap_VariableRateDomain_F2D39F6646D3868A3C0918E5BEAE5B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_91B51BEA1CEEBED7975818E5BEAE7B52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_F2D39F6646D3868A3C0918E5BEAE5B38" xlink:to="loc_us-gaap_PrimeRateMember_91B51BEA1CEEBED7975818E5BEAE7B52" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DebtInstrumentMaximumBorrowingCapacity" xlink:label="loc_cdtx_DebtInstrumentMaximumBorrowingCapacity_18856BB9EE9AF3BC265D18E5BEAE2435" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:to="loc_cdtx_DebtInstrumentMaximumBorrowingCapacity_18856BB9EE9AF3BC265D18E5BEAE2435" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_CC6A0535187A7C72021E18E5BEAF5D3C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_CC6A0535187A7C72021E18E5BEAF5D3C" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone" xlink:label="loc_cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone_4BDDAC100F941907382218E5BEAF2240" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:to="loc_cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone_4BDDAC100F941907382218E5BEAF2240" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest" xlink:label="loc_cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest_E55E220A82747120859918FA3FE5F2A0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:to="loc_cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest_E55E220A82747120859918FA3FE5F2A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CA32F38C31F2403B12C118E5BEAF9044" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CA32F38C31F2403B12C118E5BEAF9044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_A1EC5DFC5A10077C242D18E5BEAF437E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_A1EC5DFC5A10077C242D18E5BEAF437E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://cidara.com/role/DebtScheduleOfFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E6C595BC59FC07BFC81B181459D7D922" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E6C595BC59FC07BFC81B181459D7D922" xlink:to="loc_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_154EC2496AF45E4E435C181459D794DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF" xlink:to="loc_us-gaap_DebtInstrumentAxis_154EC2496AF45E4E435C181459D794DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_BF1D57EC5235C4C486FB181459D70D6C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_154EC2496AF45E4E435C181459D794DD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_BF1D57EC5235C4C486FB181459D70D6C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_BF1D57EC5235C4C486FB181459D70D6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_154EC2496AF45E4E435C181459D794DD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_BF1D57EC5235C4C486FB181459D70D6C" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TermLoanAMember" xlink:label="loc_cdtx_TermLoanAMember_66B93B16DF256EA319BB181459D71979" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BF1D57EC5235C4C486FB181459D70D6C" xlink:to="loc_cdtx_TermLoanAMember_66B93B16DF256EA319BB181459D71979" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_A0B6CE5660B1895EE92E181459D733FE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_A0B6CE5660B1895EE92E181459D733FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_51CACF11A1B3F01BC1FD181459D73E4B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A0B6CE5660B1895EE92E181459D733FE" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_51CACF11A1B3F01BC1FD181459D73E4B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_51CACF11A1B3F01BC1FD181459D73E4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A0B6CE5660B1895EE92E181459D733FE" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_51CACF11A1B3F01BC1FD181459D73E4B" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TermLoanMember" xlink:label="loc_cdtx_TermLoanMember_46950D65F4FB3837DC19181459D79103" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_51CACF11A1B3F01BC1FD181459D73E4B" xlink:to="loc_cdtx_TermLoanMember_46950D65F4FB3837DC19181459D79103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E6C595BC59FC07BFC81B181459D7D922" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BD6D3674286D909E8763181459D870F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BD6D3674286D909E8763181459D870F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_B0E87192A8786063C87E181459D8F3FD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_B0E87192A8786063C87E181459D8F3FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_47C01447493837B43F5E181459D8A24F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_47C01447493837B43F5E181459D8A24F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_8ABD515F683A9F5D61FA181459D8341F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:to="loc_us-gaap_LongTermDebt_8ABD515F683A9F5D61FA181459D8341F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://cidara.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10964069F8D7E29153CD181459E73539" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10964069F8D7E29153CD181459E73539" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8E53A4B89F07F222949B181459E69F85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8E53A4B89F07F222949B181459E69F85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_026D6E8FEBDF4D851E58181459E6683E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8E53A4B89F07F222949B181459E69F85" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_026D6E8FEBDF4D851E58181459E6683E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_026D6E8FEBDF4D851E58181459E6683E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8E53A4B89F07F222949B181459E69F85" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_026D6E8FEBDF4D851E58181459E6683E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_728EF88E0ACFAC91738E181459E65D43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_026D6E8FEBDF4D851E58181459E6683E" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_728EF88E0ACFAC91738E181459E65D43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2CEB18A04184D73AA6A0181459E6D0AE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2CEB18A04184D73AA6A0181459E6D0AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2CEB18A04184D73AA6A0181459E6D0AE" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2CEB18A04184D73AA6A0181459E6D0AE" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7E9063B6EEE1D28C2A16181459E6E042" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7E9063B6EEE1D28C2A16181459E6E042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E1E91BD1716209C18224181459E6A4BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_E1E91BD1716209C18224181459E6A4BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_504041A05B68D9F9B5FA181459E6BABB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_504041A05B68D9F9B5FA181459E6BABB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_CEFBE9041660CCA59AC6181459E69809" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_CEFBE9041660CCA59AC6181459E69809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_CEFBE9041660CCA59AC6181459E69809" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_CEFBE9041660CCA59AC6181459E69809" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5E68F5A80A8CE9A5C3A8181459E6B293" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5E68F5A80A8CE9A5C3A8181459E6B293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_15D737554B69202DFC3B181459E6555F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_15D737554B69202DFC3B181459E6555F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_D58FFCE6327C1E81768C181459E6BBCA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_D58FFCE6327C1E81768C181459E6BBCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_CEBE7D2FA9C29C663ABA181459E752A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10964069F8D7E29153CD181459E73539" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_CEBE7D2FA9C29C663ABA181459E752A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_366955CC412DB53B9648181459E73A7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_CEBE7D2FA9C29C663ABA181459E752A5" xlink:to="loc_us-gaap_AssetsFairValueDisclosureRecurring_366955CC412DB53B9648181459E73A7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_391277DB7F2DD56B5012181459E7753F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_CEBE7D2FA9C29C663ABA181459E752A5" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_391277DB7F2DD56B5012181459E7753F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://cidara.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/ShortTermInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/ShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E73E57A152FDE54C32F440112892CFB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E73E57A152FDE54C32F440112892CFB2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_DDAD4F6584F22600B4C9401128920F89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E73E57A152FDE54C32F440112892CFB2" xlink:to="loc_us-gaap_InvestmentTypeAxis_DDAD4F6584F22600B4C9401128920F89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7F2B844ABE9B2AA40D0C40112892182B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_DDAD4F6584F22600B4C9401128920F89" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7F2B844ABE9B2AA40D0C40112892182B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7F2B844ABE9B2AA40D0C40112892182B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_DDAD4F6584F22600B4C9401128920F89" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7F2B844ABE9B2AA40D0C40112892182B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_FB3EC870C3A0AAAFCA204011289230F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7F2B844ABE9B2AA40D0C40112892182B" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_FB3EC870C3A0AAAFCA204011289230F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FCED9D2FB6802F4C68E240234E38A3AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FCED9D2FB6802F4C68E240234E38A3AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5299D9FAB0E989C0A0334023F7447602" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5299D9FAB0E989C0A0334023F7447602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ED1FBA9032207AB99243402435C57770" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ED1FBA9032207AB99243402435C57770" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6FBAA6271429524E02BF40246A1D814F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6FBAA6271429524E02BF40246A1D814F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://cidara.com/role/ShortTermInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/SignificantAgreementsAndContracts" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/SignificantAgreementsAndContractsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_59AA5A4C8CEA3550F6E8181459A83511" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_59AA5A4C8CEA3550F6E8181459A83511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A1D92D3FE655073767D181459A812EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59AA5A4C8CEA3550F6E8181459A83511" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A1D92D3FE655073767D181459A812EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A1D92D3FE655073767D181459A812EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59AA5A4C8CEA3550F6E8181459A83511" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A1D92D3FE655073767D181459A812EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_774972F53A80B30B81CB181459A80F8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A1D92D3FE655073767D181459A812EF" xlink:to="loc_us-gaap_CollaborativeArrangementMember_774972F53A80B30B81CB181459A80F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_443B3E95A27464398765181459A86633" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4" xlink:to="loc_us-gaap_ProductOrServiceAxis_443B3E95A27464398765181459A86633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_DB85EE24B8B9143D8E44181459A83E60_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_443B3E95A27464398765181459A86633" xlink:to="loc_us-gaap_ProductsAndServicesDomain_DB85EE24B8B9143D8E44181459A83E60_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_DB85EE24B8B9143D8E44181459A83E60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_443B3E95A27464398765181459A86633" xlink:to="loc_us-gaap_ProductsAndServicesDomain_DB85EE24B8B9143D8E44181459A83E60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_BC2A8F2E0C38BCE42886181459A8EBE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_DB85EE24B8B9143D8E44181459A83E60" xlink:to="loc_us-gaap_ProductMember_BC2A8F2E0C38BCE42886181459A8EBE3" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase" xlink:label="loc_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase_A9EB8143160335AE0947181459A97C6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:to="loc_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase_A9EB8143160335AE0947181459A97C6B" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage" xlink:label="loc_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage_D4198CA8C16B705AA2B1181459A93289" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:to="loc_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage_D4198CA8C16B705AA2B1181459A93289" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_ReductioninResearchandDevelopmentExpense" xlink:label="loc_cdtx_ReductioninResearchandDevelopmentExpense_F58AE5E7CB3F1D98D2F9181459A95F54" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:to="loc_cdtx_ReductioninResearchandDevelopmentExpense_F58AE5E7CB3F1D98D2F9181459A95F54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BilledContractReceivables" xlink:label="loc_us-gaap_BilledContractReceivables_4C6B431F468FA8F0BD49181459A9DF2E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:to="loc_us-gaap_BilledContractReceivables_4C6B431F468FA8F0BD49181459A9DF2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="loc_us-gaap_UnbilledContractsReceivable_E62077C1F94911226ADB181459A94BA4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:to="loc_us-gaap_UnbilledContractsReceivable_E62077C1F94911226ADB181459A94BA4" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice" xlink:label="loc_cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice_82631094F0095737F3ED181459A9CC95" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:to="loc_cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice_82631094F0095737F3ED181459A9CC95" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://cidara.com/role/StockIncentivePlans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/StockIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_26E1BC619AAC54B3836EE500E62DC08D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:to="loc_us-gaap_PlanNameAxis_26E1BC619AAC54B3836EE500E62DC08D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_ADFA91293CDAC1AD5D124B240B1E83D3_9E539F612075584EA95802D1F89ABA20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_26E1BC619AAC54B3836EE500E62DC08D" xlink:to="loc_us-gaap_PlanNameDomain_ADFA91293CDAC1AD5D124B240B1E83D3_9E539F612075584EA95802D1F89ABA20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_BC55C61AF500549FA2FF8371AD0AF6CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_26E1BC619AAC54B3836EE500E62DC08D" xlink:to="loc_us-gaap_PlanNameDomain_BC55C61AF500549FA2FF8371AD0AF6CC" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_2624E5357A0B571BAB57EDE08529D420" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_BC55C61AF500549FA2FF8371AD0AF6CC" xlink:to="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_2624E5357A0B571BAB57EDE08529D420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FBA2B7D7F22459FCA81555528992DBC5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:to="loc_us-gaap_RangeAxis_FBA2B7D7F22459FCA81555528992DBC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F82CBAB86367CB810CC64B240B1E5F4B_9E539F612075584EA95802D1F89ABA20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_FBA2B7D7F22459FCA81555528992DBC5" xlink:to="loc_us-gaap_RangeMember_F82CBAB86367CB810CC64B240B1E5F4B_9E539F612075584EA95802D1F89ABA20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_ECF74E5385B55A83AF61F2E21489089C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_FBA2B7D7F22459FCA81555528992DBC5" xlink:to="loc_us-gaap_RangeMember_ECF74E5385B55A83AF61F2E21489089C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_CA3A7EFFA0F256E68CD558BC264F7A45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_ECF74E5385B55A83AF61F2E21489089C" xlink:to="loc_us-gaap_MinimumMember_CA3A7EFFA0F256E68CD558BC264F7A45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_890869B182A7537C9F84EFA249D5037A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_ECF74E5385B55A83AF61F2E21489089C" xlink:to="loc_us-gaap_MaximumMember_890869B182A7537C9F84EFA249D5037A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A00639BC59215837A306FF362AF13BC6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A00639BC59215837A306FF362AF13BC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_BCD325B7EFAA420A63144B240B1E91D0_9E539F612075584EA95802D1F89ABA20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A00639BC59215837A306FF362AF13BC6" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_BCD325B7EFAA420A63144B240B1E91D0_9E539F612075584EA95802D1F89ABA20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_2C55F392A32F5E768C9820C862591BCD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A00639BC59215837A306FF362AF13BC6" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_2C55F392A32F5E768C9820C862591BCD" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:label="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_3C8238317CA157D6BDEC2EEDF7A37680" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_2C55F392A32F5E768C9820C862591BCD" xlink:to="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_3C8238317CA157D6BDEC2EEDF7A37680" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2888BB05594D5A5C865B5B2D9C0C5156" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2888BB05594D5A5C865B5B2D9C0C5156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_AB5F6AE2E3084C0B77964B240B1F572F_9E539F612075584EA95802D1F89ABA20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2888BB05594D5A5C865B5B2D9C0C5156" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_AB5F6AE2E3084C0B77964B240B1F572F_9E539F612075584EA95802D1F89ABA20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0BAAE6B251335938A6054E48BC5781C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2888BB05594D5A5C865B5B2D9C0C5156" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0BAAE6B251335938A6054E48BC5781C5" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CommonStockSubjectToRepurchaseMember" xlink:label="loc_cdtx_CommonStockSubjectToRepurchaseMember_7F99EDB8554F5B75A0515BF0D3260451" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0BAAE6B251335938A6054E48BC5781C5" xlink:to="loc_cdtx_CommonStockSubjectToRepurchaseMember_7F99EDB8554F5B75A0515BF0D3260451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_34C85E2BE2EF5EC591FD299B81E0154C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:to="loc_us-gaap_AwardTypeAxis_34C85E2BE2EF5EC591FD299B81E0154C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F277BEE9BB99A1FF3DD94B240B1FB98E_9E539F612075584EA95802D1F89ABA20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_34C85E2BE2EF5EC591FD299B81E0154C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F277BEE9BB99A1FF3DD94B240B1FB98E_9E539F612075584EA95802D1F89ABA20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14214F9B535359D19D651036326EDF58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_34C85E2BE2EF5EC591FD299B81E0154C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14214F9B535359D19D651036326EDF58" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:label="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_0ADC1A94399B5588A7D88B730D842DA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14214F9B535359D19D651036326EDF58" xlink:to="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_0ADC1A94399B5588A7D88B730D842DA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_E2B4D95A723855548DC497FF011A0367" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14214F9B535359D19D651036326EDF58" xlink:to="loc_us-gaap_RestrictedStockMember_E2B4D95A723855548DC497FF011A0367" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_D4C42F987BD050A1BFCF53EDAD7B0D7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_D4C42F987BD050A1BFCF53EDAD7B0D7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_696617A35A60528EA9E69A37AFD2541D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_696617A35A60528EA9E69A37AFD2541D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_71650BB9573C52068C74454934E2CFF4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_71650BB9573C52068C74454934E2CFF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8D8B1CB66267595087DE77EAEEE9DEE8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8D8B1CB66267595087DE77EAEEE9DEE8" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_F4C7FAA3CEAB5CC8BE0EAB881E15FC4E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_F4C7FAA3CEAB5CC8BE0EAB881E15FC4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_06E3C09F230D56029F025395E9316CE9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_06E3C09F230D56029F025395E9316CE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4C0DE3AA6844551FAE43955D11A8D6F8" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4C0DE3AA6844551FAE43955D11A8D6F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_D0720BEEE879551EB8B71D0259287852" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_D0720BEEE879551EB8B71D0259287852" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent" xlink:label="loc_cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent_96AEE43D8A8B5F998D0EE46C7C68910B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent_96AEE43D8A8B5F998D0EE46C7C68910B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_54CBF30FBB2652C881CB5529D068B991" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_54CBF30FBB2652C881CB5529D068B991" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_79B62E4EE4465957BFCC811A9322B621" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_79B62E4EE4465957BFCC811A9322B621" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5DC1D0998CC75BDF8F45EBE6288B5393" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5DC1D0998CC75BDF8F45EBE6288B5393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_588C39F391D75ACDB4CCA592B53377B7" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_588C39F391D75ACDB4CCA592B53377B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_728051DCB5705572A8C798C071754C38" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_728051DCB5705572A8C798C071754C38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_09A19250F41653E592C5C83AF72F3F0C" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_09A19250F41653E592C5C83AF72F3F0C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://cidara.com/role/StockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9A4A14E6FB335E7C8C56ACA48DA38A74" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29C407EB80105DDDACD13707A5F639D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9A4A14E6FB335E7C8C56ACA48DA38A74" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29C407EB80105DDDACD13707A5F639D1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7053E15520BD5CC38C312D87C9ACA80C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29C407EB80105DDDACD13707A5F639D1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7053E15520BD5CC38C312D87C9ACA80C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_BBDED121016946D682B4D0A840A40FAF_9FF97FA2C0025AA88A5D6FAC1778336B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7053E15520BD5CC38C312D87C9ACA80C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_BBDED121016946D682B4D0A840A40FAF_9FF97FA2C0025AA88A5D6FAC1778336B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_17A327721CA15FD59059938EE8BEA68A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7053E15520BD5CC38C312D87C9ACA80C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_17A327721CA15FD59059938EE8BEA68A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_AC60984680785EA99B89FE95688B8D92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17A327721CA15FD59059938EE8BEA68A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_AC60984680785EA99B89FE95688B8D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_AA333408A20B57CB855A15872914A646" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17A327721CA15FD59059938EE8BEA68A" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_AA333408A20B57CB855A15872914A646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BD3BFAEC5826545AABE8A639C124068D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9A4A14E6FB335E7C8C56ACA48DA38A74" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_BD3BFAEC5826545AABE8A639C124068D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://cidara.com/role/StockIncentivePlansSummaryOfRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8796395E14DF5592BB45751A65471967" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C5A31DE7E2F551088FF5FA580A795B34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8796395E14DF5592BB45751A65471967" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C5A31DE7E2F551088FF5FA580A795B34" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8D5456FD8581598A9A314CEE5CB5D602" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C5A31DE7E2F551088FF5FA580A795B34" xlink:to="loc_us-gaap_AwardTypeAxis_8D5456FD8581598A9A314CEE5CB5D602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65CD7E93645FCA0AE72592FCBB784792_9E539F612075584EA95802D1F89ABA20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8D5456FD8581598A9A314CEE5CB5D602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65CD7E93645FCA0AE72592FCBB784792_9E539F612075584EA95802D1F89ABA20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9F3B81B973C25833A13301238CF565D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8D5456FD8581598A9A314CEE5CB5D602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9F3B81B973C25833A13301238CF565D2" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_CDEC2DF389CF55109578493F1C782A5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9F3B81B973C25833A13301238CF565D2" xlink:to="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_CDEC2DF389CF55109578493F1C782A5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_B13879571E1D5426B93789663665EFD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8796395E14DF5592BB45751A65471967" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_B13879571E1D5426B93789663665EFD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2A421EB965085B1894781897B7754349" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_B13879571E1D5426B93789663665EFD3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2A421EB965085B1894781897B7754349" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_08459F0508745280A5B0BDCB5B85064B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_B13879571E1D5426B93789663665EFD3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_08459F0508745280A5B0BDCB5B85064B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DD502CD41D855FE8B6B0E444399BE742" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_B13879571E1D5426B93789663665EFD3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DD502CD41D855FE8B6B0E444399BE742" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BEAD02972CD45D03A8B10F399B9A6A41" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_B13879571E1D5426B93789663665EFD3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BEAD02972CD45D03A8B10F399B9A6A41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_A007F57BC2485613A13BAE2325E4B61D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8796395E14DF5592BB45751A65471967" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_A007F57BC2485613A13BAE2325E4B61D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_273636C8EFAD54B9BF3BC50AD9BED30A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8796395E14DF5592BB45751A65471967" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_273636C8EFAD54B9BF3BC50AD9BED30A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://cidara.com/role/StockIncentivePlansSummaryOfStockOptionActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/StockIncentivePlansTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_C6E2A9B0895E07DA40671824607CA959" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_C6E2A9B0895E07DA40671824607CA959" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D0CF3FC56171F4EFBE4F18249A6103F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C6E2A9B0895E07DA40671824607CA959" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_D0CF3FC56171F4EFBE4F18249A6103F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6FF6D8B251974F0ECC1318249A68B665_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D0CF3FC56171F4EFBE4F18249A6103F0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6FF6D8B251974F0ECC1318249A68B665_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6FF6D8B251974F0ECC1318249A68B665" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D0CF3FC56171F4EFBE4F18249A6103F0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6FF6D8B251974F0ECC1318249A68B665" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:label="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_D63371394C82FCB2B53F18249A7A7111" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6FF6D8B251974F0ECC1318249A68B665" xlink:to="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_D63371394C82FCB2B53F18249A7A7111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_70D6B28E73169F441973181459CE0B4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_70D6B28E73169F441973181459CE0B4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5DA332846B26C667CA09181459CEBF88" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5DA332846B26C667CA09181459CEBF88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_B22B4485A89F4317DD2F181459CEF247" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_B22B4485A89F4317DD2F181459CEF247" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_CA04B074630CEE53F034181459CFA196" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_CA04B074630CEE53F034181459CFA196" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:label="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_0222B91C3942F07D1974181459CF46E8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_0222B91C3942F07D1974181459CF46E8" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CommonStockDividendsInArrearsOrDefault" xlink:label="loc_cdtx_CommonStockDividendsInArrearsOrDefault_8B9D4F08755CEED8FE91181459CFEE51" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_cdtx_CommonStockDividendsInArrearsOrDefault_8B9D4F08755CEED8FE91181459CFEE51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D5003FAC03D4286FAD9B18249A4FE850" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D5003FAC03D4286FAD9B18249A4FE850" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_654823B8598CA539D1E818249A597B94" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_654823B8598CA539D1E818249A597B94" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://cidara.com/role/StockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_919C3F1702B40E67D151181459CB1070" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6A91D7B8DD69E6AEABEF181459CA5608" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_919C3F1702B40E67D151181459CB1070" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6A91D7B8DD69E6AEABEF181459CA5608" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_46E990A053C382BCD701181459CA9485" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6A91D7B8DD69E6AEABEF181459CA5608" xlink:to="loc_us-gaap_AwardTypeAxis_46E990A053C382BCD701181459CA9485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84A89551AD109ADC8939181459CA0BEF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_46E990A053C382BCD701181459CA9485" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84A89551AD109ADC8939181459CA0BEF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84A89551AD109ADC8939181459CA0BEF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_46E990A053C382BCD701181459CA9485" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84A89551AD109ADC8939181459CA0BEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_F16DA07CC6A8E1A3E938181459CBEE09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84A89551AD109ADC8939181459CA0BEF" xlink:to="loc_us-gaap_WarrantMember_F16DA07CC6A8E1A3E938181459CBEE09" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember" xlink:label="loc_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_28874712DE798DECC3F1181459CA7F65" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84A89551AD109ADC8939181459CA0BEF" xlink:to="loc_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_28874712DE798DECC3F1181459CA7F65" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_4CA2B702151E1552C089181459CA5DDF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84A89551AD109ADC8939181459CA0BEF" xlink:to="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_4CA2B702151E1552C089181459CA5DDF" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_EmployeeStockPurchasePlanMember" xlink:label="loc_cdtx_EmployeeStockPurchasePlanMember_7BEF0F07E13222DE7760181459CAAAE7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84A89551AD109ADC8939181459CA0BEF" xlink:to="loc_cdtx_EmployeeStockPurchasePlanMember_7BEF0F07E13222DE7760181459CAAAE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CA3C9F64D662C18BD64C181459CB9A1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_919C3F1702B40E67D151181459CB1070" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CA3C9F64D662C18BD64C181459CB9A1C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://cidara.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_36F07A21C59AE7FEA98D45E5E79B2AD7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_36F07A21C59AE7FEA98D45E5E79B2AD7" xlink:to="loc_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E10A02044D1ADA58528145E5E79A59E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E10A02044D1ADA58528145E5E79A59E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D4E5A34AB826967FA71A45E5E79A1F5A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E10A02044D1ADA58528145E5E79A59E2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D4E5A34AB826967FA71A45E5E79A1F5A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D4E5A34AB826967FA71A45E5E79A1F5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E10A02044D1ADA58528145E5E79A59E2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D4E5A34AB826967FA71A45E5E79A1F5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_7C0DDEB8FD6EBE7650AD45E5E79AA6B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D4E5A34AB826967FA71A45E5E79A1F5A" xlink:to="loc_us-gaap_CollaborativeArrangementMember_7C0DDEB8FD6EBE7650AD45E5E79AA6B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_FFCEDD3B361938499CF445E5E79AC19A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_FFCEDD3B361938499CF445E5E79AC19A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6165F1640F0F0917E45045E5E79A347B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_FFCEDD3B361938499CF445E5E79AC19A" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6165F1640F0F0917E45045E5E79A347B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6165F1640F0F0917E45045E5E79A347B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_FFCEDD3B361938499CF445E5E79AC19A" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6165F1640F0F0917E45045E5E79A347B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_135A1158A3D7532B1C4C45E5E79B217E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6165F1640F0F0917E45045E5E79A347B" xlink:to="loc_us-gaap_SubsequentEventMember_135A1158A3D7532B1C4C45E5E79B217E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_A5877BDAD2A6345A47C845FB0339F61F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_36F07A21C59AE7FEA98D45E5E79B2AD7" xlink:to="loc_us-gaap_GrantsReceivable_A5877BDAD2A6345A47C845FB0339F61F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://cidara.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C863BCA7F82309669B3B1777D2E7F79A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C3848D23403E2D24FA51777D2E7B23D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C863BCA7F82309669B3B1777D2E7F79A" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C3848D23403E2D24FA51777D2E7B23D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D7CF47A7C9B1678C35311777D2E7DBBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C3848D23403E2D24FA51777D2E7B23D" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D7CF47A7C9B1678C35311777D2E7DBBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B69C8311F118B3A2AFB21777D2E7F0EE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D7CF47A7C9B1678C35311777D2E7DBBA" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B69C8311F118B3A2AFB21777D2E7F0EE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B69C8311F118B3A2AFB21777D2E7F0EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D7CF47A7C9B1678C35311777D2E7DBBA" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B69C8311F118B3A2AFB21777D2E7F0EE" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember" xlink:label="loc_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_7CAB13386BBFCA4A459D1777D2E7591D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B69C8311F118B3A2AFB21777D2E7F0EE" xlink:to="loc_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_7CAB13386BBFCA4A459D1777D2E7591D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_C8CE39386ACB5B4EEA691777D2E7D6FD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B69C8311F118B3A2AFB21777D2E7F0EE" xlink:to="loc_us-gaap_WarrantMember_C8CE39386ACB5B4EEA691777D2E7D6FD" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CommonStockSubjectToRepurchaseMember" xlink:label="loc_cdtx_CommonStockSubjectToRepurchaseMember_A88DC3BDAB0BBCD728EC1777D2E7BB6A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B69C8311F118B3A2AFB21777D2E7F0EE" xlink:to="loc_cdtx_CommonStockSubjectToRepurchaseMember_A88DC3BDAB0BBCD728EC1777D2E7BB6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3F73CF7E9D61307370BE1777D2E7FEE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C863BCA7F82309669B3B1777D2E7F79A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3F73CF7E9D61307370BE1777D2E7FEE7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>cdtx-20180331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13580E7FCAD147472D6AD4C0C84CD7D2_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515ED65082F65F30AEF74940B4AC6961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515ED65082F65F30AEF74940B4AC6961" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515ED65082F65F30AEF74940B4AC6961" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515ED65082F65F30AEF74940B4AC6961" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5DEBB09C612A2912EEC0D4C0C84DF68D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98A1ADF935A1587DAE27918CF341AF2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5DEBB09C612A2912EEC0D4C0C84DF68D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98A1ADF935A1587DAE27918CF341AF2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98A1ADF935A1587DAE27918CF341AF2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98A1ADF935A1587DAE27918CF341AF2A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98A1ADF935A1587DAE27918CF341AF2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7F8D4809BBC2C24E7302D4C0C84D4B52_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FB90EF930D365511944005101E2DD5C9" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7F8D4809BBC2C24E7302D4C0C84D4B52_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FB90EF930D365511944005101E2DD5C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FB90EF930D365511944005101E2DD5C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FB90EF930D365511944005101E2DD5C9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FB90EF930D365511944005101E2DD5C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_04285C2A0C8E947DE025D4C0C84D951D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_77DB1B05AF1A5115A32E44CA0973B30D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_04285C2A0C8E947DE025D4C0C84D951D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_77DB1B05AF1A5115A32E44CA0973B30D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_77DB1B05AF1A5115A32E44CA0973B30D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_77DB1B05AF1A5115A32E44CA0973B30D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_77DB1B05AF1A5115A32E44CA0973B30D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5BE93485A9588AF0E5FFD4C0C84DBA5F_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C742A23A8BFB513BBE1C62809020F18B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5BE93485A9588AF0E5FFD4C0C84DBA5F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C742A23A8BFB513BBE1C62809020F18B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C742A23A8BFB513BBE1C62809020F18B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C742A23A8BFB513BBE1C62809020F18B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C742A23A8BFB513BBE1C62809020F18B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8B47E232978C4ED2E20ED4C0C84DEE4C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7BA3A7697AD5585E94DCFBF26FCD79C8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Options canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8B47E232978C4ED2E20ED4C0C84DEE4C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7BA3A7697AD5585E94DCFBF26FCD79C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7BA3A7697AD5585E94DCFBF26FCD79C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7BA3A7697AD5585E94DCFBF26FCD79C8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7BA3A7697AD5585E94DCFBF26FCD79C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B42BE94E86CBD3F01A50D4C0C84DE9D3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25D913A5CD17502B9BAEC0836DBA8490" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25D913A5CD17502B9BAEC0836DBA8490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25D913A5CD17502B9BAEC0836DBA8490" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25D913A5CD17502B9BAEC0836DBA8490" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_934E9592FA876718A399D4C0C84DE0AC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_732A97F3EA6C5EA585B442F6143A7E1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_934E9592FA876718A399D4C0C84DE0AC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_732A97F3EA6C5EA585B442F6143A7E1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_732A97F3EA6C5EA585B442F6143A7E1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_732A97F3EA6C5EA585B442F6143A7E1E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_732A97F3EA6C5EA585B442F6143A7E1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5F5D6F1910D39091A2D7D4C0C84E2C6A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_01F45D060E025F28A49D8761B1BFC638" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5F5D6F1910D39091A2D7D4C0C84E2C6A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_01F45D060E025F28A49D8761B1BFC638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_01F45D060E025F28A49D8761B1BFC638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_01F45D060E025F28A49D8761B1BFC638" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_01F45D060E025F28A49D8761B1BFC638" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_F634E5F9B375084DA388D4C0C84E32EA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_DB868916A58E5391ACF680289B6F6F40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_F634E5F9B375084DA388D4C0C84E32EA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_DB868916A58E5391ACF680289B6F6F40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_DB868916A58E5391ACF680289B6F6F40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_DB868916A58E5391ACF680289B6F6F40" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_DB868916A58E5391ACF680289B6F6F40" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_BD3001B890893A1DE4F5D4C0C84E2161_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_95CB94685F7C501F85610D8A502E5E95" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_BD3001B890893A1DE4F5D4C0C84E2161_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_95CB94685F7C501F85610D8A502E5E95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_95CB94685F7C501F85610D8A502E5E95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_95CB94685F7C501F85610D8A502E5E95" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_95CB94685F7C501F85610D8A502E5E95" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3CE09F1EE2EF79C6FFC4D4C0C84E7781_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_807906759DFB5476B44965FAD8D6CE62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3CE09F1EE2EF79C6FFC4D4C0C84E7781_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_807906759DFB5476B44965FAD8D6CE62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_807906759DFB5476B44965FAD8D6CE62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_807906759DFB5476B44965FAD8D6CE62" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_807906759DFB5476B44965FAD8D6CE62" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_34E35A08B84142AFF8A6D4C0C84E0E62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F2F14FDB6EA254DCA0A4E4B1CB8ED7BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_34E35A08B84142AFF8A6D4C0C84E0E62_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F2F14FDB6EA254DCA0A4E4B1CB8ED7BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F2F14FDB6EA254DCA0A4E4B1CB8ED7BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F2F14FDB6EA254DCA0A4E4B1CB8ED7BC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F2F14FDB6EA254DCA0A4E4B1CB8ED7BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_39151EB070B041CB2FC5D4C0C84EE94B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_47D9AE0948B357419AFBF00244CF4868" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_39151EB070B041CB2FC5D4C0C84EE94B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_47D9AE0948B357419AFBF00244CF4868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_47D9AE0948B357419AFBF00244CF4868" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_47D9AE0948B357419AFBF00244CF4868" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_47D9AE0948B357419AFBF00244CF4868" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9B8303D13C9AB28A0056D4C0C84EB745_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4712558585F65AD0AD613C7A26515ED9" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4712558585F65AD0AD613C7A26515ED9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4712558585F65AD0AD613C7A26515ED9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4712558585F65AD0AD613C7A26515ED9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_59690DA556F7C7C2DD4DD4C0C84EDE83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_99C77364B87B5675AA8CC8FDC970AD9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_59690DA556F7C7C2DD4DD4C0C84EDE83_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_99C77364B87B5675AA8CC8FDC970AD9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_99C77364B87B5675AA8CC8FDC970AD9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_99C77364B87B5675AA8CC8FDC970AD9A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_99C77364B87B5675AA8CC8FDC970AD9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F4692DECD020F763C64ED4C0C84F06CD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A2A0399D84F75B2E9D9AFB963F21494B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F4692DECD020F763C64ED4C0C84F06CD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A2A0399D84F75B2E9D9AFB963F21494B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A2A0399D84F75B2E9D9AFB963F21494B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A2A0399D84F75B2E9D9AFB963F21494B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A2A0399D84F75B2E9D9AFB963F21494B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4AA875AA46A01E6F14ACD4C0C84FCCF6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_B58239DD1EF75BA6918DB4B2132A6DC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4AA875AA46A01E6F14ACD4C0C84FCCF6_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_B58239DD1EF75BA6918DB4B2132A6DC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_B58239DD1EF75BA6918DB4B2132A6DC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_B58239DD1EF75BA6918DB4B2132A6DC3" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_B58239DD1EF75BA6918DB4B2132A6DC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1DCC812714E4B874D074D4C0C84F2CA5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_52993392F7A75863BF3A1AD7FBADFA56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1DCC812714E4B874D074D4C0C84F2CA5_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_52993392F7A75863BF3A1AD7FBADFA56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_52993392F7A75863BF3A1AD7FBADFA56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_52993392F7A75863BF3A1AD7FBADFA56" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_52993392F7A75863BF3A1AD7FBADFA56" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_5D4EC4A8CBDED71A2FF6D4C0C84F0134_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0A383DB669B65206B2B3E8A396DCD20A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_5D4EC4A8CBDED71A2FF6D4C0C84F0134_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0A383DB669B65206B2B3E8A396DCD20A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0A383DB669B65206B2B3E8A396DCD20A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0A383DB669B65206B2B3E8A396DCD20A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0A383DB669B65206B2B3E8A396DCD20A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BDE081079ACA7852A7C9D4C0C84FB1A9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_03CA2D640B3A5C588E0238D696E218E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BDE081079ACA7852A7C9D4C0C84FB1A9_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_03CA2D640B3A5C588E0238D696E218E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_03CA2D640B3A5C588E0238D696E218E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_03CA2D640B3A5C588E0238D696E218E1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_03CA2D640B3A5C588E0238D696E218E1" xlink:type="arc" />
    <link:label id="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_B235620522C232861834D4C0C84F25E3_terseLabel_en-US" xlink:label="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_44F61F5BCC2752EEA2B1F30A50359DB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Aggregate Intrinsic Value</link:label>
    <link:label id="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_B235620522C232861834D4C0C84F25E3_label_en-US" xlink:label="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_44F61F5BCC2752EEA2B1F30A50359DB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]</link:label>
    <link:label id="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_B235620522C232861834D4C0C84F25E3_documentation_en-US" xlink:label="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_44F61F5BCC2752EEA2B1F30A50359DB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:label="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_44F61F5BCC2752EEA2B1F30A50359DB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_44F61F5BCC2752EEA2B1F30A50359DB3" xlink:to="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_44F61F5BCC2752EEA2B1F30A50359DB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_445B118133A3034D5EFFD4C0C84F71DE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E0673018937253558D226EC996692CA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_445B118133A3034D5EFFD4C0C84F71DE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E0673018937253558D226EC996692CA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E0673018937253558D226EC996692CA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E0673018937253558D226EC996692CA7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E0673018937253558D226EC996692CA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_68EA734161D8D6352C62D4C0C84FFC56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F2C5F4A8378D5A349877D8CF90497F34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_68EA734161D8D6352C62D4C0C84FFC56_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F2C5F4A8378D5A349877D8CF90497F34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F2C5F4A8378D5A349877D8CF90497F34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F2C5F4A8378D5A349877D8CF90497F34" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F2C5F4A8378D5A349877D8CF90497F34" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0C1F007674B11E8D6083D4C0C8551079_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F457FA02BE65FEA88BF806E357D39EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0C1F007674B11E8D6083D4C0C8551079_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F457FA02BE65FEA88BF806E357D39EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F457FA02BE65FEA88BF806E357D39EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F457FA02BE65FEA88BF806E357D39EC" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F457FA02BE65FEA88BF806E357D39EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_9072F3915FFFAEA32A6745E5E7962594_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_9072F3915FFFAEA32A6745E5E7962594" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9072F3915FFFAEA32A6745E5E7962594" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9072F3915FFFAEA32A6745E5E7962594" xlink:to="lab_us-gaap_SubsequentEventsAbstract_9072F3915FFFAEA32A6745E5E7962594" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE" xlink:to="lab_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_E10A02044D1ADA58528145E5E79A59E2_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_E10A02044D1ADA58528145E5E79A59E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_E10A02044D1ADA58528145E5E79A59E2_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_E10A02044D1ADA58528145E5E79A59E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E10A02044D1ADA58528145E5E79A59E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E10A02044D1ADA58528145E5E79A59E2" xlink:to="lab_us-gaap_TypeOfArrangementAxis_E10A02044D1ADA58528145E5E79A59E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D4E5A34AB826967FA71A45E5E79A1F5A_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D4E5A34AB826967FA71A45E5E79A1F5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D4E5A34AB826967FA71A45E5E79A1F5A_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D4E5A34AB826967FA71A45E5E79A1F5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D4E5A34AB826967FA71A45E5E79A1F5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D4E5A34AB826967FA71A45E5E79A1F5A" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D4E5A34AB826967FA71A45E5E79A1F5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_7C0DDEB8FD6EBE7650AD45E5E79AA6B3_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_7C0DDEB8FD6EBE7650AD45E5E79AA6B3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Partnership agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_7C0DDEB8FD6EBE7650AD45E5E79AA6B3_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_7C0DDEB8FD6EBE7650AD45E5E79AA6B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_7C0DDEB8FD6EBE7650AD45E5E79AA6B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_7C0DDEB8FD6EBE7650AD45E5E79AA6B3" xlink:to="lab_us-gaap_CollaborativeArrangementMember_7C0DDEB8FD6EBE7650AD45E5E79AA6B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_FFCEDD3B361938499CF445E5E79AC19A_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_FFCEDD3B361938499CF445E5E79AC19A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_FFCEDD3B361938499CF445E5E79AC19A_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_FFCEDD3B361938499CF445E5E79AC19A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_FFCEDD3B361938499CF445E5E79AC19A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_FFCEDD3B361938499CF445E5E79AC19A" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_FFCEDD3B361938499CF445E5E79AC19A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6165F1640F0F0917E45045E5E79A347B_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_6165F1640F0F0917E45045E5E79A347B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6165F1640F0F0917E45045E5E79A347B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_6165F1640F0F0917E45045E5E79A347B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6165F1640F0F0917E45045E5E79A347B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6165F1640F0F0917E45045E5E79A347B" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_6165F1640F0F0917E45045E5E79A347B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_135A1158A3D7532B1C4C45E5E79B217E_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_135A1158A3D7532B1C4C45E5E79B217E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_135A1158A3D7532B1C4C45E5E79B217E_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_135A1158A3D7532B1C4C45E5E79B217E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_135A1158A3D7532B1C4C45E5E79B217E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_135A1158A3D7532B1C4C45E5E79B217E" xlink:to="lab_us-gaap_SubsequentEventMember_135A1158A3D7532B1C4C45E5E79B217E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_36F07A21C59AE7FEA98D45E5E79B2AD7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_36F07A21C59AE7FEA98D45E5E79B2AD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_36F07A21C59AE7FEA98D45E5E79B2AD7_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_36F07A21C59AE7FEA98D45E5E79B2AD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_36F07A21C59AE7FEA98D45E5E79B2AD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_36F07A21C59AE7FEA98D45E5E79B2AD7" xlink:to="lab_us-gaap_SubsequentEventLineItems_36F07A21C59AE7FEA98D45E5E79B2AD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrantsReceivable_A5877BDAD2A6345A47C845FB0339F61F_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable_A5877BDAD2A6345A47C845FB0339F61F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partnership grant</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_A5877BDAD2A6345A47C845FB0339F61F_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable_A5877BDAD2A6345A47C845FB0339F61F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_A5877BDAD2A6345A47C845FB0339F61F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable_A5877BDAD2A6345A47C845FB0339F61F" xlink:to="lab_us-gaap_GrantsReceivable_A5877BDAD2A6345A47C845FB0339F61F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_33F0CCB4757BCF28558718E1EE66336E_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_33F0CCB4757BCF28558718E1EE66336E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_33F0CCB4757BCF28558718E1EE66336E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_33F0CCB4757BCF28558718E1EE66336E" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_33F0CCB4757BCF28558718E1EE66336E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_D7CB1542114FBC834B5618E1EE69B9BF_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_D7CB1542114FBC834B5618E1EE69B9BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_D7CB1542114FBC834B5618E1EE69B9BF_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_D7CB1542114FBC834B5618E1EE69B9BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_D7CB1542114FBC834B5618E1EE69B9BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_D7CB1542114FBC834B5618E1EE69B9BF" xlink:to="lab_us-gaap_AssetsAbstract_D7CB1542114FBC834B5618E1EE69B9BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_A851356389F396E9069818E1EE6B68C8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_A851356389F396E9069818E1EE6B68C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_A851356389F396E9069818E1EE6B68C8_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_A851356389F396E9069818E1EE6B68C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_A851356389F396E9069818E1EE6B68C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A851356389F396E9069818E1EE6B68C8" xlink:to="lab_us-gaap_AssetsCurrentAbstract_A851356389F396E9069818E1EE6B68C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B95A43186C938A43E4A718E1EE6BFE0D_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B95A43186C938A43E4A718E1EE6BFE0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B95A43186C938A43E4A718E1EE6BFE0D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B95A43186C938A43E4A718E1EE6BFE0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B95A43186C938A43E4A718E1EE6BFE0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B95A43186C938A43E4A718E1EE6BFE0D" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B95A43186C938A43E4A718E1EE6BFE0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_92570FBB7A7C6A88D05A18E1EE6B36C8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_92570FBB7A7C6A88D05A18E1EE6B36C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_92570FBB7A7C6A88D05A18E1EE6B36C8_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_92570FBB7A7C6A88D05A18E1EE6B36C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_92570FBB7A7C6A88D05A18E1EE6B36C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_92570FBB7A7C6A88D05A18E1EE6B36C8" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_92570FBB7A7C6A88D05A18E1EE6B36C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_490F0484FA4E93867E0718E1EE6C231D_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_490F0484FA4E93867E0718E1EE6C231D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_490F0484FA4E93867E0718E1EE6C231D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_490F0484FA4E93867E0718E1EE6C231D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_490F0484FA4E93867E0718E1EE6C231D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_490F0484FA4E93867E0718E1EE6C231D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_490F0484FA4E93867E0718E1EE6C231D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7398194FA4069C00080B18E1EE6CC73C_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_7398194FA4069C00080B18E1EE6CC73C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7398194FA4069C00080B18E1EE6CC73C_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_7398194FA4069C00080B18E1EE6CC73C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7398194FA4069C00080B18E1EE6CC73C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_7398194FA4069C00080B18E1EE6CC73C" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_7398194FA4069C00080B18E1EE6CC73C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CAE4CAC92360178656A318E1EE6C592E_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CAE4CAC92360178656A318E1EE6C592E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CAE4CAC92360178656A318E1EE6C592E_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CAE4CAC92360178656A318E1EE6C592E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CAE4CAC92360178656A318E1EE6C592E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CAE4CAC92360178656A318E1EE6C592E" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CAE4CAC92360178656A318E1EE6C592E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_8B7DFEA082FF872CECA318E1EE6C92E1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_8B7DFEA082FF872CECA318E1EE6C92E1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_8B7DFEA082FF872CECA318E1EE6C92E1_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_8B7DFEA082FF872CECA318E1EE6C92E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8B7DFEA082FF872CECA318E1EE6C92E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_8B7DFEA082FF872CECA318E1EE6C92E1" xlink:to="lab_us-gaap_AssetsCurrent_8B7DFEA082FF872CECA318E1EE6C92E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_786C76AA6CB5F84D0A0218E1EE6C4FDD_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_786C76AA6CB5F84D0A0218E1EE6C4FDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_786C76AA6CB5F84D0A0218E1EE6C4FDD_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_786C76AA6CB5F84D0A0218E1EE6C4FDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_786C76AA6CB5F84D0A0218E1EE6C4FDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_786C76AA6CB5F84D0A0218E1EE6C4FDD" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_786C76AA6CB5F84D0A0218E1EE6C4FDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1962816E111EC47AA17518E1EE6CD227_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_1962816E111EC47AA17518E1EE6CD227" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1962816E111EC47AA17518E1EE6CD227_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_1962816E111EC47AA17518E1EE6CD227" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1962816E111EC47AA17518E1EE6CD227" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_1962816E111EC47AA17518E1EE6CD227" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_1962816E111EC47AA17518E1EE6CD227" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_F75754D606307E09E7C718E1EE6C8536_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_F75754D606307E09E7C718E1EE6C8536" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_F75754D606307E09E7C718E1EE6C8536_label_en-US" xlink:label="lab_us-gaap_Assets_F75754D606307E09E7C718E1EE6C8536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_F75754D606307E09E7C718E1EE6C8536" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_F75754D606307E09E7C718E1EE6C8536" xlink:to="lab_us-gaap_Assets_F75754D606307E09E7C718E1EE6C8536" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6C1FED8E6A305DEB172518E1EE6C1125_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6C1FED8E6A305DEB172518E1EE6C1125" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6C1FED8E6A305DEB172518E1EE6C1125_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6C1FED8E6A305DEB172518E1EE6C1125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6C1FED8E6A305DEB172518E1EE6C1125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6C1FED8E6A305DEB172518E1EE6C1125" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6C1FED8E6A305DEB172518E1EE6C1125" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5CEACFF2DE51E4B5025B18E1EE6CEEFC_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_5CEACFF2DE51E4B5025B18E1EE6CEEFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5CEACFF2DE51E4B5025B18E1EE6CEEFC_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_5CEACFF2DE51E4B5025B18E1EE6CEEFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5CEACFF2DE51E4B5025B18E1EE6CEEFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5CEACFF2DE51E4B5025B18E1EE6CEEFC" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_5CEACFF2DE51E4B5025B18E1EE6CEEFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_4D7C9E6CEB78FB17C8C218E1EE6C7920_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_4D7C9E6CEB78FB17C8C218E1EE6C7920" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_4D7C9E6CEB78FB17C8C218E1EE6C7920_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_4D7C9E6CEB78FB17C8C218E1EE6C7920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_4D7C9E6CEB78FB17C8C218E1EE6C7920" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_4D7C9E6CEB78FB17C8C218E1EE6C7920" xlink:to="lab_us-gaap_AccountsPayableCurrent_4D7C9E6CEB78FB17C8C218E1EE6C7920" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_C8F35BE2F95DA40909F118E1EE6C5749_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_C8F35BE2F95DA40909F118E1EE6C5749" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_C8F35BE2F95DA40909F118E1EE6C5749_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_C8F35BE2F95DA40909F118E1EE6C5749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_C8F35BE2F95DA40909F118E1EE6C5749" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_C8F35BE2F95DA40909F118E1EE6C5749" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_C8F35BE2F95DA40909F118E1EE6C5749" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_CFFE71C657AF29AF41AD18E1EE6CC698_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_CFFE71C657AF29AF41AD18E1EE6CC698" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_CFFE71C657AF29AF41AD18E1EE6CC698_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_CFFE71C657AF29AF41AD18E1EE6CC698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_CFFE71C657AF29AF41AD18E1EE6CC698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_CFFE71C657AF29AF41AD18E1EE6CC698" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_CFFE71C657AF29AF41AD18E1EE6CC698" xlink:type="arc" />
    <link:label id="lab_us-gaap_LoansPayableCurrent_2B358ACBFBBF82B89C8318E1EE6C8256_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent_2B358ACBFBBF82B89C8318E1EE6C8256" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of term loan</link:label>
    <link:label id="lab_us-gaap_LoansPayableCurrent_2B358ACBFBBF82B89C8318E1EE6C8256_label_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent_2B358ACBFBBF82B89C8318E1EE6C8256" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaap_LoansPayableCurrent_2B358ACBFBBF82B89C8318E1EE6C8256" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableCurrent_2B358ACBFBBF82B89C8318E1EE6C8256" xlink:to="lab_us-gaap_LoansPayableCurrent_2B358ACBFBBF82B89C8318E1EE6C8256" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_EBEE6FD20A06C5CE8A0818E1EE6C973A_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_EBEE6FD20A06C5CE8A0818E1EE6C973A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_EBEE6FD20A06C5CE8A0818E1EE6C973A_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_EBEE6FD20A06C5CE8A0818E1EE6C973A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_EBEE6FD20A06C5CE8A0818E1EE6C973A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_EBEE6FD20A06C5CE8A0818E1EE6C973A" xlink:to="lab_us-gaap_LiabilitiesCurrent_EBEE6FD20A06C5CE8A0818E1EE6C973A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermLoansPayable_CD302F23925F5EA6626218E1EE6C4490_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermLoansPayable_CD302F23925F5EA6626218E1EE6C4490" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, less debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermLoansPayable_CD302F23925F5EA6626218E1EE6C4490_label_en-US" xlink:label="lab_us-gaap_LongTermLoansPayable_CD302F23925F5EA6626218E1EE6C4490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Payable, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaap_LongTermLoansPayable_CD302F23925F5EA6626218E1EE6C4490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLoansPayable_CD302F23925F5EA6626218E1EE6C4490" xlink:to="lab_us-gaap_LongTermLoansPayable_CD302F23925F5EA6626218E1EE6C4490" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_4B804CE45005B6808E3418E1EE6CFBEC_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_4B804CE45005B6808E3418E1EE6CFBEC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_4B804CE45005B6808E3418E1EE6CFBEC_label_en-US" xlink:label="lab_us-gaap_Liabilities_4B804CE45005B6808E3418E1EE6CFBEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_4B804CE45005B6808E3418E1EE6CFBEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_4B804CE45005B6808E3418E1EE6CFBEC" xlink:to="lab_us-gaap_Liabilities_4B804CE45005B6808E3418E1EE6CFBEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_D8DFCDA1E6B2A2D4786A18E1EE6C5FE0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_D8DFCDA1E6B2A2D4786A18E1EE6C5FE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_D8DFCDA1E6B2A2D4786A18E1EE6C5FE0_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_D8DFCDA1E6B2A2D4786A18E1EE6C5FE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_D8DFCDA1E6B2A2D4786A18E1EE6C5FE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_D8DFCDA1E6B2A2D4786A18E1EE6C5FE0" xlink:to="lab_us-gaap_CommitmentsAndContingencies_D8DFCDA1E6B2A2D4786A18E1EE6C5FE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_C49A748009CC876CAD7D18E1EE6D50C6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_C49A748009CC876CAD7D18E1EE6D50C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_C49A748009CC876CAD7D18E1EE6D50C6_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_C49A748009CC876CAD7D18E1EE6D50C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_C49A748009CC876CAD7D18E1EE6D50C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C49A748009CC876CAD7D18E1EE6D50C6" xlink:to="lab_us-gaap_StockholdersEquityAbstract_C49A748009CC876CAD7D18E1EE6D50C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_232CDB665881948B91A218E1EE6D9A79_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_232CDB665881948B91A218E1EE6D9A79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding at March 31, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_232CDB665881948B91A218E1EE6D9A79_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_232CDB665881948B91A218E1EE6D9A79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_232CDB665881948B91A218E1EE6D9A79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_232CDB665881948B91A218E1EE6D9A79" xlink:to="lab_us-gaap_PreferredStockValue_232CDB665881948B91A218E1EE6D9A79" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_B4743DDEFD038E7AB19A18E1EE6DD933_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_B4743DDEFD038E7AB19A18E1EE6DD933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2018 and December 31, 2017; 21,395,077 and 21,389,736 shares issued and outstanding, respectively, at March 31, 2018; 20,534,993 and 20,525,688 shares issued and outstanding, respectively, at December 31, 2017</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_B4743DDEFD038E7AB19A18E1EE6DD933_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_B4743DDEFD038E7AB19A18E1EE6DD933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_B4743DDEFD038E7AB19A18E1EE6DD933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_B4743DDEFD038E7AB19A18E1EE6DD933" xlink:to="lab_us-gaap_CommonStockValue_B4743DDEFD038E7AB19A18E1EE6DD933" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_BF5C6BD09CBA4D6EF8D518E1EE6D5FEA_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_BF5C6BD09CBA4D6EF8D518E1EE6D5FEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_BF5C6BD09CBA4D6EF8D518E1EE6D5FEA_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_BF5C6BD09CBA4D6EF8D518E1EE6D5FEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_BF5C6BD09CBA4D6EF8D518E1EE6D5FEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_BF5C6BD09CBA4D6EF8D518E1EE6D5FEA" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_BF5C6BD09CBA4D6EF8D518E1EE6D5FEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_436847A1131E763BC26718E1EE6D8E25_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_436847A1131E763BC26718E1EE6D8E25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_436847A1131E763BC26718E1EE6D8E25_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_436847A1131E763BC26718E1EE6D8E25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_436847A1131E763BC26718E1EE6D8E25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_436847A1131E763BC26718E1EE6D8E25" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_436847A1131E763BC26718E1EE6D8E25" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D490048C3D31F2EF5A5418E1EE6DBE22_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D490048C3D31F2EF5A5418E1EE6DBE22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D490048C3D31F2EF5A5418E1EE6DBE22_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D490048C3D31F2EF5A5418E1EE6DBE22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D490048C3D31F2EF5A5418E1EE6DBE22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D490048C3D31F2EF5A5418E1EE6DBE22" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D490048C3D31F2EF5A5418E1EE6DBE22" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_5846A0C39EE0A3A9B7AE18E1EE6DC94D_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_5846A0C39EE0A3A9B7AE18E1EE6DC94D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5846A0C39EE0A3A9B7AE18E1EE6DC94D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_5846A0C39EE0A3A9B7AE18E1EE6DC94D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_5846A0C39EE0A3A9B7AE18E1EE6DC94D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_5846A0C39EE0A3A9B7AE18E1EE6DC94D" xlink:to="lab_us-gaap_StockholdersEquity_5846A0C39EE0A3A9B7AE18E1EE6DC94D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2744270F63950831268118E1EE6DD549_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_2744270F63950831268118E1EE6DD549" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2744270F63950831268118E1EE6DD549_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_2744270F63950831268118E1EE6DD549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2744270F63950831268118E1EE6DD549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2744270F63950831268118E1EE6DD549" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_2744270F63950831268118E1EE6DD549" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_546F2F2DF6DAF134946D401128925B1D_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_546F2F2DF6DAF134946D401128925B1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_546F2F2DF6DAF134946D401128925B1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_546F2F2DF6DAF134946D401128925B1D" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_546F2F2DF6DAF134946D401128925B1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E73E57A152FDE54C32F440112892CFB2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E73E57A152FDE54C32F440112892CFB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E73E57A152FDE54C32F440112892CFB2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E73E57A152FDE54C32F440112892CFB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E73E57A152FDE54C32F440112892CFB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E73E57A152FDE54C32F440112892CFB2" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E73E57A152FDE54C32F440112892CFB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_DDAD4F6584F22600B4C9401128920F89_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_DDAD4F6584F22600B4C9401128920F89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_DDAD4F6584F22600B4C9401128920F89_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_DDAD4F6584F22600B4C9401128920F89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_DDAD4F6584F22600B4C9401128920F89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_DDAD4F6584F22600B4C9401128920F89" xlink:to="lab_us-gaap_InvestmentTypeAxis_DDAD4F6584F22600B4C9401128920F89" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_7F2B844ABE9B2AA40D0C40112892182B_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_7F2B844ABE9B2AA40D0C40112892182B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_7F2B844ABE9B2AA40D0C40112892182B_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_7F2B844ABE9B2AA40D0C40112892182B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7F2B844ABE9B2AA40D0C40112892182B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7F2B844ABE9B2AA40D0C40112892182B" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_7F2B844ABE9B2AA40D0C40112892182B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_FB3EC870C3A0AAAFCA204011289230F0_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_FB3EC870C3A0AAAFCA204011289230F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_FB3EC870C3A0AAAFCA204011289230F0_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_FB3EC870C3A0AAAFCA204011289230F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_FB3EC870C3A0AAAFCA204011289230F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_FB3EC870C3A0AAAFCA204011289230F0" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_FB3EC870C3A0AAAFCA204011289230F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FCED9D2FB6802F4C68E240234E38A3AF_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FCED9D2FB6802F4C68E240234E38A3AF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FCED9D2FB6802F4C68E240234E38A3AF_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FCED9D2FB6802F4C68E240234E38A3AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FCED9D2FB6802F4C68E240234E38A3AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FCED9D2FB6802F4C68E240234E38A3AF" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FCED9D2FB6802F4C68E240234E38A3AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5299D9FAB0E989C0A0334023F7447602_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5299D9FAB0E989C0A0334023F7447602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5299D9FAB0E989C0A0334023F7447602_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5299D9FAB0E989C0A0334023F7447602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5299D9FAB0E989C0A0334023F7447602" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5299D9FAB0E989C0A0334023F7447602" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5299D9FAB0E989C0A0334023F7447602" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ED1FBA9032207AB99243402435C57770_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ED1FBA9032207AB99243402435C57770" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ED1FBA9032207AB99243402435C57770_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ED1FBA9032207AB99243402435C57770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ED1FBA9032207AB99243402435C57770" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ED1FBA9032207AB99243402435C57770" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ED1FBA9032207AB99243402435C57770" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6FBAA6271429524E02BF40246A1D814F_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6FBAA6271429524E02BF40246A1D814F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6FBAA6271429524E02BF40246A1D814F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6FBAA6271429524E02BF40246A1D814F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6FBAA6271429524E02BF40246A1D814F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6FBAA6271429524E02BF40246A1D814F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6FBAA6271429524E02BF40246A1D814F" xlink:type="arc" />
    <link:label id="lab_cdtx_MaturityPeriodOfShortTermInvestments_D4BD7C49030F451DAD7640112893B6A0_terseLabel_en-US" xlink:label="lab_cdtx_MaturityPeriodOfShortTermInvestments_D4BD7C49030F451DAD7640112893B6A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity of available-for-sale securities (less than) (term)</link:label>
    <link:label id="lab_cdtx_MaturityPeriodOfShortTermInvestments_D4BD7C49030F451DAD7640112893B6A0_label_en-US" xlink:label="lab_cdtx_MaturityPeriodOfShortTermInvestments_D4BD7C49030F451DAD7640112893B6A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity Period Of Short Term Investments</link:label>
    <link:label id="lab_cdtx_MaturityPeriodOfShortTermInvestments_D4BD7C49030F451DAD7640112893B6A0_documentation_en-US" xlink:label="lab_cdtx_MaturityPeriodOfShortTermInvestments_D4BD7C49030F451DAD7640112893B6A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity period of short term investments.</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_MaturityPeriodOfShortTermInvestments" xlink:label="loc_cdtx_MaturityPeriodOfShortTermInvestments_D4BD7C49030F451DAD7640112893B6A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MaturityPeriodOfShortTermInvestments_D4BD7C49030F451DAD7640112893B6A0" xlink:to="lab_cdtx_MaturityPeriodOfShortTermInvestments_D4BD7C49030F451DAD7640112893B6A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_4F15732B31D1165645EA40112893E170_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_4F15732B31D1165645EA40112893E170" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_4F15732B31D1165645EA40112893E170_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_4F15732B31D1165645EA40112893E170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment Losses, Investments, Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_4F15732B31D1165645EA40112893E170" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_4F15732B31D1165645EA40112893E170" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_4F15732B31D1165645EA40112893E170" xlink:type="arc" />
    <link:label id="lab_cdtx_DebtSecuritiesAvailableForSaleGainLoss_56E4D1421CAF1A10994840112893A220_terseLabel_en-US" xlink:label="lab_cdtx_DebtSecuritiesAvailableForSaleGainLoss_56E4D1421CAF1A10994840112893A220" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on available for sale securities</link:label>
    <link:label id="lab_cdtx_DebtSecuritiesAvailableForSaleGainLoss_56E4D1421CAF1A10994840112893A220_label_en-US" xlink:label="lab_cdtx_DebtSecuritiesAvailableForSaleGainLoss_56E4D1421CAF1A10994840112893A220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available For Sale, Gain (Loss)</link:label>
    <link:label id="lab_cdtx_DebtSecuritiesAvailableForSaleGainLoss_56E4D1421CAF1A10994840112893A220_documentation_en-US" xlink:label="lab_cdtx_DebtSecuritiesAvailableForSaleGainLoss_56E4D1421CAF1A10994840112893A220" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities Available For Sale Gain Loss</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="loc_cdtx_DebtSecuritiesAvailableForSaleGainLoss_56E4D1421CAF1A10994840112893A220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DebtSecuritiesAvailableForSaleGainLoss_56E4D1421CAF1A10994840112893A220" xlink:to="lab_cdtx_DebtSecuritiesAvailableForSaleGainLoss_56E4D1421CAF1A10994840112893A220" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BC3E022B759ED570412B4B240B1E348E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BC3E022B759ED570412B4B240B1E348E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_A27533F0EA1A62EE80BA4B240B1E026D_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_26E1BC619AAC54B3836EE500E62DC08D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_A27533F0EA1A62EE80BA4B240B1E026D_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_26E1BC619AAC54B3836EE500E62DC08D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_26E1BC619AAC54B3836EE500E62DC08D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_26E1BC619AAC54B3836EE500E62DC08D" xlink:to="lab_us-gaap_PlanNameAxis_26E1BC619AAC54B3836EE500E62DC08D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_ADFA91293CDAC1AD5D124B240B1E83D3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_BC55C61AF500549FA2FF8371AD0AF6CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_ADFA91293CDAC1AD5D124B240B1E83D3_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_BC55C61AF500549FA2FF8371AD0AF6CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_BC55C61AF500549FA2FF8371AD0AF6CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_BC55C61AF500549FA2FF8371AD0AF6CC" xlink:to="lab_us-gaap_PlanNameDomain_BC55C61AF500549FA2FF8371AD0AF6CC" xlink:type="arc" />
    <link:label id="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_3A3538784612450764C04B240B1EF24F_verboseLabel_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_2624E5357A0B571BAB57EDE08529D420" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2015 EIP</link:label>
    <link:label id="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_3A3538784612450764C04B240B1EF24F_label_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_2624E5357A0B571BAB57EDE08529D420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fifteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_3A3538784612450764C04B240B1EF24F_documentation_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_2624E5357A0B571BAB57EDE08529D420" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand fifteen equity incentive plan.</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_2624E5357A0B571BAB57EDE08529D420" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_2624E5357A0B571BAB57EDE08529D420" xlink:to="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_2624E5357A0B571BAB57EDE08529D420" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_335185CE02D815FE54B34B240B1E2A25_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_FBA2B7D7F22459FCA81555528992DBC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_335185CE02D815FE54B34B240B1E2A25_label_en-US" xlink:label="lab_us-gaap_RangeAxis_FBA2B7D7F22459FCA81555528992DBC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FBA2B7D7F22459FCA81555528992DBC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_FBA2B7D7F22459FCA81555528992DBC5" xlink:to="lab_us-gaap_RangeAxis_FBA2B7D7F22459FCA81555528992DBC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_F82CBAB86367CB810CC64B240B1E5F4B_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_ECF74E5385B55A83AF61F2E21489089C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_F82CBAB86367CB810CC64B240B1E5F4B_label_en-US" xlink:label="lab_us-gaap_RangeMember_ECF74E5385B55A83AF61F2E21489089C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_ECF74E5385B55A83AF61F2E21489089C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_ECF74E5385B55A83AF61F2E21489089C" xlink:to="lab_us-gaap_RangeMember_ECF74E5385B55A83AF61F2E21489089C" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_50A954F13C4CC3ABC5084B240B1EE6DE_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_CA3A7EFFA0F256E68CD558BC264F7A45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_50A954F13C4CC3ABC5084B240B1EE6DE_label_en-US" xlink:label="lab_us-gaap_MinimumMember_CA3A7EFFA0F256E68CD558BC264F7A45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_CA3A7EFFA0F256E68CD558BC264F7A45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_CA3A7EFFA0F256E68CD558BC264F7A45" xlink:to="lab_us-gaap_MinimumMember_CA3A7EFFA0F256E68CD558BC264F7A45" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_F1274A9015439E4420114B240B1E2F78_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_890869B182A7537C9F84EFA249D5037A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_F1274A9015439E4420114B240B1E2F78_label_en-US" xlink:label="lab_us-gaap_MaximumMember_890869B182A7537C9F84EFA249D5037A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_890869B182A7537C9F84EFA249D5037A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_890869B182A7537C9F84EFA249D5037A" xlink:to="lab_us-gaap_MaximumMember_890869B182A7537C9F84EFA249D5037A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_80AEC882B2AA32AE49504B240B1EBCF4_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A00639BC59215837A306FF362AF13BC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_80AEC882B2AA32AE49504B240B1EBCF4_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A00639BC59215837A306FF362AF13BC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A00639BC59215837A306FF362AF13BC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A00639BC59215837A306FF362AF13BC6" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A00639BC59215837A306FF362AF13BC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_BCD325B7EFAA420A63144B240B1E91D0_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain_2C55F392A32F5E768C9820C862591BCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_BCD325B7EFAA420A63144B240B1E91D0_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain_2C55F392A32F5E768C9820C862591BCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_2C55F392A32F5E768C9820C862591BCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_2C55F392A32F5E768C9820C862591BCD" xlink:to="lab_us-gaap_ConversionOfStockNameDomain_2C55F392A32F5E768C9820C862591BCD" xlink:type="arc" />
    <link:label id="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_14E6BAC9FA7DBA1F81254B240B1E5A97_terseLabel_en-US" xlink:label="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_3C8238317CA157D6BDEC2EEDF7A37680" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">More than 10% of voting power</link:label>
    <link:label id="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_14E6BAC9FA7DBA1F81254B240B1E5A97_label_en-US" xlink:label="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_3C8238317CA157D6BDEC2EEDF7A37680" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">More Than Ten Percent Voting Rights Classes Of Stock [Member]</link:label>
    <link:label id="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_14E6BAC9FA7DBA1F81254B240B1E5A97_documentation_en-US" xlink:label="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_3C8238317CA157D6BDEC2EEDF7A37680" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">More than ten percent voting rights classes of stock.</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:label="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_3C8238317CA157D6BDEC2EEDF7A37680" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_3C8238317CA157D6BDEC2EEDF7A37680" xlink:to="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_3C8238317CA157D6BDEC2EEDF7A37680" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_338E164E77A7201A1FD84B240B1FE049_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2888BB05594D5A5C865B5B2D9C0C5156" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_338E164E77A7201A1FD84B240B1FE049_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2888BB05594D5A5C865B5B2D9C0C5156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2888BB05594D5A5C865B5B2D9C0C5156" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2888BB05594D5A5C865B5B2D9C0C5156" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2888BB05594D5A5C865B5B2D9C0C5156" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_AB5F6AE2E3084C0B77964B240B1F572F_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0BAAE6B251335938A6054E48BC5781C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_AB5F6AE2E3084C0B77964B240B1F572F_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0BAAE6B251335938A6054E48BC5781C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0BAAE6B251335938A6054E48BC5781C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0BAAE6B251335938A6054E48BC5781C5" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0BAAE6B251335938A6054E48BC5781C5" xlink:type="arc" />
    <link:label id="lab_cdtx_CommonStockSubjectToRepurchaseMember_B74207EA59FACDDB6DCD4B240B1F82B2_verboseLabel_en-US" xlink:label="lab_cdtx_CommonStockSubjectToRepurchaseMember_7F99EDB8554F5B75A0515BF0D3260451" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subject to repurchase</link:label>
    <link:label id="lab_cdtx_CommonStockSubjectToRepurchaseMember_B74207EA59FACDDB6DCD4B240B1F82B2_label_en-US" xlink:label="lab_cdtx_CommonStockSubjectToRepurchaseMember_7F99EDB8554F5B75A0515BF0D3260451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Subject To Repurchase [Member]</link:label>
    <link:label id="lab_cdtx_CommonStockSubjectToRepurchaseMember_B74207EA59FACDDB6DCD4B240B1F82B2_documentation_en-US" xlink:label="lab_cdtx_CommonStockSubjectToRepurchaseMember_7F99EDB8554F5B75A0515BF0D3260451" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock subject to repurchase.</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CommonStockSubjectToRepurchaseMember" xlink:label="loc_cdtx_CommonStockSubjectToRepurchaseMember_7F99EDB8554F5B75A0515BF0D3260451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CommonStockSubjectToRepurchaseMember_7F99EDB8554F5B75A0515BF0D3260451" xlink:to="lab_cdtx_CommonStockSubjectToRepurchaseMember_7F99EDB8554F5B75A0515BF0D3260451" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_0256D2F5331D069B1AC24B240B1F4519_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_34C85E2BE2EF5EC591FD299B81E0154C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_0256D2F5331D069B1AC24B240B1F4519_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_34C85E2BE2EF5EC591FD299B81E0154C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_34C85E2BE2EF5EC591FD299B81E0154C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_34C85E2BE2EF5EC591FD299B81E0154C" xlink:to="lab_us-gaap_AwardTypeAxis_34C85E2BE2EF5EC591FD299B81E0154C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F277BEE9BB99A1FF3DD94B240B1FB98E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14214F9B535359D19D651036326EDF58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F277BEE9BB99A1FF3DD94B240B1FB98E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14214F9B535359D19D651036326EDF58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14214F9B535359D19D651036326EDF58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14214F9B535359D19D651036326EDF58" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14214F9B535359D19D651036326EDF58" xlink:type="arc" />
    <link:label id="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_CADEF70B8843B91F36E74B240B1F0541_terseLabel_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_0ADC1A94399B5588A7D88B730D842DA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_CADEF70B8843B91F36E74B240B1F0541_label_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_0ADC1A94399B5588A7D88B730D842DA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fifteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_CADEF70B8843B91F36E74B240B1F0541_documentation_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_0ADC1A94399B5588A7D88B730D842DA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand fifteen employee stock purchase plan.</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:label="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_0ADC1A94399B5588A7D88B730D842DA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_0ADC1A94399B5588A7D88B730D842DA5" xlink:to="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_0ADC1A94399B5588A7D88B730D842DA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockMember_E9DEED70B7E128276C154B240B1F021C_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_E2B4D95A723855548DC497FF011A0367" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_E9DEED70B7E128276C154B240B1F021C_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_E2B4D95A723855548DC497FF011A0367" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_E2B4D95A723855548DC497FF011A0367" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_E2B4D95A723855548DC497FF011A0367" xlink:to="lab_us-gaap_RestrictedStockMember_E2B4D95A723855548DC497FF011A0367" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CD7CB793B67B8C282D4A4B240B1F5D67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CD7CB793B67B8C282D4A4B240B1F5D67_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:type="arc" />
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_55D7A004B3E991C700244B240B1F6CCB_terseLabel_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_D4C42F987BD050A1BFCF53EDAD7B0D7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Automatic increase in shares of stock available (as a percent)</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_55D7A004B3E991C700244B240B1F6CCB_label_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_D4C42F987BD050A1BFCF53EDAD7B0D7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase In Number Of Shares Authorized For Issuance Percentage</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_55D7A004B3E991C700244B240B1F6CCB_documentation_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_D4C42F987BD050A1BFCF53EDAD7B0D7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award automatic increase in number of shares authorized for issuance percentage.</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_D4C42F987BD050A1BFCF53EDAD7B0D7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_D4C42F987BD050A1BFCF53EDAD7B0D7E" xlink:to="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_D4C42F987BD050A1BFCF53EDAD7B0D7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_44DE8E80FAA8401CE8144B240B1F331B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_696617A35A60528EA9E69A37AFD2541D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_44DE8E80FAA8401CE8144B240B1F331B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_696617A35A60528EA9E69A37AFD2541D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_696617A35A60528EA9E69A37AFD2541D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_696617A35A60528EA9E69A37AFD2541D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_696617A35A60528EA9E69A37AFD2541D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9329E4825141D963756D4B240B1F03C7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_71650BB9573C52068C74454934E2CFF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term for stock options to be granted</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9329E4825141D963756D4B240B1F03C7_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_71650BB9573C52068C74454934E2CFF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_71650BB9573C52068C74454934E2CFF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_71650BB9573C52068C74454934E2CFF4" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_71650BB9573C52068C74454934E2CFF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1C2C856BCE710E8B0CED4B240B20059F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8D8B1CB66267595087DE77EAEEE9DEE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price of stock option as percentage of estimated fair value of shares on date of grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1C2C856BCE710E8B0CED4B240B20059F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8D8B1CB66267595087DE77EAEEE9DEE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8D8B1CB66267595087DE77EAEEE9DEE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8D8B1CB66267595087DE77EAEEE9DEE8" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8D8B1CB66267595087DE77EAEEE9DEE8" xlink:type="arc" />
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_888326F2F1F5A83BD96C4B240B20B266_terseLabel_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_F4C7FAA3CEAB5CC8BE0EAB881E15FC4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Voting power threshold (as a percent)</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_888326F2F1F5A83BD96C4B240B20B266_label_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_F4C7FAA3CEAB5CC8BE0EAB881E15FC4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_888326F2F1F5A83BD96C4B240B20B266_documentation_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_F4C7FAA3CEAB5CC8BE0EAB881E15FC4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_F4C7FAA3CEAB5CC8BE0EAB881E15FC4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_F4C7FAA3CEAB5CC8BE0EAB881E15FC4E" xlink:to="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_F4C7FAA3CEAB5CC8BE0EAB881E15FC4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_EF68E9CDEBA93E5DC6E84B240B201239_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_06E3C09F230D56029F025395E9316CE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Automatic increase in number of shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_EF68E9CDEBA93E5DC6E84B240B201239_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_06E3C09F230D56029F025395E9316CE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_06E3C09F230D56029F025395E9316CE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_06E3C09F230D56029F025395E9316CE9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_06E3C09F230D56029F025395E9316CE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_D4C6A6812DCE0B4868184B240B205D7D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4C0DE3AA6844551FAE43955D11A8D6F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Limit on employee's payroll deductions as a percentage of eligible compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_D4C6A6812DCE0B4868184B240B205D7D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4C0DE3AA6844551FAE43955D11A8D6F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4C0DE3AA6844551FAE43955D11A8D6F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4C0DE3AA6844551FAE43955D11A8D6F8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4C0DE3AA6844551FAE43955D11A8D6F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_89F5DEA38919C5E0DDC74B240B204FE1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_D0720BEEE879551EB8B71D0259287852" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to the ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_89F5DEA38919C5E0DDC74B240B204FE1_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_D0720BEEE879551EB8B71D0259287852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_D0720BEEE879551EB8B71D0259287852" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_D0720BEEE879551EB8B71D0259287852" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_D0720BEEE879551EB8B71D0259287852" xlink:type="arc" />
    <link:label id="lab_cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent_2B33D975C49FC6887F4D4B240B20BBAA_terseLabel_en-US" xlink:label="lab_cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent_96AEE43D8A8B5F998D0EE46C7C68910B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received from early exercise of stock options</link:label>
    <link:label id="lab_cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent_2B33D975C49FC6887F4D4B240B20BBAA_label_en-US" xlink:label="lab_cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent_96AEE43D8A8B5F998D0EE46C7C68910B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Nonvested Options, Options Subject To Early Exercise, Liability, Current</link:label>
    <link:label id="lab_cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent_2B33D975C49FC6887F4D4B240B20BBAA_documentation_en-US" xlink:label="lab_cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent_96AEE43D8A8B5F998D0EE46C7C68910B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Nonvested Options, Options Subject To Early Exercise, Liability, Current</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent" xlink:label="loc_cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent_96AEE43D8A8B5F998D0EE46C7C68910B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent_96AEE43D8A8B5F998D0EE46C7C68910B" xlink:to="lab_cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent_96AEE43D8A8B5F998D0EE46C7C68910B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_C3387272F78C30B0EFAC4B240B20220B_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_54CBF30FBB2652C881CB5529D068B991" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested shares subject to repurchase (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_C3387272F78C30B0EFAC4B240B20220B_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_54CBF30FBB2652C881CB5529D068B991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_54CBF30FBB2652C881CB5529D068B991" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_54CBF30FBB2652C881CB5529D068B991" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_54CBF30FBB2652C881CB5529D068B991" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3E602A93A6EE7E374CF14B240B202CD3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_79B62E4EE4465957BFCC811A9322B621" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value of employee stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3E602A93A6EE7E374CF14B240B202CD3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_79B62E4EE4465957BFCC811A9322B621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_79B62E4EE4465957BFCC811A9322B621" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_79B62E4EE4465957BFCC811A9322B621" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_79B62E4EE4465957BFCC811A9322B621" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8038978780DD3695D9674B240B20A4A3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5DC1D0998CC75BDF8F45EBE6288B5393" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant date fair value of employee stock options vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8038978780DD3695D9674B240B20A4A3_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5DC1D0998CC75BDF8F45EBE6288B5393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5DC1D0998CC75BDF8F45EBE6288B5393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5DC1D0998CC75BDF8F45EBE6288B5393" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5DC1D0998CC75BDF8F45EBE6288B5393" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5A775576CF0807FFE2864B240B20AE3C_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_588C39F391D75ACDB4CCA592B53377B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total unrecognized share-based compensation expense related to unvested employee stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5A775576CF0807FFE2864B240B20AE3C_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_588C39F391D75ACDB4CCA592B53377B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_588C39F391D75ACDB4CCA592B53377B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_588C39F391D75ACDB4CCA592B53377B7" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_588C39F391D75ACDB4CCA592B53377B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_D51F9407C0E7E8F61C8A4B240B206C8D_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_728051DCB5705572A8C798C071754C38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period to recognize unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_D51F9407C0E7E8F61C8A4B240B206C8D_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_728051DCB5705572A8C798C071754C38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_728051DCB5705572A8C798C071754C38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_728051DCB5705572A8C798C071754C38" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_728051DCB5705572A8C798C071754C38" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ABEC2C620F7D20ED8E944B56761E4768_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_09A19250F41653E592C5C83AF72F3F0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated unrecognized share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ABEC2C620F7D20ED8E944B56761E4768_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_09A19250F41653E592C5C83AF72F3F0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_09A19250F41653E592C5C83AF72F3F0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_09A19250F41653E592C5C83AF72F3F0C" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_09A19250F41653E592C5C83AF72F3F0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_506E3E120BE59ADDCF99181459D71A7D_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_506E3E120BE59ADDCF99181459D71A7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_506E3E120BE59ADDCF99181459D71A7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_506E3E120BE59ADDCF99181459D71A7D" xlink:to="lab_us-gaap_DebtDisclosureAbstract_506E3E120BE59ADDCF99181459D71A7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF" xlink:to="lab_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_154EC2496AF45E4E435C181459D794DD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_154EC2496AF45E4E435C181459D794DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_154EC2496AF45E4E435C181459D794DD_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_154EC2496AF45E4E435C181459D794DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_154EC2496AF45E4E435C181459D794DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_154EC2496AF45E4E435C181459D794DD" xlink:to="lab_us-gaap_DebtInstrumentAxis_154EC2496AF45E4E435C181459D794DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_BF1D57EC5235C4C486FB181459D70D6C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_BF1D57EC5235C4C486FB181459D70D6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_BF1D57EC5235C4C486FB181459D70D6C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_BF1D57EC5235C4C486FB181459D70D6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_BF1D57EC5235C4C486FB181459D70D6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BF1D57EC5235C4C486FB181459D70D6C" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_BF1D57EC5235C4C486FB181459D70D6C" xlink:type="arc" />
    <link:label id="lab_cdtx_TermLoanAMember_66B93B16DF256EA319BB181459D71979_verboseLabel_en-US" xlink:label="lab_cdtx_TermLoanAMember_66B93B16DF256EA319BB181459D71979" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Term A Loan</link:label>
    <link:label id="lab_cdtx_TermLoanAMember_66B93B16DF256EA319BB181459D71979_label_en-US" xlink:label="lab_cdtx_TermLoanAMember_66B93B16DF256EA319BB181459D71979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:label id="lab_cdtx_TermLoanAMember_66B93B16DF256EA319BB181459D71979_documentation_en-US" xlink:label="lab_cdtx_TermLoanAMember_66B93B16DF256EA319BB181459D71979" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TermLoanAMember" xlink:label="loc_cdtx_TermLoanAMember_66B93B16DF256EA319BB181459D71979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TermLoanAMember_66B93B16DF256EA319BB181459D71979" xlink:to="lab_cdtx_TermLoanAMember_66B93B16DF256EA319BB181459D71979" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_A0B6CE5660B1895EE92E181459D733FE_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_A0B6CE5660B1895EE92E181459D733FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_A0B6CE5660B1895EE92E181459D733FE_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_A0B6CE5660B1895EE92E181459D733FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_A0B6CE5660B1895EE92E181459D733FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A0B6CE5660B1895EE92E181459D733FE" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_A0B6CE5660B1895EE92E181459D733FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_51CACF11A1B3F01BC1FD181459D73E4B_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_51CACF11A1B3F01BC1FD181459D73E4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_51CACF11A1B3F01BC1FD181459D73E4B_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_51CACF11A1B3F01BC1FD181459D73E4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_51CACF11A1B3F01BC1FD181459D73E4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_51CACF11A1B3F01BC1FD181459D73E4B" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_51CACF11A1B3F01BC1FD181459D73E4B" xlink:type="arc" />
    <link:label id="lab_cdtx_TermLoanMember_46950D65F4FB3837DC19181459D79103_terseLabel_en-US" xlink:label="lab_cdtx_TermLoanMember_46950D65F4FB3837DC19181459D79103" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_cdtx_TermLoanMember_46950D65F4FB3837DC19181459D79103_label_en-US" xlink:label="lab_cdtx_TermLoanMember_46950D65F4FB3837DC19181459D79103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_cdtx_TermLoanMember_46950D65F4FB3837DC19181459D79103_documentation_en-US" xlink:label="lab_cdtx_TermLoanMember_46950D65F4FB3837DC19181459D79103" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TermLoanMember" xlink:label="loc_cdtx_TermLoanMember_46950D65F4FB3837DC19181459D79103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TermLoanMember_46950D65F4FB3837DC19181459D79103" xlink:to="lab_cdtx_TermLoanMember_46950D65F4FB3837DC19181459D79103" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_E6C595BC59FC07BFC81B181459D7D922_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_E6C595BC59FC07BFC81B181459D7D922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_E6C595BC59FC07BFC81B181459D7D922_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_E6C595BC59FC07BFC81B181459D7D922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E6C595BC59FC07BFC81B181459D7D922" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E6C595BC59FC07BFC81B181459D7D922" xlink:to="lab_us-gaap_DebtInstrumentLineItems_E6C595BC59FC07BFC81B181459D7D922" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ended:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BD6D3674286D909E8763181459D870F8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BD6D3674286D909E8763181459D870F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 31, 2018</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BD6D3674286D909E8763181459D870F8_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BD6D3674286D909E8763181459D870F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BD6D3674286D909E8763181459D870F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BD6D3674286D909E8763181459D870F8" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BD6D3674286D909E8763181459D870F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_B0E87192A8786063C87E181459D8F3FD_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_B0E87192A8786063C87E181459D8F3FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 31, 2019</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_B0E87192A8786063C87E181459D8F3FD_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_B0E87192A8786063C87E181459D8F3FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_B0E87192A8786063C87E181459D8F3FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_B0E87192A8786063C87E181459D8F3FD" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_B0E87192A8786063C87E181459D8F3FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_47C01447493837B43F5E181459D8A24F_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_47C01447493837B43F5E181459D8A24F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 31, 2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_47C01447493837B43F5E181459D8A24F_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_47C01447493837B43F5E181459D8A24F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_47C01447493837B43F5E181459D8A24F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_47C01447493837B43F5E181459D8A24F" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_47C01447493837B43F5E181459D8A24F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_8ABD515F683A9F5D61FA181459D8341F_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_8ABD515F683A9F5D61FA181459D8341F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future principal payments due under the Term A Loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_8ABD515F683A9F5D61FA181459D8341F_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_8ABD515F683A9F5D61FA181459D8341F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_8ABD515F683A9F5D61FA181459D8341F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_8ABD515F683A9F5D61FA181459D8341F" xlink:to="lab_us-gaap_LongTermDebt_8ABD515F683A9F5D61FA181459D8341F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_E7928E62A2B6703210F61766D17925ED_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_E7928E62A2B6703210F61766D17925ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_E7928E62A2B6703210F61766D17925ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_E7928E62A2B6703210F61766D17925ED" xlink:to="lab_us-gaap_IncomeStatementAbstract_E7928E62A2B6703210F61766D17925ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_5EBCA41340DE17948F4D1766D17908B4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_5EBCA41340DE17948F4D1766D17908B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_5EBCA41340DE17948F4D1766D17908B4_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_5EBCA41340DE17948F4D1766D17908B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5EBCA41340DE17948F4D1766D17908B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5EBCA41340DE17948F4D1766D17908B4" xlink:to="lab_us-gaap_OperatingExpensesAbstract_5EBCA41340DE17948F4D1766D17908B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1F5B86EE7EBAA4A7C7731766D1799DB9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1F5B86EE7EBAA4A7C7731766D1799DB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1F5B86EE7EBAA4A7C7731766D1799DB9_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1F5B86EE7EBAA4A7C7731766D1799DB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1F5B86EE7EBAA4A7C7731766D1799DB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_1F5B86EE7EBAA4A7C7731766D1799DB9" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1F5B86EE7EBAA4A7C7731766D1799DB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7AEC1743A3FCFCAD14EA1766D17948AB_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_7AEC1743A3FCFCAD14EA1766D17948AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7AEC1743A3FCFCAD14EA1766D17948AB_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_7AEC1743A3FCFCAD14EA1766D17948AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7AEC1743A3FCFCAD14EA1766D17948AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_7AEC1743A3FCFCAD14EA1766D17948AB" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_7AEC1743A3FCFCAD14EA1766D17948AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_B9CEDCA22862905313961766D1795E73_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_B9CEDCA22862905313961766D1795E73" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_B9CEDCA22862905313961766D1795E73_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_B9CEDCA22862905313961766D1795E73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_B9CEDCA22862905313961766D1795E73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_B9CEDCA22862905313961766D1795E73" xlink:to="lab_us-gaap_OperatingExpenses_B9CEDCA22862905313961766D1795E73" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_485BF17FDD027A25B21D1766D179FC5E_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_485BF17FDD027A25B21D1766D179FC5E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_485BF17FDD027A25B21D1766D179FC5E_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_485BF17FDD027A25B21D1766D179FC5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_485BF17FDD027A25B21D1766D179FC5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_485BF17FDD027A25B21D1766D179FC5E" xlink:to="lab_us-gaap_OperatingIncomeLoss_485BF17FDD027A25B21D1766D179FC5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2C088CB4ACAB6D0EA91C1766D179A910_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2C088CB4ACAB6D0EA91C1766D179A910" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2C088CB4ACAB6D0EA91C1766D179A910_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2C088CB4ACAB6D0EA91C1766D179A910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2C088CB4ACAB6D0EA91C1766D179A910" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2C088CB4ACAB6D0EA91C1766D179A910" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2C088CB4ACAB6D0EA91C1766D179A910" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_935F207DA20DA9A461EA1766D1796D4B_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_935F207DA20DA9A461EA1766D1796D4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_935F207DA20DA9A461EA1766D1796D4B_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_935F207DA20DA9A461EA1766D1796D4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_935F207DA20DA9A461EA1766D1796D4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_935F207DA20DA9A461EA1766D1796D4B" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_935F207DA20DA9A461EA1766D1796D4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_42AD770504941464295E1766D17996A6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_42AD770504941464295E1766D17996A6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_42AD770504941464295E1766D17996A6_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_42AD770504941464295E1766D17996A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_42AD770504941464295E1766D17996A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_42AD770504941464295E1766D17996A6" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_42AD770504941464295E1766D17996A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_3B6F3272EDB9BFBAE0F01766D1799D7E_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_3B6F3272EDB9BFBAE0F01766D1799D7E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3B6F3272EDB9BFBAE0F01766D1799D7E_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_3B6F3272EDB9BFBAE0F01766D1799D7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3B6F3272EDB9BFBAE0F01766D1799D7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_3B6F3272EDB9BFBAE0F01766D1799D7E" xlink:to="lab_us-gaap_NetIncomeLoss_3B6F3272EDB9BFBAE0F01766D1799D7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract_EB578B6C8701C163EACA1766D179A53E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract_EB578B6C8701C163EACA1766D179A53E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract_EB578B6C8701C163EACA1766D179A53E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract_EB578B6C8701C163EACA1766D179A53E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Reclassification Adjustments, Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract_EB578B6C8701C163EACA1766D179A53E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract_EB578B6C8701C163EACA1766D179A53E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract_EB578B6C8701C163EACA1766D179A53E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_49248980D39A2DD22AF41766D179F4AD_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_49248980D39A2DD22AF41766D179F4AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_49248980D39A2DD22AF41766D179F4AD_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_49248980D39A2DD22AF41766D179F4AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_49248980D39A2DD22AF41766D179F4AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_49248980D39A2DD22AF41766D179F4AD" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_49248980D39A2DD22AF41766D179F4AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_A5DB8A8469229D130C801766D17A89DC_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_A5DB8A8469229D130C801766D17A89DC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_A5DB8A8469229D130C801766D17A89DC_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_A5DB8A8469229D130C801766D17A89DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_A5DB8A8469229D130C801766D17A89DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_A5DB8A8469229D130C801766D17A89DC" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_A5DB8A8469229D130C801766D17A89DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_1586E938DE3614E7285D1766D17A7634_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_1586E938DE3614E7285D1766D17A7634" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_1586E938DE3614E7285D1766D17A7634_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_1586E938DE3614E7285D1766D17A7634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1586E938DE3614E7285D1766D17A7634" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_1586E938DE3614E7285D1766D17A7634" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_1586E938DE3614E7285D1766D17A7634" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9FE9024459BE5E74C4F71766D17A7563_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9FE9024459BE5E74C4F71766D17A7563" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used to compute basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9FE9024459BE5E74C4F71766D17A7563_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9FE9024459BE5E74C4F71766D17A7563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9FE9024459BE5E74C4F71766D17A7563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9FE9024459BE5E74C4F71766D17A7563" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9FE9024459BE5E74C4F71766D17A7563" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueDisclosureAbstract_EFCC5FEC66AC44E37D26D10E1E01A71D_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueDisclosureAbstract_F1E559C04D2B5DA9B2B48238B0538E8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_F1E559C04D2B5DA9B2B48238B0538E8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_F1E559C04D2B5DA9B2B48238B0538E8D" xlink:to="lab_us-gaap_DeferredRevenueDisclosureAbstract_F1E559C04D2B5DA9B2B48238B0538E8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5E95D64B4B68CEF07B75D10E1E01DFF2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_919E9175B99C599F8358DCE3E8BD841B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SIGNIFICANT AGREEMENTS AND CONTRACTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5E95D64B4B68CEF07B75D10E1E01DFF2_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_919E9175B99C599F8358DCE3E8BD841B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_919E9175B99C599F8358DCE3E8BD841B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_919E9175B99C599F8358DCE3E8BD841B" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_919E9175B99C599F8358DCE3E8BD841B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_443801643A9ADD6971B6D0A840DF944C_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158287B8EC24508788CAEC86838A7598" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK INCENTIVE PLANS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_443801643A9ADD6971B6D0A840DF944C_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158287B8EC24508788CAEC86838A7598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158287B8EC24508788CAEC86838A7598" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158287B8EC24508788CAEC86838A7598" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158287B8EC24508788CAEC86838A7598" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F85CB7FADBBB823C50FCD0A840A30948_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29C407EB80105DDDACD13707A5F639D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F85CB7FADBBB823C50FCD0A840A30948_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29C407EB80105DDDACD13707A5F639D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29C407EB80105DDDACD13707A5F639D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29C407EB80105DDDACD13707A5F639D1" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29C407EB80105DDDACD13707A5F639D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3D6591F61F1153BDC661D0A840A3A96E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_7053E15520BD5CC38C312D87C9ACA80C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3D6591F61F1153BDC661D0A840A3A96E_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_7053E15520BD5CC38C312D87C9ACA80C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7053E15520BD5CC38C312D87C9ACA80C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7053E15520BD5CC38C312D87C9ACA80C" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_7053E15520BD5CC38C312D87C9ACA80C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_BBDED121016946D682B4D0A840A40FAF_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_17A327721CA15FD59059938EE8BEA68A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_BBDED121016946D682B4D0A840A40FAF_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_17A327721CA15FD59059938EE8BEA68A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_17A327721CA15FD59059938EE8BEA68A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17A327721CA15FD59059938EE8BEA68A" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_17A327721CA15FD59059938EE8BEA68A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_301C5170E81BC9C62ABDD0A840A4D243_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_AC60984680785EA99B89FE95688B8D92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_301C5170E81BC9C62ABDD0A840A4D243_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_AC60984680785EA99B89FE95688B8D92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_AC60984680785EA99B89FE95688B8D92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_AC60984680785EA99B89FE95688B8D92" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_AC60984680785EA99B89FE95688B8D92" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8FD97AF74BFE4EA0F58ED0A840A58D0A_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_AA333408A20B57CB855A15872914A646" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8FD97AF74BFE4EA0F58ED0A840A58D0A_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_AA333408A20B57CB855A15872914A646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_AA333408A20B57CB855A15872914A646" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_AA333408A20B57CB855A15872914A646" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_AA333408A20B57CB855A15872914A646" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_E5D8901135918C9D42BBD0A840A5B0B3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9A4A14E6FB335E7C8C56ACA48DA38A74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_E5D8901135918C9D42BBD0A840A5B0B3_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9A4A14E6FB335E7C8C56ACA48DA38A74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9A4A14E6FB335E7C8C56ACA48DA38A74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9A4A14E6FB335E7C8C56ACA48DA38A74" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9A4A14E6FB335E7C8C56ACA48DA38A74" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_A71824DF837D3176F5E8D0A840A58CD2_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_BD3BFAEC5826545AABE8A639C124068D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_A71824DF837D3176F5E8D0A840A58CD2_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_BD3BFAEC5826545AABE8A639C124068D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BD3BFAEC5826545AABE8A639C124068D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_BD3BFAEC5826545AABE8A639C124068D" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_BD3BFAEC5826545AABE8A639C124068D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9DCE4D8916091D0E63034B4E90F9C3EB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0DA1E1487BCD54F1934731249D5568BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of RSU and PRSU activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9DCE4D8916091D0E63034B4E90F9C3EB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0DA1E1487BCD54F1934731249D5568BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0DA1E1487BCD54F1934731249D5568BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0DA1E1487BCD54F1934731249D5568BD" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0DA1E1487BCD54F1934731249D5568BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_257714FF6A4F5353BA0F4B240B293728_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9B5A49B2C12B5540A0E1356CDCD8B5EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_257714FF6A4F5353BA0F4B240B293728_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9B5A49B2C12B5540A0E1356CDCD8B5EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9B5A49B2C12B5540A0E1356CDCD8B5EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9B5A49B2C12B5540A0E1356CDCD8B5EB" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9B5A49B2C12B5540A0E1356CDCD8B5EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5CC91719D304F34018364B240B2EFF7C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F6F489DF1F8259C0B669EECFDD500050" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5CC91719D304F34018364B240B2EFF7C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F6F489DF1F8259C0B669EECFDD500050" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F6F489DF1F8259C0B669EECFDD500050" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F6F489DF1F8259C0B669EECFDD500050" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F6F489DF1F8259C0B669EECFDD500050" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3A2F78A34E50644579F61814599C3B58_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3A2F78A34E50644579F61814599C3B58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3A2F78A34E50644579F61814599C3B58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3A2F78A34E50644579F61814599C3B58" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3A2F78A34E50644579F61814599C3B58" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F73A24EAA772C566CE45183C77D54E6D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F73A24EAA772C566CE45183C77D54E6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F73A24EAA772C566CE45183C77D54E6D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F73A24EAA772C566CE45183C77D54E6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F73A24EAA772C566CE45183C77D54E6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F73A24EAA772C566CE45183C77D54E6D" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F73A24EAA772C566CE45183C77D54E6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4DA194481629C814D35D1814599C405B_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4DA194481629C814D35D1814599C405B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4DA194481629C814D35D1814599C405B_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4DA194481629C814D35D1814599C405B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4DA194481629C814D35D1814599C405B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4DA194481629C814D35D1814599C405B" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4DA194481629C814D35D1814599C405B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_9D7EC0F17C10A3F3895A181459CE6B28_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_9D7EC0F17C10A3F3895A181459CE6B28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9D7EC0F17C10A3F3895A181459CE6B28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_9D7EC0F17C10A3F3895A181459CE6B28" xlink:to="lab_us-gaap_EquityAbstract_9D7EC0F17C10A3F3895A181459CE6B28" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_C6E2A9B0895E07DA40671824607CA959_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_C6E2A9B0895E07DA40671824607CA959" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_C6E2A9B0895E07DA40671824607CA959_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_C6E2A9B0895E07DA40671824607CA959" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_C6E2A9B0895E07DA40671824607CA959" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C6E2A9B0895E07DA40671824607CA959" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_C6E2A9B0895E07DA40671824607CA959" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_D0CF3FC56171F4EFBE4F18249A6103F0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_D0CF3FC56171F4EFBE4F18249A6103F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_D0CF3FC56171F4EFBE4F18249A6103F0_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_D0CF3FC56171F4EFBE4F18249A6103F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D0CF3FC56171F4EFBE4F18249A6103F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D0CF3FC56171F4EFBE4F18249A6103F0" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_D0CF3FC56171F4EFBE4F18249A6103F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_6FF6D8B251974F0ECC1318249A68B665_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_6FF6D8B251974F0ECC1318249A68B665" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_6FF6D8B251974F0ECC1318249A68B665_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_6FF6D8B251974F0ECC1318249A68B665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6FF6D8B251974F0ECC1318249A68B665" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6FF6D8B251974F0ECC1318249A68B665" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_6FF6D8B251974F0ECC1318249A68B665" xlink:type="arc" />
    <link:label id="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_D63371394C82FCB2B53F18249A7A7111_terseLabel_en-US" xlink:label="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_D63371394C82FCB2B53F18249A7A7111" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Controlled equity sales agreement with Cantor Fitzgerald And Company</link:label>
    <link:label id="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_D63371394C82FCB2B53F18249A7A7111_label_en-US" xlink:label="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_D63371394C82FCB2B53F18249A7A7111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]</link:label>
    <link:label id="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_D63371394C82FCB2B53F18249A7A7111_documentation_en-US" xlink:label="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_D63371394C82FCB2B53F18249A7A7111" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:label="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_D63371394C82FCB2B53F18249A7A7111" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_D63371394C82FCB2B53F18249A7A7111" xlink:to="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_D63371394C82FCB2B53F18249A7A7111" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="lab_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_70D6B28E73169F441973181459CE0B4A_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_70D6B28E73169F441973181459CE0B4A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_70D6B28E73169F441973181459CE0B4A_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_70D6B28E73169F441973181459CE0B4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_70D6B28E73169F441973181459CE0B4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_70D6B28E73169F441973181459CE0B4A" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_70D6B28E73169F441973181459CE0B4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_5DA332846B26C667CA09181459CEBF88_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_5DA332846B26C667CA09181459CEBF88" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_5DA332846B26C667CA09181459CEBF88_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_5DA332846B26C667CA09181459CEBF88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5DA332846B26C667CA09181459CEBF88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_5DA332846B26C667CA09181459CEBF88" xlink:to="lab_us-gaap_PreferredStockSharesIssued_5DA332846B26C667CA09181459CEBF88" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_B22B4485A89F4317DD2F181459CEF247_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_B22B4485A89F4317DD2F181459CEF247" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_B22B4485A89F4317DD2F181459CEF247_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_B22B4485A89F4317DD2F181459CEF247" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_B22B4485A89F4317DD2F181459CEF247" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_B22B4485A89F4317DD2F181459CEF247" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_B22B4485A89F4317DD2F181459CEF247" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_CA04B074630CEE53F034181459CFA196_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_CA04B074630CEE53F034181459CFA196" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_CA04B074630CEE53F034181459CFA196_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_CA04B074630CEE53F034181459CFA196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_CA04B074630CEE53F034181459CFA196" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_CA04B074630CEE53F034181459CFA196" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_CA04B074630CEE53F034181459CFA196" xlink:type="arc" />
    <link:label id="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_0222B91C3942F07D1974181459CF46E8_terseLabel_en-US" xlink:label="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_0222B91C3942F07D1974181459CF46E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of votes for each share held</link:label>
    <link:label id="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_0222B91C3942F07D1974181459CF46E8_label_en-US" xlink:label="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_0222B91C3942F07D1974181459CF46E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Votes Entitlement For Each Share Held</link:label>
    <link:label id="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_0222B91C3942F07D1974181459CF46E8_documentation_en-US" xlink:label="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_0222B91C3942F07D1974181459CF46E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of votes entitlement for each share held.</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:label="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_0222B91C3942F07D1974181459CF46E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_0222B91C3942F07D1974181459CF46E8" xlink:to="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_0222B91C3942F07D1974181459CF46E8" xlink:type="arc" />
    <link:label id="lab_cdtx_CommonStockDividendsInArrearsOrDefault_8B9D4F08755CEED8FE91181459CFEE51_terseLabel_en-US" xlink:label="lab_cdtx_CommonStockDividendsInArrearsOrDefault_8B9D4F08755CEED8FE91181459CFEE51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends in arrears or default</link:label>
    <link:label id="lab_cdtx_CommonStockDividendsInArrearsOrDefault_8B9D4F08755CEED8FE91181459CFEE51_label_en-US" xlink:label="lab_cdtx_CommonStockDividendsInArrearsOrDefault_8B9D4F08755CEED8FE91181459CFEE51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Dividends In Arrears Or Default</link:label>
    <link:label id="lab_cdtx_CommonStockDividendsInArrearsOrDefault_8B9D4F08755CEED8FE91181459CFEE51_documentation_en-US" xlink:label="lab_cdtx_CommonStockDividendsInArrearsOrDefault_8B9D4F08755CEED8FE91181459CFEE51" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock dividends in arrears or default.</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CommonStockDividendsInArrearsOrDefault" xlink:label="loc_cdtx_CommonStockDividendsInArrearsOrDefault_8B9D4F08755CEED8FE91181459CFEE51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CommonStockDividendsInArrearsOrDefault_8B9D4F08755CEED8FE91181459CFEE51" xlink:to="lab_cdtx_CommonStockDividendsInArrearsOrDefault_8B9D4F08755CEED8FE91181459CFEE51" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D5003FAC03D4286FAD9B18249A4FE850_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D5003FAC03D4286FAD9B18249A4FE850" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D5003FAC03D4286FAD9B18249A4FE850_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D5003FAC03D4286FAD9B18249A4FE850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D5003FAC03D4286FAD9B18249A4FE850" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D5003FAC03D4286FAD9B18249A4FE850" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D5003FAC03D4286FAD9B18249A4FE850" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_654823B8598CA539D1E818249A597B94_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_654823B8598CA539D1E818249A597B94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_654823B8598CA539D1E818249A597B94_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_654823B8598CA539D1E818249A597B94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_654823B8598CA539D1E818249A597B94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_654823B8598CA539D1E818249A597B94" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_654823B8598CA539D1E818249A597B94" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_774972F53A80B30B81CB181459A80F8D_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_774972F53A80B30B81CB181459A80F8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subaward Agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_774972F53A80B30B81CB181459A80F8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_774972F53A80B30B81CB181459A80F8D" xlink:to="lab_us-gaap_CollaborativeArrangementMember_774972F53A80B30B81CB181459A80F8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_443B3E95A27464398765181459A86633_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_443B3E95A27464398765181459A86633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_443B3E95A27464398765181459A86633_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_443B3E95A27464398765181459A86633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_443B3E95A27464398765181459A86633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_443B3E95A27464398765181459A86633" xlink:to="lab_us-gaap_ProductOrServiceAxis_443B3E95A27464398765181459A86633" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_DB85EE24B8B9143D8E44181459A83E60_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_DB85EE24B8B9143D8E44181459A83E60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_DB85EE24B8B9143D8E44181459A83E60_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_DB85EE24B8B9143D8E44181459A83E60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_DB85EE24B8B9143D8E44181459A83E60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_DB85EE24B8B9143D8E44181459A83E60" xlink:to="lab_us-gaap_ProductsAndServicesDomain_DB85EE24B8B9143D8E44181459A83E60" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_BC2A8F2E0C38BCE42886181459A8EBE3_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_BC2A8F2E0C38BCE42886181459A8EBE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CD201 product candidate</link:label>
    <link:label id="lab_us-gaap_ProductMember_BC2A8F2E0C38BCE42886181459A8EBE3_label_en-US" xlink:label="lab_us-gaap_ProductMember_BC2A8F2E0C38BCE42886181459A8EBE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_BC2A8F2E0C38BCE42886181459A8EBE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_BC2A8F2E0C38BCE42886181459A8EBE3" xlink:to="lab_us-gaap_ProductMember_BC2A8F2E0C38BCE42886181459A8EBE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:type="arc" />
    <link:label id="lab_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase_A9EB8143160335AE0947181459A97C6B_terseLabel_en-US" xlink:label="lab_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase_A9EB8143160335AE0947181459A97C6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualifying development expenses to be reimbursed by CARB-X upon acceptance of new initial drug application</link:label>
    <link:label id="lab_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase_A9EB8143160335AE0947181459A97C6B_label_en-US" xlink:label="lab_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase_A9EB8143160335AE0947181459A97C6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Reimbursal Of Qualifying Development Expenses, Initial Phase</link:label>
    <link:label id="lab_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase_A9EB8143160335AE0947181459A97C6B_documentation_en-US" xlink:label="lab_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase_A9EB8143160335AE0947181459A97C6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Reimbursal Of Qualifying Development Expenses, Initial Phase</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase" xlink:label="loc_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase_A9EB8143160335AE0947181459A97C6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase_A9EB8143160335AE0947181459A97C6B" xlink:to="lab_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase_A9EB8143160335AE0947181459A97C6B" xlink:type="arc" />
    <link:label id="lab_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage_D4198CA8C16B705AA2B1181459A93289_terseLabel_en-US" xlink:label="lab_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage_D4198CA8C16B705AA2B1181459A93289" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualifying development expenses to be reimbursed through a Phase 1 clinical trial of CD201</link:label>
    <link:label id="lab_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage_D4198CA8C16B705AA2B1181459A93289_label_en-US" xlink:label="lab_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage_D4198CA8C16B705AA2B1181459A93289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Reimbursal Of Qualifying Development Expenses, Second Stage</link:label>
    <link:label id="lab_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage_D4198CA8C16B705AA2B1181459A93289_documentation_en-US" xlink:label="lab_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage_D4198CA8C16B705AA2B1181459A93289" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Reimbursal Of Qualifying Development Expenses, Second Stage</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage" xlink:label="loc_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage_D4198CA8C16B705AA2B1181459A93289" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage_D4198CA8C16B705AA2B1181459A93289" xlink:to="lab_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage_D4198CA8C16B705AA2B1181459A93289" xlink:type="arc" />
    <link:label id="lab_cdtx_ReductioninResearchandDevelopmentExpense_F58AE5E7CB3F1D98D2F9181459A95F54_terseLabel_en-US" xlink:label="lab_cdtx_ReductioninResearchandDevelopmentExpense_F58AE5E7CB3F1D98D2F9181459A95F54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in research and development expense</link:label>
    <link:label id="lab_cdtx_ReductioninResearchandDevelopmentExpense_F58AE5E7CB3F1D98D2F9181459A95F54_label_en-US" xlink:label="lab_cdtx_ReductioninResearchandDevelopmentExpense_F58AE5E7CB3F1D98D2F9181459A95F54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in Research and Development Expense</link:label>
    <link:label id="lab_cdtx_ReductioninResearchandDevelopmentExpense_F58AE5E7CB3F1D98D2F9181459A95F54_documentation_en-US" xlink:label="lab_cdtx_ReductioninResearchandDevelopmentExpense_F58AE5E7CB3F1D98D2F9181459A95F54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in Research and Development Expense</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_ReductioninResearchandDevelopmentExpense" xlink:label="loc_cdtx_ReductioninResearchandDevelopmentExpense_F58AE5E7CB3F1D98D2F9181459A95F54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ReductioninResearchandDevelopmentExpense_F58AE5E7CB3F1D98D2F9181459A95F54" xlink:to="lab_cdtx_ReductioninResearchandDevelopmentExpense_F58AE5E7CB3F1D98D2F9181459A95F54" xlink:type="arc" />
    <link:label id="lab_us-gaap_BilledContractReceivables_4C6B431F468FA8F0BD49181459A9DF2E_terseLabel_en-US" xlink:label="lab_us-gaap_BilledContractReceivables_4C6B431F468FA8F0BD49181459A9DF2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Billed accounts receivable</link:label>
    <link:label id="lab_us-gaap_BilledContractReceivables_4C6B431F468FA8F0BD49181459A9DF2E_label_en-US" xlink:label="lab_us-gaap_BilledContractReceivables_4C6B431F468FA8F0BD49181459A9DF2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Contracts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BilledContractReceivables" xlink:label="loc_us-gaap_BilledContractReceivables_4C6B431F468FA8F0BD49181459A9DF2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledContractReceivables_4C6B431F468FA8F0BD49181459A9DF2E" xlink:to="lab_us-gaap_BilledContractReceivables_4C6B431F468FA8F0BD49181459A9DF2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_E62077C1F94911226ADB181459A94BA4_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable_E62077C1F94911226ADB181459A94BA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled accounts receivable</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_E62077C1F94911226ADB181459A94BA4_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable_E62077C1F94911226ADB181459A94BA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="loc_us-gaap_UnbilledContractsReceivable_E62077C1F94911226ADB181459A94BA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable_E62077C1F94911226ADB181459A94BA4" xlink:to="lab_us-gaap_UnbilledContractsReceivable_E62077C1F94911226ADB181459A94BA4" xlink:type="arc" />
    <link:label id="lab_cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice_82631094F0095737F3ED181459A9CC95_terseLabel_en-US" xlink:label="lab_cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice_82631094F0095737F3ED181459A9CC95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement termination, written notice period</link:label>
    <link:label id="lab_cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice_82631094F0095737F3ED181459A9CC95_label_en-US" xlink:label="lab_cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice_82631094F0095737F3ED181459A9CC95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Agreement Termination, Period For Written Notice</link:label>
    <link:label id="lab_cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice_82631094F0095737F3ED181459A9CC95_documentation_en-US" xlink:label="lab_cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice_82631094F0095737F3ED181459A9CC95" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Agreement Termination, Period For Written Notice</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice" xlink:label="loc_cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice_82631094F0095737F3ED181459A9CC95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice_82631094F0095737F3ED181459A9CC95" xlink:to="lab_cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice_82631094F0095737F3ED181459A9CC95" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FDC5CC725E73923CD1AECB9C84CC68F4_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BAF92DE30E4A5A33B98BFC9F898288F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BAF92DE30E4A5A33B98BFC9F898288F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BAF92DE30E4A5A33B98BFC9F898288F1" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BAF92DE30E4A5A33B98BFC9F898288F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_B4B3D68B2613D17EEFB1CB9C84CDA1AA_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_21095D2B311E587898A8A274DDB98B4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">THE COMPANY AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_B4B3D68B2613D17EEFB1CB9C84CDA1AA_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_21095D2B311E587898A8A274DDB98B4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_21095D2B311E587898A8A274DDB98B4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_21095D2B311E587898A8A274DDB98B4C" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_21095D2B311E587898A8A274DDB98B4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_25158CDDE19692890C29181459E555AA_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_25158CDDE19692890C29181459E555AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_25158CDDE19692890C29181459E555AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_25158CDDE19692890C29181459E555AA" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_25158CDDE19692890C29181459E555AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8E53A4B89F07F222949B181459E69F85_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8E53A4B89F07F222949B181459E69F85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8E53A4B89F07F222949B181459E69F85_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8E53A4B89F07F222949B181459E69F85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8E53A4B89F07F222949B181459E69F85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8E53A4B89F07F222949B181459E69F85" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8E53A4B89F07F222949B181459E69F85" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_026D6E8FEBDF4D851E58181459E6683E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_026D6E8FEBDF4D851E58181459E6683E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_026D6E8FEBDF4D851E58181459E6683E_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_026D6E8FEBDF4D851E58181459E6683E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_026D6E8FEBDF4D851E58181459E6683E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_026D6E8FEBDF4D851E58181459E6683E" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_026D6E8FEBDF4D851E58181459E6683E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_728EF88E0ACFAC91738E181459E65D43_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_728EF88E0ACFAC91738E181459E65D43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_728EF88E0ACFAC91738E181459E65D43_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_728EF88E0ACFAC91738E181459E65D43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_728EF88E0ACFAC91738E181459E65D43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_728EF88E0ACFAC91738E181459E65D43" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_728EF88E0ACFAC91738E181459E65D43" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2CEB18A04184D73AA6A0181459E6D0AE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2CEB18A04184D73AA6A0181459E6D0AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2CEB18A04184D73AA6A0181459E6D0AE_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2CEB18A04184D73AA6A0181459E6D0AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2CEB18A04184D73AA6A0181459E6D0AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2CEB18A04184D73AA6A0181459E6D0AE" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2CEB18A04184D73AA6A0181459E6D0AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7E9063B6EEE1D28C2A16181459E6E042_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_7E9063B6EEE1D28C2A16181459E6E042" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEVEL 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7E9063B6EEE1D28C2A16181459E6E042_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_7E9063B6EEE1D28C2A16181459E6E042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7E9063B6EEE1D28C2A16181459E6E042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_7E9063B6EEE1D28C2A16181459E6E042" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_7E9063B6EEE1D28C2A16181459E6E042" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_E1E91BD1716209C18224181459E6A4BE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_E1E91BD1716209C18224181459E6A4BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEVEL 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_E1E91BD1716209C18224181459E6A4BE_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_E1E91BD1716209C18224181459E6A4BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E1E91BD1716209C18224181459E6A4BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_E1E91BD1716209C18224181459E6A4BE" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_E1E91BD1716209C18224181459E6A4BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_504041A05B68D9F9B5FA181459E6BABB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_504041A05B68D9F9B5FA181459E6BABB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEVEL 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_504041A05B68D9F9B5FA181459E6BABB_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_504041A05B68D9F9B5FA181459E6BABB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_504041A05B68D9F9B5FA181459E6BABB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_504041A05B68D9F9B5FA181459E6BABB" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_504041A05B68D9F9B5FA181459E6BABB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_CEFBE9041660CCA59AC6181459E69809_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_CEFBE9041660CCA59AC6181459E69809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_CEFBE9041660CCA59AC6181459E69809_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_CEFBE9041660CCA59AC6181459E69809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_CEFBE9041660CCA59AC6181459E69809" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_CEFBE9041660CCA59AC6181459E69809" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_CEFBE9041660CCA59AC6181459E69809" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_5E68F5A80A8CE9A5C3A8181459E6B293_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_5E68F5A80A8CE9A5C3A8181459E6B293" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_5E68F5A80A8CE9A5C3A8181459E6B293_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_5E68F5A80A8CE9A5C3A8181459E6B293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5E68F5A80A8CE9A5C3A8181459E6B293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_5E68F5A80A8CE9A5C3A8181459E6B293" xlink:to="lab_us-gaap_MoneyMarketFundsMember_5E68F5A80A8CE9A5C3A8181459E6B293" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_15D737554B69202DFC3B181459E6555F_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_15D737554B69202DFC3B181459E6555F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_15D737554B69202DFC3B181459E6555F_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_15D737554B69202DFC3B181459E6555F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_15D737554B69202DFC3B181459E6555F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_15D737554B69202DFC3B181459E6555F" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_15D737554B69202DFC3B181459E6555F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10964069F8D7E29153CD181459E73539_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10964069F8D7E29153CD181459E73539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10964069F8D7E29153CD181459E73539_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10964069F8D7E29153CD181459E73539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10964069F8D7E29153CD181459E73539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10964069F8D7E29153CD181459E73539" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10964069F8D7E29153CD181459E73539" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_CEBE7D2FA9C29C663ABA181459E752A5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_CEBE7D2FA9C29C663ABA181459E752A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_CEBE7D2FA9C29C663ABA181459E752A5_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_CEBE7D2FA9C29C663ABA181459E752A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_CEBE7D2FA9C29C663ABA181459E752A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_CEBE7D2FA9C29C663ABA181459E752A5" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_CEBE7D2FA9C29C663ABA181459E752A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureRecurring_366955CC412DB53B9648181459E73A7D_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureRecurring_366955CC412DB53B9648181459E73A7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureRecurring_366955CC412DB53B9648181459E73A7D_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureRecurring_366955CC412DB53B9648181459E73A7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure, Recurring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_366955CC412DB53B9648181459E73A7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureRecurring_366955CC412DB53B9648181459E73A7D" xlink:to="lab_us-gaap_AssetsFairValueDisclosureRecurring_366955CC412DB53B9648181459E73A7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_391277DB7F2DD56B5012181459E7753F_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_391277DB7F2DD56B5012181459E7753F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_391277DB7F2DD56B5012181459E7753F_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_391277DB7F2DD56B5012181459E7753F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_391277DB7F2DD56B5012181459E7753F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_391277DB7F2DD56B5012181459E7753F" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_391277DB7F2DD56B5012181459E7753F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_C85C929137F55263037DCBE48C18C943_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_D303F3AFF2D9583D84EFBC9EC5FF9519" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_C85C929137F55263037DCBE48C18C943_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_D303F3AFF2D9583D84EFBC9EC5FF9519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_D303F3AFF2D9583D84EFBC9EC5FF9519" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_D303F3AFF2D9583D84EFBC9EC5FF9519" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_D303F3AFF2D9583D84EFBC9EC5FF9519" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_A9D7C8C348E7DFCAA3C2CBFD196DA51B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_937AC3A0EACF5F09BF818EA6D6C3BA1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_A9D7C8C348E7DFCAA3C2CBFD196DA51B_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_937AC3A0EACF5F09BF818EA6D6C3BA1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_937AC3A0EACF5F09BF818EA6D6C3BA1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_937AC3A0EACF5F09BF818EA6D6C3BA1D" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_937AC3A0EACF5F09BF818EA6D6C3BA1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_CF92EEDF6597B4E742B4D4C8A1DA415C_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F924D2CDB82E58FC87495DFE89C31BB1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F924D2CDB82E58FC87495DFE89C31BB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F924D2CDB82E58FC87495DFE89C31BB1" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_F924D2CDB82E58FC87495DFE89C31BB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_EBC7A5A415C8929BC70DD4C8A1DA348C_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_893F45696EFD5009827EEF025E1BC842" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_EBC7A5A415C8929BC70DD4C8A1DA348C_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_893F45696EFD5009827EEF025E1BC842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_893F45696EFD5009827EEF025E1BC842" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_893F45696EFD5009827EEF025E1BC842" xlink:to="lab_us-gaap_NumberOfOperatingSegments_893F45696EFD5009827EEF025E1BC842" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_129507134543B7A9B273D3EF9FAB4A08_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_FF9BAB111E38578D9C24A2FBF61105BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SHORT-TERM INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_129507134543B7A9B273D3EF9FAB4A08_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_FF9BAB111E38578D9C24A2FBF61105BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_FF9BAB111E38578D9C24A2FBF61105BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_FF9BAB111E38578D9C24A2FBF61105BC" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_FF9BAB111E38578D9C24A2FBF61105BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_399C94DBDD411EAB5CB0CBE48C15CABD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_B6FA08BC474F58C590E691ED0273A349" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Financial Instruments Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_399C94DBDD411EAB5CB0CBE48C15CABD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_B6FA08BC474F58C590E691ED0273A349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_B6FA08BC474F58C590E691ED0273A349" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_B6FA08BC474F58C590E691ED0273A349" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_B6FA08BC474F58C590E691ED0273A349" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_F16DA07CC6A8E1A3E938181459CBEE09_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_F16DA07CC6A8E1A3E938181459CBEE09" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_F16DA07CC6A8E1A3E938181459CBEE09_label_en-US" xlink:label="lab_us-gaap_WarrantMember_F16DA07CC6A8E1A3E938181459CBEE09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_F16DA07CC6A8E1A3E938181459CBEE09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_F16DA07CC6A8E1A3E938181459CBEE09" xlink:to="lab_us-gaap_WarrantMember_F16DA07CC6A8E1A3E938181459CBEE09" xlink:type="arc" />
    <link:label id="lab_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_28874712DE798DECC3F1181459CA7F65_verboseLabel_en-US" xlink:label="lab_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_28874712DE798DECC3F1181459CA7F65" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and RSUs issued and outstanding</link:label>
    <link:label id="lab_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_28874712DE798DECC3F1181459CA7F65_label_en-US" xlink:label="lab_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_28874712DE798DECC3F1181459CA7F65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Options And Restricted Stock Units Issued And Outstanding [Member]</link:label>
    <link:label id="lab_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_28874712DE798DECC3F1181459CA7F65_documentation_en-US" xlink:label="lab_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_28874712DE798DECC3F1181459CA7F65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Options And Restricted Stock Units Issued And Outstanding [Member]</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember" xlink:label="loc_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_28874712DE798DECC3F1181459CA7F65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_28874712DE798DECC3F1181459CA7F65" xlink:to="lab_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_28874712DE798DECC3F1181459CA7F65" xlink:type="arc" />
    <link:label id="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_4CA2B702151E1552C089181459CA5DDF_terseLabel_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_4CA2B702151E1552C089181459CA5DDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized for future stock awards under the Company's option plans</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_4CA2B702151E1552C089181459CA5DDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_4CA2B702151E1552C089181459CA5DDF" xlink:to="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_4CA2B702151E1552C089181459CA5DDF" xlink:type="arc" />
    <link:label id="lab_cdtx_EmployeeStockPurchasePlanMember_7BEF0F07E13222DE7760181459CAAAE7_terseLabel_en-US" xlink:label="lab_cdtx_EmployeeStockPurchasePlanMember_7BEF0F07E13222DE7760181459CAAAE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized for future issuance under the ESPP</link:label>
    <link:label id="lab_cdtx_EmployeeStockPurchasePlanMember_7BEF0F07E13222DE7760181459CAAAE7_label_en-US" xlink:label="lab_cdtx_EmployeeStockPurchasePlanMember_7BEF0F07E13222DE7760181459CAAAE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_cdtx_EmployeeStockPurchasePlanMember_7BEF0F07E13222DE7760181459CAAAE7_documentation_en-US" xlink:label="lab_cdtx_EmployeeStockPurchasePlanMember_7BEF0F07E13222DE7760181459CAAAE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_EmployeeStockPurchasePlanMember" xlink:label="loc_cdtx_EmployeeStockPurchasePlanMember_7BEF0F07E13222DE7760181459CAAAE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_EmployeeStockPurchasePlanMember_7BEF0F07E13222DE7760181459CAAAE7" xlink:to="lab_cdtx_EmployeeStockPurchasePlanMember_7BEF0F07E13222DE7760181459CAAAE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CA3C9F64D662C18BD64C181459CB9A1C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CA3C9F64D662C18BD64C181459CB9A1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CA3C9F64D662C18BD64C181459CB9A1C_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CA3C9F64D662C18BD64C181459CB9A1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CA3C9F64D662C18BD64C181459CB9A1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CA3C9F64D662C18BD64C181459CB9A1C" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CA3C9F64D662C18BD64C181459CB9A1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_79CF64156B2ED8549028D0A6554A4475_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock_A994CDEC4C895BD6B49B381F51C009A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_79CF64156B2ED8549028D0A6554A4475_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock_A994CDEC4C895BD6B49B381F51C009A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_A994CDEC4C895BD6B49B381F51C009A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock_A994CDEC4C895BD6B49B381F51C009A0" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock_A994CDEC4C895BD6B49B381F51C009A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_F624F81D1039E0344763CB9C85165D81_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_E8B193FD491A59CF9D4D25FA72F7B6E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_F624F81D1039E0344763CB9C85165D81_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_E8B193FD491A59CF9D4D25FA72F7B6E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E8B193FD491A59CF9D4D25FA72F7B6E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E8B193FD491A59CF9D4D25FA72F7B6E0" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_E8B193FD491A59CF9D4D25FA72F7B6E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_A194C0E1C33F3473BF28CB9C8517E5F1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_8555A1F955A95A3E8E67856903C59C60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8555A1F955A95A3E8E67856903C59C60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_8555A1F955A95A3E8E67856903C59C60" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_8555A1F955A95A3E8E67856903C59C60" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_F89615DC53F78BCDEED7CB9C8517625A_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_31DC9A6E6A125F0CA17CE1DE12C8965D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_31DC9A6E6A125F0CA17CE1DE12C8965D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_31DC9A6E6A125F0CA17CE1DE12C8965D" xlink:to="lab_us-gaap_PreferredStockSharesIssued_31DC9A6E6A125F0CA17CE1DE12C8965D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_CDE1360FBC2DDAAF80B6CB9C851759C8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_1F18C023D46058C5B5C527B0F5A7A578" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1F18C023D46058C5B5C527B0F5A7A578" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_1F18C023D46058C5B5C527B0F5A7A578" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_1F18C023D46058C5B5C527B0F5A7A578" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1CCFA6010D653042D5E8CB9C85170675_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_6941C74781BA54B693A485B92822E8BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1CCFA6010D653042D5E8CB9C85170675_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_6941C74781BA54B693A485B92822E8BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6941C74781BA54B693A485B92822E8BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_6941C74781BA54B693A485B92822E8BB" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_6941C74781BA54B693A485B92822E8BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_DDB1264B685C27EAEA79CB9C851759CF_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_2D88F447C4F1585EA5F15A6E9D31AD4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2D88F447C4F1585EA5F15A6E9D31AD4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_2D88F447C4F1585EA5F15A6E9D31AD4E" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_2D88F447C4F1585EA5F15A6E9D31AD4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_D9113E36F518798AA57BCB9C8517B891_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_4648821D759858BD859BFE9B5AB139E3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_D9113E36F518798AA57BCB9C8517B891_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_4648821D759858BD859BFE9B5AB139E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_4648821D759858BD859BFE9B5AB139E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_4648821D759858BD859BFE9B5AB139E3" xlink:to="lab_us-gaap_CommonStockSharesIssued_4648821D759858BD859BFE9B5AB139E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_D2C3848F35A8643CB294CB9C85186E04_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_DEBEFEC38E7052B2B2AB1380B4253BCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_D2C3848F35A8643CB294CB9C85186E04_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_DEBEFEC38E7052B2B2AB1380B4253BCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_DEBEFEC38E7052B2B2AB1380B4253BCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_DEBEFEC38E7052B2B2AB1380B4253BCB" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_DEBEFEC38E7052B2B2AB1380B4253BCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_501E9728C7459DAF52AAD10E1E2EEFE6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber_371EF05E707C502BB73B4280CB13A6DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of claim or actions pending</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_501E9728C7459DAF52AAD10E1E2EEFE6_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber_371EF05E707C502BB73B4280CB13A6DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_371EF05E707C502BB73B4280CB13A6DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber_371EF05E707C502BB73B4280CB13A6DF" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber_371EF05E707C502BB73B4280CB13A6DF" xlink:type="arc" />
    <link:label id="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_455C54E900F1F4784B6CD10E1E2FFA7F_terseLabel_en-US" xlink:label="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_5A000AC2BCE2578394505F0AEDD1241B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options for individual two-year extensions</link:label>
    <link:label id="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_455C54E900F1F4784B6CD10E1E2FFA7F_label_en-US" xlink:label="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_5A000AC2BCE2578394505F0AEDD1241B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Operating Lease Options For Extension</link:label>
    <link:label id="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_455C54E900F1F4784B6CD10E1E2FFA7F_documentation_en-US" xlink:label="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_5A000AC2BCE2578394505F0AEDD1241B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of operating lease options for extension</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:label="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension_5A000AC2BCE2578394505F0AEDD1241B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension_5A000AC2BCE2578394505F0AEDD1241B" xlink:to="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_5A000AC2BCE2578394505F0AEDD1241B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_212400F560D6299F0387D10E1E2F5405_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_89DE6E2BF469597E86CD1643B326E80E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of optional individual extensions</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_212400F560D6299F0387D10E1E2F5405_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_89DE6E2BF469597E86CD1643B326E80E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_89DE6E2BF469597E86CD1643B326E80E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_89DE6E2BF469597E86CD1643B326E80E" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_89DE6E2BF469597E86CD1643B326E80E" xlink:type="arc" />
    <link:label id="lab_cdtx_IncreaseInBaseRentAnnual_50C8DD4EA68DBA2AA585D12BA230AE45_terseLabel_en-US" xlink:label="lab_cdtx_IncreaseInBaseRentAnnual_A89A05D29A5B55C5809749A107A7147C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increases in base rent (as a percent)</link:label>
    <link:label id="lab_cdtx_IncreaseInBaseRentAnnual_50C8DD4EA68DBA2AA585D12BA230AE45_label_en-US" xlink:label="lab_cdtx_IncreaseInBaseRentAnnual_A89A05D29A5B55C5809749A107A7147C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase In Base Rent Annual</link:label>
    <link:label id="lab_cdtx_IncreaseInBaseRentAnnual_50C8DD4EA68DBA2AA585D12BA230AE45_documentation_en-US" xlink:label="lab_cdtx_IncreaseInBaseRentAnnual_A89A05D29A5B55C5809749A107A7147C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase in base rent annual.</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_IncreaseInBaseRentAnnual" xlink:label="loc_cdtx_IncreaseInBaseRentAnnual_A89A05D29A5B55C5809749A107A7147C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_IncreaseInBaseRentAnnual_A89A05D29A5B55C5809749A107A7147C" xlink:to="lab_cdtx_IncreaseInBaseRentAnnual_A89A05D29A5B55C5809749A107A7147C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_4065E526F9E655054E5ED10E1E2F60C8_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_571364D7334554B99AE56F1D27C0B0FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_4065E526F9E655054E5ED10E1E2F60C8_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_571364D7334554B99AE56F1D27C0B0FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_571364D7334554B99AE56F1D27C0B0FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_571364D7334554B99AE56F1D27C0B0FA" xlink:to="lab_us-gaap_LeaseAndRentalExpense_571364D7334554B99AE56F1D27C0B0FA" xlink:type="arc" />
    <link:label id="lab_cdtx_ContractualObligationContractTerminationNoticePeriod_6BED8F3C2BD108368F96D10E1E2F4EED_terseLabel_en-US" xlink:label="lab_cdtx_ContractualObligationContractTerminationNoticePeriod_CB7246453FDB50BA8ED39D1CC96B4F14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract termination, notice period</link:label>
    <link:label id="lab_cdtx_ContractualObligationContractTerminationNoticePeriod_6BED8F3C2BD108368F96D10E1E2F4EED_label_en-US" xlink:label="lab_cdtx_ContractualObligationContractTerminationNoticePeriod_CB7246453FDB50BA8ED39D1CC96B4F14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation Contract Termination Notice Period</link:label>
    <link:label id="lab_cdtx_ContractualObligationContractTerminationNoticePeriod_6BED8F3C2BD108368F96D10E1E2F4EED_documentation_en-US" xlink:label="lab_cdtx_ContractualObligationContractTerminationNoticePeriod_CB7246453FDB50BA8ED39D1CC96B4F14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual obligation, contract termination notice period.</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_ContractualObligationContractTerminationNoticePeriod" xlink:label="loc_cdtx_ContractualObligationContractTerminationNoticePeriod_CB7246453FDB50BA8ED39D1CC96B4F14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ContractualObligationContractTerminationNoticePeriod_CB7246453FDB50BA8ED39D1CC96B4F14" xlink:to="lab_cdtx_ContractualObligationContractTerminationNoticePeriod_CB7246453FDB50BA8ED39D1CC96B4F14" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7AEC993D67B4A029A912316DE260733D_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_7AEC993D67B4A029A912316DE260733D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7AEC993D67B4A029A912316DE260733D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7AEC993D67B4A029A912316DE260733D" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_7AEC993D67B4A029A912316DE260733D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_C628EFDCD44A28BFDDE1316DE260D017_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_C628EFDCD44A28BFDDE1316DE260D017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_C628EFDCD44A28BFDDE1316DE260D017_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_C628EFDCD44A28BFDDE1316DE260D017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_C628EFDCD44A28BFDDE1316DE260D017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_C628EFDCD44A28BFDDE1316DE260D017" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_C628EFDCD44A28BFDDE1316DE260D017" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_B820D84CBC765E97F791313B6AB8DC46_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_DE0800EB1CF458098F5397C93C1D3AD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_B820D84CBC765E97F791313B6AB8DC46_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_DE0800EB1CF458098F5397C93C1D3AD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_DE0800EB1CF458098F5397C93C1D3AD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_DE0800EB1CF458098F5397C93C1D3AD5" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_DE0800EB1CF458098F5397C93C1D3AD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FAB18F6B14D992171D0C1777D2F8531E_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FAB18F6B14D992171D0C1777D2F8531E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FAB18F6B14D992171D0C1777D2F8531E_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FAB18F6B14D992171D0C1777D2F8531E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FAB18F6B14D992171D0C1777D2F8531E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FAB18F6B14D992171D0C1777D2F8531E" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FAB18F6B14D992171D0C1777D2F8531E" xlink:type="arc" />
    <link:label id="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_74581E5EC96E7877A5A01777D2F82498_terseLabel_en-US" xlink:label="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_74581E5EC96E7877A5A01777D2F82498" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unaudited Interim Financial Data</link:label>
    <link:label id="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_74581E5EC96E7877A5A01777D2F82498_label_en-US" xlink:label="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_74581E5EC96E7877A5A01777D2F82498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unaudited Interim Financial Data [Policy Text Block]</link:label>
    <link:label id="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_74581E5EC96E7877A5A01777D2F82498_documentation_en-US" xlink:label="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_74581E5EC96E7877A5A01777D2F82498" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unaudited interim financial data.</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_UnauditedInterimFinancialDataPolicyTextBlock" xlink:label="loc_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_74581E5EC96E7877A5A01777D2F82498" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_74581E5EC96E7877A5A01777D2F82498" xlink:to="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_74581E5EC96E7877A5A01777D2F82498" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_BE32A050D5323D136F731777D2F8243E_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_BE32A050D5323D136F731777D2F8243E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_BE32A050D5323D136F731777D2F8243E_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_BE32A050D5323D136F731777D2F8243E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_BE32A050D5323D136F731777D2F8243E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_BE32A050D5323D136F731777D2F8243E" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_BE32A050D5323D136F731777D2F8243E" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_1C72544D695121F376A01777D2F8E09F_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_1C72544D695121F376A01777D2F8E09F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_1C72544D695121F376A01777D2F8E09F_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_1C72544D695121F376A01777D2F8E09F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1C72544D695121F376A01777D2F8E09F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_1C72544D695121F376A01777D2F8E09F" xlink:to="lab_us-gaap_UseOfEstimates_1C72544D695121F376A01777D2F8E09F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_85A24FA1ADA915797E5D1777D2FE7608_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_85A24FA1ADA915797E5D1777D2FE7608" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_85A24FA1ADA915797E5D1777D2FE7608_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_85A24FA1ADA915797E5D1777D2FE7608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_85A24FA1ADA915797E5D1777D2FE7608" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_85A24FA1ADA915797E5D1777D2FE7608" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_85A24FA1ADA915797E5D1777D2FE7608" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_73CD051AC9F6D046F93217A621C6DDEA_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_73CD051AC9F6D046F93217A621C6DDEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, and Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_73CD051AC9F6D046F93217A621C6DDEA_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_73CD051AC9F6D046F93217A621C6DDEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_73CD051AC9F6D046F93217A621C6DDEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_73CD051AC9F6D046F93217A621C6DDEA" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_73CD051AC9F6D046F93217A621C6DDEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_7348BCCEEC5C4AB443BA1777D2FE435F_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_7348BCCEEC5C4AB443BA1777D2FE435F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments Available-for-Sale</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_7348BCCEEC5C4AB443BA1777D2FE435F_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_7348BCCEEC5C4AB443BA1777D2FE435F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_7348BCCEEC5C4AB443BA1777D2FE435F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock_7348BCCEEC5C4AB443BA1777D2FE435F" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock_7348BCCEEC5C4AB443BA1777D2FE435F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_C6D6CF3822B92FF4CDE31777D2FEB3D3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_C6D6CF3822B92FF4CDE31777D2FEB3D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_C6D6CF3822B92FF4CDE31777D2FEB3D3_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_C6D6CF3822B92FF4CDE31777D2FEB3D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_C6D6CF3822B92FF4CDE31777D2FEB3D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_C6D6CF3822B92FF4CDE31777D2FEB3D3" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_C6D6CF3822B92FF4CDE31777D2FEB3D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_ACF866EA0C65F989C0D21777D2FE361F_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_ACF866EA0C65F989C0D21777D2FE361F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent Costs</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_ACF866EA0C65F989C0D21777D2FE361F_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_ACF866EA0C65F989C0D21777D2FE361F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_ACF866EA0C65F989C0D21777D2FE361F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_ACF866EA0C65F989C0D21777D2FE361F" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_ACF866EA0C65F989C0D21777D2FE361F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_CA3F103AE2550DFDA4991777D2FEBCD3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_CA3F103AE2550DFDA4991777D2FEBCD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_CA3F103AE2550DFDA4991777D2FEBCD3_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_CA3F103AE2550DFDA4991777D2FEBCD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_CA3F103AE2550DFDA4991777D2FEBCD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_CA3F103AE2550DFDA4991777D2FEBCD3" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_CA3F103AE2550DFDA4991777D2FEBCD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_F1BD5D6200D05FE2BA8A1777D2FE9902_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_F1BD5D6200D05FE2BA8A1777D2FE9902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_F1BD5D6200D05FE2BA8A1777D2FE9902_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_F1BD5D6200D05FE2BA8A1777D2FE9902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_F1BD5D6200D05FE2BA8A1777D2FE9902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_F1BD5D6200D05FE2BA8A1777D2FE9902" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_F1BD5D6200D05FE2BA8A1777D2FE9902" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D30C6B8198142895DB221777D2FECF49_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D30C6B8198142895DB221777D2FECF49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Funding and Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D30C6B8198142895DB221777D2FECF49_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D30C6B8198142895DB221777D2FECF49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D30C6B8198142895DB221777D2FECF49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D30C6B8198142895DB221777D2FECF49" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_D30C6B8198142895DB221777D2FECF49" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_15103DF6404F0F0783011777D2FEF1B0_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_15103DF6404F0F0783011777D2FEF1B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_15103DF6404F0F0783011777D2FEF1B0_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_15103DF6404F0F0783011777D2FEF1B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_15103DF6404F0F0783011777D2FEF1B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_15103DF6404F0F0783011777D2FEF1B0" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_15103DF6404F0F0783011777D2FEF1B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ECD51324C49998442AF41777D2FEF648_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ECD51324C49998442AF41777D2FEF648" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ECD51324C49998442AF41777D2FEF648_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ECD51324C49998442AF41777D2FEF648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ECD51324C49998442AF41777D2FEF648" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ECD51324C49998442AF41777D2FEF648" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ECD51324C49998442AF41777D2FEF648" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_628F6B4B882BF7245FFA1777D2FE9A11_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_628F6B4B882BF7245FFA1777D2FE9A11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_628F6B4B882BF7245FFA1777D2FE9A11_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_628F6B4B882BF7245FFA1777D2FE9A11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_628F6B4B882BF7245FFA1777D2FE9A11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_628F6B4B882BF7245FFA1777D2FE9A11" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_628F6B4B882BF7245FFA1777D2FE9A11" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_536E51CA60052D9466F71777D2FE16F6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_536E51CA60052D9466F71777D2FE16F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_536E51CA60052D9466F71777D2FE16F6_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_536E51CA60052D9466F71777D2FE16F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_536E51CA60052D9466F71777D2FE16F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_536E51CA60052D9466F71777D2FE16F6" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_536E51CA60052D9466F71777D2FE16F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58CC1B175437028D340B1777D2FF9FF6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58CC1B175437028D340B1777D2FF9FF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58CC1B175437028D340B1777D2FF9FF6_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58CC1B175437028D340B1777D2FF9FF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58CC1B175437028D340B1777D2FF9FF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58CC1B175437028D340B1777D2FF9FF6" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58CC1B175437028D340B1777D2FF9FF6" xlink:type="arc" />
    <link:label id="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_9C90BBDBC8CA438F195D92FCBB78FAEA_terseLabel_en-US" xlink:label="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_CDEC2DF389CF55109578493F1C782A5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units and Performance-based Restricted Stock Units</link:label>
    <link:label id="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_9C90BBDBC8CA438F195D92FCBB78FAEA_label_en-US" xlink:label="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_CDEC2DF389CF55109578493F1C782A5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units And Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_9C90BBDBC8CA438F195D92FCBB78FAEA_documentation_en-US" xlink:label="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_CDEC2DF389CF55109578493F1C782A5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units and Performance-based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_CDEC2DF389CF55109578493F1C782A5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_CDEC2DF389CF55109578493F1C782A5A" xlink:to="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_CDEC2DF389CF55109578493F1C782A5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_35A5B5EA11D2E24FF65793260EEB77D7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_B13879571E1D5426B93789663665EFD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_35A5B5EA11D2E24FF65793260EEB77D7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_B13879571E1D5426B93789663665EFD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_B13879571E1D5426B93789663665EFD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_B13879571E1D5426B93789663665EFD3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_B13879571E1D5426B93789663665EFD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_329E591594670CB242F593260F0ACBBA_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2A421EB965085B1894781897B7754349" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_329E591594670CB242F593260F0ACBBA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2A421EB965085B1894781897B7754349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2A421EB965085B1894781897B7754349" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2A421EB965085B1894781897B7754349" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2A421EB965085B1894781897B7754349" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B63A6E62EAFE9CDDA9BA93260F1BFF23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_08459F0508745280A5B0BDCB5B85064B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B63A6E62EAFE9CDDA9BA93260F1BFF23_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_08459F0508745280A5B0BDCB5B85064B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_08459F0508745280A5B0BDCB5B85064B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_08459F0508745280A5B0BDCB5B85064B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_08459F0508745280A5B0BDCB5B85064B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_36180F3663C785DA229793260F2DF8C5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DD502CD41D855FE8B6B0E444399BE742" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_36180F3663C785DA229793260F2DF8C5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DD502CD41D855FE8B6B0E444399BE742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DD502CD41D855FE8B6B0E444399BE742" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DD502CD41D855FE8B6B0E444399BE742" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DD502CD41D855FE8B6B0E444399BE742" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0FB2B8007544E033A60293260F3A26DD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BEAD02972CD45D03A8B10F399B9A6A41" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0FB2B8007544E033A60293260F3A26DD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BEAD02972CD45D03A8B10F399B9A6A41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BEAD02972CD45D03A8B10F399B9A6A41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BEAD02972CD45D03A8B10F399B9A6A41" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BEAD02972CD45D03A8B10F399B9A6A41" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_88944D40FD90B92A48AC93260F47F1FA_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7393F7536E1B58A88D6252D9585C9998" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7393F7536E1B58A88D6252D9585C9998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7393F7536E1B58A88D6252D9585C9998" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7393F7536E1B58A88D6252D9585C9998" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_707426D9099CAB8C1A2F92FCBB7BB682_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_A007F57BC2485613A13BAE2325E4B61D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_A007F57BC2485613A13BAE2325E4B61D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_A007F57BC2485613A13BAE2325E4B61D" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_A007F57BC2485613A13BAE2325E4B61D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_281D74EF56E78992EC34D10E1E352934_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7AB6EEF7C6525691AC156A28D23DF831" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_281D74EF56E78992EC34D10E1E352934_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7AB6EEF7C6525691AC156A28D23DF831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7AB6EEF7C6525691AC156A28D23DF831" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7AB6EEF7C6525691AC156A28D23DF831" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7AB6EEF7C6525691AC156A28D23DF831" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C3848D23403E2D24FA51777D2E7B23D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C3848D23403E2D24FA51777D2E7B23D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C3848D23403E2D24FA51777D2E7B23D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C3848D23403E2D24FA51777D2E7B23D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C3848D23403E2D24FA51777D2E7B23D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C3848D23403E2D24FA51777D2E7B23D" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C3848D23403E2D24FA51777D2E7B23D" xlink:type="arc" />
    <link:label id="lab_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_7CAB13386BBFCA4A459D1777D2E7591D_terseLabel_en-US" xlink:label="lab_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_7CAB13386BBFCA4A459D1777D2E7591D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock options and RSUs issued and outstanding</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember" xlink:label="loc_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_7CAB13386BBFCA4A459D1777D2E7591D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_7CAB13386BBFCA4A459D1777D2E7591D" xlink:to="lab_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_7CAB13386BBFCA4A459D1777D2E7591D" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_C8CE39386ACB5B4EEA691777D2E7D6FD_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_C8CE39386ACB5B4EEA691777D2E7D6FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_C8CE39386ACB5B4EEA691777D2E7D6FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_C8CE39386ACB5B4EEA691777D2E7D6FD" xlink:to="lab_us-gaap_WarrantMember_C8CE39386ACB5B4EEA691777D2E7D6FD" xlink:type="arc" />
    <link:label id="lab_cdtx_CommonStockSubjectToRepurchaseMember_A88DC3BDAB0BBCD728EC1777D2E7BB6A_terseLabel_en-US" xlink:label="lab_cdtx_CommonStockSubjectToRepurchaseMember_A88DC3BDAB0BBCD728EC1777D2E7BB6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock subject to repurchase</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CommonStockSubjectToRepurchaseMember" xlink:label="loc_cdtx_CommonStockSubjectToRepurchaseMember_A88DC3BDAB0BBCD728EC1777D2E7BB6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CommonStockSubjectToRepurchaseMember_A88DC3BDAB0BBCD728EC1777D2E7BB6A" xlink:to="lab_cdtx_CommonStockSubjectToRepurchaseMember_A88DC3BDAB0BBCD728EC1777D2E7BB6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C863BCA7F82309669B3B1777D2E7F79A_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C863BCA7F82309669B3B1777D2E7F79A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C863BCA7F82309669B3B1777D2E7F79A_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C863BCA7F82309669B3B1777D2E7F79A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C863BCA7F82309669B3B1777D2E7F79A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C863BCA7F82309669B3B1777D2E7F79A" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C863BCA7F82309669B3B1777D2E7F79A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3F73CF7E9D61307370BE1777D2E7FEE7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3F73CF7E9D61307370BE1777D2E7FEE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3F73CF7E9D61307370BE1777D2E7FEE7_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3F73CF7E9D61307370BE1777D2E7FEE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3F73CF7E9D61307370BE1777D2E7FEE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3F73CF7E9D61307370BE1777D2E7FEE7" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3F73CF7E9D61307370BE1777D2E7FEE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_936ABFB4F86800D00619CC00CC0E4D90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_749A7DAD395A5A39806FB74496FC59F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Principal Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_936ABFB4F86800D00619CC00CC0E4D90_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_749A7DAD395A5A39806FB74496FC59F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_749A7DAD395A5A39806FB74496FC59F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_749A7DAD395A5A39806FB74496FC59F7" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_749A7DAD395A5A39806FB74496FC59F7" xlink:type="arc" />
    <link:label id="lab_cdtx_DocumentAndEntityInformationAbstract_DB11C6540C2D6EC30AD2CB8A7CD7D6AC_label_en-US" xlink:label="lab_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_cdtx_DocumentAndEntityInformationAbstract_DB11C6540C2D6EC30AD2CB8A7CD7D6AC_documentation_en-US" xlink:label="lab_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and entity information.</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DocumentAndEntityInformationAbstract" xlink:label="loc_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:to="lab_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_98812701A043CF0DE05DCB8A7CD7A3A7_terseLabel_en-US" xlink:label="lab_dei_DocumentType_FF3DD66CA6FA536C8B207A7E0C87E33C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_98812701A043CF0DE05DCB8A7CD7A3A7_label_en-US" xlink:label="lab_dei_DocumentType_FF3DD66CA6FA536C8B207A7E0C87E33C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_FF3DD66CA6FA536C8B207A7E0C87E33C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_FF3DD66CA6FA536C8B207A7E0C87E33C" xlink:to="lab_dei_DocumentType_FF3DD66CA6FA536C8B207A7E0C87E33C" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_D4F167CFA2FBDDD023B4CB8A7CD781F3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_3D20FFB6F64A55848D31ECFAC9B45721" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_D4F167CFA2FBDDD023B4CB8A7CD781F3_label_en-US" xlink:label="lab_dei_AmendmentFlag_3D20FFB6F64A55848D31ECFAC9B45721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3D20FFB6F64A55848D31ECFAC9B45721" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_3D20FFB6F64A55848D31ECFAC9B45721" xlink:to="lab_dei_AmendmentFlag_3D20FFB6F64A55848D31ECFAC9B45721" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_8826AA1858A6F2757A91CB8A7CD76136_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_CAFF74AC62855D16B00B2745E426903A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_8826AA1858A6F2757A91CB8A7CD76136_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_CAFF74AC62855D16B00B2745E426903A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_CAFF74AC62855D16B00B2745E426903A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_CAFF74AC62855D16B00B2745E426903A" xlink:to="lab_dei_DocumentPeriodEndDate_CAFF74AC62855D16B00B2745E426903A" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_8D3D71A5931BC5A0870ACB8A7CD780F2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_F3FFB15AD22D50E8A00C47019192A642" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8D3D71A5931BC5A0870ACB8A7CD780F2_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_F3FFB15AD22D50E8A00C47019192A642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_F3FFB15AD22D50E8A00C47019192A642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_F3FFB15AD22D50E8A00C47019192A642" xlink:to="lab_dei_DocumentFiscalYearFocus_F3FFB15AD22D50E8A00C47019192A642" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_10A76B3B4BF8233263F0CB8A7CD75C92_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_43B1DD1DC22B57BD8D76E5EFF6F7C10C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_10A76B3B4BF8233263F0CB8A7CD75C92_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_43B1DD1DC22B57BD8D76E5EFF6F7C10C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_43B1DD1DC22B57BD8D76E5EFF6F7C10C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_43B1DD1DC22B57BD8D76E5EFF6F7C10C" xlink:to="lab_dei_DocumentFiscalPeriodFocus_43B1DD1DC22B57BD8D76E5EFF6F7C10C" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_CDB94FDF8F21115823B8CB8A7CD775B9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_40D22603FBFB5A24AE528A59B4E15B50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_CDB94FDF8F21115823B8CB8A7CD775B9_label_en-US" xlink:label="lab_dei_EntityRegistrantName_40D22603FBFB5A24AE528A59B4E15B50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_40D22603FBFB5A24AE528A59B4E15B50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_40D22603FBFB5A24AE528A59B4E15B50" xlink:to="lab_dei_EntityRegistrantName_40D22603FBFB5A24AE528A59B4E15B50" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_B0AB1CEA91BFD7646A7BCB8A7CD74A30_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_0769C94B63C5507FAE55F8D4B537CA19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_B0AB1CEA91BFD7646A7BCB8A7CD74A30_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_0769C94B63C5507FAE55F8D4B537CA19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_0769C94B63C5507FAE55F8D4B537CA19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_0769C94B63C5507FAE55F8D4B537CA19" xlink:to="lab_dei_EntityCentralIndexKey_0769C94B63C5507FAE55F8D4B537CA19" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_A89C30361D6781B58DB1CB8A7CD7FF2E_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_9671487347075E6CB7E82176900B99E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_A89C30361D6781B58DB1CB8A7CD7FF2E_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_9671487347075E6CB7E82176900B99E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_9671487347075E6CB7E82176900B99E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_9671487347075E6CB7E82176900B99E1" xlink:to="lab_dei_CurrentFiscalYearEndDate_9671487347075E6CB7E82176900B99E1" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_992C475D623337A949FECB8A7CD79544_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_3EC18C3C35CE5A318E100B72D0B4A374" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_992C475D623337A949FECB8A7CD79544_label_en-US" xlink:label="lab_dei_EntityFilerCategory_3EC18C3C35CE5A318E100B72D0B4A374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_3EC18C3C35CE5A318E100B72D0B4A374" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_3EC18C3C35CE5A318E100B72D0B4A374" xlink:to="lab_dei_EntityFilerCategory_3EC18C3C35CE5A318E100B72D0B4A374" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_C44D95823FB9E7344EA4CB8A7CD7BFF7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_C3FB4842F91156BFB28698C292A70519" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_C44D95823FB9E7344EA4CB8A7CD7BFF7_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_C3FB4842F91156BFB28698C292A70519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_C3FB4842F91156BFB28698C292A70519" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_C3FB4842F91156BFB28698C292A70519" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_C3FB4842F91156BFB28698C292A70519" xlink:type="arc" />
    <link:label id="lab_cdtx_LoanandSecurityAgreementMember_D0B3493803A89D8A6D7318E5BEAEB556_verboseLabel_en-US" xlink:label="lab_cdtx_LoanandSecurityAgreementMember_D0B3493803A89D8A6D7318E5BEAEB556" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loan Agreement</link:label>
    <link:label id="lab_cdtx_LoanandSecurityAgreementMember_D0B3493803A89D8A6D7318E5BEAEB556_label_en-US" xlink:label="lab_cdtx_LoanandSecurityAgreementMember_D0B3493803A89D8A6D7318E5BEAEB556" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan and Security Agreement [Member]</link:label>
    <link:label id="lab_cdtx_LoanandSecurityAgreementMember_D0B3493803A89D8A6D7318E5BEAEB556_documentation_en-US" xlink:label="lab_cdtx_LoanandSecurityAgreementMember_D0B3493803A89D8A6D7318E5BEAEB556" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan and Security Agreement [Member]</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_LoanandSecurityAgreementMember" xlink:label="loc_cdtx_LoanandSecurityAgreementMember_D0B3493803A89D8A6D7318E5BEAEB556" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LoanandSecurityAgreementMember_D0B3493803A89D8A6D7318E5BEAEB556" xlink:to="lab_cdtx_LoanandSecurityAgreementMember_D0B3493803A89D8A6D7318E5BEAEB556" xlink:type="arc" />
    <link:label id="lab_cdtx_TermLoanBMember_EA62D7933E552AFF370F18E5BEAEED96_verboseLabel_en-US" xlink:label="lab_cdtx_TermLoanBMember_EA62D7933E552AFF370F18E5BEAEED96" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Term B Loan</link:label>
    <link:label id="lab_cdtx_TermLoanBMember_EA62D7933E552AFF370F18E5BEAEED96_label_en-US" xlink:label="lab_cdtx_TermLoanBMember_EA62D7933E552AFF370F18E5BEAEED96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan B [Member]</link:label>
    <link:label id="lab_cdtx_TermLoanBMember_EA62D7933E552AFF370F18E5BEAEED96_documentation_en-US" xlink:label="lab_cdtx_TermLoanBMember_EA62D7933E552AFF370F18E5BEAEED96" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan B [Member]</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TermLoanBMember" xlink:label="loc_cdtx_TermLoanBMember_EA62D7933E552AFF370F18E5BEAEED96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TermLoanBMember_EA62D7933E552AFF370F18E5BEAEED96" xlink:to="lab_cdtx_TermLoanBMember_EA62D7933E552AFF370F18E5BEAEED96" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_84F33D4253CD3F55CC4418E5BEAEE94B_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_84F33D4253CD3F55CC4418E5BEAEE94B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_84F33D4253CD3F55CC4418E5BEAEE94B_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_84F33D4253CD3F55CC4418E5BEAEE94B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_84F33D4253CD3F55CC4418E5BEAEE94B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_84F33D4253CD3F55CC4418E5BEAEE94B" xlink:to="lab_us-gaap_VariableRateAxis_84F33D4253CD3F55CC4418E5BEAEE94B" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_F2D39F6646D3868A3C0918E5BEAE5B38_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_F2D39F6646D3868A3C0918E5BEAE5B38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_F2D39F6646D3868A3C0918E5BEAE5B38_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_F2D39F6646D3868A3C0918E5BEAE5B38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_F2D39F6646D3868A3C0918E5BEAE5B38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_F2D39F6646D3868A3C0918E5BEAE5B38" xlink:to="lab_us-gaap_VariableRateDomain_F2D39F6646D3868A3C0918E5BEAE5B38" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrimeRateMember_91B51BEA1CEEBED7975818E5BEAE7B52_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember_91B51BEA1CEEBED7975818E5BEAE7B52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_91B51BEA1CEEBED7975818E5BEAE7B52_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember_91B51BEA1CEEBED7975818E5BEAE7B52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_91B51BEA1CEEBED7975818E5BEAE7B52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember_91B51BEA1CEEBED7975818E5BEAE7B52" xlink:to="lab_us-gaap_PrimeRateMember_91B51BEA1CEEBED7975818E5BEAE7B52" xlink:type="arc" />
    <link:label id="lab_cdtx_DebtInstrumentMaximumBorrowingCapacity_18856BB9EE9AF3BC265D18E5BEAE2435_terseLabel_en-US" xlink:label="lab_cdtx_DebtInstrumentMaximumBorrowingCapacity_18856BB9EE9AF3BC265D18E5BEAE2435" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loans, maximum borrowing capacity</link:label>
    <link:label id="lab_cdtx_DebtInstrumentMaximumBorrowingCapacity_18856BB9EE9AF3BC265D18E5BEAE2435_label_en-US" xlink:label="lab_cdtx_DebtInstrumentMaximumBorrowingCapacity_18856BB9EE9AF3BC265D18E5BEAE2435" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_cdtx_DebtInstrumentMaximumBorrowingCapacity_18856BB9EE9AF3BC265D18E5BEAE2435_documentation_en-US" xlink:label="lab_cdtx_DebtInstrumentMaximumBorrowingCapacity_18856BB9EE9AF3BC265D18E5BEAE2435" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DebtInstrumentMaximumBorrowingCapacity" xlink:label="loc_cdtx_DebtInstrumentMaximumBorrowingCapacity_18856BB9EE9AF3BC265D18E5BEAE2435" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DebtInstrumentMaximumBorrowingCapacity_18856BB9EE9AF3BC265D18E5BEAE2435" xlink:to="lab_cdtx_DebtInstrumentMaximumBorrowingCapacity_18856BB9EE9AF3BC265D18E5BEAE2435" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_CC6A0535187A7C72021E18E5BEAF5D3C_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_CC6A0535187A7C72021E18E5BEAF5D3C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Borrowed from the Lender</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_CC6A0535187A7C72021E18E5BEAF5D3C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_CC6A0535187A7C72021E18E5BEAF5D3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_CC6A0535187A7C72021E18E5BEAF5D3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_CC6A0535187A7C72021E18E5BEAF5D3C" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_CC6A0535187A7C72021E18E5BEAF5D3C" xlink:type="arc" />
    <link:label id="lab_cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone_4BDDAC100F941907382218E5BEAF2240_terseLabel_en-US" xlink:label="lab_cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone_4BDDAC100F941907382218E5BEAF2240" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of extension if the Milestone event is achieved</link:label>
    <link:label id="lab_cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone_4BDDAC100F941907382218E5BEAF2240_label_en-US" xlink:label="lab_cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone_4BDDAC100F941907382218E5BEAF2240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Extension in Interest-Only Payments Upon Achieving Milestone</link:label>
    <link:label id="lab_cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone_4BDDAC100F941907382218E5BEAF2240_documentation_en-US" xlink:label="lab_cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone_4BDDAC100F941907382218E5BEAF2240" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Extension in Interest-Only Payments Upon Achieving Milestone</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone" xlink:label="loc_cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone_4BDDAC100F941907382218E5BEAF2240" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone_4BDDAC100F941907382218E5BEAF2240" xlink:to="lab_cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone_4BDDAC100F941907382218E5BEAF2240" xlink:type="arc" />
    <link:label id="lab_cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest_E55E220A82747120859918FA3FE5F2A0_terseLabel_en-US" xlink:label="lab_cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest_E55E220A82747120859918FA3FE5F2A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of monthly payments of principal and interest following interest-only period</link:label>
    <link:label id="lab_cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest_E55E220A82747120859918FA3FE5F2A0_label_en-US" xlink:label="lab_cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest_E55E220A82747120859918FA3FE5F2A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Payments of Principal and Interest</link:label>
    <link:label id="lab_cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest_E55E220A82747120859918FA3FE5F2A0_documentation_en-US" xlink:label="lab_cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest_E55E220A82747120859918FA3FE5F2A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Payments of Principal and Interest</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest" xlink:label="loc_cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest_E55E220A82747120859918FA3FE5F2A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest_E55E220A82747120859918FA3FE5F2A0" xlink:to="lab_cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest_E55E220A82747120859918FA3FE5F2A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_CA32F38C31F2403B12C118E5BEAF9044_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_CA32F38C31F2403B12C118E5BEAF9044" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Variable annual rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_CA32F38C31F2403B12C118E5BEAF9044_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_CA32F38C31F2403B12C118E5BEAF9044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CA32F38C31F2403B12C118E5BEAF9044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CA32F38C31F2403B12C118E5BEAF9044" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_CA32F38C31F2403B12C118E5BEAF9044" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_A1EC5DFC5A10077C242D18E5BEAF437E_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_A1EC5DFC5A10077C242D18E5BEAF437E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prime interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_A1EC5DFC5A10077C242D18E5BEAF437E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_A1EC5DFC5A10077C242D18E5BEAF437E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_A1EC5DFC5A10077C242D18E5BEAF437E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_A1EC5DFC5A10077C242D18E5BEAF437E" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_A1EC5DFC5A10077C242D18E5BEAF437E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_E7A999AB7644C2424A9C401128CFA6C3_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_E7A999AB7644C2424A9C401128CFA6C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_E7A999AB7644C2424A9C401128CFA6C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E7A999AB7644C2424A9C401128CFA6C3" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_E7A999AB7644C2424A9C401128CFA6C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_572D7AD1E985743A3E18401128CFD914_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_572D7AD1E985743A3E18401128CFD914" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_572D7AD1E985743A3E18401128CFD914_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_572D7AD1E985743A3E18401128CFD914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_572D7AD1E985743A3E18401128CFD914" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_572D7AD1E985743A3E18401128CFD914" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_572D7AD1E985743A3E18401128CFD914" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_23FC815EB11B552773B7401128CFD04A_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_23FC815EB11B552773B7401128CFD04A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_23FC815EB11B552773B7401128CFD04A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_23FC815EB11B552773B7401128CFD04A" xlink:to="lab_us-gaap_NetIncomeLoss_23FC815EB11B552773B7401128CFD04A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_579C3A792AD0FFD6FB10401128CF2A54_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_579C3A792AD0FFD6FB10401128CF2A54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_579C3A792AD0FFD6FB10401128CF2A54_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_579C3A792AD0FFD6FB10401128CF2A54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_579C3A792AD0FFD6FB10401128CF2A54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_579C3A792AD0FFD6FB10401128CF2A54" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_579C3A792AD0FFD6FB10401128CF2A54" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAndAmortization_EF78FF3B99CF08F8145D401128CFC8B2_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_EF78FF3B99CF08F8145D401128CFC8B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_EF78FF3B99CF08F8145D401128CFC8B2_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_EF78FF3B99CF08F8145D401128CFC8B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_EF78FF3B99CF08F8145D401128CFC8B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_EF78FF3B99CF08F8145D401128CFC8B2" xlink:to="lab_us-gaap_DepreciationAndAmortization_EF78FF3B99CF08F8145D401128CFC8B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_C6F02CC6417F745B0EF7401128CFCFC9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_C6F02CC6417F745B0EF7401128CFCFC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_C6F02CC6417F745B0EF7401128CFCFC9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_C6F02CC6417F745B0EF7401128CFCFC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_C6F02CC6417F745B0EF7401128CFCFC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_C6F02CC6417F745B0EF7401128CFCFC9" xlink:to="lab_us-gaap_ShareBasedCompensation_C6F02CC6417F745B0EF7401128CFCFC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_FC055456BA793612687A401128D0E454_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_FC055456BA793612687A401128D0E454" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs and debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_FC055456BA793612687A401128D0E454_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_FC055456BA793612687A401128D0E454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_FC055456BA793612687A401128D0E454" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_FC055456BA793612687A401128D0E454" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_FC055456BA793612687A401128D0E454" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_661F9F79754EA7991BA6401128D0B808_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_661F9F79754EA7991BA6401128D0B808" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of discount or premium on short-term investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_661F9F79754EA7991BA6401128D0B808_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_661F9F79754EA7991BA6401128D0B808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_661F9F79754EA7991BA6401128D0B808" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_661F9F79754EA7991BA6401128D0B808" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_661F9F79754EA7991BA6401128D0B808" xlink:type="arc" />
    <link:label id="lab_us-gaap_StraightLineRent_5CA9030504D5AFC4F45F401128D01F07_negatedLabel_en-US" xlink:label="lab_us-gaap_StraightLineRent_5CA9030504D5AFC4F45F401128D01F07" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_StraightLineRent_5CA9030504D5AFC4F45F401128D01F07_label_en-US" xlink:label="lab_us-gaap_StraightLineRent_5CA9030504D5AFC4F45F401128D01F07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Straight Line Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StraightLineRent" xlink:label="loc_us-gaap_StraightLineRent_5CA9030504D5AFC4F45F401128D01F07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StraightLineRent_5CA9030504D5AFC4F45F401128D01F07" xlink:to="lab_us-gaap_StraightLineRent_5CA9030504D5AFC4F45F401128D01F07" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4E271D87D5C62287AD78401128D006B9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4E271D87D5C62287AD78401128D006B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4E271D87D5C62287AD78401128D006B9_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4E271D87D5C62287AD78401128D006B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4E271D87D5C62287AD78401128D006B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4E271D87D5C62287AD78401128D006B9" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4E271D87D5C62287AD78401128D006B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E6213122DAEF28DD46C7401128D071EF_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E6213122DAEF28DD46C7401128D071EF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E6213122DAEF28DD46C7401128D071EF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E6213122DAEF28DD46C7401128D071EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E6213122DAEF28DD46C7401128D071EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E6213122DAEF28DD46C7401128D071EF" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E6213122DAEF28DD46C7401128D071EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5C4650EB458529558C83401128D02E8A_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5C4650EB458529558C83401128D02E8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5C4650EB458529558C83401128D02E8A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5C4650EB458529558C83401128D02E8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5C4650EB458529558C83401128D02E8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5C4650EB458529558C83401128D02E8A" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5C4650EB458529558C83401128D02E8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_39312F03B7D91493FBBD401128D0DFA5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_39312F03B7D91493FBBD401128D0DFA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_39312F03B7D91493FBBD401128D0DFA5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_39312F03B7D91493FBBD401128D0DFA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_39312F03B7D91493FBBD401128D0DFA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_39312F03B7D91493FBBD401128D0DFA5" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_39312F03B7D91493FBBD401128D0DFA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C69A476BA95780C190DD401128D0ADBC_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C69A476BA95780C190DD401128D0ADBC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C69A476BA95780C190DD401128D0ADBC_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C69A476BA95780C190DD401128D0ADBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C69A476BA95780C190DD401128D0ADBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C69A476BA95780C190DD401128D0ADBC" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C69A476BA95780C190DD401128D0ADBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E758FCAC8FC912D37C19401128D09CA0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E758FCAC8FC912D37C19401128D09CA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E758FCAC8FC912D37C19401128D09CA0_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E758FCAC8FC912D37C19401128D09CA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E758FCAC8FC912D37C19401128D09CA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E758FCAC8FC912D37C19401128D09CA0" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E758FCAC8FC912D37C19401128D09CA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_63CE68E2EC05C5822EE2401128D051C0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_63CE68E2EC05C5822EE2401128D051C0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_63CE68E2EC05C5822EE2401128D051C0_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_63CE68E2EC05C5822EE2401128D051C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_63CE68E2EC05C5822EE2401128D051C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments_63CE68E2EC05C5822EE2401128D051C0" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments_63CE68E2EC05C5822EE2401128D051C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_A65BFC5E26FB1080B090401128D04453_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_A65BFC5E26FB1080B090401128D04453" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_A65BFC5E26FB1080B090401128D04453_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_A65BFC5E26FB1080B090401128D04453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_A65BFC5E26FB1080B090401128D04453" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_A65BFC5E26FB1080B090401128D04453" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_A65BFC5E26FB1080B090401128D04453" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A61B30E2D57A4569931C401128D0D5D9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A61B30E2D57A4569931C401128D0D5D9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A61B30E2D57A4569931C401128D0D5D9_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A61B30E2D57A4569931C401128D0D5D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A61B30E2D57A4569931C401128D0D5D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A61B30E2D57A4569931C401128D0D5D9" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A61B30E2D57A4569931C401128D0D5D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_D7321BCD006B4ED9EE28401128D05B61_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_D7321BCD006B4ED9EE28401128D05B61" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_D7321BCD006B4ED9EE28401128D05B61_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_D7321BCD006B4ED9EE28401128D05B61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_D7321BCD006B4ED9EE28401128D05B61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_D7321BCD006B4ED9EE28401128D05B61" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_D7321BCD006B4ED9EE28401128D05B61" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1695770636DF5D2DC982401128D08E51_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1695770636DF5D2DC982401128D08E51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1695770636DF5D2DC982401128D08E51_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1695770636DF5D2DC982401128D08E51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1695770636DF5D2DC982401128D08E51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1695770636DF5D2DC982401128D08E51" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1695770636DF5D2DC982401128D08E51" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2E4D1E8A342B64E3CE29401128D047C2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2E4D1E8A342B64E3CE29401128D047C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2E4D1E8A342B64E3CE29401128D047C2_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2E4D1E8A342B64E3CE29401128D047C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2E4D1E8A342B64E3CE29401128D047C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2E4D1E8A342B64E3CE29401128D047C2" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2E4D1E8A342B64E3CE29401128D047C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_1002593ACD08DDC1A193401128D0A11B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_1002593ACD08DDC1A193401128D0A11B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_1002593ACD08DDC1A193401128D0A11B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_1002593ACD08DDC1A193401128D0A11B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1002593ACD08DDC1A193401128D0A11B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_1002593ACD08DDC1A193401128D0A11B" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_1002593ACD08DDC1A193401128D0A11B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfEquity_E2F3DD60CB4F599BADAA401128D06063_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity_E2F3DD60CB4F599BADAA401128D06063" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of unvested restricted stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfEquity_E2F3DD60CB4F599BADAA401128D06063_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity_E2F3DD60CB4F599BADAA401128D06063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_E2F3DD60CB4F599BADAA401128D06063" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfEquity_E2F3DD60CB4F599BADAA401128D06063" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfEquity_E2F3DD60CB4F599BADAA401128D06063" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_AA95DBC25C5F157DD612401128D007DB_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_AA95DBC25C5F157DD612401128D007DB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_AA95DBC25C5F157DD612401128D007DB_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_AA95DBC25C5F157DD612401128D007DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_AA95DBC25C5F157DD612401128D007DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_AA95DBC25C5F157DD612401128D007DB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_AA95DBC25C5F157DD612401128D007DB" xlink:type="arc" />
    <link:label id="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A431212C6E1F25C10F01401128D0BCA3_totalLabel_en-US" xlink:label="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A431212C6E1F25C10F01401128D0BCA3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A431212C6E1F25C10F01401128D0BCA3_label_en-US" xlink:label="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A431212C6E1F25C10F01401128D0BCA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label id="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A431212C6E1F25C10F01401128D0BCA3_documentation_en-US" xlink:label="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A431212C6E1F25C10F01401128D0BCA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A431212C6E1F25C10F01401128D0BCA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A431212C6E1F25C10F01401128D0BCA3" xlink:to="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A431212C6E1F25C10F01401128D0BCA3" xlink:type="arc" />
    <link:label id="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1F6F91AC9A7DE3128C401128D0B893_periodStartLabel_en-US" xlink:label="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1F6F91AC9A7DE3128C401128D0B893" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1F6F91AC9A7DE3128C401128D0B893_label_en-US" xlink:label="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1F6F91AC9A7DE3128C401128D0B893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label id="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1F6F91AC9A7DE3128C401128D0B893_documentation_en-US" xlink:label="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1F6F91AC9A7DE3128C401128D0B893" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1F6F91AC9A7DE3128C401128D0B893" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1F6F91AC9A7DE3128C401128D0B893" xlink:to="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1F6F91AC9A7DE3128C401128D0B893" xlink:type="arc" />
    <link:label id="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45E90DA898E66D2C1911401128D0C8F6_periodEndLabel_en-US" xlink:label="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45E90DA898E66D2C1911401128D0C8F6" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45E90DA898E66D2C1911401128D0C8F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45E90DA898E66D2C1911401128D0C8F6" xlink:to="lab_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45E90DA898E66D2C1911401128D0C8F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_FEBC43257F68BE8D6621401128D02B2B_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_FEBC43257F68BE8D6621401128D02B2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flows:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_FEBC43257F68BE8D6621401128D02B2B_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_FEBC43257F68BE8D6621401128D02B2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_FEBC43257F68BE8D6621401128D02B2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_FEBC43257F68BE8D6621401128D02B2B" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_FEBC43257F68BE8D6621401128D02B2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_1D49805C4A6C3E615506401128D1C1C1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_1D49805C4A6C3E615506401128D1C1C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaid_1D49805C4A6C3E615506401128D1C1C1_label_en-US" xlink:label="lab_us-gaap_InterestPaid_1D49805C4A6C3E615506401128D1C1C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_1D49805C4A6C3E615506401128D1C1C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_1D49805C4A6C3E615506401128D1C1C1" xlink:to="lab_us-gaap_InterestPaid_1D49805C4A6C3E615506401128D1C1C1" xlink:type="arc" />
    <link:label id="lab_cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract_16B377A16409655D599E401128D1CBEC_terseLabel_en-US" xlink:label="lab_cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract_16B377A16409655D599E401128D1CBEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash financing activities:</link:label>
    <link:label id="lab_cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract_16B377A16409655D599E401128D1CBEC_label_en-US" xlink:label="lab_cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract_16B377A16409655D599E401128D1CBEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Noncash Financing Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract_16B377A16409655D599E401128D1CBEC_documentation_en-US" xlink:label="lab_cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract_16B377A16409655D599E401128D1CBEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flow non-cash financing activities disclosure.</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract" xlink:label="loc_cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract_16B377A16409655D599E401128D1CBEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract_16B377A16409655D599E401128D1CBEC" xlink:to="lab_cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract_16B377A16409655D599E401128D1CBEC" xlink:type="arc" />
    <link:label id="lab_cdtx_VestingOfEarlyExercisedStockOptions_CF46797680BD87D96594401128D1EC2C_terseLabel_en-US" xlink:label="lab_cdtx_VestingOfEarlyExercisedStockOptions_CF46797680BD87D96594401128D1EC2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of early exercised stock options</link:label>
    <link:label id="lab_cdtx_VestingOfEarlyExercisedStockOptions_CF46797680BD87D96594401128D1EC2C_label_en-US" xlink:label="lab_cdtx_VestingOfEarlyExercisedStockOptions_CF46797680BD87D96594401128D1EC2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Of Early Exercised Stock Options</link:label>
    <link:label id="lab_cdtx_VestingOfEarlyExercisedStockOptions_CF46797680BD87D96594401128D1EC2C_documentation_en-US" xlink:label="lab_cdtx_VestingOfEarlyExercisedStockOptions_CF46797680BD87D96594401128D1EC2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting of early exercised stock options.</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_VestingOfEarlyExercisedStockOptions" xlink:label="loc_cdtx_VestingOfEarlyExercisedStockOptions_CF46797680BD87D96594401128D1EC2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_VestingOfEarlyExercisedStockOptions_CF46797680BD87D96594401128D1EC2C" xlink:to="lab_cdtx_VestingOfEarlyExercisedStockOptions_CF46797680BD87D96594401128D1EC2C" xlink:type="arc" />
    <link:label id="lab_cdtx_DeferredFinancingCostIncurredButNotYetPaid_FBA05513C1F6DAB5A1C6401128D619F3_terseLabel_en-US" xlink:label="lab_cdtx_DeferredFinancingCostIncurredButNotYetPaid_FBA05513C1F6DAB5A1C6401128D619F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs incurred but not yet paid</link:label>
    <link:label id="lab_cdtx_DeferredFinancingCostIncurredButNotYetPaid_FBA05513C1F6DAB5A1C6401128D619F3_label_en-US" xlink:label="lab_cdtx_DeferredFinancingCostIncurredButNotYetPaid_FBA05513C1F6DAB5A1C6401128D619F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Financing Cost Incurred But Not Yet Paid</link:label>
    <link:label id="lab_cdtx_DeferredFinancingCostIncurredButNotYetPaid_FBA05513C1F6DAB5A1C6401128D619F3_documentation_en-US" xlink:label="lab_cdtx_DeferredFinancingCostIncurredButNotYetPaid_FBA05513C1F6DAB5A1C6401128D619F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Financing Cost Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DeferredFinancingCostIncurredButNotYetPaid" xlink:label="loc_cdtx_DeferredFinancingCostIncurredButNotYetPaid_FBA05513C1F6DAB5A1C6401128D619F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DeferredFinancingCostIncurredButNotYetPaid_FBA05513C1F6DAB5A1C6401128D619F3" xlink:to="lab_cdtx_DeferredFinancingCostIncurredButNotYetPaid_FBA05513C1F6DAB5A1C6401128D619F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_44AAB4636BF0717E2AC4D0963B20C1BD_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6133286DD63A560799250211829617CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_44AAB4636BF0717E2AC4D0963B20C1BD_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6133286DD63A560799250211829617CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6133286DD63A560799250211829617CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6133286DD63A560799250211829617CF" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6133286DD63A560799250211829617CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_601EFD024A2E60AAA8F8D10E1E3256BE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_D7A51E05F9935D2C8A9AF53D39EEE7FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Payments Required</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_601EFD024A2E60AAA8F8D10E1E3256BE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_D7A51E05F9935D2C8A9AF53D39EEE7FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_D7A51E05F9935D2C8A9AF53D39EEE7FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_D7A51E05F9935D2C8A9AF53D39EEE7FD" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_D7A51E05F9935D2C8A9AF53D39EEE7FD" xlink:type="arc" />
    <link:label id="lab_cdtx_DebtSecuritiesAvailableForSaleTableTextBlock_941EED74E5E4CFE4648F1BC782796183_terseLabel_en-US" xlink:label="lab_cdtx_DebtSecuritiesAvailableForSaleTableTextBlock_941EED74E5E4CFE4648F1BC782796183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Available-for-Sale Securities</link:label>
    <link:label id="lab_cdtx_DebtSecuritiesAvailableForSaleTableTextBlock_941EED74E5E4CFE4648F1BC782796183_label_en-US" xlink:label="lab_cdtx_DebtSecuritiesAvailableForSaleTableTextBlock_941EED74E5E4CFE4648F1BC782796183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale [Table Text Block]</link:label>
    <link:label id="lab_cdtx_DebtSecuritiesAvailableForSaleTableTextBlock_941EED74E5E4CFE4648F1BC782796183_documentation_en-US" xlink:label="lab_cdtx_DebtSecuritiesAvailableForSaleTableTextBlock_941EED74E5E4CFE4648F1BC782796183" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale [Table Text Block]</link:label>
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_cdtx_DebtSecuritiesAvailableForSaleTableTextBlock_941EED74E5E4CFE4648F1BC782796183" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DebtSecuritiesAvailableForSaleTableTextBlock_941EED74E5E4CFE4648F1BC782796183" xlink:to="lab_cdtx_DebtSecuritiesAvailableForSaleTableTextBlock_941EED74E5E4CFE4648F1BC782796183" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_53BF87B4F376849CE23ACB9C84BE0E53_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_CD4BDCD7FC005DDA9667CD2EE4E2AF20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_53BF87B4F376849CE23ACB9C84BE0E53_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_CD4BDCD7FC005DDA9667CD2EE4E2AF20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_CD4BDCD7FC005DDA9667CD2EE4E2AF20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_CD4BDCD7FC005DDA9667CD2EE4E2AF20" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_CD4BDCD7FC005DDA9667CD2EE4E2AF20" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>cdtx-20180331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://cidara.com/role/CommitmentsAndContingencies" xlink:href="cdtx-20180331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="cdtx-20180331.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsRequiredDetails" xlink:href="cdtx-20180331.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsRequiredDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CommitmentsAndContingenciesTables" xlink:href="cdtx-20180331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CompanyAndBasisOfPresentation" xlink:href="cdtx-20180331.xsd#CompanyAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CompanyAndBasisOfPresentationDetails" xlink:href="cdtx-20180331.xsd#CompanyAndBasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:href="cdtx-20180331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="cdtx-20180331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="cdtx-20180331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="cdtx-20180331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/Debt" xlink:href="cdtx-20180331.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/DebtNarrativeDetails" xlink:href="cdtx-20180331.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/DebtScheduleOfFuturePrincipalPaymentsDetails" xlink:href="cdtx-20180331.xsd#DebtScheduleOfFuturePrincipalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/DebtTables" xlink:href="cdtx-20180331.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/DocumentAndEntityInformation" xlink:href="cdtx-20180331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/FairValueMeasurements" xlink:href="cdtx-20180331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/FairValueMeasurementsDetails" xlink:href="cdtx-20180331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/FairValueMeasurementsTables" xlink:href="cdtx-20180331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/ShortTermInvestments" xlink:href="cdtx-20180331.xsd#ShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/ShortTermInvestmentsDetails" xlink:href="cdtx-20180331.xsd#ShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/ShortTermInvestmentsTables" xlink:href="cdtx-20180331.xsd#ShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SignificantAgreementsAndContracts" xlink:href="cdtx-20180331.xsd#SignificantAgreementsAndContracts" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SignificantAgreementsAndContractsDetails" xlink:href="cdtx-20180331.xsd#SignificantAgreementsAndContractsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlans" xlink:href="cdtx-20180331.xsd#StockIncentivePlans" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlansNarrativeDetails" xlink:href="cdtx-20180331.xsd#StockIncentivePlansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails" xlink:href="cdtx-20180331.xsd#StockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlansSummaryOfRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsActivityDetails" xlink:href="cdtx-20180331.xsd#StockIncentivePlansSummaryOfRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlansSummaryOfStockOptionActivityDetails" xlink:href="cdtx-20180331.xsd#StockIncentivePlansSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockIncentivePlansTables" xlink:href="cdtx-20180331.xsd#StockIncentivePlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockholdersEquity" xlink:href="cdtx-20180331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockholdersEquityNarrativeDetails" xlink:href="cdtx-20180331.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:href="cdtx-20180331.xsd#StockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/StockholdersEquityTables" xlink:href="cdtx-20180331.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SubsequentEvents" xlink:href="cdtx-20180331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SubsequentEventsDetails" xlink:href="cdtx-20180331.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cdtx-20180331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" xlink:href="cdtx-20180331.xsd#SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cdtx-20180331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="cdtx-20180331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://cidara.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_025F4F0CE0E6554D9D3B61B857598D1E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7AB6EEF7C6525691AC156A28D23DF831" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_025F4F0CE0E6554D9D3B61B857598D1E" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7AB6EEF7C6525691AC156A28D23DF831" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DE23D7EBBAD85BADB78B23A955BA333C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_371EF05E707C502BB73B4280CB13A6DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DE23D7EBBAD85BADB78B23A955BA333C" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_371EF05E707C502BB73B4280CB13A6DF" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:label="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension_5A000AC2BCE2578394505F0AEDD1241B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DE23D7EBBAD85BADB78B23A955BA333C" xlink:to="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension_5A000AC2BCE2578394505F0AEDD1241B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_89DE6E2BF469597E86CD1643B326E80E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DE23D7EBBAD85BADB78B23A955BA333C" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_89DE6E2BF469597E86CD1643B326E80E" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_IncreaseInBaseRentAnnual" xlink:label="loc_cdtx_IncreaseInBaseRentAnnual_A89A05D29A5B55C5809749A107A7147C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DE23D7EBBAD85BADB78B23A955BA333C" xlink:to="loc_cdtx_IncreaseInBaseRentAnnual_A89A05D29A5B55C5809749A107A7147C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_571364D7334554B99AE56F1D27C0B0FA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DE23D7EBBAD85BADB78B23A955BA333C" xlink:to="loc_us-gaap_LeaseAndRentalExpense_571364D7334554B99AE56F1D27C0B0FA" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_ContractualObligationContractTerminationNoticePeriod" xlink:label="loc_cdtx_ContractualObligationContractTerminationNoticePeriod_CB7246453FDB50BA8ED39D1CC96B4F14" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DE23D7EBBAD85BADB78B23A955BA333C" xlink:to="loc_cdtx_ContractualObligationContractTerminationNoticePeriod_CB7246453FDB50BA8ED39D1CC96B4F14" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsRequiredDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3A2F78A34E50644579F61814599C3B58" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F73A24EAA772C566CE45183C77D54E6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3A2F78A34E50644579F61814599C3B58" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F73A24EAA772C566CE45183C77D54E6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4DA194481629C814D35D1814599C405B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3A2F78A34E50644579F61814599C3B58" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4DA194481629C814D35D1814599C405B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_594D10590FD85F8096A16C40B0AAC850" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_D7A51E05F9935D2C8A9AF53D39EEE7FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_594D10590FD85F8096A16C40B0AAC850" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_D7A51E05F9935D2C8A9AF53D39EEE7FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/CompanyAndBasisOfPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BAF92DE30E4A5A33B98BFC9F898288F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_21095D2B311E587898A8A274DDB98B4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BAF92DE30E4A5A33B98BFC9F898288F1" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_21095D2B311E587898A8A274DDB98B4C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/CompanyAndBasisOfPresentationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6B8DD6FCFFD45E1BBDF880FA87E36DEC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F924D2CDB82E58FC87495DFE89C31BB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6B8DD6FCFFD45E1BBDF880FA87E36DEC" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_F924D2CDB82E58FC87495DFE89C31BB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_893F45696EFD5009827EEF025E1BC842" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6B8DD6FCFFD45E1BBDF880FA87E36DEC" xlink:to="loc_us-gaap_NumberOfOperatingSegments_893F45696EFD5009827EEF025E1BC842" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_33F0CCB4757BCF28558718E1EE66336E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_D7CB1542114FBC834B5618E1EE69B9BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_33F0CCB4757BCF28558718E1EE66336E" xlink:to="loc_us-gaap_AssetsAbstract_D7CB1542114FBC834B5618E1EE69B9BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_A851356389F396E9069818E1EE6B68C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D7CB1542114FBC834B5618E1EE69B9BF" xlink:to="loc_us-gaap_AssetsCurrentAbstract_A851356389F396E9069818E1EE6B68C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B95A43186C938A43E4A718E1EE6BFE0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A851356389F396E9069818E1EE6B68C8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B95A43186C938A43E4A718E1EE6BFE0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_92570FBB7A7C6A88D05A18E1EE6B36C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A851356389F396E9069818E1EE6B68C8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_92570FBB7A7C6A88D05A18E1EE6B36C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_490F0484FA4E93867E0718E1EE6C231D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A851356389F396E9069818E1EE6B68C8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_490F0484FA4E93867E0718E1EE6C231D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7398194FA4069C00080B18E1EE6CC73C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A851356389F396E9069818E1EE6B68C8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7398194FA4069C00080B18E1EE6CC73C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CAE4CAC92360178656A318E1EE6C592E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A851356389F396E9069818E1EE6B68C8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_CAE4CAC92360178656A318E1EE6C592E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8B7DFEA082FF872CECA318E1EE6C92E1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A851356389F396E9069818E1EE6B68C8" xlink:to="loc_us-gaap_AssetsCurrent_8B7DFEA082FF872CECA318E1EE6C92E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_786C76AA6CB5F84D0A0218E1EE6C4FDD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D7CB1542114FBC834B5618E1EE69B9BF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_786C76AA6CB5F84D0A0218E1EE6C4FDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1962816E111EC47AA17518E1EE6CD227" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D7CB1542114FBC834B5618E1EE69B9BF" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1962816E111EC47AA17518E1EE6CD227" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_F75754D606307E09E7C718E1EE6C8536" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D7CB1542114FBC834B5618E1EE69B9BF" xlink:to="loc_us-gaap_Assets_F75754D606307E09E7C718E1EE6C8536" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6C1FED8E6A305DEB172518E1EE6C1125" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_33F0CCB4757BCF28558718E1EE66336E" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6C1FED8E6A305DEB172518E1EE6C1125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5CEACFF2DE51E4B5025B18E1EE6CEEFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6C1FED8E6A305DEB172518E1EE6C1125" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5CEACFF2DE51E4B5025B18E1EE6CEEFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_4D7C9E6CEB78FB17C8C218E1EE6C7920" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5CEACFF2DE51E4B5025B18E1EE6CEEFC" xlink:to="loc_us-gaap_AccountsPayableCurrent_4D7C9E6CEB78FB17C8C218E1EE6C7920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_C8F35BE2F95DA40909F118E1EE6C5749" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5CEACFF2DE51E4B5025B18E1EE6CEEFC" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_C8F35BE2F95DA40909F118E1EE6C5749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_CFFE71C657AF29AF41AD18E1EE6CC698" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5CEACFF2DE51E4B5025B18E1EE6CEEFC" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_CFFE71C657AF29AF41AD18E1EE6CC698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaap_LoansPayableCurrent_2B358ACBFBBF82B89C8318E1EE6C8256" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5CEACFF2DE51E4B5025B18E1EE6CEEFC" xlink:to="loc_us-gaap_LoansPayableCurrent_2B358ACBFBBF82B89C8318E1EE6C8256" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_EBEE6FD20A06C5CE8A0818E1EE6C973A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5CEACFF2DE51E4B5025B18E1EE6CEEFC" xlink:to="loc_us-gaap_LiabilitiesCurrent_EBEE6FD20A06C5CE8A0818E1EE6C973A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaap_LongTermLoansPayable_CD302F23925F5EA6626218E1EE6C4490" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6C1FED8E6A305DEB172518E1EE6C1125" xlink:to="loc_us-gaap_LongTermLoansPayable_CD302F23925F5EA6626218E1EE6C4490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_4B804CE45005B6808E3418E1EE6CFBEC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6C1FED8E6A305DEB172518E1EE6C1125" xlink:to="loc_us-gaap_Liabilities_4B804CE45005B6808E3418E1EE6CFBEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_D8DFCDA1E6B2A2D4786A18E1EE6C5FE0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6C1FED8E6A305DEB172518E1EE6C1125" xlink:to="loc_us-gaap_CommitmentsAndContingencies_D8DFCDA1E6B2A2D4786A18E1EE6C5FE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_C49A748009CC876CAD7D18E1EE6D50C6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6C1FED8E6A305DEB172518E1EE6C1125" xlink:to="loc_us-gaap_StockholdersEquityAbstract_C49A748009CC876CAD7D18E1EE6D50C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_232CDB665881948B91A218E1EE6D9A79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C49A748009CC876CAD7D18E1EE6D50C6" xlink:to="loc_us-gaap_PreferredStockValue_232CDB665881948B91A218E1EE6D9A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_B4743DDEFD038E7AB19A18E1EE6DD933" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C49A748009CC876CAD7D18E1EE6D50C6" xlink:to="loc_us-gaap_CommonStockValue_B4743DDEFD038E7AB19A18E1EE6DD933" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_BF5C6BD09CBA4D6EF8D518E1EE6D5FEA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C49A748009CC876CAD7D18E1EE6D50C6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_BF5C6BD09CBA4D6EF8D518E1EE6D5FEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_436847A1131E763BC26718E1EE6D8E25" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C49A748009CC876CAD7D18E1EE6D50C6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_436847A1131E763BC26718E1EE6D8E25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D490048C3D31F2EF5A5418E1EE6DBE22" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C49A748009CC876CAD7D18E1EE6D50C6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D490048C3D31F2EF5A5418E1EE6DBE22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_5846A0C39EE0A3A9B7AE18E1EE6DC94D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C49A748009CC876CAD7D18E1EE6D50C6" xlink:to="loc_us-gaap_StockholdersEquity_5846A0C39EE0A3A9B7AE18E1EE6DC94D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2744270F63950831268118E1EE6DD549" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6C1FED8E6A305DEB172518E1EE6C1125" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2744270F63950831268118E1EE6DD549" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8AC178A45FF558FFB3416761899915E7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E8B193FD491A59CF9D4D25FA72F7B6E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8AC178A45FF558FFB3416761899915E7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E8B193FD491A59CF9D4D25FA72F7B6E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8555A1F955A95A3E8E67856903C59C60" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8AC178A45FF558FFB3416761899915E7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8555A1F955A95A3E8E67856903C59C60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_31DC9A6E6A125F0CA17CE1DE12C8965D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8AC178A45FF558FFB3416761899915E7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_31DC9A6E6A125F0CA17CE1DE12C8965D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1F18C023D46058C5B5C527B0F5A7A578" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8AC178A45FF558FFB3416761899915E7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1F18C023D46058C5B5C527B0F5A7A578" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6941C74781BA54B693A485B92822E8BB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8AC178A45FF558FFB3416761899915E7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6941C74781BA54B693A485B92822E8BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2D88F447C4F1585EA5F15A6E9D31AD4E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8AC178A45FF558FFB3416761899915E7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2D88F447C4F1585EA5F15A6E9D31AD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_4648821D759858BD859BFE9B5AB139E3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8AC178A45FF558FFB3416761899915E7" xlink:to="loc_us-gaap_CommonStockSharesIssued_4648821D759858BD859BFE9B5AB139E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_DEBEFEC38E7052B2B2AB1380B4253BCB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8AC178A45FF558FFB3416761899915E7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_DEBEFEC38E7052B2B2AB1380B4253BCB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_E7A999AB7644C2424A9C401128CFA6C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_572D7AD1E985743A3E18401128CFD914" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E7A999AB7644C2424A9C401128CFA6C3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_572D7AD1E985743A3E18401128CFD914" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_23FC815EB11B552773B7401128CFD04A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_572D7AD1E985743A3E18401128CFD914" xlink:to="loc_us-gaap_NetIncomeLoss_23FC815EB11B552773B7401128CFD04A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_579C3A792AD0FFD6FB10401128CF2A54" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_572D7AD1E985743A3E18401128CFD914" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_579C3A792AD0FFD6FB10401128CF2A54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_EF78FF3B99CF08F8145D401128CFC8B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_579C3A792AD0FFD6FB10401128CF2A54" xlink:to="loc_us-gaap_DepreciationAndAmortization_EF78FF3B99CF08F8145D401128CFC8B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_C6F02CC6417F745B0EF7401128CFCFC9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_579C3A792AD0FFD6FB10401128CF2A54" xlink:to="loc_us-gaap_ShareBasedCompensation_C6F02CC6417F745B0EF7401128CFCFC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_FC055456BA793612687A401128D0E454" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_579C3A792AD0FFD6FB10401128CF2A54" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_FC055456BA793612687A401128D0E454" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_661F9F79754EA7991BA6401128D0B808" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_579C3A792AD0FFD6FB10401128CF2A54" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_661F9F79754EA7991BA6401128D0B808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StraightLineRent" xlink:label="loc_us-gaap_StraightLineRent_5CA9030504D5AFC4F45F401128D01F07" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_579C3A792AD0FFD6FB10401128CF2A54" xlink:to="loc_us-gaap_StraightLineRent_5CA9030504D5AFC4F45F401128D01F07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4E271D87D5C62287AD78401128D006B9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_579C3A792AD0FFD6FB10401128CF2A54" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4E271D87D5C62287AD78401128D006B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E6213122DAEF28DD46C7401128D071EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4E271D87D5C62287AD78401128D006B9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E6213122DAEF28DD46C7401128D071EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5C4650EB458529558C83401128D02E8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4E271D87D5C62287AD78401128D006B9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5C4650EB458529558C83401128D02E8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_39312F03B7D91493FBBD401128D0DFA5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4E271D87D5C62287AD78401128D006B9" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_39312F03B7D91493FBBD401128D0DFA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C69A476BA95780C190DD401128D0ADBC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_572D7AD1E985743A3E18401128CFD914" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_C69A476BA95780C190DD401128D0ADBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E758FCAC8FC912D37C19401128D09CA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E7A999AB7644C2424A9C401128CFA6C3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E758FCAC8FC912D37C19401128D09CA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_63CE68E2EC05C5822EE2401128D051C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E758FCAC8FC912D37C19401128D09CA0" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_63CE68E2EC05C5822EE2401128D051C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_A65BFC5E26FB1080B090401128D04453" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E758FCAC8FC912D37C19401128D09CA0" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_A65BFC5E26FB1080B090401128D04453" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A61B30E2D57A4569931C401128D0D5D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E758FCAC8FC912D37C19401128D09CA0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A61B30E2D57A4569931C401128D0D5D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_D7321BCD006B4ED9EE28401128D05B61" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E758FCAC8FC912D37C19401128D09CA0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_D7321BCD006B4ED9EE28401128D05B61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1695770636DF5D2DC982401128D08E51" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E7A999AB7644C2424A9C401128CFA6C3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1695770636DF5D2DC982401128D08E51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2E4D1E8A342B64E3CE29401128D047C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1695770636DF5D2DC982401128D08E51" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2E4D1E8A342B64E3CE29401128D047C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1002593ACD08DDC1A193401128D0A11B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1695770636DF5D2DC982401128D08E51" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1002593ACD08DDC1A193401128D0A11B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_E2F3DD60CB4F599BADAA401128D06063" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1695770636DF5D2DC982401128D08E51" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity_E2F3DD60CB4F599BADAA401128D06063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_AA95DBC25C5F157DD612401128D007DB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1695770636DF5D2DC982401128D08E51" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_AA95DBC25C5F157DD612401128D007DB" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A431212C6E1F25C10F01401128D0BCA3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E7A999AB7644C2424A9C401128CFA6C3" xlink:to="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A431212C6E1F25C10F01401128D0BCA3" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1F6F91AC9A7DE3128C401128D0B893" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E7A999AB7644C2424A9C401128CFA6C3" xlink:to="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C1F6F91AC9A7DE3128C401128D0B893" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45E90DA898E66D2C1911401128D0C8F6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E7A999AB7644C2424A9C401128CFA6C3" xlink:to="loc_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45E90DA898E66D2C1911401128D0C8F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_FEBC43257F68BE8D6621401128D02B2B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E7A999AB7644C2424A9C401128CFA6C3" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_FEBC43257F68BE8D6621401128D02B2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_1D49805C4A6C3E615506401128D1C1C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_FEBC43257F68BE8D6621401128D02B2B" xlink:to="loc_us-gaap_InterestPaid_1D49805C4A6C3E615506401128D1C1C1" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract" xlink:label="loc_cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract_16B377A16409655D599E401128D1CBEC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E7A999AB7644C2424A9C401128CFA6C3" xlink:to="loc_cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract_16B377A16409655D599E401128D1CBEC" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_VestingOfEarlyExercisedStockOptions" xlink:label="loc_cdtx_VestingOfEarlyExercisedStockOptions_CF46797680BD87D96594401128D1EC2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract_16B377A16409655D599E401128D1CBEC" xlink:to="loc_cdtx_VestingOfEarlyExercisedStockOptions_CF46797680BD87D96594401128D1EC2C" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DeferredFinancingCostIncurredButNotYetPaid" xlink:label="loc_cdtx_DeferredFinancingCostIncurredButNotYetPaid_FBA05513C1F6DAB5A1C6401128D619F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract_16B377A16409655D599E401128D1CBEC" xlink:to="loc_cdtx_DeferredFinancingCostIncurredButNotYetPaid_FBA05513C1F6DAB5A1C6401128D619F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_E7928E62A2B6703210F61766D17925ED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5EBCA41340DE17948F4D1766D17908B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E7928E62A2B6703210F61766D17925ED" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5EBCA41340DE17948F4D1766D17908B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1F5B86EE7EBAA4A7C7731766D1799DB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5EBCA41340DE17948F4D1766D17908B4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1F5B86EE7EBAA4A7C7731766D1799DB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7AEC1743A3FCFCAD14EA1766D17948AB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5EBCA41340DE17948F4D1766D17908B4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7AEC1743A3FCFCAD14EA1766D17948AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_B9CEDCA22862905313961766D1795E73" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5EBCA41340DE17948F4D1766D17908B4" xlink:to="loc_us-gaap_OperatingExpenses_B9CEDCA22862905313961766D1795E73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_485BF17FDD027A25B21D1766D179FC5E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E7928E62A2B6703210F61766D17925ED" xlink:to="loc_us-gaap_OperatingIncomeLoss_485BF17FDD027A25B21D1766D179FC5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2C088CB4ACAB6D0EA91C1766D179A910" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E7928E62A2B6703210F61766D17925ED" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2C088CB4ACAB6D0EA91C1766D179A910" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_935F207DA20DA9A461EA1766D1796D4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2C088CB4ACAB6D0EA91C1766D179A910" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_935F207DA20DA9A461EA1766D1796D4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_42AD770504941464295E1766D17996A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2C088CB4ACAB6D0EA91C1766D179A910" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_42AD770504941464295E1766D17996A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3B6F3272EDB9BFBAE0F01766D1799D7E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E7928E62A2B6703210F61766D17925ED" xlink:to="loc_us-gaap_NetIncomeLoss_3B6F3272EDB9BFBAE0F01766D1799D7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract_EB578B6C8701C163EACA1766D179A53E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E7928E62A2B6703210F61766D17925ED" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract_EB578B6C8701C163EACA1766D179A53E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_49248980D39A2DD22AF41766D179F4AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract_EB578B6C8701C163EACA1766D179A53E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_49248980D39A2DD22AF41766D179F4AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_A5DB8A8469229D130C801766D17A89DC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E7928E62A2B6703210F61766D17925ED" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_A5DB8A8469229D130C801766D17A89DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1586E938DE3614E7285D1766D17A7634" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E7928E62A2B6703210F61766D17925ED" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_1586E938DE3614E7285D1766D17A7634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9FE9024459BE5E74C4F71766D17A7563" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E7928E62A2B6703210F61766D17925ED" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9FE9024459BE5E74C4F71766D17A7563" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_C6BE6F6D32DF52FE9422A94FCE2BE409" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_937AC3A0EACF5F09BF818EA6D6C3BA1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_C6BE6F6D32DF52FE9422A94FCE2BE409" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_937AC3A0EACF5F09BF818EA6D6C3BA1D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_94980B94A7775C675C1D18E5BEAE86A2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_A9D8F964DDF75BBBD04718E5BEAEA173" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94980B94A7775C675C1D18E5BEAE86A2" xlink:to="loc_us-gaap_DebtInstrumentTable_A9D8F964DDF75BBBD04718E5BEAEA173" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_A026A27F0E16A78E1E4E18E5BEAE8510" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A9D8F964DDF75BBBD04718E5BEAEA173" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_A026A27F0E16A78E1E4E18E5BEAE8510" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_CC65DB211004E7F1632F18E5BEAE41AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A026A27F0E16A78E1E4E18E5BEAE8510" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_CC65DB211004E7F1632F18E5BEAE41AB" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TermLoanMember" xlink:label="loc_cdtx_TermLoanMember_360A64E065CE49BC979E18E5BEAE4158" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_CC65DB211004E7F1632F18E5BEAE41AB" xlink:to="loc_cdtx_TermLoanMember_360A64E065CE49BC979E18E5BEAE4158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7C64A45E11D44F77DB4E18E5BEAE8D80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A9D8F964DDF75BBBD04718E5BEAEA173" xlink:to="loc_us-gaap_DebtInstrumentAxis_7C64A45E11D44F77DB4E18E5BEAE8D80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1B8C606990ECAE4E97B818E5BEAEA146" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7C64A45E11D44F77DB4E18E5BEAE8D80" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1B8C606990ECAE4E97B818E5BEAEA146" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_LoanandSecurityAgreementMember" xlink:label="loc_cdtx_LoanandSecurityAgreementMember_D0B3493803A89D8A6D7318E5BEAEB556" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1B8C606990ECAE4E97B818E5BEAEA146" xlink:to="loc_cdtx_LoanandSecurityAgreementMember_D0B3493803A89D8A6D7318E5BEAEB556" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TermLoanAMember" xlink:label="loc_cdtx_TermLoanAMember_2B64B08F1725CF9A308F18E5BEAEB4DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1B8C606990ECAE4E97B818E5BEAEA146" xlink:to="loc_cdtx_TermLoanAMember_2B64B08F1725CF9A308F18E5BEAEB4DC" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TermLoanBMember" xlink:label="loc_cdtx_TermLoanBMember_EA62D7933E552AFF370F18E5BEAEED96" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1B8C606990ECAE4E97B818E5BEAEA146" xlink:to="loc_cdtx_TermLoanBMember_EA62D7933E552AFF370F18E5BEAEED96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_84F33D4253CD3F55CC4418E5BEAEE94B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A9D8F964DDF75BBBD04718E5BEAEA173" xlink:to="loc_us-gaap_VariableRateAxis_84F33D4253CD3F55CC4418E5BEAEE94B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_F2D39F6646D3868A3C0918E5BEAE5B38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_84F33D4253CD3F55CC4418E5BEAEE94B" xlink:to="loc_us-gaap_VariableRateDomain_F2D39F6646D3868A3C0918E5BEAE5B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_91B51BEA1CEEBED7975818E5BEAE7B52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_F2D39F6646D3868A3C0918E5BEAE5B38" xlink:to="loc_us-gaap_PrimeRateMember_91B51BEA1CEEBED7975818E5BEAE7B52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A9D8F964DDF75BBBD04718E5BEAEA173" xlink:to="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DebtInstrumentMaximumBorrowingCapacity" xlink:label="loc_cdtx_DebtInstrumentMaximumBorrowingCapacity_18856BB9EE9AF3BC265D18E5BEAE2435" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:to="loc_cdtx_DebtInstrumentMaximumBorrowingCapacity_18856BB9EE9AF3BC265D18E5BEAE2435" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_CC6A0535187A7C72021E18E5BEAF5D3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_CC6A0535187A7C72021E18E5BEAF5D3C" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone" xlink:label="loc_cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone_4BDDAC100F941907382218E5BEAF2240" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:to="loc_cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone_4BDDAC100F941907382218E5BEAF2240" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest" xlink:label="loc_cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest_E55E220A82747120859918FA3FE5F2A0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:to="loc_cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest_E55E220A82747120859918FA3FE5F2A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CA32F38C31F2403B12C118E5BEAF9044" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CA32F38C31F2403B12C118E5BEAF9044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_A1EC5DFC5A10077C242D18E5BEAF437E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10D3643413697486DCB918E5BEAE59E7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_A1EC5DFC5A10077C242D18E5BEAF437E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/DebtScheduleOfFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_506E3E120BE59ADDCF99181459D71A7D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_506E3E120BE59ADDCF99181459D71A7D" xlink:to="loc_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_154EC2496AF45E4E435C181459D794DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF" xlink:to="loc_us-gaap_DebtInstrumentAxis_154EC2496AF45E4E435C181459D794DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_BF1D57EC5235C4C486FB181459D70D6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_154EC2496AF45E4E435C181459D794DD" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_BF1D57EC5235C4C486FB181459D70D6C" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TermLoanAMember" xlink:label="loc_cdtx_TermLoanAMember_66B93B16DF256EA319BB181459D71979" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BF1D57EC5235C4C486FB181459D70D6C" xlink:to="loc_cdtx_TermLoanAMember_66B93B16DF256EA319BB181459D71979" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_A0B6CE5660B1895EE92E181459D733FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_A0B6CE5660B1895EE92E181459D733FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_51CACF11A1B3F01BC1FD181459D73E4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A0B6CE5660B1895EE92E181459D733FE" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_51CACF11A1B3F01BC1FD181459D73E4B" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TermLoanMember" xlink:label="loc_cdtx_TermLoanMember_46950D65F4FB3837DC19181459D79103" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_51CACF11A1B3F01BC1FD181459D73E4B" xlink:to="loc_cdtx_TermLoanMember_46950D65F4FB3837DC19181459D79103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E6C595BC59FC07BFC81B181459D7D922" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5BA0AF85DCFFA54ACE5C181459D7A9DF" xlink:to="loc_us-gaap_DebtInstrumentLineItems_E6C595BC59FC07BFC81B181459D7D922" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E6C595BC59FC07BFC81B181459D7D922" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BD6D3674286D909E8763181459D870F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_BD6D3674286D909E8763181459D870F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_B0E87192A8786063C87E181459D8F3FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_B0E87192A8786063C87E181459D8F3FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_47C01447493837B43F5E181459D8A24F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_47C01447493837B43F5E181459D8A24F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_8ABD515F683A9F5D61FA181459D8341F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_50C4F4CBCD7A60D5862A181459D7AE1C" xlink:to="loc_us-gaap_LongTermDebt_8ABD515F683A9F5D61FA181459D8341F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4EAF88A749DD5BF2A4928BE8C94E93BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_749A7DAD395A5A39806FB74496FC59F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4EAF88A749DD5BF2A4928BE8C94E93BA" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_749A7DAD395A5A39806FB74496FC59F7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DocumentAndEntityInformationAbstract" xlink:label="loc_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_FF3DD66CA6FA536C8B207A7E0C87E33C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:to="loc_dei_DocumentType_FF3DD66CA6FA536C8B207A7E0C87E33C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3D20FFB6F64A55848D31ECFAC9B45721" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:to="loc_dei_AmendmentFlag_3D20FFB6F64A55848D31ECFAC9B45721" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_CAFF74AC62855D16B00B2745E426903A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:to="loc_dei_DocumentPeriodEndDate_CAFF74AC62855D16B00B2745E426903A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_F3FFB15AD22D50E8A00C47019192A642" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:to="loc_dei_DocumentFiscalYearFocus_F3FFB15AD22D50E8A00C47019192A642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_43B1DD1DC22B57BD8D76E5EFF6F7C10C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_43B1DD1DC22B57BD8D76E5EFF6F7C10C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_40D22603FBFB5A24AE528A59B4E15B50" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:to="loc_dei_EntityRegistrantName_40D22603FBFB5A24AE528A59B4E15B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_0769C94B63C5507FAE55F8D4B537CA19" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:to="loc_dei_EntityCentralIndexKey_0769C94B63C5507FAE55F8D4B537CA19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_9671487347075E6CB7E82176900B99E1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:to="loc_dei_CurrentFiscalYearEndDate_9671487347075E6CB7E82176900B99E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_3EC18C3C35CE5A318E100B72D0B4A374" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:to="loc_dei_EntityFilerCategory_3EC18C3C35CE5A318E100B72D0B4A374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_C3FB4842F91156BFB28698C292A70519" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_DocumentAndEntityInformationAbstract_86C1232BD1195247AA4E38E5B3708CE0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_C3FB4842F91156BFB28698C292A70519" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5D6C06793147551EBB15EBBF2E75DBFA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_D303F3AFF2D9583D84EFBC9EC5FF9519" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5D6C06793147551EBB15EBBF2E75DBFA" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_D303F3AFF2D9583D84EFBC9EC5FF9519" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_25158CDDE19692890C29181459E555AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_25158CDDE19692890C29181459E555AA" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8E53A4B89F07F222949B181459E69F85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8E53A4B89F07F222949B181459E69F85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_026D6E8FEBDF4D851E58181459E6683E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8E53A4B89F07F222949B181459E69F85" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_026D6E8FEBDF4D851E58181459E6683E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_728EF88E0ACFAC91738E181459E65D43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_026D6E8FEBDF4D851E58181459E6683E" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_728EF88E0ACFAC91738E181459E65D43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2CEB18A04184D73AA6A0181459E6D0AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2CEB18A04184D73AA6A0181459E6D0AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2CEB18A04184D73AA6A0181459E6D0AE" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7E9063B6EEE1D28C2A16181459E6E042" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7E9063B6EEE1D28C2A16181459E6E042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E1E91BD1716209C18224181459E6A4BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_E1E91BD1716209C18224181459E6A4BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_504041A05B68D9F9B5FA181459E6BABB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F2AD8A2C39E78A8D9D181459E62D98" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_504041A05B68D9F9B5FA181459E6BABB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_CEFBE9041660CCA59AC6181459E69809" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_CEFBE9041660CCA59AC6181459E69809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_CEFBE9041660CCA59AC6181459E69809" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5E68F5A80A8CE9A5C3A8181459E6B293" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5E68F5A80A8CE9A5C3A8181459E6B293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_15D737554B69202DFC3B181459E6555F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_15D737554B69202DFC3B181459E6555F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_D58FFCE6327C1E81768C181459E6BBCA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1E018183D243A1ED288D181459E662A0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_D58FFCE6327C1E81768C181459E6BBCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10964069F8D7E29153CD181459E73539" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11F95D06CA52794058DD181459E5360E" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10964069F8D7E29153CD181459E73539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_CEBE7D2FA9C29C663ABA181459E752A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10964069F8D7E29153CD181459E73539" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_CEBE7D2FA9C29C663ABA181459E752A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_366955CC412DB53B9648181459E73A7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_CEBE7D2FA9C29C663ABA181459E752A5" xlink:to="loc_us-gaap_AssetsFairValueDisclosureRecurring_366955CC412DB53B9648181459E73A7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_391277DB7F2DD56B5012181459E7753F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_CEBE7D2FA9C29C663ABA181459E752A5" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_391277DB7F2DD56B5012181459E7753F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8C516D0C5399572E9E97996ECCD3511E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_B6FA08BC474F58C590E691ED0273A349" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8C516D0C5399572E9E97996ECCD3511E" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_B6FA08BC474F58C590E691ED0273A349" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/ShortTermInvestments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5F19EF0874845E738BAC473BCCF37F1E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_FF9BAB111E38578D9C24A2FBF61105BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5F19EF0874845E738BAC473BCCF37F1E" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_FF9BAB111E38578D9C24A2FBF61105BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/ShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_546F2F2DF6DAF134946D401128925B1D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E73E57A152FDE54C32F440112892CFB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_546F2F2DF6DAF134946D401128925B1D" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E73E57A152FDE54C32F440112892CFB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_DDAD4F6584F22600B4C9401128920F89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E73E57A152FDE54C32F440112892CFB2" xlink:to="loc_us-gaap_InvestmentTypeAxis_DDAD4F6584F22600B4C9401128920F89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7F2B844ABE9B2AA40D0C40112892182B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_DDAD4F6584F22600B4C9401128920F89" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7F2B844ABE9B2AA40D0C40112892182B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_FB3EC870C3A0AAAFCA204011289230F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7F2B844ABE9B2AA40D0C40112892182B" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_FB3EC870C3A0AAAFCA204011289230F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E73E57A152FDE54C32F440112892CFB2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FCED9D2FB6802F4C68E240234E38A3AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FCED9D2FB6802F4C68E240234E38A3AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5299D9FAB0E989C0A0334023F7447602" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5299D9FAB0E989C0A0334023F7447602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ED1FBA9032207AB99243402435C57770" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ED1FBA9032207AB99243402435C57770" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6FBAA6271429524E02BF40246A1D814F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_FE7519FC858542A3477F40112892B591" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6FBAA6271429524E02BF40246A1D814F" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_MaturityPeriodOfShortTermInvestments" xlink:label="loc_cdtx_MaturityPeriodOfShortTermInvestments_D4BD7C49030F451DAD7640112893B6A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_546F2F2DF6DAF134946D401128925B1D" xlink:to="loc_cdtx_MaturityPeriodOfShortTermInvestments_D4BD7C49030F451DAD7640112893B6A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_4F15732B31D1165645EA40112893E170" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_546F2F2DF6DAF134946D401128925B1D" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_4F15732B31D1165645EA40112893E170" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="loc_cdtx_DebtSecuritiesAvailableForSaleGainLoss_56E4D1421CAF1A10994840112893A220" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_546F2F2DF6DAF134946D401128925B1D" xlink:to="loc_cdtx_DebtSecuritiesAvailableForSaleGainLoss_56E4D1421CAF1A10994840112893A220" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/ShortTermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_176596D2CF05AB7279A71BBE378A016A" xlink:type="locator" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_cdtx_DebtSecuritiesAvailableForSaleTableTextBlock_941EED74E5E4CFE4648F1BC782796183" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_176596D2CF05AB7279A71BBE378A016A" xlink:to="loc_cdtx_DebtSecuritiesAvailableForSaleTableTextBlock_941EED74E5E4CFE4648F1BC782796183" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/SignificantAgreementsAndContracts" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_F1E559C04D2B5DA9B2B48238B0538E8D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_919E9175B99C599F8358DCE3E8BD841B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_F1E559C04D2B5DA9B2B48238B0538E8D" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_919E9175B99C599F8358DCE3E8BD841B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/SignificantAgreementsAndContractsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_6604FD878C18FF0D4C8E181459A81BF0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_6604FD878C18FF0D4C8E181459A81BF0" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_59AA5A4C8CEA3550F6E8181459A83511" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_59AA5A4C8CEA3550F6E8181459A83511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A1D92D3FE655073767D181459A812EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59AA5A4C8CEA3550F6E8181459A83511" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A1D92D3FE655073767D181459A812EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_774972F53A80B30B81CB181459A80F8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0A1D92D3FE655073767D181459A812EF" xlink:to="loc_us-gaap_CollaborativeArrangementMember_774972F53A80B30B81CB181459A80F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_443B3E95A27464398765181459A86633" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4" xlink:to="loc_us-gaap_ProductOrServiceAxis_443B3E95A27464398765181459A86633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_DB85EE24B8B9143D8E44181459A83E60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_443B3E95A27464398765181459A86633" xlink:to="loc_us-gaap_ProductsAndServicesDomain_DB85EE24B8B9143D8E44181459A83E60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_BC2A8F2E0C38BCE42886181459A8EBE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_DB85EE24B8B9143D8E44181459A83E60" xlink:to="loc_us-gaap_ProductMember_BC2A8F2E0C38BCE42886181459A8EBE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_09C7B5A30F9DE9D04EC3181459A874D4" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase" xlink:label="loc_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase_A9EB8143160335AE0947181459A97C6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:to="loc_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase_A9EB8143160335AE0947181459A97C6B" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage" xlink:label="loc_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage_D4198CA8C16B705AA2B1181459A93289" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:to="loc_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage_D4198CA8C16B705AA2B1181459A93289" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_ReductioninResearchandDevelopmentExpense" xlink:label="loc_cdtx_ReductioninResearchandDevelopmentExpense_F58AE5E7CB3F1D98D2F9181459A95F54" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:to="loc_cdtx_ReductioninResearchandDevelopmentExpense_F58AE5E7CB3F1D98D2F9181459A95F54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BilledContractReceivables" xlink:label="loc_us-gaap_BilledContractReceivables_4C6B431F468FA8F0BD49181459A9DF2E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:to="loc_us-gaap_BilledContractReceivables_4C6B431F468FA8F0BD49181459A9DF2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="loc_us-gaap_UnbilledContractsReceivable_E62077C1F94911226ADB181459A94BA4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:to="loc_us-gaap_UnbilledContractsReceivable_E62077C1F94911226ADB181459A94BA4" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice" xlink:label="loc_cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice_82631094F0095737F3ED181459A9CC95" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_112F9B71C3280048BCBD181459A819EB" xlink:to="loc_cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice_82631094F0095737F3ED181459A9CC95" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/StockIncentivePlans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_516EFAA9F5875C538E66FEC7CAAC487B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158287B8EC24508788CAEC86838A7598" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_516EFAA9F5875C538E66FEC7CAAC487B" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158287B8EC24508788CAEC86838A7598" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/StockIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_35B0CCDF5D5156C88A81B18254981EFB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_35B0CCDF5D5156C88A81B18254981EFB" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_26E1BC619AAC54B3836EE500E62DC08D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:to="loc_us-gaap_PlanNameAxis_26E1BC619AAC54B3836EE500E62DC08D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_BC55C61AF500549FA2FF8371AD0AF6CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_26E1BC619AAC54B3836EE500E62DC08D" xlink:to="loc_us-gaap_PlanNameDomain_BC55C61AF500549FA2FF8371AD0AF6CC" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_2624E5357A0B571BAB57EDE08529D420" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_BC55C61AF500549FA2FF8371AD0AF6CC" xlink:to="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_2624E5357A0B571BAB57EDE08529D420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FBA2B7D7F22459FCA81555528992DBC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:to="loc_us-gaap_RangeAxis_FBA2B7D7F22459FCA81555528992DBC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_ECF74E5385B55A83AF61F2E21489089C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_FBA2B7D7F22459FCA81555528992DBC5" xlink:to="loc_us-gaap_RangeMember_ECF74E5385B55A83AF61F2E21489089C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_CA3A7EFFA0F256E68CD558BC264F7A45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_ECF74E5385B55A83AF61F2E21489089C" xlink:to="loc_us-gaap_MinimumMember_CA3A7EFFA0F256E68CD558BC264F7A45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_890869B182A7537C9F84EFA249D5037A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_ECF74E5385B55A83AF61F2E21489089C" xlink:to="loc_us-gaap_MaximumMember_890869B182A7537C9F84EFA249D5037A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A00639BC59215837A306FF362AF13BC6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A00639BC59215837A306FF362AF13BC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_2C55F392A32F5E768C9820C862591BCD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A00639BC59215837A306FF362AF13BC6" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_2C55F392A32F5E768C9820C862591BCD" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:label="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_3C8238317CA157D6BDEC2EEDF7A37680" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_2C55F392A32F5E768C9820C862591BCD" xlink:to="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_3C8238317CA157D6BDEC2EEDF7A37680" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2888BB05594D5A5C865B5B2D9C0C5156" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2888BB05594D5A5C865B5B2D9C0C5156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0BAAE6B251335938A6054E48BC5781C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2888BB05594D5A5C865B5B2D9C0C5156" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0BAAE6B251335938A6054E48BC5781C5" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CommonStockSubjectToRepurchaseMember" xlink:label="loc_cdtx_CommonStockSubjectToRepurchaseMember_7F99EDB8554F5B75A0515BF0D3260451" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0BAAE6B251335938A6054E48BC5781C5" xlink:to="loc_cdtx_CommonStockSubjectToRepurchaseMember_7F99EDB8554F5B75A0515BF0D3260451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_34C85E2BE2EF5EC591FD299B81E0154C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:to="loc_us-gaap_AwardTypeAxis_34C85E2BE2EF5EC591FD299B81E0154C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14214F9B535359D19D651036326EDF58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_34C85E2BE2EF5EC591FD299B81E0154C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14214F9B535359D19D651036326EDF58" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:label="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_0ADC1A94399B5588A7D88B730D842DA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14214F9B535359D19D651036326EDF58" xlink:to="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_0ADC1A94399B5588A7D88B730D842DA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_E2B4D95A723855548DC497FF011A0367" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14214F9B535359D19D651036326EDF58" xlink:to="loc_us-gaap_RestrictedStockMember_E2B4D95A723855548DC497FF011A0367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0065B710649D55B48C6C6254EF7DE267" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_D4C42F987BD050A1BFCF53EDAD7B0D7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_D4C42F987BD050A1BFCF53EDAD7B0D7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_696617A35A60528EA9E69A37AFD2541D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_696617A35A60528EA9E69A37AFD2541D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_71650BB9573C52068C74454934E2CFF4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_71650BB9573C52068C74454934E2CFF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8D8B1CB66267595087DE77EAEEE9DEE8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8D8B1CB66267595087DE77EAEEE9DEE8" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_F4C7FAA3CEAB5CC8BE0EAB881E15FC4E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_F4C7FAA3CEAB5CC8BE0EAB881E15FC4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_06E3C09F230D56029F025395E9316CE9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_06E3C09F230D56029F025395E9316CE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4C0DE3AA6844551FAE43955D11A8D6F8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4C0DE3AA6844551FAE43955D11A8D6F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_D0720BEEE879551EB8B71D0259287852" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_D0720BEEE879551EB8B71D0259287852" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent" xlink:label="loc_cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent_96AEE43D8A8B5F998D0EE46C7C68910B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent_96AEE43D8A8B5F998D0EE46C7C68910B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_54CBF30FBB2652C881CB5529D068B991" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_54CBF30FBB2652C881CB5529D068B991" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_79B62E4EE4465957BFCC811A9322B621" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_79B62E4EE4465957BFCC811A9322B621" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5DC1D0998CC75BDF8F45EBE6288B5393" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5DC1D0998CC75BDF8F45EBE6288B5393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_588C39F391D75ACDB4CCA592B53377B7" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_588C39F391D75ACDB4CCA592B53377B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_728051DCB5705572A8C798C071754C38" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_728051DCB5705572A8C798C071754C38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_09A19250F41653E592C5C83AF72F3F0C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72EF348DEC735798BA0018BBD4A24ACF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_09A19250F41653E592C5C83AF72F3F0C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/StockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1D1A57778AFC58D684779BA18F90AE91" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29C407EB80105DDDACD13707A5F639D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1D1A57778AFC58D684779BA18F90AE91" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29C407EB80105DDDACD13707A5F639D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7053E15520BD5CC38C312D87C9ACA80C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29C407EB80105DDDACD13707A5F639D1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7053E15520BD5CC38C312D87C9ACA80C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_17A327721CA15FD59059938EE8BEA68A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7053E15520BD5CC38C312D87C9ACA80C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_17A327721CA15FD59059938EE8BEA68A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_AC60984680785EA99B89FE95688B8D92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17A327721CA15FD59059938EE8BEA68A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_AC60984680785EA99B89FE95688B8D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_AA333408A20B57CB855A15872914A646" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17A327721CA15FD59059938EE8BEA68A" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_AA333408A20B57CB855A15872914A646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9A4A14E6FB335E7C8C56ACA48DA38A74" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29C407EB80105DDDACD13707A5F639D1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9A4A14E6FB335E7C8C56ACA48DA38A74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BD3BFAEC5826545AABE8A639C124068D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9A4A14E6FB335E7C8C56ACA48DA38A74" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_BD3BFAEC5826545AABE8A639C124068D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/StockIncentivePlansSummaryOfRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3E364813804651139C414570F20AAF57" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C5A31DE7E2F551088FF5FA580A795B34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3E364813804651139C414570F20AAF57" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C5A31DE7E2F551088FF5FA580A795B34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8D5456FD8581598A9A314CEE5CB5D602" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C5A31DE7E2F551088FF5FA580A795B34" xlink:to="loc_us-gaap_AwardTypeAxis_8D5456FD8581598A9A314CEE5CB5D602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9F3B81B973C25833A13301238CF565D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8D5456FD8581598A9A314CEE5CB5D602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9F3B81B973C25833A13301238CF565D2" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_CDEC2DF389CF55109578493F1C782A5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9F3B81B973C25833A13301238CF565D2" xlink:to="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_CDEC2DF389CF55109578493F1C782A5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8796395E14DF5592BB45751A65471967" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C5A31DE7E2F551088FF5FA580A795B34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8796395E14DF5592BB45751A65471967" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F7C3566450DE562AB9261B509782CDB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8796395E14DF5592BB45751A65471967" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F7C3566450DE562AB9261B509782CDB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_738E3B82B9785125A608E86265DCE555" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F7C3566450DE562AB9261B509782CDB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_738E3B82B9785125A608E86265DCE555" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_786547557AF65332A55A3AEC8398871D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F7C3566450DE562AB9261B509782CDB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_786547557AF65332A55A3AEC8398871D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_A6ACEFF306C65E388D102B0EB2D09EF6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F7C3566450DE562AB9261B509782CDB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_A6ACEFF306C65E388D102B0EB2D09EF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_04C4EC609CA353D2B5137FF03B78F864" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F7C3566450DE562AB9261B509782CDB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_04C4EC609CA353D2B5137FF03B78F864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_946C081CAFDC585C8E238899032CB818" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F7C3566450DE562AB9261B509782CDB4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_946C081CAFDC585C8E238899032CB818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_A007F57BC2485613A13BAE2325E4B61D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8796395E14DF5592BB45751A65471967" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_A007F57BC2485613A13BAE2325E4B61D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_273636C8EFAD54B9BF3BC50AD9BED30A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8796395E14DF5592BB45751A65471967" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_273636C8EFAD54B9BF3BC50AD9BED30A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/StockIncentivePlansSummaryOfStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515ED65082F65F30AEF74940B4AC6961" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98A1ADF935A1587DAE27918CF341AF2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515ED65082F65F30AEF74940B4AC6961" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98A1ADF935A1587DAE27918CF341AF2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FB90EF930D365511944005101E2DD5C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98A1ADF935A1587DAE27918CF341AF2A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FB90EF930D365511944005101E2DD5C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_77DB1B05AF1A5115A32E44CA0973B30D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98A1ADF935A1587DAE27918CF341AF2A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_77DB1B05AF1A5115A32E44CA0973B30D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C742A23A8BFB513BBE1C62809020F18B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98A1ADF935A1587DAE27918CF341AF2A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C742A23A8BFB513BBE1C62809020F18B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7BA3A7697AD5585E94DCFBF26FCD79C8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98A1ADF935A1587DAE27918CF341AF2A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7BA3A7697AD5585E94DCFBF26FCD79C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25D913A5CD17502B9BAEC0836DBA8490" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98A1ADF935A1587DAE27918CF341AF2A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25D913A5CD17502B9BAEC0836DBA8490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_732A97F3EA6C5EA585B442F6143A7E1E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515ED65082F65F30AEF74940B4AC6961" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_732A97F3EA6C5EA585B442F6143A7E1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_01F45D060E025F28A49D8761B1BFC638" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515ED65082F65F30AEF74940B4AC6961" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_01F45D060E025F28A49D8761B1BFC638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_DB868916A58E5391ACF680289B6F6F40" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515ED65082F65F30AEF74940B4AC6961" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_DB868916A58E5391ACF680289B6F6F40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_95CB94685F7C501F85610D8A502E5E95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_DB868916A58E5391ACF680289B6F6F40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_95CB94685F7C501F85610D8A502E5E95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_807906759DFB5476B44965FAD8D6CE62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_DB868916A58E5391ACF680289B6F6F40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_807906759DFB5476B44965FAD8D6CE62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F2F14FDB6EA254DCA0A4E4B1CB8ED7BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_DB868916A58E5391ACF680289B6F6F40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F2F14FDB6EA254DCA0A4E4B1CB8ED7BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_47D9AE0948B357419AFBF00244CF4868" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_DB868916A58E5391ACF680289B6F6F40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_47D9AE0948B357419AFBF00244CF4868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4712558585F65AD0AD613C7A26515ED9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_DB868916A58E5391ACF680289B6F6F40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4712558585F65AD0AD613C7A26515ED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_99C77364B87B5675AA8CC8FDC970AD9A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515ED65082F65F30AEF74940B4AC6961" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_99C77364B87B5675AA8CC8FDC970AD9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A2A0399D84F75B2E9D9AFB963F21494B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515ED65082F65F30AEF74940B4AC6961" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A2A0399D84F75B2E9D9AFB963F21494B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_B58239DD1EF75BA6918DB4B2132A6DC3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515ED65082F65F30AEF74940B4AC6961" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_B58239DD1EF75BA6918DB4B2132A6DC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_52993392F7A75863BF3A1AD7FBADFA56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_B58239DD1EF75BA6918DB4B2132A6DC3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_52993392F7A75863BF3A1AD7FBADFA56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0A383DB669B65206B2B3E8A396DCD20A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_B58239DD1EF75BA6918DB4B2132A6DC3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0A383DB669B65206B2B3E8A396DCD20A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_03CA2D640B3A5C588E0238D696E218E1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_B58239DD1EF75BA6918DB4B2132A6DC3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_03CA2D640B3A5C588E0238D696E218E1" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:label="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_44F61F5BCC2752EEA2B1F30A50359DB3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515ED65082F65F30AEF74940B4AC6961" xlink:to="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_44F61F5BCC2752EEA2B1F30A50359DB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E0673018937253558D226EC996692CA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_44F61F5BCC2752EEA2B1F30A50359DB3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E0673018937253558D226EC996692CA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F2C5F4A8378D5A349877D8CF90497F34" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_44F61F5BCC2752EEA2B1F30A50359DB3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F2C5F4A8378D5A349877D8CF90497F34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F457FA02BE65FEA88BF806E357D39EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_44F61F5BCC2752EEA2B1F30A50359DB3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3F457FA02BE65FEA88BF806E357D39EC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/StockIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A47E635035C5537EBDD1E5CCACD5E989" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0DA1E1487BCD54F1934731249D5568BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A47E635035C5537EBDD1E5CCACD5E989" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0DA1E1487BCD54F1934731249D5568BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9B5A49B2C12B5540A0E1356CDCD8B5EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A47E635035C5537EBDD1E5CCACD5E989" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9B5A49B2C12B5540A0E1356CDCD8B5EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F6F489DF1F8259C0B669EECFDD500050" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A47E635035C5537EBDD1E5CCACD5E989" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F6F489DF1F8259C0B669EECFDD500050" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_7B626E30558A5FA48578AA4EF732A13A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6133286DD63A560799250211829617CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7B626E30558A5FA48578AA4EF732A13A" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6133286DD63A560799250211829617CF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9D7EC0F17C10A3F3895A181459CE6B28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_C6E2A9B0895E07DA40671824607CA959" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9D7EC0F17C10A3F3895A181459CE6B28" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_C6E2A9B0895E07DA40671824607CA959" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D0CF3FC56171F4EFBE4F18249A6103F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C6E2A9B0895E07DA40671824607CA959" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_D0CF3FC56171F4EFBE4F18249A6103F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6FF6D8B251974F0ECC1318249A68B665" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D0CF3FC56171F4EFBE4F18249A6103F0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6FF6D8B251974F0ECC1318249A68B665" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:label="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_D63371394C82FCB2B53F18249A7A7111" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6FF6D8B251974F0ECC1318249A68B665" xlink:to="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_D63371394C82FCB2B53F18249A7A7111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C6E2A9B0895E07DA40671824607CA959" xlink:to="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_70D6B28E73169F441973181459CE0B4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_70D6B28E73169F441973181459CE0B4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5DA332846B26C667CA09181459CEBF88" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5DA332846B26C667CA09181459CEBF88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_B22B4485A89F4317DD2F181459CEF247" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_B22B4485A89F4317DD2F181459CEF247" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_CA04B074630CEE53F034181459CFA196" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_CA04B074630CEE53F034181459CFA196" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:label="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_0222B91C3942F07D1974181459CF46E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_0222B91C3942F07D1974181459CF46E8" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CommonStockDividendsInArrearsOrDefault" xlink:label="loc_cdtx_CommonStockDividendsInArrearsOrDefault_8B9D4F08755CEED8FE91181459CFEE51" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_cdtx_CommonStockDividendsInArrearsOrDefault_8B9D4F08755CEED8FE91181459CFEE51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D5003FAC03D4286FAD9B18249A4FE850" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D5003FAC03D4286FAD9B18249A4FE850" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_654823B8598CA539D1E818249A597B94" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4457AFBF3B8F555486501824608300F7" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_654823B8598CA539D1E818249A597B94" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/StockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_31592570E6D5EF072495181459CA192D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6A91D7B8DD69E6AEABEF181459CA5608" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_31592570E6D5EF072495181459CA192D" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6A91D7B8DD69E6AEABEF181459CA5608" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_46E990A053C382BCD701181459CA9485" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6A91D7B8DD69E6AEABEF181459CA5608" xlink:to="loc_us-gaap_AwardTypeAxis_46E990A053C382BCD701181459CA9485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84A89551AD109ADC8939181459CA0BEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_46E990A053C382BCD701181459CA9485" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84A89551AD109ADC8939181459CA0BEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_F16DA07CC6A8E1A3E938181459CBEE09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84A89551AD109ADC8939181459CA0BEF" xlink:to="loc_us-gaap_WarrantMember_F16DA07CC6A8E1A3E938181459CBEE09" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember" xlink:label="loc_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_28874712DE798DECC3F1181459CA7F65" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84A89551AD109ADC8939181459CA0BEF" xlink:to="loc_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_28874712DE798DECC3F1181459CA7F65" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_4CA2B702151E1552C089181459CA5DDF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84A89551AD109ADC8939181459CA0BEF" xlink:to="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_4CA2B702151E1552C089181459CA5DDF" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_EmployeeStockPurchasePlanMember" xlink:label="loc_cdtx_EmployeeStockPurchasePlanMember_7BEF0F07E13222DE7760181459CAAAE7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84A89551AD109ADC8939181459CA0BEF" xlink:to="loc_cdtx_EmployeeStockPurchasePlanMember_7BEF0F07E13222DE7760181459CAAAE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_919C3F1702B40E67D151181459CB1070" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6A91D7B8DD69E6AEABEF181459CA5608" xlink:to="loc_us-gaap_ClassOfStockLineItems_919C3F1702B40E67D151181459CB1070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CA3C9F64D662C18BD64C181459CB9A1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_919C3F1702B40E67D151181459CB1070" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CA3C9F64D662C18BD64C181459CB9A1C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_41F3CDFF12A951BB9A29107DC8A54B0F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_A994CDEC4C895BD6B49B381F51C009A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_41F3CDFF12A951BB9A29107DC8A54B0F" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_A994CDEC4C895BD6B49B381F51C009A0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_52B13CD9A9055713B92824CF4A9243C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_DE0800EB1CF458098F5397C93C1D3AD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_52B13CD9A9055713B92824CF4A9243C7" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_DE0800EB1CF458098F5397C93C1D3AD5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9072F3915FFFAEA32A6745E5E7962594" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9072F3915FFFAEA32A6745E5E7962594" xlink:to="loc_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E10A02044D1ADA58528145E5E79A59E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E10A02044D1ADA58528145E5E79A59E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D4E5A34AB826967FA71A45E5E79A1F5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E10A02044D1ADA58528145E5E79A59E2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D4E5A34AB826967FA71A45E5E79A1F5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_7C0DDEB8FD6EBE7650AD45E5E79AA6B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D4E5A34AB826967FA71A45E5E79A1F5A" xlink:to="loc_us-gaap_CollaborativeArrangementMember_7C0DDEB8FD6EBE7650AD45E5E79AA6B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_FFCEDD3B361938499CF445E5E79AC19A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_FFCEDD3B361938499CF445E5E79AC19A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6165F1640F0F0917E45045E5E79A347B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_FFCEDD3B361938499CF445E5E79AC19A" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6165F1640F0F0917E45045E5E79A347B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_135A1158A3D7532B1C4C45E5E79B217E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6165F1640F0F0917E45045E5E79A347B" xlink:to="loc_us-gaap_SubsequentEventMember_135A1158A3D7532B1C4C45E5E79B217E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_36F07A21C59AE7FEA98D45E5E79B2AD7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_75BB164973E50A9A822445E5E79924CE" xlink:to="loc_us-gaap_SubsequentEventLineItems_36F07A21C59AE7FEA98D45E5E79B2AD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_A5877BDAD2A6345A47C845FB0339F61F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_36F07A21C59AE7FEA98D45E5E79B2AD7" xlink:to="loc_us-gaap_GrantsReceivable_A5877BDAD2A6345A47C845FB0339F61F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_31C485BC09C6561A94A6BE08D0B7AE8E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_CD4BDCD7FC005DDA9667CD2EE4E2AF20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31C485BC09C6561A94A6BE08D0B7AE8E" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_CD4BDCD7FC005DDA9667CD2EE4E2AF20" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_68D5F5C97593A0D4299A1777D2E6B106" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C3848D23403E2D24FA51777D2E7B23D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68D5F5C97593A0D4299A1777D2E6B106" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C3848D23403E2D24FA51777D2E7B23D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D7CF47A7C9B1678C35311777D2E7DBBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C3848D23403E2D24FA51777D2E7B23D" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D7CF47A7C9B1678C35311777D2E7DBBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B69C8311F118B3A2AFB21777D2E7F0EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D7CF47A7C9B1678C35311777D2E7DBBA" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B69C8311F118B3A2AFB21777D2E7F0EE" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember" xlink:label="loc_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_7CAB13386BBFCA4A459D1777D2E7591D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B69C8311F118B3A2AFB21777D2E7F0EE" xlink:to="loc_cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember_7CAB13386BBFCA4A459D1777D2E7591D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_C8CE39386ACB5B4EEA691777D2E7D6FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B69C8311F118B3A2AFB21777D2E7F0EE" xlink:to="loc_us-gaap_WarrantMember_C8CE39386ACB5B4EEA691777D2E7D6FD" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_CommonStockSubjectToRepurchaseMember" xlink:label="loc_cdtx_CommonStockSubjectToRepurchaseMember_A88DC3BDAB0BBCD728EC1777D2E7BB6A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_B69C8311F118B3A2AFB21777D2E7F0EE" xlink:to="loc_cdtx_CommonStockSubjectToRepurchaseMember_A88DC3BDAB0BBCD728EC1777D2E7BB6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C863BCA7F82309669B3B1777D2E7F79A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6C3848D23403E2D24FA51777D2E7B23D" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C863BCA7F82309669B3B1777D2E7F79A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3F73CF7E9D61307370BE1777D2E7FEE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C863BCA7F82309669B3B1777D2E7F79A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3F73CF7E9D61307370BE1777D2E7FEE7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FAB18F6B14D992171D0C1777D2F8531E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_FAB18F6B14D992171D0C1777D2F8531E" xlink:type="arc" />
    <link:loc xlink:href="cdtx-20180331.xsd#cdtx_UnauditedInterimFinancialDataPolicyTextBlock" xlink:label="loc_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_74581E5EC96E7877A5A01777D2F82498" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_74581E5EC96E7877A5A01777D2F82498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_BE32A050D5323D136F731777D2F8243E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_BE32A050D5323D136F731777D2F8243E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1C72544D695121F376A01777D2F8E09F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_UseOfEstimates_1C72544D695121F376A01777D2F8E09F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_85A24FA1ADA915797E5D1777D2FE7608" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_85A24FA1ADA915797E5D1777D2FE7608" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_73CD051AC9F6D046F93217A621C6DDEA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_73CD051AC9F6D046F93217A621C6DDEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_7348BCCEEC5C4AB443BA1777D2FE435F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_7348BCCEEC5C4AB443BA1777D2FE435F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_C6D6CF3822B92FF4CDE31777D2FEB3D3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_C6D6CF3822B92FF4CDE31777D2FEB3D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_ACF866EA0C65F989C0D21777D2FE361F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_ACF866EA0C65F989C0D21777D2FE361F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_CA3F103AE2550DFDA4991777D2FEBCD3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_CA3F103AE2550DFDA4991777D2FEBCD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_F1BD5D6200D05FE2BA8A1777D2FE9902" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_F1BD5D6200D05FE2BA8A1777D2FE9902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D30C6B8198142895DB221777D2FECF49" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_D30C6B8198142895DB221777D2FECF49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_15103DF6404F0F0783011777D2FEF1B0" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_15103DF6404F0F0783011777D2FEF1B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ECD51324C49998442AF41777D2FEF648" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ECD51324C49998442AF41777D2FEF648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_628F6B4B882BF7245FFA1777D2FE9A11" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_628F6B4B882BF7245FFA1777D2FE9A11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_536E51CA60052D9466F71777D2FE16F6" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_536E51CA60052D9466F71777D2FE16F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58CC1B175437028D340B1777D2FF9FF6" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_EE7B86889051DFCBC1111777D2F8DA87" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58CC1B175437028D340B1777D2FF9FF6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://cidara.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7AEC993D67B4A029A912316DE260733D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_C628EFDCD44A28BFDDE1316DE260D017" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7AEC993D67B4A029A912316DE260733D" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_C628EFDCD44A28BFDDE1316DE260D017" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757364304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cidara Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001610618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,391,057<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753497744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 52,218<span></span>
</td>
<td class="nump">$ 60,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">792<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">13,973<span></span>
</td>
<td class="nump">14,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">2,035<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">68,990<span></span>
</td>
<td class="nump">77,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">936<span></span>
</td>
<td class="nump">1,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">70,247<span></span>
</td>
<td class="nump">79,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,999<span></span>
</td>
<td class="nump">2,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">4,516<span></span>
</td>
<td class="nump">4,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">1,921<span></span>
</td>
<td class="nump">2,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Current portion of term loan</a></td>
<td class="nump">2,083<span></span>
</td>
<td class="nump">2,667<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,519<span></span>
</td>
<td class="nump">12,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Term loan, less debt issuance costs</a></td>
<td class="nump">7,809<span></span>
</td>
<td class="nump">7,206<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">19,328<span></span>
</td>
<td class="nump">19,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding at March 31, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2018 and December 31, 2017; 21,395,077 and 21,389,736 shares issued and outstanding, respectively, at March 31, 2018; 20,534,993 and 20,525,688 shares issued and outstanding, respectively, at December 31, 2017</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">217,073<span></span>
</td>
<td class="nump">209,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(166,138)<span></span>
</td>
<td class="num">(149,390)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">50,919<span></span>
</td>
<td class="nump">59,744<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 70,247<span></span>
</td>
<td class="nump">$ 79,035<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753108096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">21,395,077<span></span>
</td>
<td class="nump">21,389,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">20,534,993<span></span>
</td>
<td class="nump">20,525,688<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753242944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 13,199<span></span>
</td>
<td class="nump">$ 10,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,611<span></span>
</td>
<td class="nump">3,155<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">16,810<span></span>
</td>
<td class="nump">13,398<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(16,810)<span></span>
</td>
<td class="num">(13,398)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,749)<span></span>
</td>
<td class="num">(13,398)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (16,759)<span></span>
</td>
<td class="num">$ (13,401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.80)<span></span>
</td>
<td class="num">$ (0.80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used to compute basic and diluted net loss per share (in shares)</a></td>
<td class="nump">20,894,353<span></span>
</td>
<td class="nump">16,795,366<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753218816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,749)<span></span>
</td>
<td class="num">$ (13,398)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,461<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount or premium on short-term investments</a></td>
<td class="nump">36<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StraightLineRent', window );">Deferred rent</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">482<span></span>
</td>
<td class="num">(416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">549<span></span>
</td>
<td class="num">(799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(650)<span></span>
</td>
<td class="num">(1,129)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(14,722)<span></span>
</td>
<td class="num">(14,518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(5,803)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturities of short-term investments</a></td>
<td class="nump">6,285<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by investing activities</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">11,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">6,440<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfEquity', window );">Repurchase of unvested restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,468<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(7,803)<span></span>
</td>
<td class="num">(3,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">60,813<span></span>
</td>
<td class="nump">85,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">53,010<span></span>
</td>
<td class="nump">82,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_VestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_DeferredFinancingCostIncurredButNotYetPaid', window );">Deferred financing costs incurred but not yet paid</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash flow non-cash financing activities disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CashFlowNoncashFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_DeferredFinancingCostIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Financing Cost Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_DeferredFinancingCostIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_VestingOfEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting of early exercised stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_VestingOfEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StraightLineRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between actual rental income due and rental income recognized on a straight-line basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StraightLineRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6901247472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">THE COMPANY AND BASIS OF PRESENTATION</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">THE COMPANY AND BASIS OF PRESENTATION</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Description of Business</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives. The Company&#8217;s product portfolio is comprised of proprietary product candidates for the treatment of serious fungal and bacterial infections.&#160;In March 2016, the Company formed a wholly-owned subsidiary, Cidara Therapeutics UK Limited, in England for the purpose of developing its product candidates in Europe.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced net losses and negative cash flows from operating activities since its inception. At </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, the Company had an accumulated deficit of </font><font style="font-family:Arial;font-size:9.5pt;">$166.1 million</font><font style="font-family:Arial;font-size:9.5pt;">. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure. </font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In accordance with ASU 2014-15, management is required to perform a two-step analysis over its ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company's ability to continue as a going concern (step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (step 2). The evaluation period is through one year beyond the date the financial statements were released (assumed to be through May 9, 2019).</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company has prepared cash flow forecasts which indicate, based on its current cash resources available and access to capital under its Loan Agreement with Pacific Western Bank that it will not have sufficient resources to fund its business, including its ongoing clinical trials, for at least the next 12 months from the date of this filing.  </font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company will need to raise additional capital to fund its losses from operations. It anticipates raising capital through debt and equity financing, through government funding or through collaborations or partnerships with other entities. Debt or equity financing, government funding or collaborations and partnerships with other entities may not be available on a timely basis on terms acceptable to the Company, or at all. If the Company is not able to secure adequate additional funding, the Company may be forced to delay, reduce or eliminate its research and development programs or future commercialization efforts, or to make reductions in spending, extend payment terms with suppliers, liquidate or grant rights to assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Management has developed a plan to implement cost cutting measures to reduce its working capital requirements over the next 12 months if an adequate level of financing is not secured. The plan includes the delay of certain of the Company&#8217;s development activities, a delay in hiring and a reduction of other discretionary expenditures that are within the Company&#8217;s control. Any of the actions contemplated by the implementation of this plan, if required, could have an adverse impact on the Company&#8217;s ability to achieve certain of its planned objectives during 2018, and thus, materially harm the Company&#8217;s business.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Unaudited Interim Financial Data</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;"> and </font><font style="font-family:Arial;font-size:9.5pt;">2017</font><font style="font-family:Arial;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Consolidation</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s consolidated financial statements relate to estimating the fair value of the Company&#8217;s stock options and certain accruals, including those related to nonclinical and clinical activities. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Segment Information</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as </font><font style="font-family:Arial;font-size:9.5pt;">one</font><font style="font-family:Arial;font-size:9.5pt;"> operating segment.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749492064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cash, and Cash Equivalents, and Restricted Cash</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Restricted cash represents cash held in a segregated bank account related to a commercial letter of credit to facilitate payment to a foreign supplier.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Investments Available-for-Sale</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in accumulated other comprehensive loss. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. The amortization of premiums and accretion of discounts is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income. Securities with maturity dates of 12 months or less from the date of purchase are classified as short-term investments and securities with maturity dates of more than 12 months are classified as long-term investments.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company&#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. Periodically, the Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Patent Costs</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications), and such costs are included in general and administrative expenses in the accompanying statements of operations.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Income Taxes</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company follows the FASB's ASC 740, Income Taxes, in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the "Tax Act"), which among other provisions, reduced the U.S. corporate tax rate from 35% to 21%, effective January 1, 2018.&#160; Due to the timing of the enactment and the complexity involved in applying the provisions of the Tax Act, the Company made reasonable estimates of the effects and recorded provisional amounts in our financial statements as of December 31, 2017.  As the Company collects and prepares necessary data, and continues to interpret the Tax Act and any additional guidance issued by the U.S. Treasury Department, the Internal Revenue Service (IRS) and other standard-setting bodies, the Company may make adjustments to the provisional amounts. Those adjustments may affect deferred tax balances.  However, due to the valuation allowance position, the Company expects there will be no net impact to the financial statements. The Company did not make any such adjustments during the quarter ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">. Any adjustments to account for the tax effects of the Tax Act would be made in a subsequent quarter.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company recognizes revenues when customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under Accounting Standards Update ("ASU") No. 2014-09 ("ASU 2014-09"): (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Grant Funding</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company has received research and development funding through a grant from CARB-X, a public-private partnership focused on antibacterials. The Company has evaluated the terms of the grant to assess its obligations and the classification of funding received. Amounts billable for funded research and development are recognized in the statement of operations as a reduction to research and development expense over the grant period as the related costs are incurred to meet the Company's obligations.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Research and Development Costs</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Comprehensive Loss</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. The Company&#8217;s only component of other comprehensive loss is unrealized losses on marketable securities. Comprehensive losses have been reflected in the condensed consolidated statements of operations and comprehensive loss for all periods presented.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Stock-based Compensation</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company accounts for stock-based compensation expense related to employee stock options and employee stock purchase plan rights by estimating the fair value on the date of grant using the Black-Scholes option pricing model.&#160;The fair value of Restricted Stock Units (RSUs) and Performance-based RSUs (PRSUs) granted to employees is estimated based on the closing price of the Company's common stock on the date of grant. &#160;For awards subject to time-based vesting conditions, stock-based compensation expense is recognized ratably over the requisite service period of the awards. For awards subject to performance-based vesting conditions, the Company assesses the probability of achievement of the individual milestones under the stock-based awards and recognizes stock-based compensation expense over the implicit service period commencing once the Company believes the performance criteria is probable of achievement.  The Company accounts for stock options, RSUs, and PRSUs granted to non-employees using the fair value approach. These stock-based awards are subject to periodic revaluation over their vesting terms. </font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested restricted common stock subject to repurchase, warrants, and RSUs and options outstanding under the Company&#8217;s stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock options and RSUs issued and outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,352,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,130,426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">17,331</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">17,331</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock subject to repurchase</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">5,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">21,197</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,375,312</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,168,954</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company follows ASC 820-10 issued by the FASB with respect to fair value reporting for financial assets and liabilities.  The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, and long-term debt. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, prepaid expenses, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. The fair value of short-term investments is based upon market prices quoted on the last day of the fiscal period or other observable market inputs. The Company believes that the fair value of long-term debt approximates its carrying value.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recently Issued Accounting Standards</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Recently Issued Accounting Standards Not Yet Adopted</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">During 2016, the FASB issued ASU 2016-02, &#8220;Leases,&#8221; which requires that operating lease arrangements longer than 12 months result in an entity recognizing an asset and liability. The updated guidance is effective for interim and annual periods beginning after December 15, 2018, and early adoption is permitted. The Company currently expects that its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and operating lease liabilities upon the adoption of ASU&#160;2016-02, which will increase the total assets and total liabilities that it reports relative to such amounts prior to adoption.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Recently Adopted Accounting Standards</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">During 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)," which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 outlines a five-step process for revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards, and also requires enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenues and cash flows from contracts with customers.  Numerous ASUs were issued in 2016 and 2017 to require additional disclosures, to provide clarification on a number of specific issues pertaining to ASU 2014-09, and to defer the effective date for ASU 2014-09 to interim and annual periods beginning after December 31, 2017.  The Company adopted ASC 606 effective January 1, 2018.  The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749572816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM INVESTMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">SHORT-TERM INVESTMENTS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SHORT-TERM INVESTMENTS</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:9.5pt;">The following table summarizes the available-for-sale securities held at </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;"> and </font><font style="font-family:Arial;font-size:9.5pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:9.5pt;"> (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">As of March 31, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Corporate debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,991</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">As of December 31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Corporate debt</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">14,509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">14,501</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">14,509</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">14,501</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">All available-for-sale securities held at </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;"> and </font><font style="font-family:Arial;font-size:9.5pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:9.5pt;"> had maturities of less than </font><font style="font-family:Arial;font-size:9.5pt;">one year</font><font style="font-family:Arial;font-size:9.5pt;">.  Unrealized gains and losses on available-for-sale securities are included as a component of other comprehensive loss. The securities in unrealized loss positions have not been in a continuous unrealized loss position for 12 months or longer.  The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.  The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. During the three months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;"> and </font><font style="font-family:Arial;font-size:9.5pt;">2017</font><font style="font-family:Arial;font-size:9.5pt;">, respectively, the Company did not recognize any impairment or gains or losses on sales of available-for-sale securities.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -Glossary Debt Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6509901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6379141&amp;loc=d3e15032-111544<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -Glossary Equity Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6511694<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27405-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6901268416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">FAIR VALUE MEASUREMENTS</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company follows ASC 820-10, Fair Value Measurements and Disclosures, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on the borrowing rates available to the Company for loans with similar terms, which is considered a Level 2 input as described below, the Company believes that the fair value of long-term debt approximates its carrying value.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company classifies investments in money market funds within Level 1 as the prices are available from quoted prices in active markets.  Investments in commercial paper, corporate debt and reverse repurchase agreements are classified within Level 2 as these instruments are valued using observable market inputs including reported trades, broker/dealer quotes, bids and/or offers.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">None</font><font style="font-family:Arial;font-size:9.5pt;"> of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The following tables summarize the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">TOTAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">LEVEL 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">LEVEL 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">LEVEL 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">U.S. Treasury reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">46,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">46,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Corporate debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total assets at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">66,011</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">59,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">U.S. Treasury reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">48,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">48,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Corporate debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">15,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">15,101</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total assets at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">74,657</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11,556</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">63,101</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6901264240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">DEBT</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-style:italic;font-weight:bold;">Term Loans</font><font style="font-family:Arial;font-size:9.5pt;">&#8212; On October 3, 2016, the Company entered into a loan and security agreement, (the "Loan Agreement"), with Pacific Western Bank, as the collateral agent and a lender (the "Lender"), pursuant to which the Lender agreed to lend to the Company up to&#160;</font><font style="font-family:Arial;font-size:9.5pt;">$20.0 million</font><font style="font-family:Arial;font-size:9.5pt;">&#160;in a series of term loans. Contemporaneously, the Company borrowed&#160;</font><font style="font-family:Arial;font-size:9.5pt;">$10.0 million</font><font style="font-family:Arial;font-size:9.5pt;">&#160;from the Lender (the "Term A Loan").</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Under the terms of the Loan Agreement, because the Company achieved of positive Phase 2 clinical results from the STRIVE Phase 2 clinical trial of rezafungin by March 31, 2018 (the "Milestone"), the Company may, at its sole discretion through&#160;October&#160;3, 2018, borrow from the Lender up to an additional&#160;</font><font style="font-family:Arial;font-size:9.5pt;">$10.0 million</font><font style="font-family:Arial;font-size:9.5pt;">&#160;(the "Term B Loan," and together with the Term A Loan, the "Term Loans").  Upon the occurrence of certain events, including but not limited to the Company&#8217;s failure to satisfy its payment obligations under the Loan Agreement, the breach of certain of its other covenants under the Loan Agreement, including any future milestone put into place to replace the Milestone, or the occurrence of a material adverse change, the collateral agent will have the right, among other remedies, to declare all principal and interest and other amounts due to the Lender under the Loan Agreement immediately due and payable.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company&#8217;s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of the Company&#8217;s current and future assets, other than its intellectual property, which is subject to a double negative pledge.&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Term Loans mature on October&#160;3, 2020 (the "Maturity Date").&#160; Payments under the Term Loans will be interest-only through October 2, 2018, which includes an extension of&#160;</font><font style="font-family:Arial;font-size:9.5pt;">six months</font><font style="font-family:Arial;font-size:9.5pt;">&#160;which was triggered when the Milestone was achieved. The interest-only period will be followed by&#160;</font><font style="font-family:Arial;font-size:9.5pt;">24</font><font style="font-family:Arial;font-size:9.5pt;">&#160;monthly payments of principal and interest. The Term Loans will bear interest at a variable annual rate equal to the greater of (i)&#160;</font><font style="font-family:Arial;font-size:9.5pt;">4.5%</font><font style="font-family:Arial;font-size:9.5pt;">&#160;or (ii)&#160;the Lender&#8217;s prime interest rate plus&#160;</font><font style="font-family:Arial;font-size:9.5pt;">1.0%</font><font style="font-family:Arial;font-size:9.5pt;">. At </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, the Term Loans bear interest at </font><font style="font-family:Arial;font-size:9.5pt;">5.75</font><font style="font-family:Arial;font-size:9.5pt;">%.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">As of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, future principal payments due under the Term A Loan are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Year ended:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">December 31, 2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">December 31, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total future principal payments due under the Term A Loan</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">10,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6901268416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Preferred Stock</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Under the amended and restated certificate of incorporation, the Company&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to&#160;</font><font style="font-family:Arial;font-size:9.5pt;">10,000,000</font><font style="font-family:Arial;font-size:9.5pt;">&#160;shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had&#160;</font><font style="font-family:Arial;font-size:9.5pt;">10,000,000</font><font style="font-family:Arial;font-size:9.5pt;">&#160;shares of preferred stock authorized and&#160;</font><font style="font-family:Arial;font-size:9.5pt;">no</font><font style="font-family:Arial;font-size:9.5pt;"> shares of preferred stock issued or outstanding at&#160;</font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">. </font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Common Stock</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company had&#160;</font><font style="font-family:Arial;font-size:9.5pt;">200,000,000</font><font style="font-family:Arial;font-size:9.5pt;">&#160;shares of common stock authorized as of&#160;</font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">. Holders of outstanding shares of common stock are entitled to&#160;</font><font style="font-family:Arial;font-size:9.5pt;">one</font><font style="font-family:Arial;font-size:9.5pt;">&#160;vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company&#8217;s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company&#8217;s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in the net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. The common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are&#160;</font><font style="font-family:Arial;font-size:9.5pt;">no</font><font style="font-family:Arial;font-size:9.5pt;"> dividends in arrears or default. All shares of common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In November 2017, the Company began to sell shares of common stock under a controlled equity sales agreement with Cantor Fitzgerald &amp; Co.  During the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;"> months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, the Company sold </font><font style="font-family:Arial;font-size:9.5pt;">847,937</font><font style="font-family:Arial;font-size:9.5pt;"> shares of common stock for net proceeds of approximately </font><font style="font-family:Arial;font-size:9.5pt;">$6.4 million</font><font style="font-family:Arial;font-size:9.5pt;"> after deducting placement agent fees. </font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Common Stock Reserved for Future Issuance</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock reserved for future issuance is as follows (in common stock equivalent shares):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">17,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">17,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Stock options and RSUs issued and outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,352,640</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,099,173</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Authorized for future stock awards under the Company's option plans</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">789,288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,006,307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Authorized for future issuance under the ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">586,148</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">380,875</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">5,745,407</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,503,686</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6901271536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK INCENTIVE PLANS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK INCENTIVE PLANS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">STOCK INCENTIVE PLANS</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2015 Equity Incentive Plan</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Equity Incentive Plan (&#8220;2015 EIP&#8221;).&#160;&#160;Under the 2015 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors, or consultants of the Company.&#160;&#160;The number of shares of stock available for issuance under the 2015 EIP will be automatically increased each January 1 by&#160;</font><font style="font-family:Arial;font-size:9.5pt;">4%</font><font style="font-family:Arial;font-size:9.5pt;">&#160;of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31 or such lesser number as determined by the Company&#8217;s board of directors.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2015 EIP. Stock options granted by the Company generally vest over a&#160;</font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;">- or </font><font style="font-family:Arial;font-size:9.5pt;">four</font><font style="font-family:Arial;font-size:9.5pt;">-year period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to </font><font style="font-family:Arial;font-size:9.5pt;">10</font><font style="font-family:Arial;font-size:9.5pt;"> years&#160;from the date of grant. The exercise price for stock options granted under the 2015 EIP must be at a price no less than&#160;</font><font style="font-family:Arial;font-size:9.5pt;">100%</font><font style="font-family:Arial;font-size:9.5pt;">&#160;of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than&#160;</font><font style="font-family:Arial;font-size:9.5pt;">10%</font><font style="font-family:Arial;font-size:9.5pt;">&#160;of the voting power of all classes of stock of the Company, the exercise price shall be no less than&#160;</font><font style="font-family:Arial;font-size:9.5pt;">110%</font><font style="font-family:Arial;font-size:9.5pt;">&#160;of the estimated value on the date of grant.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2015 Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Employee Stock Purchase Plan ("ESPP").&#160;The number of shares of stock available for issuance under the ESPP will be automatically increased each January 1 by the lesser of (i)&#160;</font><font style="font-family:Arial;font-size:9.5pt;">1%</font><font style="font-family:Arial;font-size:9.5pt;">&#160;of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31, (ii)&#160;</font><font style="font-family:Arial;font-size:9.5pt;">490,336</font><font style="font-family:Arial;font-size:9.5pt;">&#160;shares, or (iii) such lesser number as determined by the Company&#8217;s board of directors.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The ESPP allows substantially all employees to purchase the Company&#8217;s common stock through a payroll deduction at a price equal to </font><font style="font-family:Arial;font-size:9.5pt;">85%</font><font style="font-family:Arial;font-size:9.5pt;"> of the lower of the fair market value of the stock as of the beginning or the end of each purchase period.&#160;An employee&#8217;s payroll deductions under the ESPP are limited to </font><font style="font-family:Arial;font-size:9.5pt;">15%</font><font style="font-family:Arial;font-size:9.5pt;"> of the employee&#8217;s eligible compensation.  During the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;"> months ended&#160;</font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">,&#160;</font><font style="font-family:Arial;font-size:9.5pt;">no</font><font style="font-family:Arial;font-size:9.5pt;">&#160;shares were issued pursuant to the ESPP.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Restricted Stock</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company permits exercise of certain stock options prior to vesting.&#160;&#160;Any such exercised shares are restricted and subject to repurchase by the Company until the conditions for vesting are met.&#160;&#160;At </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;"> and </font><font style="font-family:Arial;font-size:9.5pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:9.5pt;">, the liabilities for the cash received from the early exercise of stock options were </font><font style="font-family:Arial;font-size:9.5pt;">$12,000</font><font style="font-family:Arial;font-size:9.5pt;"> and </font><font style="font-family:Arial;font-size:9.5pt;">$21,000</font><font style="font-family:Arial;font-size:9.5pt;">, respectively, and were classified in accrued liabilities on the balance sheet. The Company reduces the liability as the underlying shares vest in accordance with the vesting terms outlined in the stock option agreements, which are generally </font><font style="font-family:Arial;font-size:9.5pt;">4 years</font><font style="font-family:Arial;font-size:9.5pt;">.  At </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, </font><font style="font-family:Arial;font-size:9.5pt;">5,341</font><font style="font-family:Arial;font-size:9.5pt;"> unvested shares were subject to repurchase by the Company.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Restricted Stock Units</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The following table summarizes RSU and PRSU activity during the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;"> months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Number of<br clear="none"/>RSUs and PRSUs</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">227,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">RSUs and PRSUs granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">30,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">RSUs and PRSUs vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">RSUs and PRSUs canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Outstanding at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">257,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">For the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;"> months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, stock-based compensation expense related to RSUs and PRSUs was approximately </font><font style="font-family:Arial;font-size:9.5pt;">$67,000</font><font style="font-family:Arial;font-size:9.5pt;">.  At </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, estimated unrecognized compensation expense related to RSUs and PRSUs granted to employees was approximately </font><font style="font-family:Arial;font-size:9.5pt;">$1.4 million</font><font style="font-family:Arial;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Stock Options</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The following table summarizes stock option activity during the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;"> months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Contractual Life</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">in Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Total Aggregate</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Intrinsic Value (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,099,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">7.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">8.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,009,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(12,147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Options canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(1,136</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Outstanding at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,095,140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">8.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">837</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Vested and expected to vest at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,095,140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6.90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">8.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">837</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Exercisable at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,937,526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">7.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">7.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">746</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Stock-based compensation expense recognized for restricted shares, RSUs, PRSUs, stock options, and the ESPP has been reported in the statements of operations as follows (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">821</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">619</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,461</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,051</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The weighted-average grant date fair value of employee stock options granted by the Company during the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;"> months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;"> was </font><font style="font-family:Arial;font-size:9.5pt;">$3.02</font><font style="font-family:Arial;font-size:9.5pt;"> per share. The total grant date fair value of employee stock options that vested during the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;"> months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;"> was </font><font style="font-family:Arial;font-size:9.5pt;">$1.2 million</font><font style="font-family:Arial;font-size:9.5pt;">. As of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, total unrecognized share-based compensation expense related to unvested employee stock options of the Company was approximately </font><font style="font-family:Arial;font-size:9.5pt;">$8.4 million</font><font style="font-family:Arial;font-size:9.5pt;">. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately </font><font style="font-family:Arial;font-size:9.5pt;">2.3</font><font style="font-family:Arial;font-size:9.5pt;"> years.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">As of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, total unrecognized compensation expense related to the ESPP was approximately </font><font style="font-family:Arial;font-size:9.5pt;">$0.4 million</font><font style="font-family:Arial;font-size:9.5pt;">. This unrecognized compensation cost is expected to be recognized over approximately </font><font style="font-family:Arial;font-size:9.5pt;">0.9 years</font><font style="font-family:Arial;font-size:9.5pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6901268704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenue Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">SIGNIFICANT AGREEMENTS AND CONTRACTS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SIGNIFICANT AGREEMENTS AND CONTRACTS</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Combating Antibiotic Resistant Bacteria Accelerator (CARB-X) Subaward Agreement</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">On March 30, 2017, the Company entered into a Cost Reimbursement Research Subaward Agreement (the "Subaward Agreement") with the Trustees of Boston University. Under the Subaward Agreement, the Company is a subawardee under the CARB-X program. CARB-X is a public-private partnership focused on antibacterials, created by the U.S. Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), and National Institute of Allergy and Infectious Diseases (NIAID). CARB-X is funded by BARDA and the London-based Wellcome Trust, a global charitable foundation (Wellcome), and administered by the Boston University School of Law.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The subaward was intended to support development of the Company's CD201 product candidate.  Under the Subaward Agreement, during an initial phase that began on April 1, 2017 and ends upon acceptance by the U.S. Food and Drug Administration of an initial new drug application, CARB-X would reimburse up to </font><font style="font-family:Arial;font-size:9.5pt;">$3.9 million</font><font style="font-family:Arial;font-size:9.5pt;"> of qualifying development expenses. If all of the milestones in such initial phase are met, the CARB-X Joint Oversight Committee will evaluate the progress made in such initial phase and determine whether to exercise its option to fund a second stage. During the second stage, CARB-X would reimburse up to </font><font style="font-family:Arial;font-size:9.5pt;">$3.0 million</font><font style="font-family:Arial;font-size:9.5pt;"> of qualifying development expenses through a Phase 1 clinical trial. Such second stage would be subject to a new subaward agreement.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Under the Subaward Agreement, the Company is reimbursed for direct costs incurred plus allowable indirect costs which consist of fringe benefits and allowable general and administrative expenses.  For the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;"> month period ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, the Company recognized reductions to research and development expenses of approximately </font><font style="font-family:Arial;font-size:9.5pt;">$3,000</font><font style="font-family:Arial;font-size:9.5pt;"> for costs eligible for reimbursement under the Subaward Agreement.  As of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, billed accounts receivable were </font><font style="font-family:Arial;font-size:9.5pt;">$0.1 million</font><font style="font-family:Arial;font-size:9.5pt;"> and unbilled accounts receivable were </font><font style="font-family:Arial;font-size:9.5pt;">$0.2 million</font><font style="font-family:Arial;font-size:9.5pt;"> related to reimbursable expenses under the Subaward Agreement.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Subaward Agreement can be terminated upon the delivery of </font><font style="font-family:Arial;font-size:9.5pt;">30</font><font style="font-family:Arial;font-size:9.5pt;"> days written notice to the Company for default or convenience. Upon receipt of a notice of termination, the Company must discontinue contract activities and CARB-X must pay the Company a final settlement based on eligible expenses incurred under the Subaward Agreement.&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Based on preclinical studies of CD201 as well as preclinical studies of antibody-drug conjugates (ADCs) from the Cloudbreak program, the Company decided in February 2018 to cease development of CD201 to focus on the more promising ADCs for the same indication. Based on the decision to focus efforts on the ADCs, the Company will no longer be seeking funding under the Subaward Agreement relating to CD201.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6597360752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Litigation</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are </font><font style="font-family:Arial;font-size:9.5pt;">no</font><font style="font-family:Arial;font-size:9.5pt;"> claims or actions pending against the Company as of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;"> which will have, individually or in the aggregate, a material adverse effect on its business, liquidity, financial position, or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in such matters may arise from time to time that may harm the Company&#8217;s business.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Lease Obligations</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In June 2014, the Company entered into an operating lease agreement for laboratory and office space in San Diego, California. Amendments for additional space were entered into in February 2015, March 2015, and August 2015.&#160;&#160;The lease expires in December 2018 with options for </font><font style="font-family:Arial;font-size:9.5pt;">two</font><font style="font-family:Arial;font-size:9.5pt;"> individual </font><font style="font-family:Arial;font-size:9.5pt;">two</font><font style="font-family:Arial;font-size:9.5pt;">-year extensions. The lease is subject to charges for common area maintenance and other costs, and base rent is subject to </font><font style="font-family:Arial;font-size:9.5pt;">3%</font><font style="font-family:Arial;font-size:9.5pt;"> annual increases every July. Rent expense is being recorded on a straight-line basis over the life of the lease.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Future minimum payments required under the lease as of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;"> are summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">562</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">562</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Rent expense was </font><font style="font-family:Arial;font-size:9.5pt;">$174,000</font><font style="font-family:Arial;font-size:9.5pt;"> and </font><font style="font-family:Arial;font-size:9.5pt;">$179,000</font><font style="font-family:Arial;font-size:9.5pt;"> for the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;"> months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;"> and </font><font style="font-family:Arial;font-size:9.5pt;">2017</font><font style="font-family:Arial;font-size:9.5pt;">, respectively.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Contractual Obligations</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company enters into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or within </font><font style="font-family:Arial;font-size:9.5pt;">30</font><font style="font-family:Arial;font-size:9.5pt;"> days of notice.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749598480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SUBSEQUENT EVENTS</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In May 2018, the Company announced that it and Rutgers University had been awarded a </font><font style="font-family:Arial;font-size:9.5pt;">$5.5 million</font><font style="font-family:Arial;font-size:9.5pt;"> partnership grant from the U.S. National Institute of Allergy and Infectious Diseases ("NIAID") of the National Institutes of Health ("NIH"), an agency of the United States Department of Health and Human Services.  The grant will fund the continued research and development of the Company's Cloudbreak antibody-drug conjugate ("ADC") platform.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753142496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced net losses and negative cash flows from operating activities since its inception. At </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, the Company had an accumulated deficit of </font><font style="font-family:Arial;font-size:9.5pt;">$166.1 million</font><font style="font-family:Arial;font-size:9.5pt;">. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure. </font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">In accordance with ASU 2014-15, management is required to perform a two-step analysis over its ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company's ability to continue as a going concern (step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (step 2). The evaluation period is through one year beyond the date the financial statements were released (assumed to be through May 9, 2019).</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company has prepared cash flow forecasts which indicate, based on its current cash resources available and access to capital under its Loan Agreement with Pacific Western Bank that it will not have sufficient resources to fund its business, including its ongoing clinical trials, for at least the next 12 months from the date of this filing.  </font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company will need to raise additional capital to fund its losses from operations. It anticipates raising capital through debt and equity financing, through government funding or through collaborations or partnerships with other entities. Debt or equity financing, government funding or collaborations and partnerships with other entities may not be available on a timely basis on terms acceptable to the Company, or at all. If the Company is not able to secure adequate additional funding, the Company may be forced to delay, reduce or eliminate its research and development programs or future commercialization efforts, or to make reductions in spending, extend payment terms with suppliers, liquidate or grant rights to assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Management has developed a plan to implement cost cutting measures to reduce its working capital requirements over the next 12 months if an adequate level of financing is not secured. The plan includes the delay of certain of the Company&#8217;s development activities, a delay in hiring and a reduction of other discretionary expenditures that are within the Company&#8217;s control. Any of the actions contemplated by the implementation of this plan, if required, could have an adverse impact on the Company&#8217;s ability to achieve certain of its planned objectives during 2018, and thus, materially harm the Company&#8217;s business.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_UnauditedInterimFinancialDataPolicyTextBlock', window );">Unaudited Interim Financial Data</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Unaudited Interim Financial Data</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;"> and </font><font style="font-family:Arial;font-size:9.5pt;">2017</font><font style="font-family:Arial;font-size:9.5pt;">.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Consolidation</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s consolidated financial statements relate to estimating the fair value of the Company&#8217;s stock options and certain accruals, including those related to nonclinical and clinical activities. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Segment Information</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as </font><font style="font-family:Arial;font-size:9.5pt;">one</font><font style="font-family:Arial;font-size:9.5pt;"> operating segment.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, and Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cash, and Cash Equivalents, and Restricted Cash</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Restricted cash represents cash held in a segregated bank account related to a commercial letter of credit to facilitate payment to a foreign supplier.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments Available-for-Sale</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Investments Available-for-Sale</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in accumulated other comprehensive loss. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. The amortization of premiums and accretion of discounts is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income. Securities with maturity dates of 12 months or less from the date of purchase are classified as short-term investments and securities with maturity dates of more than 12 months are classified as long-term investments.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company&#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. Periodically, the Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Patent Costs</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications), and such costs are included in general and administrative expenses in the accompanying statements of operations.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Income Taxes</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company follows the FASB's ASC 740, Income Taxes, in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the "Tax Act"), which among other provisions, reduced the U.S. corporate tax rate from 35% to 21%, effective January 1, 2018.&#160; Due to the timing of the enactment and the complexity involved in applying the provisions of the Tax Act, the Company made reasonable estimates of the effects and recorded provisional amounts in our financial statements as of December 31, 2017.  As the Company collects and prepares necessary data, and continues to interpret the Tax Act and any additional guidance issued by the U.S. Treasury Department, the Internal Revenue Service (IRS) and other standard-setting bodies, the Company may make adjustments to the provisional amounts. Those adjustments may affect deferred tax balances.  However, due to the valuation allowance position, the Company expects there will be no net impact to the financial statements. The Company did not make any such adjustments during the quarter ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">. Any adjustments to account for the tax effects of the Tax Act would be made in a subsequent quarter.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company recognizes revenues when customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under Accounting Standards Update ("ASU") No. 2014-09 ("ASU 2014-09"): (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"></font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Under the Subaward Agreement, the Company is reimbursed for direct costs incurred plus allowable indirect costs which consist of fringe benefits and allowable general and administrative expenses.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Grant Funding and Research and Development Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Grant Funding</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company has received research and development funding through a grant from CARB-X, a public-private partnership focused on antibacterials. The Company has evaluated the terms of the grant to assess its obligations and the classification of funding received. Amounts billable for funded research and development are recognized in the statement of operations as a reduction to research and development expense over the grant period as the related costs are incurred to meet the Company's obligations.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Research and Development Costs</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Comprehensive Loss</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. The Company&#8217;s only component of other comprehensive loss is unrealized losses on marketable securities. Comprehensive losses have been reflected in the condensed consolidated statements of operations and comprehensive loss for all periods presented.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Stock-based Compensation</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company accounts for stock-based compensation expense related to employee stock options and employee stock purchase plan rights by estimating the fair value on the date of grant using the Black-Scholes option pricing model.&#160;The fair value of Restricted Stock Units (RSUs) and Performance-based RSUs (PRSUs) granted to employees is estimated based on the closing price of the Company's common stock on the date of grant. &#160;For awards subject to time-based vesting conditions, stock-based compensation expense is recognized ratably over the requisite service period of the awards. For awards subject to performance-based vesting conditions, the Company assesses the probability of achievement of the individual milestones under the stock-based awards and recognizes stock-based compensation expense over the implicit service period commencing once the Company believes the performance criteria is probable of achievement.  The Company accounts for stock options, RSUs, and PRSUs granted to non-employees using the fair value approach. These stock-based awards are subject to periodic revaluation over their vesting terms. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested restricted common stock subject to repurchase, warrants, and RSUs and options outstanding under the Company&#8217;s stock option plans. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company follows ASC 820-10 issued by the FASB with respect to fair value reporting for financial assets and liabilities.  The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, and long-term debt. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, prepaid expenses, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. The fair value of short-term investments is based upon market prices quoted on the last day of the fiscal period or other observable market inputs. The Company believes that the fair value of long-term debt approximates its carrying value.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recently Issued Accounting Standards</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Recently Issued Accounting Standards Not Yet Adopted</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">During 2016, the FASB issued ASU 2016-02, &#8220;Leases,&#8221; which requires that operating lease arrangements longer than 12 months result in an entity recognizing an asset and liability. The updated guidance is effective for interim and annual periods beginning after December 15, 2018, and early adoption is permitted. The Company currently expects that its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and operating lease liabilities upon the adoption of ASU&#160;2016-02, which will increase the total assets and total liabilities that it reports relative to such amounts prior to adoption.</font></div><div style="line-height:120%;padding-top:24px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Recently Adopted Accounting Standards</font></div><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">During 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)," which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 outlines a five-step process for revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards, and also requires enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenues and cash flows from contracts with customers.  Numerous ASUs were issued in 2016 and 2017 to require additional disclosures, to provide clarification on a number of specific issues pertaining to ASU 2014-09, and to defer the effective date for ASU 2014-09 to interim and annual periods beginning after December 31, 2017.  The Company adopted ASC 606 effective January 1, 2018.  The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_UnauditedInterimFinancialDataPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_UnauditedInterimFinancialDataPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749544192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock options and RSUs issued and outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,352,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,130,426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">17,331</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">17,331</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock subject to repurchase</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">5,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">21,197</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,375,312</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,168,954</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749557408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM INVESTMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available-for-Sale Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:9.5pt;">The following table summarizes the available-for-sale securities held at </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;"> and </font><font style="font-family:Arial;font-size:9.5pt;">December&#160;31, 2017</font><font style="font-family:Arial;font-size:9.5pt;"> (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">As of March 31, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Corporate debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,991</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">As of December 31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Corporate debt</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">14,509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">14,501</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">14,509</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">14,501</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749472288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Financial Instruments Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The following tables summarize the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">TOTAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">LEVEL 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">LEVEL 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">LEVEL 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">U.S. Treasury reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">46,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">46,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Corporate debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">13,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total assets at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">66,011</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">59,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">U.S. Treasury reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">48,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">48,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Corporate debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">15,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">15,101</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total assets at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">74,657</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11,556</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">63,101</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749557408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Principal Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">As of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">, future principal payments due under the Term A Loan are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Year ended:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">December 31, 2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">December 31, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total future principal payments due under the Term A Loan</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">10,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6901296896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock reserved for future issuance is as follows (in common stock equivalent shares):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">17,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">17,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Stock options and RSUs issued and outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,352,640</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,099,173</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Authorized for future stock awards under the Company's option plans</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">789,288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,006,307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Authorized for future issuance under the ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">586,148</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">380,875</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">5,745,407</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,503,686</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21553-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6649259152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK INCENTIVE PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU and PRSU activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The following table summarizes RSU and PRSU activity during the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;"> months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Number of<br clear="none"/>RSUs and PRSUs</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">227,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">RSUs and PRSUs granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">30,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">RSUs and PRSUs vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">RSUs and PRSUs canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Outstanding at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">257,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">The following table summarizes stock option activity during the </font><font style="font-family:Arial;font-size:9.5pt;">three</font><font style="font-family:Arial;font-size:9.5pt;"> months ended </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Contractual Life</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">in Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Total Aggregate</font></div><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Intrinsic Value (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">3,099,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">7.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">8.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,009,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(12,147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Options canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">(1,136</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">11.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Outstanding at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,095,140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">8.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">837</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Vested and expected to vest at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">4,095,140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">6.90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">8.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">837</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Exercisable at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,937,526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">7.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">7.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">746</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Stock-based compensation expense recognized for restricted shares, RSUs, PRSUs, stock options, and the ESPP has been reported in the statements of operations as follows (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">821</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">619</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,461</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">1,051</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749556032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Payments Required</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Future minimum payments required under the lease as of </font><font style="font-family:Arial;font-size:9.5pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:9.5pt;"> are summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">562</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">Total minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;">562</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6649421488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="nump">$ 166,138<span></span>
</td>
<td class="nump">$ 149,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759721072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">4,375,312<span></span>
</td>
<td class="nump">3,168,954<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember', window );">Common stock options and RSUs issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">4,352,640<span></span>
</td>
<td class="nump">3,130,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">17,331<span></span>
</td>
<td class="nump">17,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdtx_CommonStockSubjectToRepurchaseMember', window );">Common stock subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">5,341<span></span>
</td>
<td class="nump">21,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdtx_CommonStockSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdtx_CommonStockSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759239904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM INVESTMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 13,991,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,509,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(18,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 13,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,501,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_MaturityPeriodOfShortTermInvestments', window );">Maturity of available-for-sale securities (less than) (term)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Impairment of available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_DebtSecuritiesAvailableForSaleGainLoss', window );">Gains (losses) on available for sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">13,991,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,509,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(18,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 13,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,501,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_DebtSecuritiesAvailableForSaleGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Available For Sale Gain Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_DebtSecuritiesAvailableForSaleGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_MaturityPeriodOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity period of short term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_MaturityPeriodOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)-(g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759972112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - Fair Value Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 66,011<span></span>
</td>
<td class="nump">$ 74,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Fair value of assets</a></td>
<td class="nump">6,038<span></span>
</td>
<td class="nump">11,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Fair value of assets</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Fair value of assets</a></td>
<td class="nump">13,973<span></span>
</td>
<td class="nump">15,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">LEVEL 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">6,038<span></span>
</td>
<td class="nump">11,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">LEVEL 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Fair value of assets</a></td>
<td class="nump">6,038<span></span>
</td>
<td class="nump">11,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">LEVEL 1 | U.S. Treasury reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Fair value of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">LEVEL 1 | Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Fair value of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">LEVEL 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">59,973<span></span>
</td>
<td class="nump">63,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">LEVEL 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Fair value of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">LEVEL 2 | U.S. Treasury reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Fair value of assets</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">LEVEL 2 | Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Fair value of assets</a></td>
<td class="nump">13,973<span></span>
</td>
<td class="nump">15,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">LEVEL 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">LEVEL 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Fair value of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">LEVEL 3 | U.S. Treasury reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Fair value of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">LEVEL 3 | Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Fair value of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureRecurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureRecurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753319152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Narrative (Details) - Term Loan<br></strong></div></th>
<th class="th">
<div>Oct. 03, 2016 </div>
<div>USD ($) </div>
<div>payment</div>
</th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember', window );">Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_DebtInstrumentMaximumBorrowingCapacity', window );">Term loans, maximum borrowing capacity</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone', window );">Period of extension if the Milestone event is achieved</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest', window );">Number of monthly payments of principal and interest following interest-only period | payment</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Variable annual rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember', window );">Loan Agreement | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Prime interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember', window );">Term A Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Borrowed from the Lender</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember', window );">Term B Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_DebtInstrumentMaximumBorrowingCapacity', window );">Term loans, maximum borrowing capacity</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Extension in Interest-Only Payments Upon Achieving Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_DebtInstrumentExtensioninInterestOnlyPaymentsUponAchievingMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_DebtInstrumentMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_DebtInstrumentMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Payments of Principal and Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_DebtInstrumentNumberofPaymentsofPrincipalandInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cdtx_LoanandSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cdtx_LoanandSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cdtx_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cdtx_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cdtx_TermLoanBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cdtx_TermLoanBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759179824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Future Principal Payments (Details) - Term A Loan - Term Loan<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Year ended:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">December 31, 2018</a></td>
<td class="nump">$ 833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">December 31, 2019</a></td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">December 31, 2020</a></td>
<td class="nump">4,167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total future principal payments due under the Term A Loan</a></td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cdtx_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cdtx_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753219248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>vote_per_share </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_NumberOfVotesEntitlementForEachShareHeld', window );">Number of votes for each share held | vote_per_share</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_CommonStockDividendsInArrearsOrDefault', window );">Dividends in arrears or default | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember', window );">Controlled equity sales agreement with Cantor Fitzgerald And Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock sold (in shares)</a></td>
<td class="nump">847,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds | $</a></td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CommonStockDividendsInArrearsOrDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock dividends in arrears or default.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CommonStockDividendsInArrearsOrDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_NumberOfVotesEntitlementForEachShareHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of votes entitlement for each share held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_NumberOfVotesEntitlementForEachShareHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753215888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">5,745,407<span></span>
</td>
<td class="nump">4,503,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">17,331<span></span>
</td>
<td class="nump">17,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember', window );">Stock options and RSUs issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">4,352,640.00<span></span>
</td>
<td class="nump">3,099,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_TwoThousandFifteenEquityIncentivePlanMember', window );">Authorized for future stock awards under the Company's option plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">789,288<span></span>
</td>
<td class="nump">1,006,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_EmployeeStockPurchasePlanMember', window );">Authorized for future issuance under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">586,148<span></span>
</td>
<td class="nump">380,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_CommonStockOptionsAndRestrictedStockUnitsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760212592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK INCENTIVE PLANS  - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of employee stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Grant date fair value of employee stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized share-based compensation expense related to unvested employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period to recognize unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage', window );">Automatic increase in shares of stock available (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of stock option as percentage of estimated fair value of shares on date of grant</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Limit on employee's payroll deductions as a percentage of eligible compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issued pursuant to the ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period to recognize unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Estimated unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent', window );">Cash received from early exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdtx_CommonStockSubjectToRepurchaseMember', window );">Subject to repurchase | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested shares subject to repurchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Automatic increase in number of shares available for issuance (in shares)</a></td>
<td class="nump">490,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage', window );">Automatic increase in shares of stock available (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term for stock options to be granted</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of stock option as percentage of estimated fair value of shares on date of grant</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold', window );">Voting power threshold (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP | More than 10% of voting power</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of stock option as percentage of estimated fair value of shares on date of grant</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award automatic increase in number of shares authorized for issuance percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Nonvested Options, Options Subject To Early Exercise, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNonvestedOptionsOptionsSubjectToEarlyExerciseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdtx_CommonStockSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdtx_CommonStockSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759144704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,461,000<span></span>
</td>
<td class="nump">$ 1,051,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember', window );">Restricted Stock Units and Performance-based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">227,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">257,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Estimated unrecognized share-based compensation expense</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759519312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK INCENTIVE PLANS - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">3,099,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,009,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(12,147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled (in shares)</a></td>
<td class="num">(1,136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">4,095,140<span></span>
</td>
<td class="nump">3,099,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">4,095,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">1,937,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 7.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">4.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled (in dollars per share)</a></td>
<td class="nump">11.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">6.90<span></span>
</td>
<td class="nump">$ 7.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 7.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, life</a></td>
<td class="text">8 years 4 months 17 days<span></span>
</td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, life</a></td>
<td class="text">8 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, life</a></td>
<td class="text">7 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract', window );"><strong>Total Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 837<span></span>
</td>
<td class="nump">$ 2,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6901351600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 1,461<span></span>
</td>
<td class="nump">$ 1,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">640<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 821<span></span>
</td>
<td class="nump">$ 619<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6901295360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS (Details) - Subaward Agreement - CD201 product candidate - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase', window );">Qualifying development expenses to be reimbursed by CARB-X upon acceptance of new initial drug application</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage', window );">Qualifying development expenses to be reimbursed through a Phase 1 clinical trial of CD201</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_ReductioninResearchandDevelopmentExpense', window );">Reduction in research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Billed accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice', window );">Agreement termination, written notice period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ReductioninResearchandDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ReductioninResearchandDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Agreement Termination, Period For Written Notice</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueRecognitionAgreementTerminationPeriodForWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Reimbursal Of Qualifying Development Expenses, Initial Phase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesInitialPhase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Reimbursal Of Qualifying Development Expenses, Second Stage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueRecognitionReimbursalOfQualifyingDevelopmentExpensesSecondStage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BilledContractReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BilledContractReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(c)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68054760&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6653330080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>option </div>
<div>claim1</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claim or actions pending | claim1</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_NumberOfOperatingLeaseOptionsForExtension', window );">Number of options for individual two-year extensions | option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Term of optional individual extensions</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_IncreaseInBaseRentAnnual', window );">Annual increases in base rent (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense | $</a></td>
<td class="nump">$ 174<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cdtx_ContractualObligationContractTerminationNoticePeriod', window );">Contract termination, notice period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ContractualObligationContractTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual obligation, contract termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ContractualObligationContractTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_IncreaseInBaseRentAnnual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in base rent annual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_IncreaseInBaseRentAnnual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_NumberOfOperatingLeaseOptionsForExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating lease options for extension</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_NumberOfOperatingLeaseOptionsForExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749515776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Payments Required (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2018</a></td>
<td class="nump">$ 562<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6609772992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>May 10, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Partnership agreement | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Partnership grant</a></td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MZP^_F[ +QN[M/S:^"C8U_+J+Y@M02P,$%     @ $X&J3)E<G",0!@  G"<
M !,   !X;"]T:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T
M$W-I=MNTF83M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY
M\^XN8NB&B)3R>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2
MP]R"BPA+>!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?
M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA
M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M
M&N#C\7@XMLO2BW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_K
MFVB<"HU;3]-K=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K
M>A(5M>5 TR  6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T
M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)
MI#-ZG7TZSFN4?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R
M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
MLR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(
MR-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J
M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1
MCVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.
MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.
M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07
M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!
M_]':-\*K^(+ .7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7
M<LW(QU2ODRG8.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD
M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W
M<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-M
MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(
M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R
M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>
M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X
MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5
MYYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(C
ME1P&%A<RY%#NDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>
MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+
MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y
M,M\Y<-LZW@->YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,
M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:
M,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_
M 5!+ P04    "  3@:I,\? %4U4"  "O!P  &    'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;'U5VXZ;,!#]%<0'+#:W7$20DE15*[52M%6WSPZ9!+0&4]L)
MV[^O;5C*8M,7;(_/F3-CQIZL8_Q5E #2>ZMI(W9^*66[#0)1E% 3\<1::-3.
ME?&:2+7DMT"T',C%D&H:A BE04VJQL\S8SOQ/&-W2:L&3MP3][HF_,\!*.MV
M/O;?#<_5K93:$.192V[P ^3/]L35*AB]7*H:&E&QQN-PW?E[O#WB2!,,XJ6"
M3DSFGD[ES-BK7GR]['RD(P(*A=0NB!H>< 1*M2<5Q^_!J3]J:N)T_N[]LTE>
M)7,F HZ,_JHNLMSY:]^[P)7<J7QFW1<8$DI\;\C^&SR *KB.1&D4C KS]8J[
MD*P>O*A0:O+6CU5CQJ[?B:.!YB:$ R$<"6'Z7T(T$**1@&.3?!^92?43D23/
M..L\WO^MENBBP-M('6:AC>;LS)[*5BCK(T=9\-!N!L2A1X03!!X1@?(]"H0N
M@4-HT<./ D<;$;D%(F<&D:%'$WKLIL=.>FSH\82>S [ 1J1N@<0ID%CTU4S
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MPSB=9NZ\O[R/7QIC=UJ^-437#QZ;_P%02P,$%     @ $X&J3),&R5%& @
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M.5=,@Z*%1CSKD]\XJ-E1F=M<WXO^^-,/%.^&HUTTGB_7?P%02P,$%     @
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MOFSL?VV,!Y2RN\(1:O&#+8:"VH?C)SS;:<PFPYM^_D%L^<;%;U!+ P04
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MZ[FF9"[^"UQ ^?"@Q.<H4=FXDG*P#O7,XJ5H\3;MLHO[.-U<\QFV#> S@"^
MVYB'38FB\@?A1)$9'(F9>M^+\,3[ _>]*8,SMB+>>?'6>R_%/N$9NP2B.>8X
MQ?!US!+!//N2@F^E./+_X'P;GFPJ3"(\^4MALDV0;A*DD2#]L,2MF/2?)&S5
M4PVFB=-D28E#%R=YY5T&]BX^(OL3/DW[5V$:V5ER1N=?-O:_1G3@I>RN_ BU
M_H,MAH+:A>,G?S;3F$V&PW[^06SYQL5O4$L#!!0    ( !.!JDR N\7FM0$
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MUQ$4CCE-Z#7P+)O6A0 KLEXT\ W<]_YDO,<6E4IJZ*S$CABH<_J8'(YIP$?
M#PFC7=DD=')&? W.YRJGNU 0*"A=4!#^N, 3*!6$?!D_9TVZI S$M7U5_QA[
M][V<A84G5"^R<FU.WU-202T&Y9YQ_ 1S/_>4S,U_@0LH#P^5^!PE*AN_I!RL
M0SVK^%*T>)M.V<5SG/6OM&T"GPG\AL"F1+'R#\*)(C,X$C/-OA?ABI,#][,I
M0S".(O[SQ5L?O13)PSYCER T8XX3AJ\Q"X)Y]24%WTIQY/_0^39]OUGA/M+W
MZ^S)?P3238$T"J1_M9C>M+B%N;])PE8SU6":N$V6E#AT<9-7T65A'WF\DS_P
M:=N_"M/(SI(S.G^S<?XUH@-?RN[.KU#K']CB**A=,!^\;:8UFQR'_?R"V/*,
MB]]02P,$%     @ $X&J3&GT^42W 0  T@,  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL;5/M;ILP%'T5RP]0!Y(T401(3:MJDS8IZK3MMP,7L.H/
M9IO0O?VN#66LXX_M>WW.N1^^S@9C7UT+X,F;DMKEM/6^.S'FRA84=W>F XTW
MM;&*>S1MPUQG@5>1I"1+-YM[IKC0M,BB[V*+S/1>"@T72URO%+>_SR#-D-.$
MOCM>1-/ZX&!%UO$&OH'_WETL6FQ6J80"[831Q$*=TX?D=-X%? 3\$#"XQ9F$
M2J[&O ;C<Y7334@())0^*'#<;O (4@8A3./7I$GGD(&X/+^K/\?:L98K=_!H
MY$]1^3:G1THJJ'DO_8L9/L%4SYZ2J?@O< .)\) )QBB-='$E9>^\49,*IJ+X
MV[@+'?=AO-DG$VV=D$Z$="8<8QPV!HJ9/W'/B\R:@=BQ]QT/3YR<4NQ-&9RQ
M%?$.DW?HO17)X3YCMR T8<XC)EUB9@1#]3E$NA;BG/Y'3]?IV]4,MY&^749/
M]NL"NU6!7138_5/BX4.):YCCAR!LT5,%MHG3Y$AI>ATG>>&=!_8AC6_R%SY.
M^U=N&Z$=N1J/+QO[7QOC 5/9W.$(M?C!9D-"[</Q@&<[CMEH>---/XC-W[CX
M U!+ P04    "  3@:I,DA600;8!  #2 P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6QM4]MNG# 0_17+'Q #N^EN5X"4352U4BNM4K5]]L( 5GRA
MMEG2O^_8$(I27FS/^)PS%X_ST=@7UP%X\JJD=@7MO.]/C+FJ \7=G>E!XTUC
MK.(>3=LRUUO@=20IR;(D^< 4%YJ6>?1=;)F;P4NAX6*)&Y3B]L\9I!D+FM(W
MQ[-H.Q\<K,Q[WL)W\#_ZBT6++2JU4*"=,)I8: KZD)[.^X"/@)\"1K<ZDU#)
MU9B78'RI"YJ$A$!"Y8,"Q^T&CR!E$,(T?L^:= D9B.OSF_JG6#O6<N4.'HW\
M)6K?%?1(20T-'Z1_-N-GF.NYIV0N_BO<0"(\9((Q*B-=7$DU.&_4K(*I*/XZ
M[4+'?9QN#H>9MDW(9D*V$(XQ#IL"Q<R?N.=E;LU([-3[GH<G3D\9]J8*SMB*
M>(?)._3>RO3P,6>W(#1CSA,F6V,6!$/U)42V%>*<_4?/MNF[S0QWD;Y;1T^/
MVP+[38%]%-BO!8[)NQ*W,.^+9*N>*K!MG"9'*C/H.,DK[S*P#UE\DW_P:=J_
M<=L*[<C5>'S9V/_&& ^82G*'(]3A!UL,"8T/QP.>[31FD^%-/_\@MGSC\B]0
M2P,$%     @ $X&J3#?_1%>V 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL=5-A;]P@#/TKB!]0[DC6G4Y)I%ZGJI,VZ=1IVV<N<1)4"!F0
M2_?O9TB:9EWV!;#Q>\\V)AN-?78M@"<O6G4NIZWW_9$Q5[:@A;LQ/71X4QNK
MA4?3-LSU%D0505HQOMO=,BUD1XLL^LZVR,S@E>S@;(D;M!;V]PF4&7.ZIZ^.
M)]FT/CA8D?6B@6_@O_=GBQ9;6"JIH7/2=,1"G=.[_?&4AO@8\$/"Z%9G$BJY
M&/,<C,]53G<A(5!0^L @<+O"/2@5B#"-7S,G720#<'U^97^(M6,M%^'@WJB?
MLO)M3@^45%"+0?DG,S["7,\'2N;BO\ 5%(:'3%"C-,K%E92#\T;/+)B*%B_3
M+KNXC]--<IAAVP ^ _@".$0=-@G%S#\)+XK,FI'8J?>]"$^\/W+L31F<L17Q
M#I-WZ+T6^P//V#40S3&G*8:O8Y8(ANR+!-^2./%_X'P;GFQFF$1XLE;G_]%/
M-PG22)#^56+RKL2MF/2="%OU5(-MXC0Y4IJABY.\\BX#>\?CF[R%3]/^5=A&
M=HY<C,>7C?VOC?& J>QN<(1:_&"+H:#VX?@1SW8:L\GPII]_$%N^<?$'4$L#
M!!0    ( !.!JDPB*Y3@MP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;&U3[6[;(!1]%<0#E(0X;139EII.4R=M4M1JVV]B7]NH8%S <??V
MO6#7\SK_ >[EG',_N*2#L2^N ?#D3:O69;3QOCLRYHH&M' WIH,6;RICM?!H
MVIJYSH(H(TDKQC>;6Z:%;&F>1M_9YJGIO9(MG"UQO=;"_CF!,D-&M_3#\23K
MQ@<'R]-.U/ ,_F=WMFBQ6:64&EHG34LL5!F]WQY/2<!'P"\)@UN<2:CD8LQ+
M,+Z5&=V$A$!!X8."P.T*#Z!4$,(T7B=-.H<,Q.7Y0_UKK!UKN0@'#T;]EJ5O
M,GJ@I(1*],H_F>$1IGKVE$S%?X<K*(2'3#!&892+*REZYXV>5# 5+=[&7;9Q
M'\:;?3+1U@E\(O"9<(AQV!@H9OY%>)&GU@S$CKWO1'CB[9%C;XK@C*V(=YB\
M0^\UWQ[V*;L&H0ES&C%\B9D1#-7G$'PMQ(G_1^?K]-UJAKM(WRVC\V1=(%D5
M2*) \D^)MY]*7,/<?0K"%CW58.LX38X4IF_C)"^\\\#>\_@F?^'CM/\0MI:M
M(Q?C\65C_RMC/& JFQL<H08_V&PHJ'PXWN'9CF,V&MYTTP]B\S?.WP%02P,$
M%     @ $X&J3$I+#M#4 0  G 0  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL=53;;MP@$/T5Q <$F_5>LK(M91-5K=1*JU1-GUE[?%' N(#7Z=\7
ML..Z6_)BF.',.3-CAG24ZE4W  :]"=[I##?&]$="=-& 8/I.]M#9DTHJP8PU
M54UTKX"5/DAP0J-H1P1K.YRGWG=6>2H'P]L.S@KI00BF?I^ RS'#,7YW/+=U
M8YR#Y&G/:O@.YD=_5M8B"TO9"NAT*SNDH,KP0WP\[1S> UY:&/5JCUPE%RE?
MG?&ES'#D$@(.A7$,S"Y7> 3.'9%-X]?,B1=)%[C>O[-_\K7;6BY,PZ/D/]O2
M-!D^8%1"Q09NGN7X&>9ZMAC-Q7^%*W +=YE8C4)R[;^H&+218F:QJ0CV-JUM
MY]=Q.MDG<U@X@,X!= DX>!TR"?G,GYAA>:KDB-34^YZY7QP?J>U-X9R^%?[,
M)J^M]YK'AT-*KHYHQIPF#%UC%@2Q[(L$#4F<Z'_A-!R^"6:X\>&;M3K=APF2
M($'B"9)_2KR_*3& N8_"(MN@R#9 $-^(A# ?M&(7%-D%"#8W(B%,<B-"5K=#
M@*K]7&A4R*'S,[GR+J/W0/WM^@N?YO8;4W7;:721QMY1?Y,J*0W85*([6W!C
MGXK%X% 9M]W;O9H&9C*,[.>W@"P/4OX'4$L#!!0    ( !.!JDSA-4,FMP$
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MP69#0NW#\0;/=ARST?"FFWX0F[]Q\1=02P,$%     @ $X&J3&-!C>GI 0
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M!"5D4E-0];C %LI2,RD=OWI2=ZBI$\?K*_M'8UZ9V5,!6U;^+ XR7[D+USG
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M971S+W-H965T,C@N>&ULE5;;CILP$/T5Q >L,?=$!*F;JFJE5HJV:OOL)).
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MP095S,.^'WL5*6MWE=FSG5AE_*Q86=.=<.2YJHCXNZ&,MTL7N>\'+^6I4.;
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MHS++1*]%-ZVZC>)-/XF]X>_ ZA]02P,$%     @ $X&J3$1E%S17 @  +@@
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M3KO3VH'G2QY\4[U_3DL@H'-AN_=[,_U44^#T,+\7LCS:^B]02P,$%     @
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M&W]9'S*0P._RO$2Q"?10A#FPN#F.8\_CL9C-Q'(&:BKM]KZ2R<9Y#=3B\:&
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MJOOK3EED;=!N"!N,Q"V@.S$Q.G]H!4.L?QZ]Y>"$>(@[(-R-,RCU&#B   $
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M@N3/6;G":RQ&T$'R=N7\CLMB+N&+9('!E;O@,[(#5.C^^(HB'H@2U>R+*#'
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M_QCKFGYF*@823A'2W6,-^KS93(Y?.U_R'O"5$TJ2=^V0YFXD"<4R^]YVF"R
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MFGK(C2DKOF9J4V3"+:([A>]68F;H$N"*"F)X4?:,J<9UT?SZDG=?T+[;V3]
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M;M$!86R-04@:"3JYMD*O[C3D%>V4'/)J4PA-)K6I#^03B.WV97EJX!!-[5D
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MO2D5D(?);%C6Y?)!,R4NU1GUL9*KDW9]IO]^C23R757CB-T^P,]XR9XC.=\
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M<^0YOYB5?/>KHNWC\)?E]C=02P,$%     @ $X&J3(-)186> 0  2A@  !H
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M&GZW9@2W#Y?*/CYCF'IW_TCIT&^Q9K@^_.=BF/H;8:[^.MC^ %!+ P04
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M2#Z,61[JL^[OQ.P+4$L! A0#%     @ $X&J3!\CSP/     $P(   L
M         ( !     %]R96QS+RYR96QS4$L! A0#%     @ $X&J3&;S"V""
M    L0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"
M% ,4    "  3@:I,4YOM'^\    K @  $0              @ &9 0  9&]C
M4')O<',O8V]R92YX;6Q02P$"% ,4    "  3@:I,F5R<(Q &  "<)P  $P
M            @ &W @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M !.!JDSQ\ 5350(  *\'   8              "  ?@(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    "  3@:I,O6#>':D#  #\$   &
M            @ &#"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ $X&J3),&R5%& @  N <  !@              ( !8@\  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( !.!JDQY OH+S0(  &L*
M   8              "  =X1  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    "  3@:I,$GWU5_D#  ".$@  &               @ 'A%
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ $X&J3!RU;2NQ
M 0  T@,  !@              ( !$!D  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( !.!JDQ"%]K@LP$  -(#   8              "
M ?<:  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  3@:I,
M>M/2X;0!  #2 P  &               @ '@'   >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ $X&J3&?T13JU 0  T@,  !@
M     ( !RAX  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M !.!JDR[5>9WL@$  -(#   9              "  ;4@  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ $X&J3%0&X"BS 0  T@,  !D
M             ( !GB(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    "  3@:I,P0<*;K0!  #2 P  &0              @ &()   >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( !.!JDSI\AJKM $
M -(#   9              "  7,F  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ $X&J3%]J=\^S 0  T@,  !D              ( !
M7B@  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  3@:I,
M@+O%YK4!  #2 P  &0              @ %(*@  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( !.!JDP%,H;TC (  $0*   9
M      "  30L  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ $X&J3#E0>.JR 0  T@,  !D              ( !]RX  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  3@:I,:?3Y1+<!  #2 P
M&0              @ '@,   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( !.!JDR2%9!!M@$  -(#   9              "  <XR  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ $X&J3#?_1%>V
M 0  T@,  !D              ( !NS0  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    "  3@:I,(BN4X+<!  #2 P  &0
M@ &H-@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !.!
MJDQ*2P[0U $  )P$   9              "  98X  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ $X&J3.$U0R:W 0  T@,  !D
M         ( !H3H  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    "  3@:I,8T&-Z>D!  "V!   &0              @ &//   >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( !.!JDS\ AO:5@(  *<'
M   9              "  :\^  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ $X&J3.G]'^#' @  \0H  !D              ( !/$$
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  3@:I,$+WW
M?*8#  #A$P  &0              @ $Z1   >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( !.!JDR0;8/20P(  !8(   9
M  "  1=(  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M$X&J3,TN19?/ 0  C00  !D              ( !D4H  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    "  3@:I,P=&4UF "   :"   &0
M            @ &73   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( !.!JDQ$91<T5P(  "X(   9              "  2Y/  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ $X&J3.>7#Y*' P
M"Q$  !D              ( !O%$  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    "  3@:I, C;$.&("  #&!P  &0              @ %Z
M50  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( !.!JDQ+
M/5NX/@,  'H-   9              "  1-8  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ $X&J3.F&EN<J @  ?08  !D
M     ( !B%L  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !.!JDR*3-B3)U4  $@Y 0 4              "
M 35F  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( !.!JDRR*U9Y
M90(  "4-   -              "  8Z[  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ $X&J3"P&KJ]/ P  U!D   \              ( !'KX  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( !.!JDR#246%G@$  $H8   :
M      "  9K!  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( !.!JDQFK-&@I0$  *48   3              "  7##  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     P #   @T  $;%      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>88</ContextCount>
  <ElementCount>190</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>33</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0002000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CompanyAndBasisOfPresentation</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - SHORT-TERM INVESTMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/ShortTermInvestments</Role>
      <ShortName>SHORT-TERM INVESTMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - STOCK INCENTIVE PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/StockIncentivePlans</Role>
      <ShortName>STOCK INCENTIVE PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SignificantAgreementsAndContracts</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - SHORT-TERM INVESTMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/ShortTermInvestmentsTables</Role>
      <ShortName>SHORT-TERM INVESTMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/ShortTermInvestments</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/Debt</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/StockholdersEquity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - STOCK INCENTIVE PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/StockIncentivePlansTables</Role>
      <ShortName>STOCK INCENTIVE PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/StockIncentivePlans</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CompanyAndBasisOfPresentationDetails</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/CompanyAndBasisOfPresentation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - SHORT-TERM INVESTMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/ShortTermInvestmentsDetails</Role>
      <ShortName>SHORT-TERM INVESTMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/ShortTermInvestmentsTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - DEBT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DebtNarrativeDetails</Role>
      <ShortName>DEBT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - DEBT - Schedule of Future Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DebtScheduleOfFuturePrincipalPaymentsDetails</Role>
      <ShortName>DEBT - Schedule of Future Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/StockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - STOCK INCENTIVE PLANS  - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/StockIncentivePlansNarrativeDetails</Role>
      <ShortName>STOCK INCENTIVE PLANS  - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - STOCK INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/StockIncentivePlansSummaryOfRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsActivityDetails</Role>
      <ShortName>STOCK INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - STOCK INCENTIVE PLANS - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/StockIncentivePlansSummaryOfStockOptionActivityDetails</Role>
      <ShortName>STOCK INCENTIVE PLANS - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - STOCK INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/StockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>STOCK INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SignificantAgreementsAndContractsDetails</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/SignificantAgreementsAndContracts</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Payments Required (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsRequiredDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Payments Required (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cdtx-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2410401 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/SubsequentEvents</ParentRole>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cdtx-20180331.xml</File>
    <File>cdtx-20180331.xsd</File>
    <File>cdtx-20180331_cal.xml</File>
    <File>cdtx-20180331_def.xml</File>
    <File>cdtx-20180331_lab.xml</File>
    <File>cdtx-20180331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2016-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001610618-18-000042-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001610618-18-000042-xbrl.zip
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M%8.X)0:."4]%R%17BZ0 ;=52R#+Y2'6&.D*KA[6.LCL/9*.OB$Z%R)#U#L%
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M8B>=>PTS<M9')GQO=T>=O)/V$R5B1L.*E@_GC:.S;U:_8+[V=[KU[_/H[)\
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M3_))2G29#5ME5H 1&8S.P 36IC<%]V!1S_JC!6G]GUWI:_VN&A[^_>O6VWD
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MDFLMITJ]$S?T<ED0U<05<4LEK2]C0S/,4U853>+HHE:E,D4TP@>91$WQKNE
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M_P[9:P^YZS=C24D=]V P]&Q@FW__[__Z:S34T/ <("/_&_/HC6]@CYC+^%$
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M:NS/D(.N+A*JMFY6LUC O#F<LZ6%?K2<P*/DMN6US'B#2?CD&L"!_@AX<LX
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MKL>&#Q\7QI)^7QT,I@EADSZMA7!#"Y@Y<_B?(?-US0_-&4"!@"AK6<"TGFO
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MD$N.?F&_2A%LFN$\%,J8D DHJSTV8XZ/\A]?$=P1V+L7T(#D@ ?.0%ZJU+I
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MH46?TW@D<3B-215\)L8=<?0FLVWYS-^NRE?TV<>;?_EY?RI_Y%8P@S\!C65
M%UKVQL)G'Z(_UMQ"R:+2"81)D%=S8]+H[CF(8DWUQB_/AY%M#&B3>WKEZZ]]
M_Z1?/^W5J\V?RN8O.QMY36411C!I\"1LM:TR-H\6I\^DPN<#YMW#A)^&N\G0
M #LPY&-3OP^VZ!XP5YD."B</A)/?$X?6/]!KH[!2866AL/(3>1 56BJT?'NT
M3%(Z=H6WJK1Z@$JKN5/X5H!?6$+C*WK3G$8B8Z6F=SJ'+UA[$;F+JAC?@5*S
M%0=3'*P0K;<4&U-L3+$QQ<8.P,;>[>5S?AVP$F([EQ(F[Q5S4\Q-,;>B,C>T
M,ELUI9[EH9Y=]@VN"-+">M*Y89.J^Z7J?KV1NTR5_#H*[SIOS4LQ,,7 5.%"
MQ<44%U-<[$*X6)[.LEV!IIQFBK<IWJ9XVXGYRI1R]G8^L]=RM2CGL?6"',>W
MBY(\ -Q.#58*KQ1>*;Q2>'4JL%)XI? J=UA=]D4E?=Z2:KI6[N\0Z*>2552V
M:=%8HL))E6VJL/*DL%)EFRJT+ I:JFS3/!W-A\DV/036;CV0HH#R0-<<Z]![
M3:AP<6XXZGJCW'ESD)W+Y89*:3C*M:UB98J5'3^<3O$SQ<\4/U/\[%B!=0>*
MJWL!N/:*MRL*MJD\5,7D%),K.),C^_- 25P7J*]=]CTOO:824HO,QLXZ6OB
MOK1+C196EUB*@2D&=BX>-,7%%!=37$QQL9/TFZE\5,7:%&M3K.VM+4Q5\NA0
M+K-?J='@IN=?HDR_9%TIF!VW][1MJUZ:Q^RE.3.LJ',Q%UV+J4<R=2W.8P)
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M?K]7Z0\ZPVJS7#]:Y_>CM7GG 4@O<ST58WN;]UN&62 @>6Y\/P0:3LY NPN
M8 S/>CJ3J.C[EUW#7P<![0N0XN_ ![N6NP 664CE7#)GH(2FX"6C[ET/I*#8
MU=UW^N6Z7-6U2*A4RQ\_,5(#XF\J'Z78DWJ&%-XNB!*#8&+C"Z"K>08H0$*\
M"UU(R,-$28)W0SL@%<O14$,(EC$WPX'@6P,9@] 1N11H0IL+%Q9)HFG(+1"E
M#&4YFTP$JR29A:+0XW,A"QTG!&$KI!U*Z"EW2"$P)O!0DKI=:0AA(H0L"&,X
M= ,/% 4TS+! 32* >4L9U0?XFB<PA/T40IM @IK0*EA .X41!%0BA<T/QW_
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M5K5=:_=Z@\:@VZBUN\-N4VG]P<=_ !<)M%'HX$(+*9K2Y(%N%V";# @">9U
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MK';*M?*H.JK5N_5R8S!L]:J#4;_=;+>[[4ZS6RT?5:P>0LZD^#"=,BF>@%'
M%!'CW#"@6QY\8.%BV :,9N.]O@!_.F I"8\AI9+)\XAYE6&;H1U["6@$AM$D
M@0Q2 N3W\7S@==- QSEZ,EW-=\&F"&V+ GM@_NMX[G<D]>9S#!A "TU#A^N#
M8:/F2R/Y[S_D1NE/%1S<>IR9:.9R- K0(8Q G]/3RAN:],05?"8>6)R0"?:
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ME!N@6>H</K!;,1K%:$Y0(SM$&D4M/\U+(=N!M"DE]@ZK\9^"7&S7\HMH>3'
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M72.4 ^='Q,G3&I4AI(A'OB6;!0'5\@0IP4!*X@,3PT0YB+K!PEB2"*370!C
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M?)P*G2')6?F),98^I;,F2755H:XJ3@A=;TC\:_?&3U9\=(W*G.'1C;IWO;^
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M51GO)2VVR#+*>""%TQ1]ETRJC*D22 ELSIKF;M-@':3 6ER'^.TSF.#'MTJ
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M4R*;J,HMSY?>..L4WEN&@6B 2C="BF^JV732^Y?9#:^#@/8%^,+O@&U=RUT
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M76J-MN\FW)LY,X-:@*2LW%33>>)(I.KIDGYU65M8#):HU*29Q>4)8TUW0MZ
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ML&#5&B W*I.FO;OZ<M.]&5R]CQ+YUH>A=(A_,L,.9O3X/Z^HP"HE&9AQ>4.
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M/\>>77*]Z:_5<KGV*_[\*SYX)9\/E@MX'A@;I7%>X="_KHW]]__^ZZ\X#O^
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MZ@0DQ#E2=>:"%%4'2%Q8_Y8:>(K!$!H@"LNZ%I_-J%1K:;?)[!9G$A;V$--
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M7Y#F**KV7R#8P0SICA.!S8[/QU"]?$T/GT/[F\7\GRO[^--_ 5!+ P04
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MIC]1QX^MM$ZP^Y-3@W3H#YM*?3GX)X$.T?\<IN=[7:K@X=]7,.&<2(X\Q4H
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M\3@*91O9\JF83'Q1QD)M;#MK"9)HB.--1 X=#),48EIB+B1CF#'JO#TA&'S
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MFM%UFRB=L+G8$L_F7_-Q-AW/WL8#D2PM9V>E?;C3_7$34:5T(K2TP9X6G-+
M8"N\DW#3E\#H^IN%UMX6:U#CK6#4A[/AP3,**WOE[?3>)JJBV^%0-8FE(&S,
ME0'8$B28C^=4JQT1\4[0^M[,UI[G:M@%WAY8/= F;(]G@?2KMW8_9:,L_YJ-
MSX[GS>%Z$A8P1@%M*H51-.90<V*%!95<R_KWTEM[,:LUXC2.5MNGP@].+>_.
M!>Y-GC'E4!EZ$59*OY@ORBP.AWC#Z64<;4HH#?:0@V#P \?"@D\W\[^&@%>:
M]9[+T293,?.\%M8RZ9AR2KO-KD;1P/)A'VU6UM011YO'(3+HH\UZ61Z"22LE
M4(!B@P72QG*P 57)L %^CD>8E96Z-V_#<<@,)D[Y&5QE%T2)^.JCLA!(98V0
M>.-L4R#H:MA'HS59TL6=]GK _DG=YA >Y"'M,V9L/TS]5XS>F\X/YJ1\\%WB
M(;,*<&.8$@XJ["06&_O$.? <[\BVJM*B.3";<,.MHW9#AY[*VK#R 81?WCLE
M.'30?W+5"1*"$PZ1=5S&%T>B_;O!DOL38D+ZN^#0!:5ZPK\V"[]\*[Y<%8M9
M:-OG%_,LFVZN MV+D][/MB.J2(A12(=M5-@_+3-4&R"V<%)KZR]B_5T?Z(Q5
M[>%<FST[GUG?SY@#Q1(>(  >< <Q0G$$< 8VTBOEZA\1]W<_L#.6-(MM#\?+
M)KW)Y^EDY?_>Z0&L=NA<K:[$*&RD9\0RA@P4VC)B-BN^5+#+5TI.\B+7=5.U
MC5BGGN0V[_0LSF?9[XLP=-W7.*8[::1O7_<C>:JXNW<523 +,X]"T% 9IAKO
M5#!M"'4TV#@:*=OG99Z'(A]T=3_Q><*IUI 1R;&C0$DE$"+KWDE$C!N*C_MT
M]3QQ >-$- ;MWX[+\]G%O=7\@)_[R>\3!X$""!!BPXJNJ* H3IA+0!25;KA9
MC4_2;M$\-)WE$KAGO@7K[$,Q3>_^Y=ZYZNYTF35K2BQQ5&&BM$!,,NX5AVJ#
M!_14#=M-?:*.'Q^-=(+=GYP:I/]XV%3J:Z\T"70H5I>\[W7I(&/V%TRX =8Z
M+;QE3CO.8KJ 36\5TP-,1-J:/G_8'S4(7&=G7H^6[</'\SM*)-X;9RW6F$&)
M!9$Q''73/P-E_9GC>%=P?X9+,^#TJ/S#IY:[RB0,,NH#:"!ZCB3DCE"PZ2,F
M7 _;'#E9<X>9<!).+Y,3@S0GAD.%05#@H,7PY/<)Q%1!2(7"EE.,-#3$;-T$
MH:O#,Q0:T--^S=="IBNMKS+)KD*"#_BU'G^:!.N:<VV518IA0A7A1A#J-<#+
MQU8ZC3JII>O3O5LG8M*F\WN;22N_G.87^2@(JD:C8C&=Y]/+C\4D'^6MN<*K
M-/TAF[\K9K./6;D\4.C;E:V"<.-\LHAF_.=LM"A#E[.9^SZ:+(( /E IGMXM
MYNLG+%U:3D-GMN)7<7TWU41B!,,Z'O4+A(%D3&JL(>?<HL!=7LWH;CLX_,3.
M5H\G;Z*AA)FPM N+, '8(8N(5W2#J$:XRT=7][KGNZ?0SJCU'G ?]$' B7CH
MVZ<K.!0VWUZKB>7!U.6*&QEVQ5P83#'<*,=JW:57L&80?K<<?>Q1'(QJ.G-@
M/REPI;#H0T43S:01H9,QTDUCA92/5O-ZP@+.#=O/, @N5.+GR9#_$<@V2 ?&
MB^38'R.@FANE(<:":>V-(HI0:3<H4'E"QOCVCE<:4VS3P=''83GLNQM&&(=E
MZ(N*C_D0YQ23VV''_ !?$FB<%TT T\2T\7EQ_K_9:/ZE^)3=K"-G*\\+.\LF
M2@AKL+9* QWO/"'AS-:VU&R *?-;'_A-@=6O'5)YV577T2_6W@YO57^"/<?&
M<R<M@QAPS(%V6ZVX$\+F.UYA.G1U] %\[P[A 3B&#P9IKZ&)?YR'V>$??_D_
M4$L#!!0    ( !.!JDR([I=Y98L  *_"!@ 5    8V1T>"TR,#$X,#,S,5]L
M86(N>&UL[+UM<^,XMB;X?7X%MV<WICO"V8U7 KA[[YW :W?&9*5STJ[JN5&Q
MH9 M.E/3MNB6Y*S*^^L7I$A)=MHR01(D,W>[HJO\(A//>0[X'.#@ /C7__[[
MW6WR)5MOEOGJW_X _PS^D&2KZWRQ7'WZMS_\?/%&7NBW;__PW__]O_SK__'F
MS?]2']\E)K]^N,M6VT2OL_DV6R2_+;>?D[\OLLT_DIMU?I?\/5__8_EE_N;-
M[H^2\HO;Y>H?_U+\ZVJ^R9+?-\M_V5Q_SN[F[_+K^;9L^_-V>_\O?_G+;[_]
M]N??K]:W?\[7G_Z" ,!_V?_5BY\HOGM3?^Q-\:,W$+W!\,^_;Q9_2+R%JTW9
M=H-&ZH___LWG?\/EIZ$0XB_E;_<?W2R?^Z!_+/S+__KIW45IYYOE:K.=KZZS
M/_S[?TF2'1WK_#;[F-TDQ7]__OCV173B+\4G_K+*/A5\?\C6RWQQL9VOM^_F
M5]FMAU$^[?,ZNWG^$;?K]:,G% R)@B&8%@S]UU<>O/UZG_W;'S;+N_M;3\]?
M.N!O 7C[+=A8Z$H2WK<!>8K5IP_L&>^E?W6S?A%_^\B>,>\ZFETM8O3?IX_M
M&7N_D*/VC'P[O^VY9WSSR!<QWQ:?>N>_JCY8//V$_):-5Z)Z].#L]VVV6F2+
M4C0?/3I9+O[M#_ZKV</FS:?Y_'YFEIOKVWSSL,[.;W1^=Y^M-F5@^9C=%M!U
MOMEN+C[/UUFA\HL/\Z]%#-O(J\UV/;_>SB"F'%CFM#20,,*02:4A&FA.M&$&
MS<I69]GJS<\7-<;R1[VBH)!:DU+ D4NIPT!:QX@@0!&I4Y'"/X2P^:V?UMDF
M?UA?[X*<AU_$^)U%_WX GN0WR3'TI,*>E.#/DA+^FQ)_4AN0_%J;\/_\ZU\.
MW#SR6G[]7#<L@=_,-U<E^HI&;P5,_Y+=;C?U3]X4/WD#8!74_VL_?#]U9'X]
MM"-W?KDM!D'YNGJ!'O5SN;Y.\O4B6_O!6?U'\_7U*QV@^L1?KG,_XKC?OGG4
M%XI!VCC&YJ.\+#N./27/\?N-CI0-JJ+!8TARO?9O2U8 4%\/'ZDPR=_FZ\7Y
M??'!S?G#MACH%0/HC_GMK<O7Q2]GU%BE@- I1!()B*S5H-(7XU)N9MM]U'U5
M9")!%%Q":9S 5$+*F9$6,0&Y=IA Z9 ,$9_M"V.($PKT_N'N*EL7ZE."W[PH
M))-R6[.P\!UX+"Q<' >!1\'BR*;DZNMSP2(I#3M+*M/\%P?CDE\+\Y+*OH%C
M21PGG8@Q(_>*:<2>L4G()_6FCA:K=NH[8XX;PH%02B.-B&48H%KOB*)H=O\D
M23"D]%48G1+ >BJ!P2FE$ I" * 00(N,H5J$J-Y3<QH+X!&LL^0J^[1<K0K]
MNIK?%DF>Y(_+5;(IP]B?1HMC35TZ> B+X,=)1*^S9&?9=QNV=O"'B5B!G>"'
M"U:A]L>+4ZT\,52(^JO_X';S=K5+[OUUG6\V,T 0IQI)+V%6$&8L0+16-$'A
MH'.IY_ Q9A14@$H'I2>22HPL(5H"P;#R_$:>2%7(DD\%-*]<H\6B5KX;)AK%
M=MMX\6AG6>)]OK.M^(FW[ON*2<^X)V)4ZM(9?HRXU(F!GB-3=V\TCDW;_/H?
M;S>;AVQA'M8^$E8KH*56EK^L(-G?L_7UTL.=464%)IQ*03F7#ECJ7"U?2E(W
M.U[8>5W%P@%H1I!$6'+E%(58*0MUBOSP'B#@(%>-1.K$DE;CZ)+5D#K$EPC\
M-PP?(Q$_>G2H[3D*$ -'AF#F3PE_/#=.1-<C&OA4MF-S.=2,P>7KFVRY??"P
MZR RXXHPBS 2C&MB#;((V%HVK"5Z]DWI0_01Z',PF9)8LE0P:2CEU ^0C7;*
MH=1IPX3F+<3]I6*.!@I_762R;L><0+1RY3 3B&CN&SU$'%DV6I#HWSD1IP]=
MNL)$PLR8#/0\?>CNC?%67Q1!?GQ++$^U,M@!/]G9KS9;87"U^E*7N(V0LT?4
M"(@EU08R"I 22EH-.$[]Z)L3 <+77IZOUVNZ\I+MEHU#EETFJ5CC)N&;>O7'
M4*L.]D=/PH=Y8BBE^B7;^*&D7"WL[_?9=5D(6OSH6_A^;FX%%<A)SE(&N<1"
M[ 4,2#UD9KXQ:(:1%,QA*U--K?0!0A&"7 J)#QH6VLCI^AW.Q$-*L@IILLV3
M+_['XXV\^_/X,,/Q49P]WAC]J,_8HSY3_/@'6)%NZLR(,;+W_O1CA,[^:>DY
MHD;RVU"!MLJMS:]NLPHG==2D#@H(#!9 0(D,J_35(IW*(2/JM^@ =(0:D()B
M&=<A+HDP/@Y !973*0[*>+0(G4> Q@N5+7PV3$R,ZZ[1US *N[[/^/:-8R(&
MLO:=X,>(6!WL[SDT=?7$"&FIOV?+3Y^+>/HE6\\_9?7*SX?U\CHKJIMOJNIF
ME_I9 '5"83]I]0-_B3FO!0\C.VB0:@'?*)YR 5,_"K 4>[W6+N4 <:%2ESH2
ME-1J$<5JF$F%<[](FY1(1ZL?[LW[@Q<8C^'XB50@O]*91MNH.;QWA\F@]MW5
M?HRH&Y.@>#G8.+Z<6-R>*8,!@(H+P 66T%CBZ'YV E,XZA:?D\@%U4J0E%/'
M-/6#)TY3/\7BD@)DJ15T*AM_%KZOS->;Q+>QFY*.MP>H6T^85.#NU?W?1[3^
M(4/T^'&Y<4_Z_U0P;L[*.!$XT&N]A=U-4+WZ20NPMD X:"VRC@F=.J=)+;B,
M<=CK/+E'W!PP 5)&A7&*$I8J0D1*G33<I-JF:(0-3=%C[)!N[RG.3M3C_<?:
M3?O-4-]7Q.W/HUVB[@C]ZCN)O&,P$QI]1_/>8!%XOZFEF1H3BZD$7'$""9+.
M<9G6:@R\$8,&X3#H#CE(G%&IE8@2HR60Q!(%M>+6,*4'BL./MWZ-'HE[=O]
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M94<8.3[&[P,3"YIGU8RRW-9\9/0/$DR?]><8$;9;Q_K!PVY'<H:*Q7WX</0
M?7C2[H_.MY^S]>7G^:J:E<^DLAKI% ''# +6<"L(431E*;2$I7P2L?I5*X"0
M4" *'($IQ=8/F#35'$O'D,,.Z,AAV^Z/;PR:\4XD=G?O(R.'\4&[QU@1_;E@
M?ORPW1\EI>W)UAM?YY-_D-C^FI/'"/.]=;P?/.+WQ]-0P;]GSS8=!YCL:FN6
MF^O;?/.PSN359KN>7V]GM#A_P\)BBQL5TACMA( <$BH,@[+QJ08MGQY/'0M
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MFQ:,3E%UVIAQ4GM:\]+H8)OBZKMW^7PE?\J*S62S-%4"*Y@:AVAJ)89"[9N
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M6-^&W!.R'-E;T]#GV$9^<]7] )PVKZ&X]=_FN[NGCQJM-A,Q1@1#CF+)@<)
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M\O7?U\OM-EN]S[?+ZVS&48HA$,0!("C#S&%;K_\+K46C.UWCHX@L:7NDR?8
M]2SY;8<Q694@D_L2>Z>\:I^.:944'\DG/:3"#SZZ//;1#GQY5F4%/]GAGXR?
M.F6]1_)7C[GNWOS6-L'=G,+F:>T(;IE$\F (.T^GL*,QVW2$?[[^-%\M_[-L
MN#@E([\MBO@+9*O%AR)C6[T5YS?.PUM=+^>W%_XGN[HZ>;4I(_[,&4VU9HA:
MA@7"VD!IM1*:$ZW]A*3I\+4?,$HZ@8S%P!)))<9*<.6T<%QPQ+F+>#;D,?[=
MX31["\JDX+$-Q0+TWHKD8$;R:VW(P&6PO9!_8A ]K'.G,=P>V.9\S-<I,+GY
ML%FNLLW&9)OK]?*^0J7FF^7F_.88W&7V^U9Y3O\Q4T1ADW*%4H@-9-8Z!2N1
M,1)*&93U#&\>>?&E!BD,H:6<>?,E+W:P&E,P0G3D0?OEWVRBSW_Z(-__1R+?
MFT3)B[<7R;E+/GRT%_;]I;Q\>_X^,#,:P0<-4Z;CTA^82ZW )D=H2SDO\18Z
M_DC7?RTP)R7H@14\G-532=AX+IJ&-L<T\&G:-C:73577S9?K7^:W#YE9;JYO
M\\U#<=-'+?2(0LJU,1:*5" N@$95"ME22AN_VYW:B/<6%["2$E=R!&RTT=8I
MEDZ\E;V0.XWWKQ]3\@B=K^4[)3>;K-QD_FXYOUK>^OE=MODIFQ<8%N?%J8,/
MZ_5R]<E_X'V^6M??EBJP.] *0N??>9!J21$3!%!N3(T/IR!H67<X5)''/4?O
M;06[')X65845UC(6'X-O=PK@@'X,%-))N;"UZO;FO;AZW)7L)N(]F$,GIO3#
MV?U26!B8^> 8HKX>O29NG?WS(5M=?RU/3>*^ 4D4%PXPAQ 21%1+:3;UL_%&
M2U=]MA=9]X]P)7M@+16]"ZN!6CT0H6$J_"R7HQRGUH"G)@+: \L3D\8^+'I)
M]'IC*UC.GFNW.GH)H-2DECNKC".&TV*:6[><<MQNL-NAO<&&L6=)G]+6A>%
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MGY$S':5Y2M$9;6G)Y334I"WXLI?^%+AO47QUR?;'XK[<O#UYIYA#9#C@BC.
M<Y9KK/9MZYRD04?%^VDQ]GY&#=+.Z6[+S5V++*<G7CUW-P:G-'"G8\_F >!T
M%,F+NG.;(+U2/PW]ZMFFYYLC$1CSGL3-M]_X^L;]Q[U2_7V^<MLSQQ?F7_]Y
MC6V69U*E&'#W$)]*$3$L@R#G! ))E-)!3S9$!1)9&QVHBV2^ODG<5\D)OOJ[
M1RNJ7PB<'4;UD.?L<2K."9Q=.F^\[I9G+GGCMZ:BR5WX/S=?'<*MTU#P84Q]
M/M\=CE]?O;]<?[?-NW#S8I$P0U1(J;7$$G&!4"9X$U]0AH.FQNU;B:S41V#;
MA'^?+U?N%-_/-J/]^9,E/TR8.U#II[K#L!@FJ4=,TU''-WDZ(WW=N9V&KO5@
M1]EWKPO>1G 5(#;5E/+C<OM_Y*:X6>[<5S.K=$2:C$(H&#3&/8C:K EJD:DL
M<!>A=3NQ\\=3:-5F0@4M<=B"MQ+:D^F]DS (C\$;"2<4.C 7IRQ.1ZS.T'=^
M9Z$SZ=,0K%XL>;FOT!,[_HN$*_O3KW\OUL5FOK(Y'+^Y6ZZ7VPK#]V)_R7S[
M7$&Y-)00S5-)L&&4R53!!DQ&0%".%0E"9*F[GKM[-XDLM[O +8I8E/LN*([.
M=N@*8P7X(ME#KF:X3T$W!2TF--%M1_/9U<BH?IN&IL8V\L5ZY0"<^D]H%^5=
M\7G^XWESDF<&I!G7$.-4&<418P?AEV&Y8^M&HD]G':[$ @O=\&U/F^_<=0#&
M0J>N#5G3T;NW:#H[<^W([#0TJ[L9+^:MO?#BJSL?B^_%^J'X6"S*K^OE:P=:
M#! **V+)42DV&@I.#]-EQE(8(D#=6XNL1'N R0G",$'J@4\_91J6RC")>H7%
MZ6C5N\2=$:W^2)^&>O5H3QFK>X;JV;:PO^OV(Y2%L"KOW1+@/I?;;TFHS.9N
M@@)& 8*4827@(8.3!K$P1>O>7F1-^_MF;J>JYJ&N&+'?R*U 5W\Y@=UF/ML+
MX;Z2-RS7H:+W!JE[@%-2P'=Y/*N!_7EA*BK8HT4O=+!OM@(>1[S?%-]<A?_O
M19U5OGXB!V";5BI#4(I,:M*<9BEHFK<BG08^E-A/H]&W*DYP5L5O@I])[(E<
MW]V*$7@-W;HXI;3&.!W-\R7P[.9%SSZ8AOKU;];+%Q=C\.:]Q^&JQ+AJW#<.
MB$51%Y*IWD.QJGQ9[;E89->V-S>'5K14&&0023O'9A0AR TZ("$H[%ATA/9C
M'Y)VKV/^[*K+WR2GH -W.F(0[[G-,3+G@7L<#NTK=%_L7RVK,LH#YJ0"/1EA
M;4'UN7V.B(Z;AMQ&M?#Y#D=T-GU%^'G5KN?23Z K(8$$I5"8'")LS'$Q@ ,0
M(KA=VXHLKEVK+7:FTD]"AV0Q3"Y?EC&<3IKY#FMGE*\OOJ>A<KU94\;IE6'J
M9>;+S3_FJX?BUV*^?=@4QU.%S]O'&=$82$[2%$/%$"$F;]H'Q 35!.ROU<B*
MYH F%5)WZ.]8)>5RO=UMJI(?@;/K'OGV$[MQJ Z3O1.63U!.1_J\.3PC@OW[
M81IR&,&N,G8/#I/(#\7O)X7"-N7:?KFHWRE\ P:5$@B08Y3E*:0J0ZG8PS#,
MA"EE[XU'WV5VB??J,;G<;A_LI.^D-O\G5]E[OKD)5,S^Z?<3SE&9#]-/"_64
MZ*=@IR.CH8R>4=-HSIF&J,8SKQRHDP>41#S>MJL6YWY;+W=;.X6W>7!5Q\#B
MJ>;YK_W:KX5[M7O&)$N%4$)2R5%&#6!8,6BD$#DUW.^6<T]0I-(2*I-1)@W&
M(&4XIXAE!LB<0H[C/Q]XN#1;04LJ;-4JVXD1^P6YUW\YH-#? )X[K]43=%KP
MSOIK_N+/_"7.^"OY5VU%2(7& 1P74+9Q6@YL5\NQAX'WOB/]RCYVIO.5N#NP
MGR90(') 8\M1QD(?6XTG;[:+Q^.O7,\?W;?X[S;;=]?F=X\GZR57NV_%YO.W
M^7ZQ?ONAK*ZS6IO*U<J4&_>/9AEVCPEK#H""&B*;6."<99"D6@N;;(2]F#0L
M= $RFEO2@08*(T@$RW+*",D(P=I$OW#PUHY;<F)P\N4Q.?V]O=%)9?5%4MM]
MNL:55)8G.VOZ?N/.3BL.UMLO'US7<TMDU<=:*7.,)'M*/"/35+M:EWW9/T0O
MZV=+=Y(=;,!]X5BN#MY2'KW/36,./55RO#:RQX<YM>R@5H!9!IG&#&"&2)Y*
M 1$TN%)KDW([^>"S^JG=3[OY9C>9]&"/'7($@1:,X)1B 2A#.;5_YC;,8)2%
M'>!^;J:W?)\\L7B1?"F^+M=NUS'Y,E^YY#+Y:;E.MI7$_G5R4=NW"TPF8$?P
M^Q\F5O_I0G)MUKC1.+!#_7\3B$-Y&3X&M_+<^.&WNF"UO5SOGRT7).-$$ZBY
MT4PJQ9G@M?0"80P,NK$_&.B4(LQ,:AG/$88TM=.]5"@IL* X)4A$GI!7:*RN
M3C"RAGIW[, :T;%3C:NUR8GM.[71?Y:P^M25HT35EKWISQY4V](R6$SMY+?Q
M0^H_JGS@ #\C@*;&3K\SF5.L.(2L7GXT4!DJ\6Q=?)W;?_!Y"I'U&7:E< JE
M0D!1C(VF@HA4(X0RQH3.D5\9!E8+\ LSO<6X!C7%^!KJZK'C:PSW3CR^[CO/
MGRZ^/G7E*/&U96_ZL\?7MK0,%E\[^6W\^&K*S6VQ/+4@-0(*FJ9VBHUTFME)
M3@IKW<TX)$I-*L2^A"\T5Q9P[IR 59IQ*H"%;NEGG'#D=QVI<Y25;GEX-<TX
MV\+E8X?:2&Z>>+0]6/WG"[@O'#I*S&W?K?[L8;<#,X-%WJ[>&S_X/E_OII0A
MI%!J%$L%@QQ1+FL=1KD!IMFNU>N;L>/N<^1YQC*3NQM%0&#**54$NDM%F&+I
MKH^';]8V1K;;JBWJ&F<A^[1_, 6=XDZ;;R_XLZMG:UY&VVD+\YRO<O)5Y>/B
MYG5#]L7/9GEJ)T;$:AYCD@LJ 8=F?SI>"$+A['NQ^5+Z3C8\&^4VW34X%Q(B
MB@G(.,@$US"#6"-!@ I1K%-\_GGD26V=Q6D>6=0(AQ4J/];.J$S/M$]#(OHV
MJHS:58/+ MXMZZ?#W)MM976IK5@OEL56+;>+5>EN#Q^OLD$*5(ZTP43GE#&H
M98842#70&;:31118'#"DZ9P+HK7))<$0$P:X!)AP2!7,E*%9[#HM\NK77R\_
M_ZH_?/Z4\ \JD5<?/E]^^+O^("_UI^!J@;UR[C<O'Y'NL*GU"=#Z <M3J,D1
M:_*O,<L'!G!Y1B\C.64:NAG+N)<%!>-QZ#T]7'PK;AY6Q=4MM^W?+%</KI+6
MIV+QL%GN+!+]8[%ZN"ENC&7)J?M#?5?NZO9Y"9O/[NW&&9$910X22C,-E7LB
M&==7AG4N+-"@0T/#0HM]5V=O37)UFYS:DQP-2AJ+$F=2<F*3^T<OZT59(7&6
MA5ZY&=CCGJNOTW5VX )KX^?2P\^WS_U<MO)SG,E_KQXY-\,?Q_73B#5C&?]\
MKCZF#[PJ1[AH6:ZK:>=^%< &S=>NQM;%:.P/3Y;4]M=E<SM!!UE&B1!&<L01
M9JJ!A1GPBDZ#@8D]+ZA,2+;5G?2R-J)^5>'3;]MD65?T<7\OC\@[7E;O@;57
M9&1PATS@POJ@YI8C=?RP1/9_S]W"XJZY&$^ESIAM@[O#@4AK3EC3AB(F* \-
M^^0AA^WO-;*WR[A$20R>\'$FKK?C;1IAN27VLH^>TRXH?GKX\E_%8O>Y_%C<
MV[[S;;XM]NVZ]7"9"<5%*H14.:1:'H*Q(/X5DWII;<CQL:U1)KLRV1QP]A?$
MWB3!(TIU)W!:8:@'>]Z(,WTQY;WMTRT!_F6Y+BYWQ=W6CG>2"<ES0V&6,D*8
MR$0#S^3,:]P-#BKR\.QMY<-9E%0F!2Y_#.=>OX6/27HV;,FCMV4.'Z?&V3_L
MR0GG=AB']O,T$JGAS7Z^2SD.[P-%&W[GZGG.,I-GTN2:*0*R-,_R5.@#-JV#
M2F@-@VB .//S09.V1TTJGFC28KY:/*P.FE3] _NS=;%+5NYMBWNK3=7)J_8G
MH0=R\"#!)H)O1XDT%TEMR1\JR-20XT680.?^*<)+J,W]QI96C(=O[/XZW^V1
M7=W^4JZ_?BXV=ZKXLJN6ZH_[RRPC7!B!#"74/6:<$L"D3%/[?XT4"WH_,[CQ
M'#&>*ZXRACGF&:,I,2)'B!$C,3.QP\7IIIUYV+E#&M>;Y7JQO)^OFNL/@:7L
M^^<_="-U!.K;;Y4>P;J_.;@_6S_>)0[P?O]SQ,?A CGUVNSLV3W3T.-XYKVY
M81F%1Z_55[6O'LW7-]I& G=DN2K<6QUS_K+=;>:+W4P) "3!*)50$2VSE"LH
M!>6Y5+DB7/I4/?=JB!()8 :% H!AB'+.D<ZHQL(&%"IUQ"=S&WA5*?,:8'*"
M,/E7@S&D;'D_Y 94)A^<Y';%QP]DN[W9HB9[>43ZMX[+VSXLO+6\W2N#$UC>
M[M>>,E9?\U.LFV)Y:/:S_1<S1BF >0IXBFSZF2J=8M6,'9YQKS6#%Q]J3*84
M(9(3PW%&)!4PS7FN4TESG64R<AYW&!P.C)_8A/-R7K"C4M)2E\^R<29CVA:+
MOWTMO_\/:Y-+EI#[PFD&.LF1GMO[BCBTIF1<#6@/N^S8%?Q'-+>??>,^WZSF
M7V<*&4!R:3@T0BF5PDR@INM28+Q*]KW\U$S!U!A!#$$<8W>N*P/:-B*90#B'
ML2\P', D#HW_H ZDYOU1'8^5P$4P/T)Z&-=/+'YC8+=C9?R1W1)WV;4_A$?K
MZ^9&L9KOBAFED' .**9616".<\Y TY$)R+P>''S[TR4W)D=<$D@Q5H"(-!4P
M1U@C2%B:Q=X>/D2L&I6=3-PD#E=X* \DS3^FQ^.K97#WI:K'./^$@W<"?CN^
MQM>'COA?20&Z,!&B%V:Y7<Q7_RSF&V._LYU9)5(YX)AE0$C,4YJ[VNG[T)<:
M&*H8SS_?9%;W +93;ZAPJBE/4XEL LT @YR$E8[KHADUKL0!2RIDX:H13)V_
M;L1DK:5R^!/6HW8\X^$=]6C+VG3TH[4%KRA(-S;"-:16K+HMD/*<")LU"W<
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M_?>K  EWEYE<JV+?A.8$VKE4EFF,(3<FRU/3-*$5"]'LT(^.+M(.4"(2ARE
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M+\*:I8I31C4A"DK P"$7D-20?>C5ZW>NP0T )3SP-JACA=W"59Q_-^#^887
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MZ?+O'R[-I>0?/B=<RJO?/GR^_/#WY/KJETMYJ3\%3CIZ(MQS5C$\UX'3AB/
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M-!X('^_QM!LZC=!ULK*&;IC[Q4W1EHPZ2^2*89%.EX''72PK>@B&KS=(#/,
M&<,(Y)X3JD$@=TN=-Y=<R&-0"&Q$/)UY#(_T8QO^3V],,5L>EHL7EBX+X^SS
M BIVD7@#*"64Z<!4S&*"$E<K#EC@2*V9O=9.ZG> R99DU&7%HVPI\B=T;(>]
MNM?K+E_<S=Y,OV1KMN_/\S^APX0QZ*7GDE/B H,DU(IMN*,%Z&:CMJ];_88%
MZ"X$V%TJ=YGF-[?SM_DT^["_XLGS1Q-JE 084$ L5=X03ZC?4 0]J%,DM_I>
M[@](UA=-5V +K"GC5> V6_W[B!GK U\5(O_JG23$(0ZMX)8:AE"83BP7&RX
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M WUS#W10[,62\<]SJ[;Y6A^*R<0796S4AE*<-)#$<X,I8X0"ZRA#2DO$H*9
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M,S,Q+GAS9%!+ 0(4 Q0    ( !.!JDSIJ)@GXQ(  ".X   5
M  "  9W#  !C9'1X+3(P,3@P,S,Q7V-A;"YX;6Q02P$"% ,4    "  3@:I,
M!+NA2$@G   -U@$ %0              @ &SU@  8V1T>"TR,#$X,#,S,5]D
M968N>&UL4$L! A0#%     @ $X&J3(CNEWEEBP  K\(& !4
M ( !+OX  &-D='@M,C Q.# S,S%?;&%B+GAM;%!+ 0(4 Q0    ( !.!JDP5
MKC5!;4L  +JQ P 5              "  <:) 0!C9'1X+3(P,3@P,S,Q7W!R
;92YX;6Q02P4&      8 !@"* 0  9M4!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
